<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004878.pub3" GROUP_ID="ARI" ID="613001042012413581" MERGED_FROM="" MODIFIED="2013-05-06 02:57:02 +0100" MODIFIED_BY="Liz Dooley" REVIEW_NO="A036" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2013-05-06 02:57:02 +0100" MODIFIED_BY="Liz Dooley">
<TITLE MODIFIED="2010-03-02 22:08:15 +1000" MODIFIED_BY="[Empty name]">Glucocorticoids for acute viral bronchiolitis in infants and young children</TITLE>
<CONTACT MODIFIED="2013-05-06 02:57:02 +0100" MODIFIED_BY="Liz Dooley"><PERSON ID="9B59478682E26AA200C3FEB6F44498DB" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ricardo</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Fernandes</LAST_NAME><POSITION>Clinical Researcher</POSITION><EMAIL_1>fernandescunharicardo@gmail.com</EMAIL_1><EMAIL_2>rmfernandes@campus.ul.pt</EMAIL_2><ADDRESS><DEPARTMENT>Laboratory of Clinical Pharmacology and Therapeutics</DEPARTMENT><ORGANISATION>Faculty of Medicine, University of Lisbon, Instituto de Medicina Molecular</ORGANISATION><ADDRESS_1>Avenida Professor Egas Moniz</ADDRESS_1><CITY>Lisboa</CITY><ZIP>1649-028</ZIP><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1>+ 351 21 797 34 53</PHONE_1><FAX_1>+ 351 21 781 96 88</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-05-06 02:57:02 +0100" MODIFIED_BY="Liz Dooley"><PERSON ID="9B59478682E26AA200C3FEB6F44498DB" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ricardo</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Fernandes</LAST_NAME><POSITION>Clinical Researcher</POSITION><EMAIL_1>fernandescunharicardo@gmail.com</EMAIL_1><EMAIL_2>rmfernandes@campus.ul.pt</EMAIL_2><ADDRESS><DEPARTMENT>Laboratory of Clinical Pharmacology and Therapeutics</DEPARTMENT><ORGANISATION>Faculty of Medicine, University of Lisbon, Instituto de Medicina Molecular</ORGANISATION><ADDRESS_1>Avenida Professor Egas Moniz</ADDRESS_1><CITY>Lisboa</CITY><ZIP>1649-028</ZIP><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1>+ 351 21 797 34 53</PHONE_1><FAX_1>+ 351 21 781 96 88</FAX_1></ADDRESS></PERSON><PERSON ID="5181AE9182E26AA2017F61BBC7800C63" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Liza</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Bialy</LAST_NAME><SUFFIX>BSc</SUFFIX><POSITION>Project Coordinator</POSITION><EMAIL_1>lbialy@ualberta.ca</EMAIL_1><URL>http://www.ualberta.ca/ARCHE/</URL><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>University of Alberta</ORGANISATION><ADDRESS_1>9428 Aberhart Centre One</ADDRESS_1><ADDRESS_2>11402 University Avenue</ADDRESS_2><CITY>Edmonton</CITY><ZIP>T6G 2J3</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+780 492 6184</PHONE_1><PHONE_2>+780 407 6435</PHONE_2></ADDRESS></PERSON><PERSON ID="19902" ROLE="AUTHOR"><FIRST_NAME>Ben</FIRST_NAME><LAST_NAME>Vandermeer</LAST_NAME><SUFFIX>BSc, MSc</SUFFIX><POSITION>Statistician</POSITION><EMAIL_1>bv1@ualberta.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>University of Alberta</ORGANISATION><ADDRESS_1>4-496B Edmonton Clinic Health Academy (ECHA)</ADDRESS_1><ADDRESS_2>11405 - 87 Avenue</ADDRESS_2><CITY>Edmonton</CITY><ZIP>T6G 1C9</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 492 6355</PHONE_1><FAX_1>+1 780 248 5625</FAX_1></ADDRESS></PERSON><PERSON ID="11506" ROLE="AUTHOR"><FIRST_NAME>Lisa</FIRST_NAME><LAST_NAME>Tjosvold</LAST_NAME><POSITION>Child Health Research Librarian</POSITION><EMAIL_1>tjosvold@ualberta.ca</EMAIL_1><ADDRESS><DEPARTMENT>Alberta Research Centre for Child Health Evidence</DEPARTMENT><ORGANISATION>University of Alberta</ORGANISATION><ADDRESS_1>Aberhart Centre One, Room 9420</ADDRESS_1><ADDRESS_2>11402 University Ave.</ADDRESS_2><CITY>Edmonton</CITY><ZIP>T6G 2J3</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 492 0550</PHONE_1><FAX_1>+1 780 407 6435</FAX_1></ADDRESS></PERSON><PERSON ID="3EAE70D982E26AA2001AB0E3CC7C1AFE" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Amy</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Plint</LAST_NAME><POSITION>Clinician Scientist</POSITION><EMAIL_1>plint@cheo.on.ca</EMAIL_1><ADDRESS><DEPARTMENT>Departments of Pediatrics and Emergency Medicine</DEPARTMENT><ORGANISATION>University of Ottawa</ORGANISATION><CITY>Ottawa</CITY><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 613 737 7600, ext 3237</PHONE_1><FAX_1>+1 613 738 4885</FAX_1></ADDRESS></PERSON><PERSON ID="12313" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Hema</FIRST_NAME><LAST_NAME>Patel</LAST_NAME><POSITION>Program Head, Intensive Ambulatory Care Service / Clinical Investigation Unit</POSITION><EMAIL_1>hema.patel@muhc.mcgill.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>The Montreal Children's Hospital</ORGANISATION><ADDRESS_1>McGill University Health Centre</ADDRESS_1><ADDRESS_2>2300 Tupper Street, Room A216</ADDRESS_2><CITY>Montreal</CITY><ZIP>H3H 1P3</ZIP><REGION>Quebec</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 514 412 4420</PHONE_1><FAX_1>+1 514 412 4424</FAX_1></ADDRESS></PERSON><PERSON ID="12282" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>David</FIRST_NAME><MIDDLE_INITIALS>W</MIDDLE_INITIALS><LAST_NAME>Johnson</LAST_NAME><POSITION>Pediatric Emergency Physician and Medical Toxicologist</POSITION><EMAIL_1>david.johnson@albertahealthservices.ca</EMAIL_1><MOBILE_PHONE>+1 403 473 6442</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>Faculty of Medicine, University of Calgary, Alberta Children's Hospital</ORGANISATION><ADDRESS_1>2888 Shaganappi Trail NW</ADDRESS_1><CITY>Calgary</CITY><ZIP>T3B 6A8</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 403 955 7507</PHONE_1><FAX_1>+1 403 955 7552</FAX_1></ADDRESS></PERSON><PERSON ID="5344" ROLE="AUTHOR"><FIRST_NAME>Terry</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Klassen</LAST_NAME><SUFFIX>MD, MSc, FRCPC</SUFFIX><POSITION>Director</POSITION><EMAIL_1>tklassen@mich.ca</EMAIL_1><URL>http://www.mich.ca</URL><MOBILE_PHONE>+1 780 970 3615</MOBILE_PHONE><ADDRESS><ORGANISATION>Manitoba Institute of Child Health</ORGANISATION><ADDRESS_1>513-715 McDermot Avenue</ADDRESS_1><CITY>Winnipeg</CITY><ZIP>MB R3E 3P4</ZIP><REGION>Manitoba</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 204 789 3754</PHONE_1></ADDRESS></PERSON><PERSON ID="12166" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Lisa</FIRST_NAME><LAST_NAME>Hartling</LAST_NAME><SUFFIX>MSc</SUFFIX><POSITION>Assistant Professor</POSITION><EMAIL_1>hartling@ualberta.ca</EMAIL_1><EMAIL_2>lisa.hartling@ualberta.ca</EMAIL_2><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>University of Alberta</ORGANISATION><ADDRESS_1>Aberhart Centre One, Room 9424</ADDRESS_1><ADDRESS_2>11402 University Avenue</ADDRESS_2><CITY>Edmonton</CITY><ZIP>T6G 2J3</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 492 6124</PHONE_1><FAX_1>+1 780 407 6435</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-01-30 08:10:23 +1000" MODIFIED_BY="Ricardo Fernandes">
<UP_TO_DATE>
<DATE DAY="21" MONTH="1" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="21" MONTH="1" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="21" MONTH="1" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2013-05-06 11:02:36 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-05-06 11:02:36 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="1" YEAR="2013"/>
<DESCRIPTION>
<P>Our conclusions remain unchanged</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-05-06 11:02:15 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="1" YEAR="2013"/>
<DESCRIPTION>
<P>Searches conducted. No new trials were included in this update. We excluded 10 new potentially relevant publications after full-text review (<LINK REF="STD-Bai-2010" TYPE="STUDY">Bai 2010</LINK>; <LINK REF="STD-Gerasymov-2010" TYPE="STUDY">Gerasymov 2010</LINK>; <LINK REF="STD-Jartti-2011" TYPE="STUDY">Jartti 2011</LINK>; <LINK REF="STD-Karaatmaca-2010" TYPE="STUDY">Karaatmaca 2010</LINK>; <LINK REF="STD-Lukkarinen-2011" TYPE="STUDY">Lukkarinen 2011</LINK>; <LINK REF="STD-Martini-2009" TYPE="STUDY">Martini 2009</LINK>; <LINK REF="STD-Principi-2011" TYPE="STUDY">Principi 2011</LINK>; <LINK REF="STD-Smart-2009" TYPE="STUDY">Smart 2009</LINK>; <LINK REF="STD-van-Woensel-2011" TYPE="STUDY">van Woensel 2011</LINK>; <LINK REF="STD-Zhu-2009" TYPE="STUDY">Zhu 2009</LINK>)</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-12-21 09:26:18 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="9" YEAR="2010"/>
<DESCRIPTION>
<P>Corrected references and text in Results - Effects of interventions - Glucocorticoid and bronchodilator (epinephrine or salbutamol) versus placebo.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2010-09-17 17:05:34 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="5" YEAR="2010"/>
<DESCRIPTION>
<P>A new team of authors have updated this previously withdrawn review. Current evidence suggests combined glucocorticoids and epinephrine may be effective in reducing outpatient admissions in this patient group.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-09-17 17:05:42 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>Searches conducted. Eleven new trials (<LINK REF="STD-Barlas-1998" TYPE="STUDY">Barlas 1998</LINK>; <LINK REF="STD-Bentur-2005" TYPE="STUDY">Bentur 2005</LINK>; <LINK REF="STD-Cade-2000" TYPE="STUDY">Cade 2000</LINK>; <LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-Gomez-2007" TYPE="STUDY">Gomez 2007</LINK>; <LINK REF="STD-Kuyucu-2004" TYPE="STUDY">Kuyucu 2004</LINK>; <LINK REF="STD-Mesquita-2009" TYPE="STUDY">Mesquita 2009</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>; <LINK REF="STD-Richter-1998" TYPE="STUDY">Richter 1998</LINK>; <LINK REF="STD-Teeratakulpisarn-2007" TYPE="STUDY">Teeratakulpisarn 2007</LINK>; <LINK REF="STD-Zhang-2003" TYPE="STUDY">Zhang 2003</LINK>) have been included and 61 new trials have been excluded in this update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-08-21 16:01:19 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2008-07-01 07:16:20 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="4" MONTH="1" YEAR="2007"/>
<DESCRIPTION>
<P>Feedback added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="5" YEAR="2004"/>
<DESCRIPTION>
<P>Substantive amendment.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-05-22 01:55:06 +1000" MODIFIED_BY="Ricardo M Fernandes">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2010-05-22 01:55:06 +1000" MODIFIED_BY="Ricardo M Fernandes">
<SOURCE MODIFIED="2010-05-22 01:55:06 +1000" MODIFIED_BY="Ricardo M Fernandes">
<NAME>Canadian Institutes of Health Research</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION>
<P>Knowledge Synthesis Grant (FRN 91767)</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2010-05-22 00:40:32 +1000" MODIFIED_BY="Ricardo M Fernandes">
<NAME>Programme for Advanced Medical Education (Fundação Calouste Gulbenkian, Fundação Champalimaud, Ministério da Saúde and Fundação para a Ciência e Tecnologia)</NAME>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<DESCRIPTION>
<P>Fellowship (Ricardo M Fernandes)</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2010-05-22 00:42:56 +1000" MODIFIED_BY="Ricardo M Fernandes">
<NAME>Cochrane Incentives Funding Scheme</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Grant</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-05-06 03:25:05 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-04-05 00:55:56 +1000" MODIFIED_BY="Ricardo M Fernandes">
<TITLE MODIFIED="2010-08-11 03:17:04 +1000" MODIFIED_BY="Ricardo M Fernandes">Glucocorticoids for acute viral bronchiolitis in infants and young children under two years of age</TITLE>
<SUMMARY_BODY MODIFIED="2013-04-05 00:55:56 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Bronchiolitis is the most common acute infection of the airways and lungs during the first years of life. It is caused by viruses,<SUP> </SUP>the most common being respiratory syncytial virus. The<SUP> </SUP>illness starts similar to a cold, with symptoms such as a runny nose,<SUP> </SUP>mild fever and cough. It later leads to fast, troubled and often noisy<SUP> </SUP>breathing (for example, wheezing). While the disease is often mild for most healthy babies and young children, it is a major cause of clinical illness and financial health burden worldwide. Hospitalisations have risen in high-income countries, there is substantial healthcare use and bronchiolitis may be linked with preschool wheezing disorders and the child later developing asthma.</P>
<P>There is variation in how physicians manage bronchiolitis, reflecting the absence of clear scientific evidence for any treatment approach. Anti-inflammatory drugs like glucocorticoids (for example, prednisolone or dexamethasone) have been used based on apparent similarities between bronchiolitis and asthma. However, no clear benefit of their use has been shown.</P>
<P>Our systematic review found 17 controlled studies involving 2596 affected children that used these drugs for a short duration and assessed short-term outcomes. When comparing glucocorticoids to placebo, no differences were found for either hospital admissions or length of hospital stay. There was no substantial benefit in other health outcomes. These findings are consistent and likely to be applicable in diverse settings.</P>
<P>Exploratory results from one large high-quality trial suggest that combined treatment of systemic glucocorticoids (dexamethasone) and bronchodilators (epinephrine) may significantly reduce hospital admissions. There were no relevant short-term adverse effects that were any different from those seen with an inactive placebo, while long-term safety was not assessed. Further research is needed to confirm the efficacy, safety and applicability of this promising approach.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-05-03 08:45:22 +1000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-08-15 05:03:39 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Previous systematic reviews have not shown clear benefit of glucocorticoids for acute viral bronchiolitis, but their use remains considerable. Recent large trials add substantially to current evidence and suggest novel glucocorticoid-including treatment approaches.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-06-10 08:47:38 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>To review the efficacy and safety of systemic and inhaled glucocorticoids in children with acute viral bronchiolitis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2012, Issue 12), MEDLINE (1950 to January week 2, 2013), EMBASE (1980 to January 2013), LILACS (1982 to January 2013), Scopus® (1823 to January 2013) and IRAN MedEx (1998 to November 2009).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Randomised controlled trials (RCTs) comparing short-term systemic or inhaled glucocorticoids versus placebo or another intervention in children under 24 months with acute bronchiolitis (first episode with wheezing). Our primary outcomes were: admissions by days 1 and 7 for outpatient studies; and length of stay (LOS) for inpatient studies. Secondary outcomes included clinical severity parameters, healthcare use, pulmonary function, symptoms, quality of life and harms.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Two authors independently extracted data on study and participant characteristics, interventions and outcomes. We assessed risk of bias and graded strength of evidence. We meta-analysed inpatient and outpatient results separately using random-effects models. We pre-specified subgroup analyses, including the combined use of bronchodilators used in a protocol.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-05-03 08:45:22 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>We included 17 trials (2596 participants); three had low overall risk of bias. Baseline severity, glucocorticoid schemes, comparators and outcomes were heterogeneous. Glucocorticoids did not significantly reduce outpatient admissions by days 1 and 7 when compared to placebo (pooled risk ratios (RRs) 0.92; 95% confidence interval (CI) 0.78 to 1.08 and 0.86; 95% CI 0.7 to 1.06, respectively). There was no benefit in LOS for inpatients (mean difference -0.18 days; 95% CI -0.39 to 0.04). Unadjusted results from a large factorial low risk of bias RCT found combined high-dose systemic dexamethasone and inhaled epinephrine reduced admissions by day 7 (baseline risk of admission 26%; RR 0.65; 95% CI 0.44 to 0.95; number needed to treat 11; 95% CI 7 to 76), with no differences in short-term adverse effects. No other comparisons showed relevant differences in primary outcomes.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-01-07 10:59:50 +1000" MODIFIED_BY="[Empty name]">
<P>Current evidence does not support a clinically relevant effect of systemic or inhaled glucocorticoids on admissions or length of hospitalisation. Combined dexamethasone and epinephrine may reduce outpatient admissions, but results are exploratory and safety data limited. Future research should further assess the efficacy, harms and applicability of combined therapy.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-05-06 03:25:05 +1000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Acute viral bronchiolitis is the most common acute infection of the lower respiratory tract during the first year of life (<LINK REF="REF-Wright-1989" TYPE="REFERENCE">Wright 1989</LINK>). It is diagnosed clinically in infants and young children, based on a history of rhinorrhoea and low-grade fever that progress to cough and respiratory distress, with findings of tachypnoea, chest retractions and wheeze, crackles, or both, on examination (<LINK REF="REF-Bush-2007" TYPE="REFERENCE">Bush 2007</LINK>; <LINK REF="REF-Smyth-2006" TYPE="REFERENCE">Smyth 2006</LINK>; <LINK REF="REF-Taussig-2008" TYPE="REFERENCE">Taussig 2008</LINK>). Respiratory syncytial virus (RSV) is responsible for the majority of cases, usually in seasonal epidemics (<LINK REF="REF-Smyth-2006" TYPE="REFERENCE">Smyth 2006</LINK>; <LINK REF="REF-Yusuf-2007" TYPE="REFERENCE">Yusuf 2007</LINK>). Other viral agents, particularly rhinovirus, human metapneumovirus, bocavirus and adenovirus, may also be involved as single or dual infections (<LINK REF="REF-Calvo-2010" TYPE="REFERENCE">Calvo 2010</LINK>; <LINK REF="REF-Kusel-2006" TYPE="REFERENCE">Kusel 2006</LINK>; <LINK REF="REF-Mansbach-2008b" TYPE="REFERENCE">Mansbach 2008b</LINK>; <LINK REF="REF-Mansbach-2012" TYPE="REFERENCE">Mansbach 2012</LINK>). Although bronchiolitis is usually a straightforward diagnosis, some variability in its definition exists. This may be due to poor agreement on the identification of early childhood wheezing phenotypes and worldwide differences in disease semantics (<LINK REF="REF-Brand-2008" TYPE="REFERENCE">Brand 2008</LINK>; <LINK REF="REF-Everard-2009" TYPE="REFERENCE">Everard 2009</LINK>; <LINK REF="REF-Mansbach-2008a" TYPE="REFERENCE">Mansbach 2008a</LINK>).</P>
<P>Bronchiolitis is a major cause of clinical morbidity and its financial health burden is substantial. Population-based studies in developed countries suggest an incidence ratio of approximately 10% within the first year of life, with hospital admissions up to 3% (<LINK REF="REF-Koehoorn-2008" TYPE="REFERENCE">Koehoorn 2008</LINK>; <LINK REF="REF-Mansbach-2005" TYPE="REFERENCE">Mansbach 2005</LINK>; <LINK REF="REF-Shay-1999" TYPE="REFERENCE">Shay 1999</LINK>; <LINK REF="REF-Wright-1989" TYPE="REFERENCE">Wright 1989</LINK>). While mortality is rare, hospitalisations have increased steadily in North America and Europe over the past 10 to 20 years (<LINK REF="REF-Langley-2003" TYPE="REFERENCE">Langley 2003</LINK>; <LINK REF="REF-Shay-1999" TYPE="REFERENCE">Shay 1999</LINK>; <LINK REF="REF-van-Woensel-2002" TYPE="REFERENCE">van Woensel 2002</LINK>), with rising inpatient health care costs (<LINK REF="REF-Langley-1997" TYPE="REFERENCE">Langley 1997</LINK>; <LINK REF="REF-Paramore-2004" TYPE="REFERENCE">Paramore 2004</LINK>; <LINK REF="REF-Pelletier-2006" TYPE="REFERENCE">Pelletier 2006</LINK>). Additionally, a majority of cases with mild illness cared for in the community are responsible for a considerable number of outpatient visits, loss of parental work time and decreased quality of life (<LINK REF="REF-Carroll-2008" TYPE="REFERENCE">Carroll 2008</LINK>; <LINK REF="REF-Mansbach-2007" TYPE="REFERENCE">Mansbach 2007</LINK>; <LINK REF="REF-Robbins-2006" TYPE="REFERENCE">Robbins 2006</LINK>). RSV infection, including bronchiolitis, is a major cause of childhood morbidity and mortality at a global level (<LINK REF="REF-Nair-2010" TYPE="REFERENCE">Nair 2010</LINK>).</P>
<P>Bronchiolitis involves acute inflammation of the bronchiolar airways initiated by viral infection, regardless of the causative agent. Airway oedema, necrosis and mucous plugging are the hallmark pathological features, and air flow obstruction ensues (<LINK REF="REF-Taussig-2008" TYPE="REFERENCE">Taussig 2008</LINK>). Factors underlying disease severity are only partially understood, but clinical determinants include lower age, prematurity, chronic lung, heart or neurological disease, immunodeficiency and ethnicity (<LINK REF="REF-Damore-2008" TYPE="REFERENCE">Damore 2008</LINK>; <LINK REF="REF-Figueras_x002d_Aloy-2008" TYPE="REFERENCE">Figueras-Aloy 2008</LINK>; <LINK REF="REF-Meissner-2003" TYPE="REFERENCE">Meissner 2003</LINK>; <LINK REF="REF-Simoes-2003" TYPE="REFERENCE">Simoes 2003</LINK>; <LINK REF="REF-Simoes-2008" TYPE="REFERENCE">Simoes 2008</LINK>). There is likely a complex interplay between host (i.e. genetic markers), agent (i.e. viral loads, specific agents and co-infections) and environmental factors (i.e. crowding, tobacco smoke exposure) (<LINK REF="REF-Colosia-2012" TYPE="REFERENCE">Colosia 2012</LINK>; <LINK REF="REF-Collins-2008" TYPE="REFERENCE">Collins 2008</LINK>; <LINK REF="REF-DiFranza-2012" TYPE="REFERENCE">DiFranza 2012</LINK>; <LINK REF="REF-Mansbach-2012" TYPE="REFERENCE">Mansbach 2012</LINK>; <LINK REF="REF-Miyairi-2008" TYPE="REFERENCE">Miyairi 2008;</LINK> <LINK REF="REF-Papadopoulos-2002" TYPE="REFERENCE">Papadopoulos 2002</LINK>). Basic, translational and clinical research studies are elucidating the association between bronchiolitis, preschool wheezing disorders and later asthma (<LINK REF="REF-Martinez-2005" TYPE="REFERENCE">Martinez 2005</LINK>; <LINK REF="REF-Perez_x002d_Yarza-2007" TYPE="REFERENCE">Perez-Yarza 2007</LINK>; <LINK REF="REF-Singh-2007" TYPE="REFERENCE">Singh 2007</LINK>; <LINK REF="REF-Sly-2010" TYPE="REFERENCE">Sly 2010</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-01-22 08:08:00 +1000" MODIFIED_BY="[Empty name]">
<P>The current treatment for bronchiolitis is controversial. There is substantial variation in its management throughout the world, reflecting the absence of clear evidence for any single treatment approach (<LINK REF="REF-Babl-2008" TYPE="REFERENCE">Babl 2008</LINK>; <LINK REF="REF-Barben-2003" TYPE="REFERENCE">Barben 2003</LINK>; <LINK REF="REF-Brand-2000" TYPE="REFERENCE">Brand 2000</LINK>; <LINK REF="REF-Gonzalez-2010" TYPE="REFERENCE">Gonzalez 2010</LINK>; <LINK REF="REF-Mansbach-2005" TYPE="REFERENCE">Mansbach 2005</LINK>; <LINK REF="REF-Plint-2004" TYPE="REFERENCE">Plint 2004</LINK>). Many interventions failed to show consistent and relevant effects (<LINK REF="REF-Bialy-2011" TYPE="REFERENCE">Bialy 2011)</LINK>. Recently, both nebulised epinephrine and hypertonic saline have emerged as options for improving relevant outcomes in outpatient and inpatient populations, respectively (<LINK REF="REF-Hartling-2011a" TYPE="REFERENCE">Hartling 2011a</LINK>; <LINK REF="REF-Zhang-2011" TYPE="REFERENCE">Zhang 2011</LINK>). However, no routine treatment is yet recommended by most evidence-based clinical practice guidelines worldwide (<LINK REF="REF-AAP-2006" TYPE="REFERENCE">AAP 2006</LINK>; <LINK REF="REF-Baumer-2007" TYPE="REFERENCE">Baumer 2007</LINK>; <LINK REF="REF-Turner-2008" TYPE="REFERENCE">Turner 2008</LINK>).</P>
<P>The case of glucocorticoids highlights the uncertainties of research in this field. Trials assessing their use date back to the 1960s, with different potencies, modes of administration, dosages and regimens of these drugs having been recommended (<LINK REF="STD-Connolly-1969" TYPE="STUDY">Connolly 1969</LINK>; <LINK REF="REF-Leer-1969" TYPE="REFERENCE">Leer 1969</LINK>). However, results from randomised clinical trials (RCTs) have been heterogeneous, leading to ongoing controversy regarding their use. Differences in participants, care settings and outcomes may account for these conflicting results, and have led to distinct interpretations (<LINK REF="REF-Everard-2009" TYPE="REFERENCE">Everard 2009</LINK>; <LINK REF="REF-Guilbert-2011" TYPE="REFERENCE">Guilbert 2011</LINK>; <LINK REF="REF-Hall-2007" TYPE="REFERENCE">Hall 2007</LINK>; <LINK REF="REF-Weinberger-2003" TYPE="REFERENCE">Weinberger 2003</LINK>; <LINK REF="STD-Weinberger-2007" TYPE="STUDY">Weinberger 2007</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Glucocorticoid use in bronchiolitis was originally thought to have equivalent benefits to those in acute asthma. Similarities between clinical findings were expected to express equivalent biological and physiological mechanisms attributable to inflammation (<LINK REF="REF-Leer-1969" TYPE="REFERENCE">Leer 1969</LINK>). However, evidence suggests there is heterogeneity in inflammatory pathways and mediators activated in different wheezing phenotypes which may underlie bronchiolitis (for example, neutrophil- versus eosinophil-mediated inflammation) (<LINK REF="REF-Halfhide-2008" TYPE="REFERENCE">Halfhide 2008</LINK>). Mechanistic studies have shown that glucocorticoids have limited anti-inflammatory effects in this condition (<LINK REF="STD-Buckingham-2002" TYPE="STUDY">Buckingham 2002</LINK>; <LINK REF="REF-Somers-2009" TYPE="REFERENCE">Somers 2009</LINK>) and there is an ongoing debate regarding their efficacy in acute virus-induced wheezing in preschool children (<LINK REF="REF-Bush-2009" TYPE="REFERENCE">Bush 2009</LINK>; <LINK REF="REF-Ducharme-2009" TYPE="REFERENCE">Ducharme 2009</LINK>; <LINK REF="STD-Panickar-2009" TYPE="STUDY">Panickar 2009</LINK>). Further, potential benefits need to be considered in light of possible short- and long-term adverse effects of glucocorticoid use. While the interactive effect of bronchodilators and glucocorticoids has been widely known in asthma, both at a clinical and biological level, its use as a putative treatment option in bronchiolitis has only been explored recently (<LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-01-07 11:55:30 +1000" MODIFIED_BY="[Empty name]">
<P>While guideline implementation has changed prescription patterns, glucocorticoids are still widely used (<LINK REF="REF-Barben-2000" TYPE="REFERENCE">Barben 2000</LINK>; <LINK REF="REF-Barben-2008" TYPE="REFERENCE">Barben 2008</LINK>; <LINK REF="REF-David-2010" TYPE="REFERENCE">David 2010</LINK>). The latest version of this review integrated critical results from the two largest multi-centre studies in this area (<LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>) and examined the use of combined therapy with bronchodilators or adrenaline. We continue to update the current body of evidence in order to adequately assess the efficacy and safety of glucocorticoids in bronchiolitis.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-01-07 11:52:42 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>To review the efficacy and safety of systemic and inhaled glucocorticoids in children with acute viral bronchiolitis.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-03-19 23:24:20 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<CRIT_STUDIES MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>We included RCTs irrespective of risk of bias, sample size, publication status or language of publication.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Studies should include infants and young children &#8804; 24 months of age with acute viral bronchiolitis. Bronchiolitis was defined clinically as a first episode of acute wheezing, respiratory distress and clinical evidence of a viral infection (cough, coryza, fever). Many bronchiolitis trial reports do not specify clinical findings required for participant inclusion (<LINK REF="REF-King-2004" TYPE="REFERENCE">King 2004</LINK>); we included all studies if other diagnoses (for example, pneumonia) could be excluded. We did not restrict inclusion based on specific findings on examination (for example, crackles) or viral aetiology.</P>
<P>We excluded studies in which any participant had a history of wheezing or respiratory distress (one or more previous episodes), a formal diagnosis of asthma, or if reporting of these items was unclear. We focused on first time wheezing so results could be directly pertinent to infants with 'typical' viral bronchiolitis, as opposed to children with acute recurrent wheezing. We did not exclude trials based on other reported participant characteristics, including gestational age and co-morbidities.</P>
<P>We included studies of both inpatients and outpatients (ambulatory care and/or emergency department), and excluded trials in the intensive care setting or with intubated and/or ventilated participants.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-09-17 01:44:53 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>The interventions of interest were short-term systemic or inhaled glucocorticoids administered for the acute care of bronchiolitis. We considered all types of glucocorticoids, dosages, durations and routes of administration. Glucocorticoids could be administered alone or combined with co-interventions (for example, bronchodilators), used with or without a fixed protocol. We excluded trials assessing the use of longer courses of glucocorticoids started during the acute phase for the prevention of post-bronchiolitic wheezing.</P>
<P>Comparators included either placebo or another intervention (for example, bronchodilators, other glucocorticoid). Inhaled isotonic saline is frequently used as a placebo control for inhaled drugs. We excluded studies comparing different doses or regimens of the same glucocorticoid.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>We selected primary outcomes based a priori on clinical relevance and patient importance; secondary outcomes assessed other relevant health domains (clinical severity, pulmonary function, healthcare use, patient/parent-reported symptoms and status, and harms). We included studies if they reported numeric data on at least one primary or secondary outcomes assessed within the first month after acute bronchiolitis. We considered different timings of outcome assessment, based on a priori relevance and available data.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-08-17 08:25:22 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Rate of admission by days one and seven for outpatient studies.</LI>
<LI>Length of stay (LOS) for inpatient studies.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<OL>
<LI>Clinical severity scores.</LI>
<LI>O<SUB>2</SUB> saturation, respiratory rate and heart rate.</LI>
<LI>Hospital re-admissions (for inpatient studies) and return healthcare visits (for all studies); LOS (for outpatient studies).</LI>
<LI>Pulmonary function tests.</LI>
<LI>Symptoms and quality of life.</LI>
<LI>Short- and long-term adverse events.</LI>
</OL>
<P>We selected the following time points and intervals for clinical scores, O<SUB>2 </SUB>saturation, respiratory and heart rate: 60 and 120 minutes, three to six hours, six to 12 hours, 12 to 24 hours, 24 to 72 hours, and three to 10 days. The time points selected for re-admissions and return visits were days 1 to 10, and 11 to 30. We also considered data on all other reported outcomes.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-03-19 23:18:57 +1000" MODIFIED_BY="[Empty name]">
<P>The previous version of this review used an inclusive search strategy as part of a comprehensive systematic review evaluating the effect of three types of interventions in bronchiolitis (glucocorticoids, epinephrine and other bronchodilators) (<LINK REF="REF-Hartling-2011b" TYPE="REFERENCE">Hartling 2011b</LINK>).</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-03-19 23:18:57 +1000" MODIFIED_BY="[Empty name]">
<P>Previously we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2009, Issue 4), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register, MEDLINE (1950 to November Week 2, 2009), EMBASE (1980 to Week 47, 2009), LILACS (Latin American and Caribbean Center on Health Sciences Information) (1982 to 25 November 2009), Scopus® (1823 to 25 November 2009) and IRAN MedEx (1998 to 26 November 2009).</P>
<P>We developed search strings by scanning search strategies of relevant systematic reviews and examining index terms of potentially relevant studies. We applied and modified a validated RCT filter according to each database (<LINK REF="REF-Glanville-2006" TYPE="REFERENCE">Glanville 2006</LINK>). We applied no publication or language restrictions. The search strings for each database can be found in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> to <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>.</P>
<P>For this 2013 update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) 2012, Issue 12, part of <I>The Cochrane Library, </I>www.thecochranelibrary.com (accessed 21 January 2013), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register, MEDLINE (October 2009 to January week 2, 2013), EMBASE (November 2009 to January 2013), LILACS (Latin American and Caribbean Center on Health Sciences Information) (2009 to January 2013) and Scopus (2009 to January 2013) (<LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Clare Dooley">
<P>To identify unpublished studies and studies in progress we searched the following clinical trials registers on 1 August 2012: ClinicalTrials.gov and ICTRP Search Portal &#8211; World Health Organization. We searched the following conference proceedings: Pediatric Academic Societies (2003 to 2012), European Respiratory Society (2003 to 2011), American Thoracic Society (2006 to 2012).</P>
<P>We identified additional published, unpublished or ongoing studies by handsearching reference lists and included or excluded studies of relevant reviews. In addition, we contacted topic specialists.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-03-19 23:24:20 +1000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-01-07 11:58:32 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Five review authors (AP, LB, LH, NH or RF) independently screened the titles, keywords and abstracts (when available) to determine if an article met the inclusion criteria. These review authors independently assessed the full text of all articles classified as 'include' or unclear' using a standardised form. We resolved disagreements by consensus or by an arbitrator (AP, TK, DJ, or RF).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-01-07 11:59:32 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>We extracted data using a standardised form in paper or electronic format (available from authors). Seven review authors extracted data (LB, LH, AM, HM, RF, OT or JF) and three review authors (LB, AM or RF) independently checked for accuracy and completeness. We resolved discrepancies by consensus or in consultation with a third review author (TK, AP or DJ). A statistician (BV) checked all quantitative data during analysis. Extracted data included study characteristics, funding, inclusion/exclusion criteria, participant characteristics, interventions, outcomes and results.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-03-19 23:20:50 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>We used the Cochrane 'Risk of bias' assessment tool, which includes seven domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other sources of bias (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We assessed blinding and incomplete outcome data separately for the following groups of outcomes: healthcare use (rate of admission, LOS, hospital re-admissions and return healthcare visits); clinical parameters (clinical severity scores, O<SUB>2 </SUB>saturation, respiratory rate and heart rate); pulmonary function; patient/parent-reported outcomes (symptoms and quality of life measures) and other outcomes such as adverse events. Where trial protocols or trial registers were unavailable, we assessed selective outcome reporting by comparing outcomes reported in the methods and results sections. We summarised risk of bias for each study across outcomes based on individual domain assessments ('high' if one or more domains were high; 'low' if all domains were low; 'unclear' for all other studies).</P>
<P>Three review authors (LB, LH or RF) independently assessed the risk of bias of the included studies; we resolved discrepancies by consensus. One review author (OT) assessed study reports written in Turkish. We pilot tested the risk of bias tool on a sample of five studies and used the results to adapt decision rules (available from authors).</P>
<SUBSECTION>
<HEADING LEVEL="4">Grading the body of evidence</HEADING>
<P>We used the Evidence-Based Practice Centers Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, based on the standard GRADE system (<LINK REF="REF-GRADE-2009" TYPE="REFERENCE">GRADE 2009</LINK>; <LINK REF="REF-Owens-2010" TYPE="REFERENCE">Owens 2010</LINK>), to assess domain-specific and overall strength of evidence on three relevant outcomes: length of stay or admission rate, clinical severity scores and adverse events. Two review authors (LH, RF) independently graded the body of evidence using adapted decision rules.</P>
<P>We examined the following domains: risk of bias, consistency, directness and precision. Risk of bias was considered as low or medium, as we only included RCTs. There is limited evidence regarding clinically significant and patient-important between-group differences in this field. We therefore defined a priori thresholds of clinical relevance based on expert opinion and GRADE guidance for the precision domain: risk ratio reduction &gt; 20% for admissions, reduction in LOS &gt; 0.5 days and clinical scale effect sizes based on GRADE guidance (<LINK REF="REF-GRADE-2009" TYPE="REFERENCE">GRADE 2009</LINK>). We graded overall strength of evidence 'high', 'moderate' or 'low' based on the likelihood of further research changing our confidence in the estimate of effect (when evidence was unavailable or did not permit estimation of an effect, it was considered insufficient).</P>
<P>All decisions were made explicitly and inter-rater agreement was calculated (data available from authors). We resolved discrepancies by consensus among two review authors (LH, RF).</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>We pooled dichotomous variables using risk ratios (RRs). We derived the number needed to treat to benefit (NNTB) for significant results from primary outcomes. Since the only comparison with significant differences was based on a single trial, the NNTB is shown for that trial's baseline risk.</P>
<P>We analysed measurement scale outcomes as continuous variables. For continuous variables measured on the same scale (for example, respiratory rate), we calculated mean differences (MD) for individual studies and mean differences for the pooled estimates. For those measured on different scales (for example, clinical scores), we calculated MDs for separate studies and standardised MD (SMD) for the pooled estimates. We used changes from baseline for all continuous variables.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Some of the studies included in this review were multi-arm or factorial studies in which more than two intervention groups were eligible to contribute several comparisons to a single meta-analysis. For example, a trial might compare glucocorticoid versus placebo in two arms, and glucocorticoid + bronchodilator versus placebo + bronchodilator in another two arms, with both contributing to the overall glucocorticoid versus placebo comparison. When the comparisons were independent, i.e. with no intervention group in common, we included data from these arms with no transformation and we shown them separately in each forest plot. If needed and feasible, we pooled the active groups to avoid double-counting of the comparator group when there was more than one active group: for example, two glucocorticoid groups versus placebo. We did not include any treatment groups twice in the same meta-analysis.</P>
<P>Guidance regarding the analysis of factorial trials mandates caution when results suggest positive interaction/additive effects ('synergism') between study treatments (<LINK REF="REF-McAlister-2003" TYPE="REFERENCE">McAlister 2003</LINK>; <LINK REF="REF-Montgomery-2003" TYPE="REFERENCE">Montgomery 2003</LINK>). This was the case for a large trial included in this review. We therefore chose to include comparisons separately in meta-analysis ('within the table analysis'): for example, for the glucocorticoid versus placebo comparison, we included separately glucocorticoid + bronchodilator versus placebo + bronchodilator and glucocorticoid + placebo versus double placebo. We also performed sensitivity analysis pooling all arms ('at the margins analysis').</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-03-19 23:22:18 +1000" MODIFIED_BY="[Empty name]">
<P>We extracted information on incomplete outcome data and we classified trials that performed intention-to-treat (ITT) analysis as either ITT with all data, ITT with imputation of missing data, ITT with available case analysis, per protocol analysis or treatment-received analysis (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We did not impute missing data for drop-outs. We estimated unreported means from figures or imputed from medians if possible. We computed standard deviations (SDs) from available data (i.e. standard errors, confidence intervals (CI) or P values) when missing. Failing this, we estimated them from ranges and inter-quartile ranges, or imputed them from a similar study. When standard deviations of change from baseline values were unavailable, we estimated correlation at 0.5 (<LINK REF="REF-Follmann-1992" TYPE="REFERENCE">Follmann 1992</LINK>; <LINK REF="REF-Wiebe-2006" TYPE="REFERENCE">Wiebe 2006</LINK>). We occasionally encountered clinical score results presented as dichotomous data, for example, using a cut-off score or time-to-event analysis. When methods were feasible and assumptions judged reasonable, we used existing approaches to re-express odds ratios as standardised mean differences, thus allowing dichotomous and continuous data to be pooled together (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). When data were unavailable for one of the predefined timings of outcome measurement, we used the time point closest or any time point in the range. If there was more than one time point, we chose the one with the largest magnitude of change.</P>
<P>We did not contact trial authors of the individual studies to obtain additional data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-01-04 16:07:19 +1000" MODIFIED_BY="[Empty name]">
<P>We quantified statistical heterogeneity using the I<SUP>2</SUP> statistic. We used the following intervals for interpreting I<SUP>2</SUP> statistic values: 0% to 30% low heterogeneity; 30% to 50% moderate heterogeneity; 50% to 75% substantial heterogeneity; and 75% to 100% considerable heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). </P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-01-04 16:07:19 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed reporting biases for the main comparisons and primary outcomes by visual interpretation of funnel plots and testing for funnel plot asymmetry (Egger test) (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>We meta-analysed quantitative results within the different comparisons when studies were consistent on clinical grounds and had available outcome data; we imposed no restrictions based on risk of bias. We performed separate meta-analyses for studies involving inpatients and outpatients.</P>
<P>We combined results using random-effects models regardless of heterogeneity, due to expected differences in interventions, outcomes and measurement instruments. We calculated fixed-effect models in a sensitivity analysis. We conducted meta-analyses of dichotomous outcomes using Mantel-Haenszel methods. We used inverse variance methods for continuous outcomes and measurement scales, and combined dichotomous and continuous data into a standardised mean difference whenever needed (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). All results are reported with 95% CI. We used Review Manager software for data management and analysis (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-03-19 23:24:20 +1000" MODIFIED_BY="[Empty name]">
<P>We planned to investigate heterogeneity by conducting subgroup analyses based on pre-specified study- and participant-level characteristics. The following subgroups were considered:</P>
<OL>
<LI>Protocolised use of bronchodilators (studies with protocolised use versus no/unclear protocolised use).</LI>
<LI>RSV status (studies with all participants exclusively RSV-positive versus some RSV-negative/unspecified RSV status).</LI>
<LI>Age of participants (studies with all participants exclusively less than 12 months of age versus some participants older than 12 months/unspecified age).</LI>
<LI>Atopy (studies with all participants exclusively atopic versus some participants not atopic/unspecified atopic status).</LI>
<LI>Glucocorticoid: type of glucocorticoids; and daily and overall dose (high versus low).</LI>
</OL>
<P>We explored potential positive or negative (i.e. 'synergistic' or 'antagonistic') interactions between glucocorticoids and bronchodilators by distinguishing trials where bronchodilator use was protocolised (i.e. comparing glucocorticoids + bronchodilator versus placebo + bronchodilator) from studies where use was either at the discretion of the physician or not allowed (<LINK REF="REF-Gurusamy-2009" TYPE="REFERENCE">Gurusamy 2009</LINK>). The choice of RSV, age and atopy was based on clinical or biological evidence suggesting possible effect modification of glucocorticoid effects by these parameters. We studied drug type and dose to explore distinct glucocorticoid pharmacokinetic and pharmacodynamic properties; dosing was based on prednisolone equivalents.</P>
<P>We planned to perform subgroup analyses only on the review's primary outcomes. We also collected data from studies that analysed these subgroups at a study level. We assessed subgroup differences comparing changes in effect estimate and CI overlap; statistical tests or meta-regression techniques were not used.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>We decided a priori to perform sensitivity analyses on primary outcome results of trials with overall low risk of bias. We also checked for differences in the direction and magnitude of primary outcome results when using fixed-effect models, as well as using pooled data from all factorial trial arms ('at the margins analysis').</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-05-06 03:25:05 +1000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-03-19 23:27:39 +1000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>The initial 2009 comprehensive search of all electronic databases identified 2249 records, of which 344 were potentially relevant. Handsearching had identified four more studies and overall 348 full-text articles had been assessed for eligibility. Of 91 studies that used glucocorticoids, 17 trials fulfilled inclusion criteria.</P>
<P>The 2013 search identified 280 further records, of which 13 were assessed for eligibility using full text but all were excluded (flowchart in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-03-19 23:27:39 +1000" MODIFIED_BY="[Empty name]">
<P>We included 17 trials with 2596 randomised participants. We considered different comparisons separately between glucocorticoids, alone or with fixed co-interventions, and either placebo or active controls. Included trials contributed to one or more comparisons, depending on trial arms (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Design, centres and sample sizes</HEADING>
<P>Fifteen trials were parallel-designed, 14 of which were double-armed (<LINK REF="STD-Bentur-2005" TYPE="STUDY">Bentur 2005</LINK>; <LINK REF="STD-Berger-1998" TYPE="STUDY">Berger 1998</LINK>; <LINK REF="STD-Cade-2000" TYPE="STUDY">Cade 2000</LINK>; <LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-De-Boeck-1997" TYPE="STUDY">De Boeck 1997</LINK>; <LINK REF="STD-Goebel-2000" TYPE="STUDY">Goebel 2000</LINK>; <LINK REF="STD-Gomez-2007" TYPE="STUDY">Gomez 2007</LINK>; <LINK REF="STD-Klassen-1997" TYPE="STUDY">Klassen 1997</LINK>; <LINK REF="STD-Mesquita-2009" TYPE="STUDY">Mesquita 2009</LINK>; <LINK REF="STD-Richter-1998" TYPE="STUDY">Richter 1998</LINK>; <LINK REF="STD-Roosevelt-1996" TYPE="STUDY">Roosevelt 1996</LINK>; <LINK REF="STD-Schuh-2002" TYPE="STUDY">Schuh 2002</LINK>; <LINK REF="STD-Teeratakulpisarn-2007" TYPE="STUDY">Teeratakulpisarn 2007</LINK>; <LINK REF="STD-Zhang-2003" TYPE="STUDY">Zhang 2003</LINK>) and one was six-armed (<LINK REF="STD-Barlas-1998" TYPE="STUDY">Barlas 1998</LINK>). Two trials were factorial two-by-two (<LINK REF="STD-Kuyucu-2004" TYPE="STUDY">Kuyucu 2004</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>).</P>
<P>Eleven trials were single-centred and five included multiple centres (range: 2 to 20) (<LINK REF="STD-Cade-2000" TYPE="STUDY">Cade 2000</LINK>; <LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-Goebel-2000" TYPE="STUDY">Goebel 2000</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>; <LINK REF="STD-Teeratakulpisarn-2007" TYPE="STUDY">Teeratakulpisarn 2007</LINK>); one trial did not clearly report this item (<LINK REF="STD-Bentur-2005" TYPE="STUDY">Bentur 2005</LINK>). All trials were conducted in a single country, either in North, Central or South America, Europe and the Middle East or Asia.</P>
<P>Sample size calculations were reported in 12 trials (<LINK REF="STD-Bentur-2005" TYPE="STUDY">Bentur 2005</LINK>; <LINK REF="STD-Berger-1998" TYPE="STUDY">Berger 1998</LINK>; <LINK REF="STD-Cade-2000" TYPE="STUDY">Cade 2000</LINK>; <LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-Klassen-1997" TYPE="STUDY">Klassen 1997</LINK>; <LINK REF="STD-Mesquita-2009" TYPE="STUDY">Mesquita 2009</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>; <LINK REF="STD-Richter-1998" TYPE="STUDY">Richter 1998</LINK>; <LINK REF="STD-Roosevelt-1996" TYPE="STUDY">Roosevelt 1996</LINK>; <LINK REF="STD-Schuh-2002" TYPE="STUDY">Schuh 2002</LINK>; <LINK REF="STD-Teeratakulpisarn-2007" TYPE="STUDY">Teeratakulpisarn 2007</LINK>; <LINK REF="STD-Zhang-2003" TYPE="STUDY">Zhang 2003</LINK>); the outcome used for sample size calculation was the reported primary outcome in all except one trial (<LINK REF="STD-Richter-1998" TYPE="STUDY">Richter 1998</LINK>). The overall median number of participants per trial was 72 (range 32 to 800), with two large trials counting 600 and 800 (<LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>, respectively), and all others fewer than 200.</P>
<P>Funding was reported in nine studies, three of which had pharmaceutical industry support (<LINK REF="STD-Cade-2000" TYPE="STUDY">Cade 2000</LINK>; <LINK REF="STD-Richter-1998" TYPE="STUDY">Richter 1998</LINK>; <LINK REF="STD-Schuh-2002" TYPE="STUDY">Schuh 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Setting and participants</HEADING>
<P>Outpatients were included in eight trials, with 1824 randomised participants and a median of 85 participants per trial (range: 42 to 800) (<LINK REF="STD-Barlas-1998" TYPE="STUDY">Barlas 1998</LINK>; <LINK REF="STD-Berger-1998" TYPE="STUDY">Berger 1998</LINK>; <LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-Goebel-2000" TYPE="STUDY">Goebel 2000</LINK>; <LINK REF="STD-Kuyucu-2004" TYPE="STUDY">Kuyucu 2004</LINK>; <LINK REF="STD-Mesquita-2009" TYPE="STUDY">Mesquita 2009</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>; <LINK REF="STD-Schuh-2002" TYPE="STUDY">Schuh 2002</LINK>). Outpatient settings mostly included paediatric emergency departments. Nine trials included inpatients only, with 772 participants and a median of 61 participants per trial (range: 32 to 179) (<LINK REF="STD-Bentur-2005" TYPE="STUDY">Bentur 2005</LINK>; <LINK REF="STD-Cade-2000" TYPE="STUDY">Cade 2000</LINK>; <LINK REF="STD-De-Boeck-1997" TYPE="STUDY">De Boeck 1997</LINK>; <LINK REF="STD-Gomez-2007" TYPE="STUDY">Gomez 2007</LINK>; <LINK REF="STD-Klassen-1997" TYPE="STUDY">Klassen 1997</LINK>; <LINK REF="STD-Richter-1998" TYPE="STUDY">Richter 1998</LINK>; <LINK REF="STD-Roosevelt-1996" TYPE="STUDY">Roosevelt 1996</LINK>; <LINK REF="STD-Teeratakulpisarn-2007" TYPE="STUDY">Teeratakulpisarn 2007</LINK>; <LINK REF="STD-Zhang-2003" TYPE="STUDY">Zhang 2003</LINK>). Few details were reported regarding criteria for hospitalisation and the type of admission unit in which patients received care, except for one inpatient trial report (<LINK REF="STD-Teeratakulpisarn-2007" TYPE="STUDY">Teeratakulpisarn 2007</LINK>).</P>
<P>In most trials bronchiolitis was defined by clinical findings; wheezing was always required. Three trials restricted inclusion to bronchodilator responders (<LINK REF="STD-Goebel-2000" TYPE="STUDY">Goebel 2000</LINK> - outpatients; <LINK REF="STD-Teeratakulpisarn-2007" TYPE="STUDY">Teeratakulpisarn 2007 </LINK>and <LINK REF="STD-Zhang-2003" TYPE="STUDY">Zhang 2003</LINK> - inpatients). Seven trials only included participants under the age of 12 months, all of which had a mean or median participant age below six months (<LINK REF="STD-Bentur-2005" TYPE="STUDY">Bentur 2005</LINK>; <LINK REF="STD-Cade-2000" TYPE="STUDY">Cade 2000</LINK>; <LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>; <LINK REF="STD-Richter-1998" TYPE="STUDY">Richter 1998</LINK>; <LINK REF="STD-Roosevelt-1996" TYPE="STUDY">Roosevelt 1996</LINK>; <LINK REF="STD-Zhang-2003" TYPE="STUDY">Zhang 2003</LINK>).</P>
<P>Bronchiolitis severity thresholds were used for inclusion in eight outpatient (<LINK REF="STD-Barlas-1998" TYPE="STUDY">Barlas 1998</LINK>; <LINK REF="STD-Berger-1998" TYPE="STUDY">Berger 1998</LINK>; <LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-Goebel-2000" TYPE="STUDY">Goebel 2000</LINK>; <LINK REF="STD-Kuyucu-2004" TYPE="STUDY">Kuyucu 2004</LINK>; <LINK REF="STD-Mesquita-2009" TYPE="STUDY">Mesquita 2009</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>; <LINK REF="STD-Schuh-2002" TYPE="STUDY">Schuh 2002</LINK>) and two inpatient trials (<LINK REF="STD-Gomez-2007" TYPE="STUDY">Gomez 2007</LINK>; <LINK REF="STD-Klassen-1997" TYPE="STUDY">Klassen 1997</LINK>). Severity was based on clinical scales or respiratory parameters, and thresholds varied. The Respiratory Distress Assessment Instrument (RDAI) baseline score thresholds varied between two and six (less than four usually considered mild bronchiolitis).</P>
<P>Thirteen trials reported testing for RSV at least in a portion of participants, and three trials only included RSV-positive patients (<LINK REF="STD-Bentur-2005" TYPE="STUDY">Bentur 2005</LINK>; <LINK REF="STD-Cade-2000" TYPE="STUDY">Cade 2000</LINK>; <LINK REF="STD-De-Boeck-1997" TYPE="STUDY">De Boeck 1997</LINK>). Prevalence of RSV in the remaining 10 trials varied from 33% to 89% (<LINK REF="STD-Barlas-1998" TYPE="STUDY">Barlas 1998</LINK>; <LINK REF="STD-Berger-1998" TYPE="STUDY">Berger 1998</LINK>; <LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-Goebel-2000" TYPE="STUDY">Goebel 2000</LINK>; <LINK REF="STD-Klassen-1997" TYPE="STUDY">Klassen 1997</LINK>; <LINK REF="STD-Mesquita-2009" TYPE="STUDY">Mesquita 2009</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>; <LINK REF="STD-Richter-1998" TYPE="STUDY">Richter 1998</LINK>; <LINK REF="STD-Roosevelt-1996" TYPE="STUDY">Roosevelt 1996</LINK>; <LINK REF="STD-Schuh-2002" TYPE="STUDY">Schuh 2002</LINK>).</P>
<P>Atopic status was reported in nine trials (<LINK REF="STD-Barlas-1998" TYPE="STUDY">Barlas 1998</LINK>; <LINK REF="STD-Berger-1998" TYPE="STUDY">Berger 1998</LINK>; <LINK REF="STD-Cade-2000" TYPE="STUDY">Cade 2000</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>; <LINK REF="STD-Richter-1998" TYPE="STUDY">Richter 1998</LINK>; <LINK REF="STD-Roosevelt-1996" TYPE="STUDY">Roosevelt 1996</LINK>; <LINK REF="STD-Schuh-2002" TYPE="STUDY">Schuh 2002</LINK>; <LINK REF="STD-Teeratakulpisarn-2007" TYPE="STUDY">Teeratakulpisarn 2007</LINK>; <LINK REF="STD-Zhang-2003" TYPE="STUDY">Zhang 2003</LINK>), while one trial reported a family history of wheezing (<LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>). Definitions for atopy and methods of assessment were rarely provided, and when reported were heterogeneous. No trials excluded participants with a history of atopy.</P>
<P>Children with chronic cardiac, pulmonary or neurological conditions or immunodeficiency were frequently excluded. All or some premature infants were explicitly excluded in seven trials (<LINK REF="STD-Cade-2000" TYPE="STUDY">Cade 2000</LINK>; <LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-De-Boeck-1997" TYPE="STUDY">De Boeck 1997</LINK>; <LINK REF="STD-Goebel-2000" TYPE="STUDY">Goebel 2000</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>; <LINK REF="STD-Schuh-2002" TYPE="STUDY">Schuh 2002</LINK>; <LINK REF="STD-Teeratakulpisarn-2007" TYPE="STUDY">Teeratakulpisarn 2007</LINK>). Other criteria for exclusion were length of illness and glucocorticoid-related parameters (previous use, history of adverse events, specific contraindications to their use).</P>
<P>Subgroup analyses within studies were reported in five trials (<LINK REF="STD-Bentur-2005" TYPE="STUDY">Bentur 2005</LINK>; <LINK REF="STD-Cade-2000" TYPE="STUDY">Cade 2000</LINK>; <LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>; <LINK REF="STD-Teeratakulpisarn-2007" TYPE="STUDY">Teeratakulpisarn 2007</LINK>), two of which being pre-specified (<LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>). Subgroups were based on age, RSV status, family or personal history of atopy and eczema, duration and severity of illness, and exposure to smoke and/or dampness.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>There was heterogeneity regarding the choice of glucocorticoid, its dosage, route of administration and duration of treatment. Dexamethasone was the most frequently tested drug (11 trials). Nine trials used systemic dexamethasone, either oral (<LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-Klassen-1997" TYPE="STUDY">Klassen 1997</LINK>; <LINK REF="STD-Mesquita-2009" TYPE="STUDY">Mesquita 2009</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>; <LINK REF="STD-Schuh-2002" TYPE="STUDY">Schuh 2002</LINK>), intramuscular (<LINK REF="STD-Kuyucu-2004" TYPE="STUDY">Kuyucu 2004</LINK>; <LINK REF="STD-Roosevelt-1996" TYPE="STUDY">Roosevelt 1996</LINK>; <LINK REF="STD-Teeratakulpisarn-2007" TYPE="STUDY">Teeratakulpisarn 2007</LINK>) or intravenous (<LINK REF="STD-De-Boeck-1997" TYPE="STUDY">De Boeck 1997</LINK>). Single-day doses were administered for one to five days. Initial dosing was higher (0.5 to 1 mg/kg), with later doses ranging from 0.15 to 0.6 mg/kg. The highest overall dose was seen in <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK> and <LINK REF="STD-Schuh-2002" TYPE="STUDY">Schuh 2002</LINK> (1 mg/kg followed by 0.6 mg/kg for five days), and the lowest in <LINK REF="STD-Mesquita-2009" TYPE="STUDY">Mesquita 2009</LINK> (single-dose 0.5 mg/kg). Two trials used inhaled dexamethasone (0.2 mg to 0.25 mg every four to six hours), at least for one day, or until discharge for inpatients (<LINK REF="STD-Bentur-2005" TYPE="STUDY">Bentur 2005</LINK>; <LINK REF="STD-Gomez-2007" TYPE="STUDY">Gomez 2007</LINK>). Systemic prednisone or prednisolone were tested in four trials, three oral (<LINK REF="STD-Berger-1998" TYPE="STUDY">Berger 1998</LINK>; <LINK REF="STD-Goebel-2000" TYPE="STUDY">Goebel 2000</LINK>; <LINK REF="STD-Zhang-2003" TYPE="STUDY">Zhang 2003</LINK>) and one intravenous (<LINK REF="STD-Barlas-1998" TYPE="STUDY">Barlas 1998</LINK>). Duration varied between one and five days (1 to 2 mg/kg/day, once or twice daily). Three trials used inhaled budesonide (0.5 mg to 1 mg, once or twice daily) for one to six weeks (<LINK REF="STD-Barlas-1998" TYPE="STUDY">Barlas 1998</LINK>; <LINK REF="STD-Cade-2000" TYPE="STUDY">Cade 2000</LINK>; <LINK REF="STD-Richter-1998" TYPE="STUDY">Richter 1998</LINK>).</P>
<P>Details on placebos were reported in nine trials. Inhaled placebos included mist (<LINK REF="STD-Barlas-1998" TYPE="STUDY">Barlas 1998</LINK>) and 0.9% saline (<LINK REF="STD-Bentur-2005" TYPE="STUDY">Bentur 2005</LINK>; <LINK REF="STD-Richter-1998" TYPE="STUDY">Richter 1998</LINK>). Protocolised standard of care was used as a control arm in <LINK REF="STD-Zhang-2003" TYPE="STUDY">Zhang 2003</LINK>.</P>
<P>Eleven trials used protocolised bronchodilators in both glucocorticoid and placebo arms. The choice of bronchodilator, its dose and frequency varied substantially. Seven trials used salbutamol (<LINK REF="STD-Barlas-1998" TYPE="STUDY">Barlas 1998</LINK>; <LINK REF="STD-Berger-1998" TYPE="STUDY">Berger 1998</LINK>; <LINK REF="STD-Goebel-2000" TYPE="STUDY">Goebel 2000</LINK>; <LINK REF="STD-Gomez-2007" TYPE="STUDY">Gomez 2007</LINK>; <LINK REF="STD-Klassen-1997" TYPE="STUDY">Klassen 1997</LINK>; <LINK REF="STD-Kuyucu-2004" TYPE="STUDY">Kuyucu 2004</LINK>; <LINK REF="STD-Schuh-2002" TYPE="STUDY">Schuh 2002</LINK>), four used epinephrine (<LINK REF="STD-Bentur-2005" TYPE="STUDY">Bentur 2005</LINK>; <LINK REF="STD-Kuyucu-2004" TYPE="STUDY">Kuyucu 2004</LINK>; <LINK REF="STD-Mesquita-2009" TYPE="STUDY">Mesquita 2009</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>) and one used salbutamol and ipratropium bromide (<LINK REF="STD-De-Boeck-1997" TYPE="STUDY">De Boeck 1997</LINK>). Nebulised salbutamol was administered during emergency department stay (first two to four hours), or each four to six hours at home or during hospitalisation (1.5 mg to 2.5 mg, or 0.15 mg/kg). Oral administration was also allowed in <LINK REF="STD-Goebel-2000" TYPE="STUDY">Goebel 2000</LINK>. Nebulised epinephrine was administered every six hours to inpatients, or once or twice in the emergency department for outpatients (1 mg to 3 mg). All other trials used bronchodilators at the discretion of the attending physician, often with guidance on the choice of drug and dosage. Additional use of glucocorticoids was often restricted. Supportive measures, i.e. oxygen and intravenous or nasogastric fluids, were usually reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>Pre-defined primary outcomes were specified in 12 trials (<LINK REF="STD-Cade-2000" TYPE="STUDY">Cade 2000</LINK>; <LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-Goebel-2000" TYPE="STUDY">Goebel 2000</LINK>; <LINK REF="STD-Klassen-1997" TYPE="STUDY">Klassen 1997</LINK>; <LINK REF="STD-Kuyucu-2004" TYPE="STUDY">Kuyucu 2004</LINK>; <LINK REF="STD-Mesquita-2009" TYPE="STUDY">Mesquita 2009</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>; <LINK REF="STD-Richter-1998" TYPE="STUDY">Richter 1998</LINK>; <LINK REF="STD-Roosevelt-1996" TYPE="STUDY">Roosevelt 1996</LINK>; <LINK REF="STD-Schuh-2002" TYPE="STUDY">Schuh 2002</LINK>; <LINK REF="STD-Teeratakulpisarn-2007" TYPE="STUDY">Teeratakulpisarn 2007</LINK>; <LINK REF="STD-Zhang-2003" TYPE="STUDY">Zhang 2003</LINK>), three of which reported more than one primary outcome (<LINK REF="STD-Kuyucu-2004" TYPE="STUDY">Kuyucu 2004</LINK>; <LINK REF="STD-Richter-1998" TYPE="STUDY">Richter 1998</LINK>; <LINK REF="STD-Teeratakulpisarn-2007" TYPE="STUDY">Teeratakulpisarn 2007</LINK>). Only the two largest trials used admission as a primary outcome (<LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>). Other primary outcomes included clinical scales (<LINK REF="STD-Goebel-2000" TYPE="STUDY">Goebel 2000</LINK>; <LINK REF="STD-Klassen-1997" TYPE="STUDY">Klassen 1997</LINK>; <LINK REF="STD-Kuyucu-2004" TYPE="STUDY">Kuyucu 2004</LINK>; <LINK REF="STD-Mesquita-2009" TYPE="STUDY">Mesquita 2009</LINK>; <LINK REF="STD-Richter-1998" TYPE="STUDY">Richter 1998</LINK>; <LINK REF="STD-Schuh-2002" TYPE="STUDY">Schuh 2002</LINK>), clinical severity parameters or duration of disease (<LINK REF="STD-Kuyucu-2004" TYPE="STUDY">Kuyucu 2004</LINK>; <LINK REF="STD-Roosevelt-1996" TYPE="STUDY">Roosevelt 1996</LINK>; <LINK REF="STD-Teeratakulpisarn-2007" TYPE="STUDY">Teeratakulpisarn 2007</LINK>) and symptoms (<LINK REF="STD-Cade-2000" TYPE="STUDY">Cade 2000</LINK>; <LINK REF="STD-Zhang-2003" TYPE="STUDY">Zhang 2003</LINK>). Timings of primary outcome assessment were reported in 11 trials, six of which used multiple time points. Sample size calculations were either not reported or based on secondary outcomes in <LINK REF="STD-Goebel-2000" TYPE="STUDY">Goebel 2000</LINK>, <LINK REF="STD-Kuyucu-2004" TYPE="STUDY">Kuyucu 2004</LINK> and <LINK REF="STD-Richter-1998" TYPE="STUDY">Richter 1998</LINK>.</P>
<P>Reported outcomes included healthcare use domains and clinical severity parameters (all trials), pulmonary function (<LINK REF="STD-De-Boeck-1997" TYPE="STUDY">De Boeck 1997</LINK>), patient/parent-reported symptoms and status (seven trials: <LINK REF="STD-Berger-1998" TYPE="STUDY">Berger 1998</LINK>; <LINK REF="STD-Cade-2000" TYPE="STUDY">Cade 2000</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>; <LINK REF="STD-Roosevelt-1996" TYPE="STUDY">Roosevelt 1996</LINK>; <LINK REF="STD-Schuh-2002" TYPE="STUDY">Schuh 2002</LINK>; <LINK REF="STD-Teeratakulpisarn-2007" TYPE="STUDY">Teeratakulpisarn 2007</LINK>; <LINK REF="STD-Zhang-2003" TYPE="STUDY">Zhang 2003</LINK>) and other outcomes, including adverse events (10 trials: <LINK REF="STD-Bentur-2005" TYPE="STUDY">Bentur 2005</LINK>; <LINK REF="STD-Cade-2000" TYPE="STUDY">Cade 2000</LINK>; <LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-Klassen-1997" TYPE="STUDY">Klassen 1997</LINK>; <LINK REF="STD-Kuyucu-2004" TYPE="STUDY">Kuyucu 2004</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>; <LINK REF="STD-Richter-1998" TYPE="STUDY">Richter 1998</LINK>; <LINK REF="STD-Roosevelt-1996" TYPE="STUDY">Roosevelt 1996</LINK>; <LINK REF="STD-Teeratakulpisarn-2007" TYPE="STUDY">Teeratakulpisarn 2007</LINK>; <LINK REF="STD-Zhang-2003" TYPE="STUDY">Zhang 2003</LINK>). Not all outcome and time point results were reported.</P>
<P>Admission rates were assessed in all eight outpatient trials, both by day 1 (all trials) and day 7 (three trials; <LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>; <LINK REF="STD-Schuh-2002" TYPE="STUDY">Schuh 2002</LINK>). <LINK REF="STD-Kuyucu-2004" TYPE="STUDY">Kuyucu 2004 </LINK>and <LINK REF="STD-Goebel-2000" TYPE="STUDY">Goebel 2000</LINK> reported admissions by days 5 and 6, respectively, and were pooled with day 7 results. LOS was reported in eight of nine inpatient trials (except <LINK REF="STD-Roosevelt-1996" TYPE="STUDY">Roosevelt 1996</LINK>) and three outpatient trials (<LINK REF="STD-Berger-1998" TYPE="STUDY">Berger 1998</LINK>; <LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-Goebel-2000" TYPE="STUDY">Goebel 2000</LINK>). Criteria for admission or discharge were rarely reported. Considerable variability was found in control group admission rates (from 0% to 44% by day 1, and 0% to 49% by day 7) and mean LOS (0.8 to 6.6 days) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Hospital re-admissions for inpatients and return healthcare visits up to one month were mentioned in six trials, with variable assessment methods (<LINK REF="STD-Berger-1998" TYPE="STUDY">Berger 1998</LINK>; <LINK REF="STD-Klassen-1997" TYPE="STUDY">Klassen 1997</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>; <LINK REF="STD-Roosevelt-1996" TYPE="STUDY">Roosevelt 1996</LINK>; <LINK REF="STD-Schuh-2002" TYPE="STUDY">Schuh 2002</LINK>; <LINK REF="STD-Teeratakulpisarn-2007" TYPE="STUDY">Teeratakulpisarn 2007</LINK>).</P>
<P>Clinical severity scales were assessed in all except one trial (<LINK REF="STD-Zhang-2003" TYPE="STUDY">Zhang 2003</LINK>), often using more than one scale (<LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>; <LINK REF="STD-Richter-1998" TYPE="STUDY">Richter 1998</LINK>; <LINK REF="STD-Schuh-2002" TYPE="STUDY">Schuh 2002</LINK>). Measurement instruments were developed specifically for nine trials (<LINK REF="STD-Barlas-1998" TYPE="STUDY">Barlas 1998</LINK>; <LINK REF="STD-Bentur-2005" TYPE="STUDY">Bentur 2005</LINK>; <LINK REF="STD-Berger-1998" TYPE="STUDY">Berger 1998</LINK>; <LINK REF="STD-Cade-2000" TYPE="STUDY">Cade 2000</LINK>; <LINK REF="STD-De-Boeck-1997" TYPE="STUDY">De Boeck 1997</LINK>; <LINK REF="STD-Goebel-2000" TYPE="STUDY">Goebel 2000</LINK>; <LINK REF="STD-Richter-1998" TYPE="STUDY">Richter 1998</LINK>; <LINK REF="STD-Roosevelt-1996" TYPE="STUDY">Roosevelt 1996</LINK>; <LINK REF="STD-Teeratakulpisarn-2007" TYPE="STUDY">Teeratakulpisarn 2007</LINK>), mostly based on previous scales by <LINK REF="REF-Schuh-1990" TYPE="REFERENCE">Schuh 1990</LINK>, <LINK REF="REF-Tal-1983" TYPE="REFERENCE">Tal 1983</LINK> and <LINK REF="REF-Westley-1978" TYPE="REFERENCE">Westley 1978</LINK>. The RDAI was used in eight trials (<LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-Gomez-2007" TYPE="STUDY">Gomez 2007</LINK>; <LINK REF="STD-Klassen-1997" TYPE="STUDY">Klassen 1997</LINK>; <LINK REF="STD-Kuyucu-2004" TYPE="STUDY">Kuyucu 2004</LINK>; <LINK REF="STD-Mesquita-2009" TYPE="STUDY">Mesquita 2009</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>; <LINK REF="STD-Richter-1998" TYPE="STUDY">Richter 1998</LINK>; <LINK REF="STD-Schuh-2002" TYPE="STUDY">Schuh 2002</LINK>). <LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK> and <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK> also used the Respiratory Assessment Change Score (RACS), based on RDAI and respiratory rate (both originally reported by <LINK REF="REF-Lowell-1987" TYPE="REFERENCE">Lowell 1987</LINK>). All scales included items on wheezing and accessory muscle use; other respiratory items (for example, timing or location of wheezing) or disease domains (for example, general status, nutrition) were less frequently used. Oxygen saturation, respiratory and heart rates were reportedly measured in most trials. Heterogeneity in timings of repeated measurements was found; the two most frequently time points assessed were 60 minutes and three to six hours.</P>
<P>Measurement of patient/parent-reported symptoms was inconsistent. Five trials reported symptoms data (<LINK REF="STD-Cade-2000" TYPE="STUDY">Cade 2000</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>; <LINK REF="STD-Richter-1998" TYPE="STUDY">Richter 1998</LINK>; <LINK REF="STD-Roosevelt-1996" TYPE="STUDY">Roosevelt 1996</LINK>; <LINK REF="STD-Teeratakulpisarn-2007" TYPE="STUDY">Teeratakulpisarn 2007</LINK>). There were differences in the specific symptoms addressed (for example, respiratory, feeding), the measurement instrument used (i.e. questionnaires, diaries) and the time points of assessment. No trial reported the use of generic or disease-specific quality of life instruments.</P>
<P>Other reported outcomes included temperature measurements (<LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>; <LINK REF="STD-Roosevelt-1996" TYPE="STUDY">Roosevelt 1996</LINK>), time to resolution or length of illness (<LINK REF="STD-Roosevelt-1996" TYPE="STUDY">Roosevelt 1996</LINK>; <LINK REF="STD-Zhang-2003" TYPE="STUDY">Zhang 2003</LINK>), and duration of oxygen therapy or fluids (<LINK REF="STD-Bentur-2005" TYPE="STUDY">Bentur 2005</LINK>; <LINK REF="STD-Richter-1998" TYPE="STUDY">Richter 1998</LINK>; <LINK REF="STD-Roosevelt-1996" TYPE="STUDY">Roosevelt 1996</LINK>; <LINK REF="STD-Teeratakulpisarn-2007" TYPE="STUDY">Teeratakulpisarn 2007</LINK>; <LINK REF="STD-Zhang-2003" TYPE="STUDY">Zhang 2003</LINK>). Data on the use of bronchodilator co-interventions were often reported as an outcome.</P>
<P>Adverse events were mentioned in six trials (<LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-Goebel-2000" TYPE="STUDY">Goebel 2000</LINK>; <LINK REF="STD-Klassen-1997" TYPE="STUDY">Klassen 1997</LINK>; <LINK REF="STD-Kuyucu-2004" TYPE="STUDY">Kuyucu 2004</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>; <LINK REF="STD-Teeratakulpisarn-2007" TYPE="STUDY">Teeratakulpisarn 2007</LINK>). Five of these studies assessed specific gastrointestinal, endocrine or infectious complications. There was heterogeneity and incomplete reporting regarding which adverse events were pre-specified, their definitions and measurement methods. All adverse effects were short-term and no study assessed long-term harms.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-01-07 12:27:32 +1000" MODIFIED_BY="[Empty name]">
<P>Eighty-four out of 361 excluded papers involved glucocorticoids. Motives for exclusion from this subset mostly included inappropriate population (for example, trials including participants with a history of previous wheezing, or &gt; 24 months old), type of publication and non-RCT study design (<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-05-06 03:25:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>We assessed overall risk of bias as 'low' in three trials, as 'high' in seven and 'unclear' in seven. The glucocorticoid and epinephrine versus placebo comparison included one low risk of bias trial. All other comparisons included mostly high risk of bias trials (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<P>We found adequate sequence generation and allocation concealment in 10 and 11 trials, respectively (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). We considered blinding adequate in 10 out of 17 trials for the review primary outcomes and clinical severity parameters. Incomplete reporting explained most 'unclear' assessments. Incomplete outcome data were adequately addressed in 12 out of 17 studies for the review primary outcomes, and 11 out of 17 for clinical severity outcomes; it was unclear or inadequate when there was imbalanced attrition between groups, mostly in longer follow-up assessments.</P>
<P>We considered nine out of 17 studies free from risk of selective outcome reporting. Assessment of this item was challenging given the large number of outcomes reported, the diversity of measurement time points, and the fact that trial protocols were not available. Using trial registry searches, we identified three trial registers and used that data to complete assessments (<LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK>; <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>; <LINK REF="STD-Teeratakulpisarn-2007" TYPE="STUDY">Teeratakulpisarn 2007</LINK>).</P>
<P>Regarding publication bias and small study effects, there was no asymmetry in funnel plots for the primary outcomes in the glucocorticoids versus placebo comparison by visual inspection or statistical testing (Egger test for admissions and length of stay, P = 0.98 and P = 0.77, respectively) (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
<P>Other types of bias assessed as 'unclear' included baseline imbalances, or active arm contamination with other related co-interventions (<LINK REF="STD-Kuyucu-2004" TYPE="STUDY">Kuyucu 2004</LINK> and <LINK REF="STD-Schuh-2002" TYPE="STUDY">Schuh 2002</LINK>, respectively).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-05-03 00:50:40 +1000" MODIFIED_BY="[Empty name]">
<P>Results are summarised by comparison, setting and type of outcome. GRADE assessments for the two main comparisons - glucocorticoid versus placebo and glucocorticoid and bronchodilator versus placebo are shown in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> and <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>. All meta-analyses used random-effects models; fixed-effect models did not modify the direction and magnitude of results unless mentioned.</P>
<SUBSECTION>
<HEADING LEVEL="3">Glucocorticoid versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Outpatients</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes</HEADING>
<P>All eight outpatient studies reported admissions by day 1, and five also reported admissions by day 7. Complete outcome data were available for 1762 participants by day 1 (out of 1824 randomised) and 1530 participants by day 7 (out of 1612 randomised).</P>
<P>The pooled risk ratios (RRs) for admissions by days 1 and 7 were 0.92 (95% confidence interval (CI) 0.78 to 1.08) and 0.86 (95% CI 0.7 to 1.06), respectively, with no significant differences between groups (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). Heterogeneity was low for day 1 results and moderate for day 7 (I<SUP>2 </SUP>statistic = 0% and 31%, respectively). There was no relevant change in the magnitude or direction of results when using pooled data from both <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK> arms. Sensitivity analyses for both trials with low overall risk of bias showed comparable results (<LINK REF="CMP-001.22" TYPE="ANALYSIS">Analysis 1.22</LINK>). Overall strength of evidence for these findings was high for day 1 results and moderate for day 7, the latter due to some imprecision in the effect estimate (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>; <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>Subgroup analysis of studies using protocolised bronchodilator found lower pooled RRs for admissions by both days 1 and 7, but the CIs between subgroups overlapped (<LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>; <LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>). For admissions by day 7, the estimate for RR was 0.68 (95% CI 0.44 to 1.05) for protocolised bronchodilator trials (four trials, 581 participants), and 0.95 (95% CI 0.82 to 1.11) for other trials (two trials, 949 participants). Heterogeneity was low in both subgroups.</P>
<P>The two largest outpatient studies only included participants under 12 months of age, while six smaller studies also included older patients (<LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>; <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>). For admissions by day 7, estimates were 0.92 (95% CI 0.80 to 1.06) and 0.67 (95% CI 0.25 to 1.83), for &lt; 12 months (two trials, 1346 participants) and trials including older participants (three trials, 184 participants), respectively. Trials including older participants had a lower effect estimate, but a large CI overlapped with the other subgroup and there was substantial heterogeneity (I<SUP>2 </SUP>statistic = 60%).</P>
<P>No subgroup analysis according to respiratory syncytial virus (RSV) or atopic status was performed, since no outpatient trial restricted inclusion based on these parameters. <LINK REF="STD-Corneli-2007" TYPE="STUDY">Corneli 2007</LINK> and <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK> reported pre-specified subgroup analyses based on atopic status, with no statistically significant differences. <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK> also reported no differences according to RSV status, duration of illness and severity. We chose not to perform analyses based on glucocorticoid type or dose due to heterogeneity in glucocorticoid schemes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<P>Clinical score data were available for time points/intervals between 60 minutes and 3 to 10 days (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>; <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>). Different sets of studies with different scales contributed to each time point, with most data at 60 minutes (four trials, 1006 participants); no trial assessed the period between 24 to 72 hours. There were no significant differences between groups at any time point. Strength of evidence for these findings was high at 60 minutes, with precise and consistent results (standardised mean difference (SMD) -0.04; 95% CI -0.16 to 0.09; I<SUP>2 </SUP>statistic = 0%). Evidence was weaker for later results due to imprecision and substantial heterogeneity.</P>
<P>Six trials reported outcome data on oxygen saturation between 60 minutes and 24 to 72 hours (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). Data were most frequently reported at 60 minutes (three trials, 936 participants). At three to six hours, results favoured placebo (mean difference (MD) -0.43; 95% CI -0.84 to -0.02; units: %), while for all other time points there were no significant differences between groups.</P>
<P>Respiratory and heart rate data were both reported in six outpatient trials, between 60 minutes and 3 to 10 days (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>). The most frequently assessed time point for both outcomes was 60 minutes; no trial assessed the period between 24 to 72 hours. There were no significant differences between groups for any of these outcomes.</P>
<P>Regarding other health services outcomes, pooled data from three trials (255 participants) reporting length of stay (LOS) of admitted patients did not show significant differences between groups (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). Return to healthcare visits for bronchiolitis symptoms were only assessed in two trials (863 participants), both showing considerable event rate for a three to four-week follow-up period (26% to 53% in all groups; <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). Pooled results did not show significant differences between groups (RR 1.04; 95% CI 0.80 to 1.35) (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
<P>
<LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK> reported data on parent-reported symptoms regarding time to return to normal feeding, sleeping, breathing and no coughing (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>). There were no statistically significant differences between glucocorticoid and placebo groups. No outpatient trials assessed or reported pulmonary function or quality of life outcomes.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Inpatients</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes</HEADING>
<P>Eight inpatient trials reported data on LOS (633 participants), with no significant mean difference between glucocorticoid and placebo groups (MD -0.18 days; 95% CI -0.39 to 0.04; I<SUP>2 </SUP>statistic = 16%) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>). On a sensitivity analysis using fixed-effect models and including all studies, the mean difference reached statistical significance favouring glucocorticoids, with a similar magnitude (MD -0.14 days; 95% CI -0.25 to -0.03). We graded the strength of evidence as high given its precision, consistency and 'Risk of bias' assessments for all included trials (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>; <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>Subgroup analyses showed a statistically significant reduction in LOS in trials with protocolised bronchodilator (-0.12 days; 95% CI -0.23 to -0.00; four trials, 206 participants), although CIs overlapped between subgroups (<LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>). Heterogeneity was low in the protocolised group results (I<SUP>2 </SUP>statistic = 0%) and moderate in the other subgroup (I<SUP>2 </SUP>statistic = 38%).</P>
<P>In subgroup analyses according to age and RSV status, CIs overlapped between subgroups for both parameters (<LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK> and <LINK REF="CMP-001.21" TYPE="ANALYSIS">Analysis 1.21</LINK>). Heterogeneity was low in both &lt; 12 months and RSV-only trial results, and moderate in the other subgroups.</P>
<P>We did not perform subgroup analyses based on atopic status and glucocorticoid type and dose for the reasons mentioned previously.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<P>Clinical score data were only available for intervals between three to six hours and 24 to 72 hours (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>; <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>). Glucocorticoids were favoured at earlier time points (three to six hours, one trial, 174 participants: SMD -1.03 (95% CI -1.87 to -0.19); and 6 to 12 hours, three trials, 269 participants: SMD -0.62 (95% CI -1.00 to -0.23). There were no statistically significant differences at later time points. We assessed the overall strength of evidence for these findings as low or moderate, due to imprecision and low or unknown consistency, often with considerable heterogeneity.</P>
<P>Only two trials reported outcomes of oxygen saturation and respiratory rate at time points between 6 to 12 hours and 24 to 72 hours, one of which also reported heart rate at 12 to 24 hours (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>; <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>). There were no significant differences between groups for any outcome or time point.</P>
<P>Both hospital re-admissions and return healthcare visits were reported by three inpatient studies, with distinct durations of follow-up; no significant differences were found between groups (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>; <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>; <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</P>
<P>Three inpatient trials reported data on parent-reported symptoms (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>). Different sets of symptoms were measured at distinct time points, and methods of measurement and analysis varied. In <LINK REF="STD-Teeratakulpisarn-2007" TYPE="STUDY">Teeratakulpisarn 2007</LINK> time to being symptom free was significantly shorter in the glucocorticoid group, while <LINK REF="STD-Cade-2000" TYPE="STUDY">Cade 2000</LINK> used a different analysis and did not shown any statistically significant differences. There were no differences regarding respiratory symptoms and feeding in both <LINK REF="STD-Cade-2000" TYPE="STUDY">Cade 2000</LINK> and <LINK REF="STD-Roosevelt-1996" TYPE="STUDY">Roosevelt 1996</LINK>. No inpatient trials assessed or reported quality of life outcomes.</P>
<P>
<LINK REF="STD-De-Boeck-1997" TYPE="STUDY">De Boeck 1997</LINK> reported results from pulmonary function tests on day three. No differences were found in minute ventilation, dynamic lung compliance, and inspiratory and expiratory pulmonary resistance, both before and after nebulised bronchodilator.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">All patients</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>Six trials reported adverse events. Five assessed specific glucocorticoid-related harms including the two largest studies (<LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>). We considered all harms data together regardless of patient setting in order to adequately assess the safety profile of glucocorticoids. Data were available from 600 to 1579 participants for each safety outcome. We did not pool results given the heterogeneity in definitions, methods and timings of assessment. Individual trial analysis did not show significant differences between glucocorticoids and placebo regarding the occurrence of vomiting, gastrointestinal bleeding, hypertension, pneumonia or varicella.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Glucocorticoid and bronchodilator (epinephrine or salbutamol) versus placebo</HEADING>
<P>Both outpatient trials assessing either of these comparisons used different severity thresholds for patient inclusion: Respiratory Distress Assessment Instrument (RDAI) score above four in <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK> (moderate disease), and scores between 4 and 10 using a trial-specific clinical scale in <LINK REF="STD-Barlas-1998" TYPE="STUDY">Barlas 1998</LINK> (mild to moderate disease).</P>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes</HEADING>
<P>The factorial trial <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK> included a comparison of oral dexamethasone and nebulised epinephrine against double placebo (399 analysed participants). This was the largest trial included in the review, with low overall risk of bias. The RRs for admissions by days 1 and 7 were 0.65 (95% CI 0.40 to 1.05) and 0.65 (95% CI 0.44 to 0.95), respectively (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). There was a statistically significant reduction in admissions by day 7, with a relative risk reduction estimate of 35%. Absolute risk reduction was 9% (95% CI 1 to 17), and the number needed to treat to benefit (NNTB) to reduce one admission by day 7 was 11 (95% CI 7 to 76); these results were obtained through unadjusted analysis. However, the factorial trial design requires special methodological considerations, since this was not the study's main comparison, and there was an unanticipated additive/synergistic effect between epinephrine and dexamethasone. Reported analyses adjusted for multiple comparisons were above the threshold for statistical significance (RR 0.65; 95% CI 0.41 to 1.03). We graded the overall strength of evidence as low for these results given their imprecision and the fact that they were obtained from a single trial (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
<P>
<LINK REF="STD-Barlas-1998" TYPE="STUDY">Barlas 1998</LINK>, a small high risk of bias trial, compared intravenous prednisolone and nebulised salbutamol versus placebo. Admissions by day 1 (30 participants) showed no statistically significant differences between groups (RR 0.67; 95% CI 0.13 to 3.44) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<P>Clinical score results at 60 minutes favoured glucocorticoid and epinephrine (SMD -0.34; 95% CI -0.54 to -0.14) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>), while having an increased heart rate (MD 8.44; 95% CI 4.85 to 12.03) (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>). No differences were found between groups regarding oxygen saturation and respiratory rate (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). There were also no differences regarding return healthcare visits for bronchiolitis symptoms (RR 1.11; 95% CI 0.89 to 1.38) (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>; <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>). Symptom results showed reduced time to normal feeding and quiet breathing in the glucocorticoid and epinephrine group (mean symptom duration ratios: 0.63; 95% CI 0.5 to 0.8 and 0.83; 95% CI 0.69 to 1.00) (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>). No differences were found in time to normal sleeping and time to no coughing.</P>
<P>Results for clinical scores, oxygen saturation and heart rate at 60 minutes, 120 minutes and three to six hours did not show any differences between groups in the single trial comparing glucocorticoid and salbutamol versus placebo (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>; <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>; <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>). No further secondary outcomes were assessed in this comparison.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other comparisons</HEADING>
<P>These included glucocorticoid versus bronchodilator (epinephrine or salbutamol), glucocorticoid and bronchodilator (epinephrine or salbutamol) versus different bronchodilator (epinephrine or salbutamol), and direct comparisons between different types of glucocorticoid (prednisolone versus budesonide). All trials were performed in the outpatient setting, and all except one were small-sized and had a high risk of bias.</P>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes</HEADING>
<P>The glucocorticoid versus epinephrine comparison included data from two trials (444 participants) for admissions by day 1, and one trial by day 7 (399 participants). Risk of bias was low for one trial and high for the other. There were no significant differences between groups at both time points (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). Only one small high risk of bias trial included data on day 1 admissions for both glucocorticoid versus salbutamol (45 participants) and glucocorticoid and salbutamol versus epinephrine comparisons (30 participants), with no differences between arms (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>; <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>). There were no admissions in another trial including the latter comparison, as well as glucocorticoid and epinephrine versus salbutamol (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>; <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>).</P>
<P>
<LINK REF="STD-Barlas-1998" TYPE="STUDY">Barlas 1998</LINK> multi-arm trial also performed an unblinded comparison between systemic prednisolone and inhaled budesonide, with no statistically significant differences in admissions by day 1 (<LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<P>When compared to glucocorticoid at 60 minutes, epinephrine use was associated with lower clinical scores (SMD 0.31; 95% CI 0.12 to 0.50) and higher oxygen saturation (MD -0.99; 95% CI -1.46 to -0.52; units: %) (two trials, 442 participants), while heart rate was lower with glucocorticoids (MD -7.56 bpm; 95% CI -11.34 to -3.79) and there were no differences in respiratory rate (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>; <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>; <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>). There were no differences in the single trial assessing clinical scores and heart rate at later time points.</P>
<P>Salbutamol was also favoured when compared to glucocorticoids, in clinical scores at 60 minutes and three to six hours (SMD 0.65; 95% CI 0.01 to 1.28; and SMD 0.70; 95% CI 0.06 to 1.34, respectively), but not at 120 minutes (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>). Heart rate at 120 minutes was lower in glucocorticoid group (MD -7.53 bpm; 95% CI -14.28 to -0.78) and there were no differences in oxygen saturation at any time point (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>; <LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>).</P>
<P>At 3 to 10 days, clinical scores and respiratory rate results favoured glucocorticoids and epinephrine as compared to salbutamol (SMD -1.22; 95% CI -1.98 to -0.46, and MD -13.70; 95% CI -20.56 to -6.84, respectively) (<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>; <LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>; <LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>). There were no other differences at earlier time points and regarding heart rate.</P>
<P>Oxygen saturation at 60 and 120 minutes was higher in the epinephrine group when compared to glucocorticoid and salbutamol (MD -1.54; 95% CI -2.85 to -0.23, and MD -1.27; 95% CI -2.41 to -0.13, respectively) (<LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>; <LINK REF="CMP-007.03" TYPE="ANALYSIS">Analysis 7.3</LINK>; <LINK REF="CMP-007.04" TYPE="ANALYSIS">Analysis 7.4</LINK>; <LINK REF="CMP-007.05" TYPE="ANALYSIS">Analysis 7.5</LINK>). No other statistically significant differences were found in clinical scores, oxygen saturation or respiratory or heart rate at other time points.</P>
<P>When comparing systemic prednisolone and inhaled budesonide, oxygen saturation results favoured budesonide at 60 minutes and 120 minutes (MD -1.46; 95% CI -2.74 to -0.18, and MD -1.73; 95% CI -3.06 to -0.40, respectively), and heart rate was lower with prednisolone at three to six hours (<LINK REF="CMP-008.03" TYPE="ANALYSIS">Analysis 8.3</LINK>; <LINK REF="CMP-008.04" TYPE="ANALYSIS">Analysis 8.4</LINK>). No differences were found in all other outcomes and time points (<LINK REF="CMP-008.02" TYPE="ANALYSIS">Analysis 8.2</LINK>).</P>
<P>
<LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK> reported safety assessments comparing glucocorticoid and epinephrine (<LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>). Pallor was observed in 7.5% of participants in the glucocorticoid group, compared to 11.1% in the epinephrine group. There were no significant differences in vomiting, bleeding, hypertension, varicella and tremor between glucocorticoids and epinephrine. No other trial from any of the other comparisons reported adverse events data.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-03-19 23:43:13 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Results from this review do not suggest a clinically relevant stand-alone effect of systemic or inhaled glucocorticoids in either outpatient and inpatient settings (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). There were no statistically significant differences in outpatient admissions by days 1 and 7, and pooled RR estimates favouring glucocorticoids versus placebo were below commonly used thresholds for clinical relevance. Strength of evidence was moderate to high, indicating our confidence in these effect estimates. There were also no differences in secondary outcomes, particularly clinical scores, oxygen saturation and respiratory symptoms. For inpatient trials, precise and consistent results did not show differences in length of stay (LOS) as compared to placebo. The lower boundary of the pooled estimate confidence interval (CI) was about nine hours, likely excluding a clinically relevant benefit from glucocorticoids. While clinical score results were superior during the first day of treatment, no consistent differences were found at later time points or in any other secondary outcomes. Subgroup analyses according to age and respiratory syncytial virus (RSV) status did not suggest effect modification by these factors; heterogeneity did not allow adequate analysis of atopy and glucocorticoid type or dose.  </P>
<P>Exploratory evidence suggests that combined glucocorticoids and bronchodilators may have clinically relevant benefits. A large factorial trial with low risk of bias found that high-dose dexamethasone with epinephrine reduced admissions by day 7 when compared to placebo, in outpatients with moderately severe bronchiolitis (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). The unadjusted risk ratio (RR) reduction estimate was 36%, and 11 children with bronchiolitis had to be treated to reduce one admission given the study's baseline risk. Clinical scores and symptoms results supported this benefit. However, these are the findings of a single study and should be interpreted cautiously. There were methodological issues with trial design and results may have arisen by chance. Further evidence regarding combined therapy is scarce and imprecise, and exploratory subgroup analysis was not conclusive as to an additive/synergistic effect of glucocorticoids combined with bronchodilators.</P>
<P>No relevant differences were found in short-term general and intervention-specific adverse effects for these comparisons. However, balancing harms and benefits of glucocorticoids alone or combined was hampered by the lack of long-term safety data.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-03-19 23:42:19 +1000" MODIFIED_BY="Liz Dooley">
<P>The heterogeneous definition of bronchiolitis is often a motive for controversy when interpreting trial and review results (<LINK REF="REF-DiTraglia-2004" TYPE="REFERENCE">DiTraglia 2004</LINK>; <LINK REF="REF-Weinberger-2003" TYPE="REFERENCE">Weinberger 2003</LINK>; <LINK REF="STD-Weinberger-2007" TYPE="STUDY">Weinberger 2007</LINK>). There is no international consensus due to variation in semantics and clinical findings (for example, in the UK, 'crackles' are often key to diagnosis, as opposed to 'wheeze' in North America) (<LINK REF="REF-Everard-2009" TYPE="REFERENCE">Everard 2009</LINK>). A first episode of wheezing may be a manifestation of wheezing phenotypes with heterogeneous biological, genetic, viral or environmental determinants, and distinct prognosis (<LINK REF="REF-Brand-2008" TYPE="REFERENCE">Brand 2008</LINK>; <LINK REF="REF-Martinez-2005" TYPE="REFERENCE">Martinez 2005</LINK>; <LINK REF="REF-Sly-2008" TYPE="REFERENCE">Sly 2008</LINK>). However, research is still ongoing to identify simple, valid and universal discriminative and prognostic tools to prospectively distinguish between them (<LINK REF="REF-Brand-2008" TYPE="REFERENCE">Brand 2008</LINK>; <LINK REF="REF-Schultz-2010" TYPE="REFERENCE">Schultz 2010</LINK>; <LINK REF="REF-Sly-2008" TYPE="REFERENCE">Sly 2008</LINK>). We used a pragmatic definition and focused on first time wheezing so results could be directly pertinent to infants with 'typical' viral bronchiolitis, as opposed to those with acute recurrent wheezing or asthma.</P>
<P>We found variability in both bronchiolitis severity and glucocorticoids schemes, but this did not affect the consistency of results. Baseline disease in outpatients was often moderate, but the use of different clinical criteria and scales limited the comparison between trials, particularly for inpatients. The wide range of control group admission rates and LOS can be partially explained by differing disease severity, but it also reflects variation in bronchiolitis management, for example, different admission/discharge criteria and standards of care (<LINK REF="REF-Babl-2008" TYPE="REFERENCE">Babl 2008</LINK>; <LINK REF="REF-Barben-2003" TYPE="REFERENCE">Barben 2003</LINK>; <LINK REF="REF-Brand-2000" TYPE="REFERENCE">Brand 2000</LINK>; <LINK REF="REF-Christakis-2005" TYPE="REFERENCE">Christakis 2005</LINK>; <LINK REF="REF-Gonzalez-2010" TYPE="REFERENCE">Gonzalez 2010</LINK>; <LINK REF="REF-Mallory-2003" TYPE="REFERENCE">Mallory 2003</LINK>; <LINK REF="REF-Mansbach-2005" TYPE="REFERENCE">Mansbach 2005</LINK>). Our findings were consistent in trials performed worldwide, and results likely apply to settings with different resources and management strategies.</P>
<P>Most studies were restricted to healthy infants, often excluding children with chronic conditions and prematurity. Lack of evidence for this subset of patients is problematic, since many are particularly at risk of adverse outcomes (<LINK REF="REF-Damore-2008" TYPE="REFERENCE">Damore 2008</LINK>; <LINK REF="REF-Figueras_x002d_Aloy-2008" TYPE="REFERENCE">Figueras-Aloy 2008</LINK>; <LINK REF="REF-Meissner-2003" TYPE="REFERENCE">Meissner 2003</LINK>). Epidemiological studies have highlighted the short- and long-term impact of RSV disease in prematurity (<LINK REF="REF-Figueras_x002d_Aloy-2008" TYPE="REFERENCE">Figueras-Aloy 2008</LINK>; <LINK REF="REF-Simoes-2008" TYPE="REFERENCE">Simoes 2008</LINK>), and underlying changes in respiratory pathophysiology may limit the external validity of our results in these populations.  </P>
<P>Results from subgroup analyses did not identify any subset of participants with a different response to glucocorticoids. Older aged and atopic children are at higher risk of recurrent wheezing and asthma (<LINK REF="REF-Castro_x002d_Rodriguez-2000" TYPE="REFERENCE">Castro-Rodriguez 2000</LINK>), and both factors have been traditionally proposed as markers of underlying glucocorticoid-responsive phenotypes in first-time wheezers (<LINK REF="STD-Weinberger-2007" TYPE="STUDY">Weinberger 2007</LINK>). We found no conclusive evidence of such effect with age. We were unable to study atopy, but subgroup analyses from individual studies did not identify any significant differences. Specific viruses may also modulate response, as RSV and rhinovirus infections are associated with recurrent wheezing and the latter is a stronger predictor and possibly more responsive to glucocorticoids (<LINK REF="REF-Jackson-2008" TYPE="REFERENCE">Jackson 2008</LINK>; <LINK REF="REF-Korppi-2007" TYPE="REFERENCE">Korppi 2007</LINK>; <LINK REF="REF-Lehtinen-2007" TYPE="REFERENCE">Lehtinen 2007</LINK>; <LINK REF="REF-Stein-1999" TYPE="REFERENCE">Stein 1999</LINK>). We found no differences according to RSV status, while other viral aetiologies were not reported. Accumulating evidence shows that glucocorticoids have reduced effectiveness in later acute recurrent wheezing (<LINK REF="REF-Bush-2009" TYPE="REFERENCE">Bush 2009</LINK>; <LINK REF="STD-Panickar-2009" TYPE="STUDY">Panickar 2009</LINK>). Further, each of these factors per se has limited prognostic accuracy in defining stable wheezing phenotypes (<LINK REF="REF-Brand-2008" TYPE="REFERENCE">Brand 2008</LINK>; <LINK REF="REF-Simpson-2010" TYPE="REFERENCE">Simpson 2010</LINK>; <LINK REF="REF-Sly-2008" TYPE="REFERENCE">Sly 2008</LINK>). Our results suggest that 'typical' viral bronchiolitis is not glucocorticoid-responsive. Potential methodological limitations include the use of aggregated data and heterogeneity in definition, ascertainment and reporting of subgroups.</P>
<P>We found promising exploratory results from one large trial using combined dexamethasone with epinephrine for moderately ill outpatients. Although reliance on findings from single precise well-conducted trials is often reasonable (<LINK REF="REF-Glasziou-2010" TYPE="REFERENCE">Glasziou 2010</LINK>), in this factorial trial the additive interaction between treatments was unanticipated, and this limits the interpretation of its results (<LINK REF="REF-McAlister-2003" TYPE="REFERENCE">McAlister 2003</LINK>; <LINK REF="REF-Montgomery-2003" TYPE="REFERENCE">Montgomery 2003</LINK>). Our observational and exploratory subgroup analyses of protocolised bronchodilators may indirectly support an additive effect, but findings were not conclusive for both outpatients and inpatients. The latter are often a separate population due to differences in severity, duration of symptoms or non-response to initial bronchodilators, and these may affect response to therapy. Replication is therefore needed to improve our confidence in the direction, precision and magnitude of the effect estimates for outpatients, and its applicability for inpatients.  </P>
<P>Whether results from combination therapy can be generalisable to different glucocorticoid or bronchodilator schemes is also not known. Systemic dexamethasone is favoured in another common viral respiratory disorder, croup (<LINK REF="REF-Bjornson-2008" TYPE="REFERENCE">Bjornson 2008</LINK>). Its long half-life and stronger potency may account for its effect, but underlying pathological changes are distinct between these two conditions. <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK> used multiple high doses of dexamethasone. A previous dose-finding trial suggested similar results with a single high dose, although there was no placebo comparator (<LINK REF="STD-Schuh-2008" TYPE="STUDY">Schuh 2008</LINK>); the lowest efficacious dose remains unknown. The choice of bronchodilator is also undecided. A recently updated Cochrane review on epinephrine in bronchiolitis showed a reduction in first day outpatient admissions, as well as other short-term severity outcomes (<LINK REF="REF-Hartling-2011a" TYPE="REFERENCE">Hartling 2011a</LINK>). This might explain part of the early benefit of combined therapy seen in <LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>. Further research is needed to clarify whether combined epinephrine is superior to combined salbutamol, particularly given the variation in bronchodilator choice in practice. </P>
<P>Evidence from basic and translational research may support a synergistic effect of combined therapy, but it is not clear how this reconciles with the limited effect of glucocorticoids alone. Inflammation pathways and mediators involved in bronchiolitis seem to be distinct from those in glucocorticoid-sensitive asthma. Innate immunity, specific cytokine dysregulation patterns and neutrophilic inflammation may be relevant for some early wheezing phenotypes (<LINK REF="REF-Bont-2009" TYPE="REFERENCE">Bont 2009</LINK>; <LINK REF="REF-Halfhide-2008" TYPE="REFERENCE">Halfhide 2008</LINK>), which could explain the limited biological action of glucocorticoids alone (<LINK REF="STD-Buckingham-2002" TYPE="STUDY">Buckingham 2002</LINK>; <LINK REF="REF-Lehtinen-2007" TYPE="REFERENCE">Lehtinen 2007</LINK>; <LINK REF="REF-Somers-2009" TYPE="REFERENCE">Somers 2009</LINK>). Paradoxically, clinical and biological synergism between glucocorticoids and bronchodilators has been a major topic in asthma treatment (<LINK REF="REF-Giembycz-2008" TYPE="REFERENCE">Giembycz 2008</LINK>). Two-way molecular interactions exist, including beta<SUB>2</SUB>-agonist-stimulated glucocorticoid-mediated gene transcription (<LINK REF="REF-Kaur-2008" TYPE="REFERENCE">Kaur 2008</LINK>) and glucocorticoid-induced increase in the transcription of the ß<SUB>2</SUB>-receptor gene (<LINK REF="REF-Black-2009" TYPE="REFERENCE">Black 2009</LINK>). Epinephrine&#8217;s &#945;-adrenergic vasoconstricting and oedema-reducing activity could confer an additional short-term benefit. Whether these mechanisms are involved in acute bronchiolitis therapy, and the role of specific types and doses of bronchodilators and glucocorticoids, is unknown.  </P>
<P>These positive results should be balanced against incomplete data on harms. Safety concerns are expected when considering the widespread use of epinephrine and glucocorticoids in young children with viral wheezing, particularly with repeated high glucocorticoid doses (<LINK REF="REF-Bush-2009" TYPE="REFERENCE">Bush 2009</LINK>; <LINK REF="REF-Frey-2009" TYPE="REFERENCE">Frey 2009</LINK>). Current data from RCTs and observational studies in croup suggest a favourable short-term safety profile from both dexamethasone and epinephrine (<LINK REF="REF-Bjornson-2008" TYPE="REFERENCE">Bjornson 2008;</LINK> <LINK REF="REF-Zhang-2005" TYPE="REFERENCE">Zhang 2005</LINK>). Considering all trials, our results do not suggest any serious or frequent short-term expected or unexpected harms from glucocorticoids in the absence of co-morbidities. However, the power to detect important differences was limited due to the infrequent occurrence of events, and adverse event detection was heterogeneous. Glucocorticoids also raises long-term safety issues. Their use in prematurity for neonatal respiratory distress has been associated with effects on adrenal function, cardiovascular responses, somatic and lung growth, and neurodevelopment (<LINK REF="REF-Doyle-2010" TYPE="REFERENCE">Doyle 2010</LINK>; <LINK REF="REF-Karemaker-2008a" TYPE="REFERENCE">Karemaker 2008a</LINK>; <LINK REF="REF-Karemaker-2008b" TYPE="REFERENCE">Karemaker 2008b</LINK>; <LINK REF="REF-Onland-2008" TYPE="REFERENCE">Onland 2008</LINK>; <LINK REF="REF-Wilson_x002d_Costello-2009" TYPE="REFERENCE">Wilson-Costello 2009</LINK>). Evidence is scarce, however, regarding effects of short-term use in otherwise healthy term infants, and none of these were studied in included trials. Further pharmacoepidemiologic data are needed to permit adequate short and long-term risk-benefit assessments.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-03-19 23:43:13 +1000" MODIFIED_BY="[Empty name]">
<P>Two key factors affected the strength of evidence: potential risk of bias in the included studies, and sparsity of data for many of the outcomes and comparisons, with imprecise estimates and unknown consistency across studies. </P>
<P>A majority of trials had unclear risk of bias, usually due to incomplete or inadequate reporting, and many comparisons only included small trials at high risk of bias. Inadequate allocation concealment and blinding were likely to be relevant given the nature of interventions (for example, inhaled versus systemic administration) and outcome assessments (for example, physician-based admissions or discharge decisions). Incomplete outcome data were often found, with losses of follow-up in outpatient trials. However, for the main glucocorticoid versus placebo comparison, sensitivity analyses restricted to low risk of bias trials did not change the direction or magnitude of results for primary outcomes, highlighting their consistency.</P>
<P>Sparsity of data was a result of a large number of comparisons as well as variability in the choice of outcomes and timing of assessments. Within trials, this also led to frequent uncertainties regarding selective outcome reporting. The message around consistency and relevance of outcomes is not new to this field (<LINK REF="REF-Flores-1997" TYPE="REFERENCE">Flores 1997</LINK>; <LINK REF="REF-King-2004" TYPE="REFERENCE">King 2004</LINK>; <LINK REF="REF-Klassen-1996" TYPE="REFERENCE">Klassen 1996</LINK>). The absence of standardised, validated and patient-important outcome measures has been a serious threat to bronchiolitis trial validity. Our primary outcomes focused on hospital use, which has clear implications for patients, families and health services. However, there is no guidance supporting the choice of methodologically sound and patient-important outcomes. Lack of reporting of admission and discharge criteria is also problematic given the wide variation in bronchiolitis management. Additionally, the choice of clinical scales was inconsistent. The Respiratory Distress Assessment Instrument (RDAI) was used in a considerable number of trials, but its clinimetric properties - for example, responsiveness and interpretability - are not well known, which limits the interpretation of findings. This was compounded by the absence of quality of life measures. Further work is needed to define a core set of clinically important efficacy and safety outcome measures and timing of assessments, for trials and systematic reviews in this field.<BR/>
</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Some limitations have already been described, others should also be highlighted. We did not obtain further data from authors of included studies, which might have clarified 'Risk of bias' assessments and further added to reported trial characteristics and secondary outcome results. There is scarce guidance on how to investigate synergism/antagonism at a systematic review level, therefore our approach should be considered exploratory, including our use of factorial trial results. However, we performed sensitivity analyses of different analysis methods and these did not show a change in the direction of results. Our choice of outcome time intervals may have been a source of heterogeneity, although it was limited by the sparsity of reported data. Limitations of subgroup analyses are well known and have been addressed. Grading of evidence was limited by the lack of guidance regarding clinically relevant differences in studied outcomes.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-01-22 08:12:25 +1000" MODIFIED_BY="[Empty name]">
<P>Two previous non-Cochrane systematic reviews assessed the use of glucocorticoids in acute bronchiolitis, one of which also performed meta-analysis (<LINK REF="STD-Garrison-2000" TYPE="STUDY">Garrison 2000</LINK>; <LINK REF="REF-King-2004" TYPE="REFERENCE">King 2004</LINK>). None of the reviews included data from the two recent large glucocorticoid outpatient trials. There was some discordance in inclusion criteria regarding population and interventions: <LINK REF="STD-Garrison-2000" TYPE="STUDY">Garrison 2000</LINK> only included inpatient trials and was restricted to systemic glucocorticoids, and no review excluded previous wheezing. The choice of primary outcomes and their definitions, timings and analysis also differed. While <LINK REF="STD-Garrison-2000" TYPE="STUDY">Garrison 2000</LINK> highlighted a statistically significant reduction in LOS for inpatients, this analysis used a modified outcome definition. When comparing similar analyses for this outcome, quantitative results were comparable between all reviews, including ours, and suggest no relevant benefit from glucocorticoids in inpatients. Outpatient descriptive and quantitative results from <LINK REF="REF-King-2004" TYPE="REFERENCE">King 2004</LINK> also found no difference in admissions. No previous review assessed the hypothesis of synergism between glucocorticoids and bronchodilators at an analysis level, while subgroup analyses assessing possible dose-response and effect modifiers like age and RSV status showed similar negative results. </P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-03-19 23:46:00 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-03-19 23:46:00 +1000" MODIFIED_BY="[Empty name]">
<P>Current evidence does not support a clinically relevant effect of systemic or inhaled glucocorticoids on admissions or length of stay, when used alone in infants with bronchiolitis defined as a first episode of wheezing. Clinical score results suggest some short-term benefit of glucocorticoids for inpatients, but no differences were found in other secondary outcomes. Absence of treatment effects was consistent throughout studies despite substantial heterogeneity regarding included populations, interventions and outcomes, and this finding is likely to be applicable in diverse settings.</P>
<P>Exploratory results from a single large trial suggest combined high-dose systemic dexamethasone and epinephrine may reduce outpatient admissions in moderately severe bronchiolitis. These findings should be interpreted cautiously and may have arisen by chance. While no relevant differences were reported in short-term adverse events, long-term safety data were missing. Efficacy, harms and applicability of combined therapy need to be clarified further. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>A large randomised controlled trial is needed to replicate and complement findings from combination therapy with glucocorticoid and bronchodilator for outpatients. Additional aims could include assessing the minimum efficacious glucocorticoid dose and the most adequate co-intervention. This strategy could also be tested in inpatient settings. Choice of comparators should take into account the wide variability in bronchodilator use, so that valid results may be more easily implemented. Further investigation of parent-reported outcomes is needed, as well as data to assess the long-term safety of this association. Future trials should use standardised sets of outcome measures in this field.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>The review authors gratefully acknowledge the following individuals for their contributions to this project: Ms. Andrea Milne (data extraction), Ms. Annabritt Chisholm (article retrieval), Ms. Heather McPhee (data extraction), Ms. Nicola Hooton (protocol development, study selection), Dr. Özge Tunçalp (Turkish translation) and Dr. João Franco (Spanish translation and data extraction). We acknowledge Robert Platt and Juan Manuel Lozano, who authored the previous version of this review but were not involved in the current update. We would also like to thank the Acute Respiratory Infections Group editorial team, particularly Liz Dooley (Managing Editor) and Sarah Thorning (Trials Search Co-ordinator) for their invaluable review and editing of the manuscript. We also wish to thank the following people for commenting on the 2010 updated review: Janet Wale, Hesham El-Sayed, Teresa Neeman and Peter Morris.</P>
<P>RF was supported by the Programme for Advanced Medical Education, sponsored by Fundação Calouste Gulbenkian, Fundação Champalimaud, Ministério da Saúde e Fundação para a Ciência e Tecnologia, Portugal.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-01-07 12:53:47 +1000" MODIFIED_BY="[Empty name]">
<P>AP, HP, DJ and TK are authors of one or more RCTs included in this review. Assessment of eligibility, risk of bias and strength of evidence of these trials were performed by other review authors. The review authors declare no other real or perceived conflicts of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Ricardo M Fernandes (RF): guarantor of the review, involved at all phases. Contribution: review update design and implementation, search strategy, screening of search results, data extraction and entry, 'Risk of bias' and GRADE assessments, data analysis, interpretation of results, manuscript writing and revision.<BR/>Liza M Bialy (LB): screening results, data extraction and entry, 'Risk of bias' assessments, manuscript writing and revision.<BR/>Ben Vandermeer (BV): review update design, data entry and analysis, manuscript revision.<BR/>Lisa Tjosvold (LT): search strategy and implementation, article retrieval, manuscript revision.<BR/>Amy C Plint (AC): review update, screening of search results, interpretation of results, manuscript revision.<BR/>Hema Patel (HP): protocol design, screening of search results, interpretation of results, manuscript revision. Responsible for the previous Cochrane review (2004).<BR/>David W Johnson (DJ): review update, screening of search results, interpretation of results, manuscript revision.<BR/>Terry P Klassen (TK): review update, interpretation of results, manuscript revision.<BR/>Lisa Hartling (LH): review update and implementation, screening of search results, 'Risk of bias' and GRADE assessments, interpretation of results, manuscript writing and revision.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>The protocol limited the selection to studies testing systemic glucocorticoids only; we later decided to also include studies with inhaled glucocorticoids. Not all planned subgroup analyses were performed due to the reduced number of trials and data heterogeneity.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2010-05-22 00:18:15 +1000" MODIFIED_BY="Ricardo M Fernandes"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<STUDY DATA_SOURCE="PUB" ID="STD-Barlas-1998" MODIFIED="2010-06-25 23:47:57 +1000" MODIFIED_BY="[Empty name]" NAME="Barlas 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-06-25 23:47:57 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - CCTR&lt;br&gt;AN - CN-00200476&lt;/p&gt;" NOTES_MODIFIED="2010-06-25 23:47:57 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Barlas C, Kiper N, Göçmen A, Ozçelik U, Dilber E, Anadol D, et al</AU>
<TI>Racemic adrenaline and other treatment regimens in mild and moderate bronchiolitis</TI>
<SO>Cocuk Sagligi Ve Hastaliklari Dergisi</SO>
<YR>1998</YR>
<VL>41</VL>
<NO>2</NO>
<PG>155-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_" MODIFIED="2010-06-25 23:48:38 +1000" MODIFIED_BY="[Empty name]" NAME="Barlas 1998 (G+S vs S)" YEAR="1998">
<REFERENCE MODIFIED="2010-06-25 23:48:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barlas C, Kiper N, Göçmen A, Ozçelik U, Dilber E, Anadol D, et al</AU>
<TI>Racemic adrenaline and other treatment regimens in mild and moderate bronchiolitis</TI>
<SO>Cocuk Sagligi Ve Hastaliklari Dergisi</SO>
<YR>1998</YR>
<VL>41</VL>
<NO>2</NO>
<PG>155-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_" MODIFIED="2010-06-25 23:48:17 +1000" MODIFIED_BY="[Empty name]" NAME="Barlas 1998 (G vs P)" YEAR="1998">
<REFERENCE MODIFIED="2010-06-25 23:48:17 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barlas C, Kiper N, Göçmen A, Ozçelik U, Dilber E, Anadol D, et al</AU>
<TI>Racemic adrenaline and other treatment regimens in mild and moderate bronchiolitis</TI>
<SO>Cocuk Sagligi Ve Hastaliklari Dergisi</SO>
<YR>1998</YR>
<VL>41</VL>
<NO>2</NO>
<PG>155-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bentur-2005" MODIFIED="2010-05-24 13:31:40 +1000" MODIFIED_BY="[Empty name]" NAME="Bentur 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-05-24 13:31:40 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 16188807&lt;br&gt;NLM full journal name - Acta paediatrica (Oslo, Norway : 1992)&lt;br&gt;JC - bgc, 9205968&lt;br&gt;SB - IM&lt;br&gt;CP - Norway&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Comparative Study&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-05-24 13:31:40 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bentur L, Shoseyov D, Feigenbaum D, Gorichovsky Y, Bibi H</AU>
<TI>Dexamethasone inhalations in RSV bronchiolitis: a double-blind, placebo-controlled study</TI>
<SO>Acta Paediatrica</SO>
<YR>2005</YR>
<VL>94</VL>
<NO>7</NO>
<PG>866-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berger-1998" MODIFIED="2010-06-27 02:28:12 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Berger 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-06-27 02:28:12 +1000" MODIFIED_BY="Ricardo M Fernandes" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Berger I, Argaman Z, Schwartz SB, Segal E, Kiderman A, Branski D, et al</AU>
<TI>Efficacy of glucocorticoids in acute bronchiolitis: short-term and long-term follow-up</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1998</YR>
<VL>26</VL>
<PG>162-6</PG>
<PB>Wiley-Liss, Inc</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cade-2000" MODIFIED="2010-06-27 02:28:27 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Cade 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-06-27 02:28:27 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 10648365&lt;br&gt;NLM full journal name - Archives of disease in childhood&lt;br&gt;JC - 6xg, 0372434&lt;br&gt;SB - AIM, IM&lt;br&gt;CP - ENGLAND&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Multicenter Study&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 02:28:27 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cade A, Brownlee KG, Conway SP, Haigh D, Short A, Brown J, et al</AU>
<TI>Randomised placebo controlled trial of nebulised glucocorticoids in acute respiratory syncytial viral bronchiolitis</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2000</YR>
<VL>82</VL>
<NO>2</NO>
<PG>126-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corneli-2007" MODIFIED="2013-03-19 21:52:44 +1000" MODIFIED_BY="[Empty name]" NAME="Corneli 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-03-19 21:52:44 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 17652648&lt;br&gt;CM - Comment in: Evid Based Med. 2008 Aug;13(4):114; PMID: 18667673, Comment in: J Fam Pract. 2007 Nov;56(11):890; PMID: 17982758, Comment in: J Pediatr. 2008 Jan;152(1):143-4; PMID: 18154921, Comment in: N Engl J Med. 2007 Jul 26;357(4):402-4; PMID: 17652656, Comment in: N Engl J Med. 2007 Oct 18;357(16):1659-60; author reply 1660; PMID: 17948342, Comment in: N Engl J Med. 2007 Oct 18;357(16):1659; author reply 1660; PMID: 17942880, Comment in: N Engl J Med. 2007 Oct 18;357(16):1659; author reply 1660; PMID: 17948343&lt;br&gt;NLM full journal name - The New England journal of medicine&lt;br&gt;JC - 0255562, now&lt;br&gt;SB - AIM, IM&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Multicenter Study&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, U.S. Gov't, P.H.S&lt;br&gt;SI - ClinicalTrials.gov&lt;br&gt;SA - ClinicalTrials.gov/NCT00119002&lt;br&gt;NO - R40MC042980100 (United States PHS HHS)&lt;br&gt;NO - U03MC00001 (United States PHS HHS)&lt;br&gt;NO - U03MC00006 (United States PHS HHS)&lt;br&gt;NO - U03MC00007 (United States PHS HHS)&lt;br&gt;NO - U03MC00008 (United States PHS HHS)&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2013-03-19 21:52:44 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corneli HM, Zorc JJ, Mahajan P, Shaw KN, Holubkov R, Reeves SD, et al</AU>
<TI>A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2007</YR>
<VL>357</VL>
<NO>4</NO>
<PG>331-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Boeck-1997" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="De Boeck 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Boeck K, Van der Aa N, Van Lierde S, Corbeel L, Eeckels R</AU>
<TI>Respiratory syncytial virus bronchiolitis: a double-blind dexamethasone efficacy study</TI>
<SO>Journal of Pediatrics</SO>
<YR>1997</YR>
<VL>131</VL>
<NO>6</NO>
<PG>919-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goebel-2000" NAME="Goebel 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goebel J, Estrada B, Quinonez J, Nagi N, Sanford D, Boerth RC</AU>
<TI>Prednisolone plus albuterol versus albuterol alone in mild to moderate bronchiolitis</TI>
<SO>Clinical Pediatrics</SO>
<YR>2000</YR>
<VL>39</VL>
<NO>4</NO>
<PG>213-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gomez-2007" MODIFIED="2010-05-24 13:33:32 +1000" MODIFIED_BY="[Empty name]" NAME="Gomez 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-05-24 13:33:32 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 17722445&lt;br&gt;OT - Uso de dexametasona y salbutamol nebulizados en bronquiolitis aguda. Estudio clinico comparativo&lt;br&gt;NLM full journal name - Gaceta medica de Mexico&lt;br&gt;JC - fff, 0010333&lt;br&gt;SB - IM&lt;br&gt;CP - Mexico&lt;br&gt;PT - Comparative Study&lt;br&gt;PT - English Abstract&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;LG - Spanish&lt;/p&gt;" NOTES_MODIFIED="2010-05-24 13:33:32 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gomez-y-Lopez RE, Hernandez-Sierra JF, Torres-Ruvalcaba BA, Martinez-Puente E, del Carmen Martinez-Garcia M</AU>
<TI>Comparative clinical study of dexamethasone vs. nebulized salbutamol in acute bronchiolitis</TI>
<SO>Gaceta Medica de Mexico</SO>
<YR>2007</YR>
<VL>143</VL>
<NO>3</NO>
<PG>189-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klassen-1997" MODIFIED="2010-05-24 13:33:42 +1000" MODIFIED_BY="[Empty name]" NAME="Klassen 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-05-24 13:33:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klassen TP, Sutcliffe T, Watters LK, Wells GA, Allen UD, Li MM</AU>
<TI>Dexamethasone in salbutamol-treated inpatients with acute bronchiolitis: a randomized, controlled trial</TI>
<SO>Journal of Pediatrics</SO>
<YR>1997</YR>
<VL>130</VL>
<NO>2</NO>
<PG>191-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuyucu-2004" MODIFIED="2010-06-25 23:50:20 +1000" MODIFIED_BY="[Empty name]" NAME="Kuyucu 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-06-25 23:50:20 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 15491380&lt;br&gt;NLM full journal name - Pediatrics international : official journal of the Japan Pediatric Society&lt;br&gt;JC - db6, 100886002&lt;br&gt;SB - IM&lt;br&gt;CP - Australia&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-06-25 23:50:20 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuyucu S, Unal S, Kuyucu N, Yilgor E</AU>
<TI>Additive effects of dexamethasone in nebulized salbutamol or L-epinephrine treated infants with acute bronchiolitis</TI>
<SO>Pediatrics International</SO>
<YR>2004</YR>
<VL>46</VL>
<NO>5</NO>
<PG>539-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" MODIFIED="2010-06-25 23:50:25 +1000" MODIFIED_BY="[Empty name]" NAME="Kuyucu 2004 (G+E vs P+E)" YEAR="">
<REFERENCE MODIFIED="2010-06-25 23:50:25 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuyucu S, Unal S, Kuyucu N, Yilgor E</AU>
<TI>Additive effects of dexamethasone in nebulized salbutamol or L-epinephrine treated infants with acute bronchiolitis</TI>
<SO>Pediatrics International</SO>
<YR>2004</YR>
<VL>46</VL>
<NO>5</NO>
<PG>539-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_" MODIFIED="2010-06-25 23:50:28 +1000" MODIFIED_BY="[Empty name]" NAME="Kuyucu 2004 (G+S vs P+S)" YEAR="">
<REFERENCE MODIFIED="2010-06-25 23:50:28 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuyucu S, Unal S, Kuyucu N, Yilgor E</AU>
<TI>Additive effects of dexamethasone in nebulized salbutamol or L-epinephrine treated infants with acute bronchiolitis</TI>
<SO>Pediatrics International</SO>
<YR>2004</YR>
<VL>46</VL>
<NO>5</NO>
<PG>539-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mesquita-2009" MODIFIED="2010-05-24 13:34:44 +1000" MODIFIED_BY="[Empty name]" NAME="Mesquita 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-05-24 13:34:44 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mesquita M, Castro-Rodriguez JA, Heinichen L, Fariña E, Iramain R</AU>
<TI>Single oral dose of dexamethasone in outpatients with bronchiolitis: a placebo controlled trial</TI>
<SO>Allergologia et Immunopathologia</SO>
<YR>2009</YR>
<VL>37</VL>
<NO>2</NO>
<PG>63-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plint-2009" MODIFIED="2013-03-19 21:53:35 +1000" MODIFIED_BY="[Empty name]" NAME="Plint 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-03-19 21:53:35 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20090514&lt;br&gt;IS - 1533-4406 (Electronic)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Multicenter Study&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;RN - 0 (Bronchodilator Agents)&lt;br&gt;RN - 0 (Glucocorticoids)&lt;br&gt;RN - 50-02-2 (Dexamethasone)&lt;br&gt;RN - 51-43-4 (Epinephrine)&lt;br&gt;SB - AIM&lt;br&gt;SB - IM&lt;br&gt;360/20/2079 [pii];10.1056/NEJMoa0900544 [doi]&lt;/p&gt;" NOTES_MODIFIED="2013-03-19 21:53:35 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plint AC, Johnson DW, Patel H, Wiebe N, Correll R, Brant R, et al</AU>
<TI>Epinephrine and dexamethasone in children with bronchiolitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>1533-4406</NO>
<PG>2079-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]" NAME="Plint 2009 (G+E vs P+E)" YEAR="">
<REFERENCE MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plint AC, Johnson DW, Patel H, Wiebe N, Correll R, Brant R, et al</AU>
<TI>Epinephrine and dexamethasone in children with bronchiolitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>1533-4406</NO>
<PG>2079-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]" NAME="Plint 2009 (G+P vs P+P)" YEAR="">
<REFERENCE MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plint AC, Johnson DW, Patel H, Wiebe N, Correll R, Brant R, et al</AU>
<TI>Epinephrine and dexamethasone in children with bronchiolitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>1533-4406</NO>
<PG>2079-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richter-1998" MODIFIED="2010-05-24 13:35:41 +1000" MODIFIED_BY="[Empty name]" NAME="Richter 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-05-24 13:35:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richter H, Seddon P</AU>
<TI>Early nebulized budesonide in the treatment of bronchiolitis and the prevention of postbronchiolitic wheezing</TI>
<SO>Journal of Pediatrics</SO>
<YR>1998</YR>
<VL>132</VL>
<NO>5</NO>
<PG>849-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roosevelt-1996" MODIFIED="2010-03-23 04:18:43 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Roosevelt 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roosevelt G, Sheehan K, Grupp-Phelan J, Tanz RR, Listernic R</AU>
<TI>Dexamethasone in bronchiolitis: a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>348</VL>
<NO>9023</NO>
<PG>292-305</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schuh-2002" MODIFIED="2010-05-24 13:35:58 +1000" MODIFIED_BY="[Empty name]" NAME="Schuh 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-05-24 13:35:58 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schuh S, Coates AL, Binnie R, Allin T, Goia C, Corey M, et al</AU>
<TI>Efficacy of oral dexamethasone in outpatients with acute bronchiolitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>2002</YR>
<VL>140</VL>
<PG>27-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teeratakulpisarn-2007" MODIFIED="2010-05-24 13:36:33 +1000" MODIFIED_BY="[Empty name]" NAME="Teeratakulpisarn 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-05-24 13:36:33 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 17394255&lt;br&gt;CM - Comment in: Pediatr Pulmonol. 2007 Oct;42(10):984-5; author reply 986; PMID: 17588244&lt;br&gt;NLM full journal name - Pediatric pulmonology&lt;br&gt;JC - owh, 8510590&lt;br&gt;SB - IM&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-05-24 13:36:33 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teeratakulpisarn J, Limwattananon C, Tanupattarachai S, Limwattananon S, Teeratakulpisarn S, Kosalaraksa P</AU>
<TI>Efficacy of dexamethasone injection for acute bronchiolitis in hospitalized children: a randomized, double-blind, placebo-controlled trial</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2007</YR>
<VL>42</VL>
<NO>5</NO>
<PG>433-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2003" MODIFIED="2010-05-24 13:37:04 +1000" MODIFIED_BY="[Empty name]" NAME="Zhang 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-05-24 13:37:04 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 12969212&lt;br&gt;NLM full journal name - Journal of paediatrics and child health&lt;br&gt;JC - arp, 9005421&lt;br&gt;SB - IM&lt;br&gt;CP - Australia&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-05-24 13:37:04 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang L, Ferruzzi E, Bonfanti T, Auler MI, D'Avila NE, Faria CS, et al</AU>
<TI>Long and short-term effect of prednisolone in hospitalized infants with acute bronchiolitis</TI>
<SO>Journal of Paediatrics and Child Health</SO>
<YR>2003</YR>
<VL>39</VL>
<NO>7</NO>
<PG>548-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1989" MODIFIED="2010-06-30 03:57:09 +1000" MODIFIED_BY="[Empty name]" NAME="Anonymous 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-06-30 03:57:09 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 2565522&lt;br&gt;NLM full journal name - Lancet&lt;br&gt;JC - 2985213r, l0s, 0053266&lt;br&gt;SB - AIM, IM&lt;br&gt;CP - ENGLAND&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-06-30 03:57:09 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Inhaled steroids and recurrent wheeze after bronchiolitis</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>1</VL>
<NO>8645</NO>
<PG>999-1000</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bacharier-2008" MODIFIED="2010-06-27 02:32:27 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Bacharier 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-06-27 02:32:27 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 18973936&lt;br&gt;IN - Department of Pediatrics, Washington University and St Louis Children's Hospital, St Louis, MO 63110, USA. bacharier_L@kids.wustl.edu&lt;br&gt;CM - Comment in: J Allergy Clin Immunol. 2008 Dec;122(6):1136-7; PMID: 19084109&lt;br&gt;AS - J Allergy Clin Immunol. 122(6):1127-1135.e8, 2008 Dec&lt;br&gt;JC - h53, 1275002&lt;br&gt;SB - AIM, IM&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Multicenter Study&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, N.I.H., Extramural&lt;br&gt;SI - ClinicalTrials.gov&lt;br&gt;SA - ClinicalTrials.gov/NCT00000622&lt;br&gt;NO - 5U10 HL064287 (United States NHLBI NIH HHS)&lt;br&gt;NO - 5U10 HL064288 (United States NHLBI NIH HHS)&lt;br&gt;NO - 5U10 HL064295 (United States NHLBI NIH HHS)&lt;br&gt;NO - 5U10 HL064305 (United States NHLBI NIH HHS)&lt;br&gt;NO - 5U10 HL064307 (United States NHLBI NIH HHS)&lt;br&gt;NO - 5U10 HL064313 (United States NHLBI NIH HHS)&lt;br&gt;NO - M01 RR00036 (United States NCRR NIH HHS)&lt;br&gt;NO - M01 RR00051 (United States NCRR NIH HHS)&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 02:32:27 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bacharier LB, Phillips BR, Zeiger RS, Szefler SJ, Martinez FD, Lemanske RFJr, et al</AU>
<TI>Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>2008</YR>
<VL>122</VL>
<NO>6</NO>
<PG>1127-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bai-2010" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]" NAME="Bai 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bai J, Xu PR</AU>
<TI>Montelukast in the treatment of bronchiolitis, a multi-center, randomized, three-blind, placebo-controlled trial</TI>
<SO>Chinese Journal of Evidence-Based Medicine</SO>
<YR>2010</YR>
<VL>10</VL>
<PG>1011-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berger-1996" MODIFIED="2010-06-27 02:32:41 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Berger 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-06-27 02:32:41 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - CCTR&lt;br&gt;AN - CN-00382316&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 02:32:41 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berger I</AU>
<TI>A double-blind placebo-controlled study on the efficacy of corticosteroids in infants with bronchiolitis</TI>
<SO>European Respiratory Journal</SO>
<YR>1996</YR>
<VL>9</VL>
<NO>Suppl 23</NO>
<PG>246</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bibi-2004" MODIFIED="2010-06-27 02:32:50 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Bibi 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-06-27 02:32:50 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;Cited By (since 1996): 1&lt;br&gt;Export Date: 4 March 2009&lt;br&gt;Source: Scopus&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 02:32:50 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bibi H</AU>
<TI>A double blind study to determine the benefit of inhaled corticosteroids in bronchiolitis</TI>
<SO>European Respiratory Journal</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>Suppl 48</NO>
<PG>A282</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blom-2007" MODIFIED="2013-01-22 15:12:46 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Blom 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-01-22 15:12:46 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 17253528&lt;br&gt;NLM full journal name - Cochrane database of systematic reviews (Online)&lt;br&gt;JC - 100909747&lt;br&gt;SB - IM&lt;br&gt;CP - England&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Meta-Analysis&lt;br&gt;PT - Review&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2013-01-22 15:12:46 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="COCHRANE_REVIEW">
<AU>Blom D, Ermers M, Bont L, van Aalderen WM, van Woensel JB</AU>
<TI>Inhaled corticosteroids during acute bronchiolitis in the prevention of post-bronchiolitic wheezing</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-01-22 15:12:46 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-01-22 15:12:46 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004881.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bont-2006" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Bont 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 16906644&lt;br&gt;CM - Comment on: N Engl J Med. 2006 May 11;354(19):1998-2005; PMID: 16687712&lt;br&gt;NLM full journal name - The New England journal of medicine&lt;br&gt;JC - 0255562, now&lt;br&gt;SB - AIM, IM&lt;br&gt;CP - United States&lt;br&gt;PT - Comment&lt;br&gt;PT - Letter&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2013-03-19 23:09:05 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bont L, Kimpen JL, Ermers MJ</AU>
<TI>Inhaled corticosteroids and children</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>355</VL>
<NO>6</NO>
<PG>624-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buckingham-2002" MODIFIED="2010-05-24 13:39:54 +1000" MODIFIED_BY="[Empty name]" NAME="Buckingham 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-05-24 13:39:54 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buckingham SC, Jafri HS, Bush AJ, Carubelli CM, Sheeran P, Hardy RD, et al</AU>
<TI>A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2002</YR>
<VL>185</VL>
<NO>9</NO>
<PG>1222-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-B_x00fc_low-1999" MODIFIED="2010-06-11 01:07:40 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Bülow 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-05-24 13:40:04 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bülow SM, Nir M, Levin E, Friis B, Thomsen LL, Nielson JE, et al</AU>
<TI>Prednisolone treatment of respiratory syncytial virus infection: a randomized controlled trial of 147 infants</TI>
<SO>Pediatrics</SO>
<YR>1999</YR>
<VL>104</VL>
<NO>6</NO>
<PG>e77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-06-11 01:06:59 +1000" MODIFIED_BY="Ricardo M Fernandes"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Callen-Blecua-2000" MODIFIED="2010-07-13 13:56:09 +1000" MODIFIED_BY="[Empty name]" NAME="Callen Blecua 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-07-13 13:56:09 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 11203411&lt;br&gt;OT - Glucocorticoides inhalados y sibilancias posbronquiolitis&lt;br&gt;NLM full journal name - Anales espanoles de pediatria&lt;br&gt;JC - 49n, 0420463&lt;br&gt;SB - IM&lt;br&gt;CP - SPAIN&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - English Abstract&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Multicenter Study&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;LG - Spanish&lt;/p&gt;" NOTES_MODIFIED="2010-07-13 13:56:09 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Callen Blecua M, Aizpurua Galdeano P, Ozcoidi Erro I, Mancisidor Aguinagalde L, Guedea Adiego C, Busselo Ortega E, et al</AU>
<TI>Inhaled corticosteroids and wheezing post-bronchiolitis</TI>
<SO>Anales Españoles de Pediatría</SO>
<YR>2000</YR>
<VL>52</VL>
<NO>4</NO>
<PG>351-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chao-2003" MODIFIED="2010-05-24 13:43:08 +1000" MODIFIED_BY="[Empty name]" NAME="Chao 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-05-24 13:43:08 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 14983653&lt;br&gt;NLM full journal name - Acta paediatrica Taiwanica = Taiwan er ke yi xue hui za zhi&lt;br&gt;JC - dp8, 100958202&lt;br&gt;SB - IM&lt;br&gt;CP - China (Republic: 1949- )&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-05-24 13:43:08 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chao LC, Lin YZ, Wu WF, Huang FY</AU>
<TI>Efficacy of nebulized budesonide in hospitalized infants and children younger than 24 months with bronchiolitis</TI>
<SO>Acta Paediatrica Taiwan</SO>
<YR>2003</YR>
<VL>44</VL>
<NO>6</NO>
<PG>332-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chipps-2008" MODIFIED="2010-05-24 13:43:20 +1000" MODIFIED_BY="[Empty name]" NAME="Chipps 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-24 13:43:20 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - EMBASE&lt;br&gt;UI - 2009166639&lt;br&gt;CP - United States&lt;br&gt;LG - English&lt;br&gt;PT - Journal: Note&lt;br&gt;EM - 200917&lt;br&gt;DD - 20090422&lt;/p&gt;" NOTES_MODIFIED="2010-05-24 13:43:20 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chipps BE</AU>
<TI>A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis</TI>
<SO>Pediatrics</SO>
<YR>2008</YR>
<VL>122</VL>
<NO>Suppl 4</NO>
<PG>215</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Connolly-1969" MODIFIED="2010-03-23 09:30:08 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Connolly 1969" YEAR="1969">
<REFERENCE MODIFIED="2010-03-23 04:40:54 +1000" MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Connolly JH, Field CMB, Glasgow JFT, Slattery CM, MacLynn DM</AU>
<TI>A double blind trial of prednisolone in epidemic bronchiolitis due to respiratory syncytial virus</TI>
<SO>Acta Paediatrica Scandinavica</SO>
<YR>1969</YR>
<VL>58</VL>
<NO>2</NO>
<PG>116-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cornell-2007" MODIFIED="2010-03-23 09:32:56 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Cornell 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-03-23 09:32:56 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - EMBASE&lt;br&gt;UI - 2007555889&lt;br&gt;CP - United States&lt;br&gt;LG - English&lt;br&gt;PT - Journal: Review&lt;br&gt;EM - 200700&lt;br&gt;DD - 20071204&lt;/p&gt;" NOTES_MODIFIED="2010-03-23 09:32:56 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cornell HM, Zorc JJ, Majahan P, Shaw KN, Holubkov R, Reeves SD, et al</AU>
<TI>Does dexamethasone improve bronchiolitis in infants?</TI>
<SO>Journal of Family Practice</SO>
<YR>2007</YR>
<VL>56</VL>
<NO>11</NO>
<PG>890</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Csonka-2003" MODIFIED="2010-05-24 13:43:55 +1000" MODIFIED_BY="[Empty name]" NAME="Csonka 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-05-24 13:43:55 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 14657816&lt;br&gt;CM - Comment in: J Pediatr. 2003 Dec;143(6):700-2; PMID: 14657809&lt;br&gt;NLM full journal name - The Journal of pediatrics&lt;br&gt;JC - jlz, 0375410&lt;br&gt;SB - AIM, IM&lt;br&gt;CP - United States&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-05-24 13:43:55 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Csonka P, Kaila M, Laippala P, Iso-Mustajarvi M, Vesikari T, Ashorn P</AU>
<TI>Oral prednisolone in the acute management of children age 6 to 35 months with viral respiratory infection-induced lower airway disease: a randomized, placebo-controlled trial</TI>
<SO>Journal of Pediatrics</SO>
<YR>2003</YR>
<VL>143</VL>
<NO>6</NO>
<PG>725-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dabbous-1966" MODIFIED="2010-06-27 02:33:58 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Dabbous 1966" YEAR="1966">
<REFERENCE MODIFIED="2010-06-27 02:33:58 +1000" MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dabbous IA, Tkachyk JS, Stamm SJ</AU>
<TI>A double blind study on the effects of corticosteroids in the treatment of bronchiolitis</TI>
<SO>Pediatrics</SO>
<YR>1966</YR>
<VL>37</VL>
<NO>3</NO>
<PG>477-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-da-Silva-2007" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="da Silva 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - CCTR&lt;br&gt;AN - CN-00689927&lt;br&gt;OT - Efetividade e seguranca da budesonida nebulizada no controle da crise aguda de sibilancia em criancas menores de tres anos nao responsivas ao fenoterol&lt;/p&gt;" NOTES_MODIFIED="2013-03-19 23:09:05 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="BOOK">
<AU>da Silva ML</AU>
<SO>Effectiveness and Safety of Budesonide Nebulised in Control of Acute Crisis of Wheezing in Children Under Three Years not Responsive to Fenoterol [Dissertation]</SO>
<YR>2007</YR>
<PB>Universidade Estadual Paulista</PB>
<CY>São Paulo, SP</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daugbjerg-1993" MODIFIED="2010-06-27 04:39:00 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Daugbjerg 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-06-27 04:39:00 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 8338988&lt;br&gt;IN - Department of Paediatrics, State University Hospital, Copenhagen, Denmark&lt;br&gt;AS - Acta Paediatrica 82(6-7):547-51, 1993 Jun-Jul&lt;br&gt;JC - bgc, 9205968&lt;br&gt;SB - IM&lt;br&gt;CP - NORWAY&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Comparative Study&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Multicenter Study&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 04:39:00 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daugbjerg P, Brenoe E, Forchhammer H, Frederiksen B, Glazowski MJ, Ibsen KK, et al</AU>
<TI>A comparison between nebulized terbutaline, nebulized corticosteroid and systemic corticosteroid for acute wheezing in children up to 18 months of age</TI>
<SO>Acta Paediatrica</SO>
<YR>1993</YR>
<VL>82</VL>
<NO>6-7</NO>
<PG>547-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dennis-1963" MODIFIED="2010-05-24 13:45:01 +1000" MODIFIED_BY="[Empty name]" NAME="Dennis 1963" YEAR="1963">
<REFERENCE MODIFIED="2010-05-24 13:45:01 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Cited By (since 1996): 6&lt;br&gt;Export Date: 4 March 2009&lt;br&gt;Source: Scopus&lt;/p&gt;" NOTES_MODIFIED="2010-05-24 13:45:01 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dennis J</AU>
<TI>Steroids in the treatment of obstructive bronchiolitis</TI>
<SO>Southern Medical Journal</SO>
<YR>1963</YR>
<VL>56</VL>
<PG>1436</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doornebal-2009" MODIFIED="2010-06-27 02:34:59 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Doornebal 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-06-27 02:34:59 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 19374093&lt;br&gt;IN - Isala klinieken, Amalia Kinderafdeling, Zwolle. n.doornebal@isala.nl&lt;br&gt;OT - Kinderen jonger dan 1 jaar met acute dyspneu en piepen: geen orale corticoglucocorticoiden voorschrijven&lt;br&gt;AS - Ned Tijdschr Geneeskd. 153(10):440-2, 2009 Mar 7&lt;br&gt;JC - nuk, 0400770&lt;br&gt;SB - IM&lt;br&gt;CP - Netherlands&lt;br&gt;PT - Case Reports&lt;br&gt;PT - Journal Article&lt;br&gt;LG - Dutch&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 02:34:59 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doornebal N, Brand PL</AU>
<TI>Children younger than 1 year with acute dyspnea and wheezing: don't prescribe oral corticosteroids</TI>
<SO>Nederlands Tijdschrift voor Geneeskunde</SO>
<YR>2009</YR>
<VL>153</VL>
<NO>10</NO>
<PG>440-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ermers-2008" MODIFIED="2010-06-27 02:35:10 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Ermers 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-06-27 02:35:10 +1000" MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ermers M, Rovers M, Woensel J, Kimpen J, Bont L</AU>
<TI>High-dose inhaled corticosteroids prevent wheeze following respiratory syncytial virus infection: a randomized double-blind placebo-controlled trial</TI>
<SO>European Respiratory Journal</SO>
<YR>2008</YR>
<VL>32</VL>
<NO>Suppl 52</NO>
<PG>720</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ermers-2009" MODIFIED="2013-01-04 15:55:33 +1000" MODIFIED_BY="[Empty name]" NAME="Ermers 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-04 15:55:33 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ermers MJJ, Rovers MM, Van Woensel JB, Kimpen JLL, Bont LJ</AU>
<TI>The effect of high dose inhaled corticosteroids on wheeze in infants after respiratory syncytial virus infection: randomised double blind placebo controlled trial</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>338</VL>
<PG>996</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Filippskii-1983" MODIFIED="2010-06-30 03:54:04 +1000" MODIFIED_BY="[Empty name]" NAME="Filippskii 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-06-30 03:54:04 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 6657390&lt;br&gt;OT - O vozmozhnostiakh primeneniia gliukokortikoglucocorticoidnoi terapii pri ostrom bronkhiolite u detei rannego vozrasta&lt;br&gt;NLM full journal name - Pediatriia&lt;br&gt;JC - oyl, 0405563&lt;br&gt;SB - IM&lt;br&gt;CP - USSR&lt;br&gt;PT - Journal Article&lt;br&gt;LG - Russian&lt;/p&gt;" NOTES_MODIFIED="2010-06-30 03:54:04 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Filippskii GK, Tkacheva NV, Raozhina VI, Ivanov NN, Filimonova II</AU>
<TI>Possibilities of using glucocorticoid therapy for acute bronchiolitis in very young children</TI>
<SO>Pediatriia</SO>
<YR>1983</YR>
<VL>8</VL>
<PG>71-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fox-1999" MODIFIED="2010-05-24 13:45:52 +1000" MODIFIED_BY="[Empty name]" NAME="Fox 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-05-24 13:45:52 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 10086941&lt;br&gt;NLM full journal name - Archives of disease in childhood&lt;br&gt;JC - 6xg, 0372434&lt;br&gt;SB - AIM, IM&lt;br&gt;CP - ENGLAND&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-05-24 13:45:52 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fox GF, Everard ML, Marsh MJ, Milner AD</AU>
<TI>Randomised controlled trial of budesonide for the prevention of post-bronchiolitis wheezing</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1999</YR>
<VL>80</VL>
<NO>4</NO>
<PG>343-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garrison-2000" MODIFIED="2010-06-27 02:35:30 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Garrison 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-06-27 02:35:30 +1000" MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garrison MM, Christakis DA, Harvey E, Cummings P, Lavis RL</AU>
<TI>Systemic corticosteroids in infant bronchiolitis: a meta-analysis</TI>
<SO>Pediatrics</SO>
<YR>2000</YR>
<VL>105</VL>
<NO>4</NO>
<PG>e44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerasymov-2010" MODIFIED="2012-12-21 09:10:54 +1000" MODIFIED_BY="[Empty name]" NAME="Gerasymov 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-12-21 09:10:54 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gerasymov S</AU>
<TI>High-dose vs low-dose nebulized budesonide suspension in a sleeping infant with bronchiolitis [Abstract]</TI>
<SO>European Respiratory Society Annual Congress Abstract Book</SO>
<YR>2010</YR>
<PG>[E3461]</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hall-2008" MODIFIED="2010-05-24 13:46:07 +1000" MODIFIED_BY="[Empty name]" NAME="Hall 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-24 13:46:07 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - EMBASE&lt;br&gt;UI - 2007610702&lt;br&gt;IN - (Hall) University of Rochester, Rochester, NY, United States&lt;br&gt;CP - United States&lt;br&gt;LG - English&lt;br&gt;PT - Journal: Article&lt;br&gt;EM - 200801&lt;br&gt;DD - 20080101&lt;/p&gt;" NOTES_MODIFIED="2010-05-24 13:46:07 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hall CB</AU>
<TI>Dexamethasone of no benefit in moderate-to-severe bronchiolitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>2008</YR>
<VL>152</VL>
<NO>1</NO>
<PG>143-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoekstra-2004" MODIFIED="2010-06-27 02:35:43 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Hoekstra 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-06-27 02:35:43 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - EMBASE&lt;br&gt;UI - 2004283144&lt;br&gt;IN - (Hoekstra, Kapitein) Centre for Pediatric Allergology, Wilhelmina Children's Hospital, University Medical Centre, 3508 AB, Utrecht, Netherlands. (Van Der Ent, Arets) Centre for Pediatric Pulmonology, Wilhelmina Children's Hospital, University Medical Centre, 3508 AB, Utrecht, Netherlands&lt;br&gt;CP - United States&lt;br&gt;LG - English&lt;br&gt;PT - Journal: Letter&lt;br&gt;EM - 200400&lt;br&gt;DD - 20070402&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 02:35:43 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoekstra MO, Kapitein B, Van Der Ent CK, Arets HGM</AU>
<TI>Are inhaled corticosteroids safe and effective in infants with asthma-like symptoms?</TI>
<SO>Pediatrics</SO>
<YR>2004</YR>
<VL>114</VL>
<NO>1</NO>
<PG>325</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jartti-2002" MODIFIED="2010-03-23 09:32:56 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Jartti 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-03-23 09:32:56 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - EMBASE&lt;br&gt;UI - 2002339057&lt;br&gt;IN - (Jartti, Vanto, Heikkinen, Ruuskanen) Department of Pediatrics, Turku University Hospital, Turku, Finland&lt;br&gt;CP - United States&lt;br&gt;LG - English&lt;br&gt;PT - Journal: Review&lt;br&gt;EM - 200200&lt;br&gt;DD - 20070424&lt;/p&gt;" NOTES_MODIFIED="2010-03-23 09:32:56 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jartti T, Vanto T, Heikkinen T, Ruuskanen O</AU>
<TI>Systemic glucocorticoids in childhood expiratory wheezing: relation between age and viral etiology with efficacy</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>9</NO>
<PG>873-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jartti-2006" MODIFIED="2010-05-24 13:46:40 +1000" MODIFIED_BY="[Empty name]" NAME="Jartti 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-24 13:46:40 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 16732144&lt;br&gt;NLM full journal name - The Pediatric infectious disease journal&lt;br&gt;JC - oxj, 8701858&lt;br&gt;SB - IM&lt;br&gt;CP - United States&lt;br&gt;PT - Comparative Study&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-05-24 13:46:40 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jartti T, Lehtinen P, Vanto T, Hartiala J, Vuorinen T, Makela MJ, et al</AU>
<TI>Evaluation of the efficacy of prednisolone in early wheezing induced by rhinovirus or respiratory syncytial virus</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>6</NO>
<PG>482-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jartti-2007" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]" NAME="Jartti 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 17968992&lt;br&gt;IN - Department of Pediatrics, Turku University Hospital, Turku, Finland. tuomas.jartti@utu.fi&lt;br&gt;AS - Pediatr Pulmonol. 42(12):1125-33, 2007 Dec&lt;br&gt;JC - owh, 8510590&lt;br&gt;SB - IM&lt;br&gt;CP - United States&lt;br&gt;PT - Comparative Study&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2013-03-19 23:09:05 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jartti T, Lehtinen P, Vanto T, Vuorinen T, Hiekkanen H, Hartiala J, et al</AU>
<TI>Atopic characteristics of wheezing children and responses to prednisolone</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2007</YR>
<VL>42</VL>
<NO>12</NO>
<PG>1125-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jartti-2011" MODIFIED="2012-12-21 09:11:51 +1000" MODIFIED_BY="[Empty name]" NAME="Jartti 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-12-21 09:11:51 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jartti T, Soderlund-Venermo M, Allander T, Vuorinen T, Hedman K, Ruuskanen O</AU>
<TI>No efficacy of prednisolone in acute wheezing associated with human bocavirus infection</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2011</YR>
<VL>30</VL>
<PG>521-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kajosaari-2000" MODIFIED="2010-06-27 02:36:01 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Kajosaari 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-06-27 02:36:01 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 10981531&lt;br&gt;NLM full journal name - Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology&lt;br&gt;JC - bu6, 9106718&lt;br&gt;SB - IM&lt;br&gt;CP - DENMARK&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 02:36:01 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kajosaari M, Syvanen P, Forars M, Juntunen-Backman K</AU>
<TI>Inhaled corticosteroids during and after respiratory syncytial virus-bronchiolitis may decrease subsequent asthma</TI>
<SO>Pediatric Allergy and Immunology</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>3</NO>
<PG>198-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karaatmaca-2010" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]" NAME="Karaatmaca 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karaatmaca B, Aydoan M, Piraneci R, Bicnuller S</AU>
<TI>Comparison of the effectiveness of nebulized budesonide, salbutamol and adrenaline in the treatment of acute bronchiolitis: a randomized double blind placebo controlled clinical trial</TI>
<SO>Allergy: European Journal of Allergy and Clinical Immunology</SO>
<YR>2010</YR>
<VL>65</VL>
<NO>Suppl 92</NO>
<PG>716-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kelm_x002d_Kahl-2008" MODIFIED="2010-06-27 02:36:12 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Kelm-Kahl 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-06-27 02:36:12 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - EMBASE&lt;br&gt;UI - 2008103333&lt;br&gt;CP - Germany&lt;br&gt;OT - Bronchiolitis - Einmalige corticoglucocorticoidgabe hat keinen einfluss auf klinikeinweisung&lt;br&gt;LG - German&lt;br&gt;PT - Journal: Note&lt;br&gt;EM - 200812&lt;br&gt;DD - 20080318&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 02:36:12 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelm-Kahl I</AU>
<TI>A single dose of corticosteroids has no influence on the rate of hospital admission for children with bronchiolitis</TI>
<SO>Pneumologie</SO>
<YR>2008</YR>
<VL>62</VL>
<NO>2</NO>
<PG>63-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kitowicz-2007" MODIFIED="2010-07-13 13:44:32 +1000" MODIFIED_BY="[Empty name]" NAME="Kitowicz 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-07-13 13:44:32 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 17896613&lt;br&gt;NLM full journal name - The Journal of the Oklahoma State Medical Association&lt;br&gt;JC - jh3, 7503043&lt;br&gt;SB - IM&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-07-13 13:44:32 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kitowicz A, Criswell DF</AU>
<TI>Do inhaled corticosteroids improve oxygen saturation in infants with respiratory syncytial virus (RSV) bronchiolitis?</TI>
<SO>Journal of the Oklahoma State Medical Association</SO>
<YR>2007</YR>
<VL>100</VL>
<NO>7</NO>
<PG>266</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koumbourlis-2009" MODIFIED="2010-06-27 02:36:28 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Koumbourlis 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-06-27 02:36:28 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - EMBASE&lt;br&gt;UI - 2009241209&lt;br&gt;IN - (Koumbourlis) Schneider Children's Hospital, New Hyde Park, NY 11040, United States&lt;br&gt;CP - United States&lt;br&gt;LG - English&lt;br&gt;PT - Journal: Letter&lt;br&gt;EM - 200923&lt;br&gt;DD - 20090603&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 02:36:28 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koumbourlis AC</AU>
<TI>Oral corticosteroids in children with wheezing</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>16</NO>
<PG>1673</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leer-1969a" MODIFIED="2010-06-27 02:37:05 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Leer 1969a" YEAR="1969">
<REFERENCE MODIFIED="2010-06-27 02:37:05 +1000" MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leer JA, Bloomfield N, Green JL, Heimlick EM, Hyde JS, Moffett HL, et al</AU>
<TI>Corticosteroids treatment in bronchiolitis</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1969</YR>
<VL>117</VL>
<NO>5</NO>
<PG>495-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leer-1969b" MODIFIED="2010-06-27 02:37:00 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Leer 1969b" YEAR="1969">
<REFERENCE MODIFIED="2010-06-27 02:37:00 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 4888573&lt;br&gt;NLM full journal name - JAMA : the journal of the American Medical Association&lt;br&gt;JC - 7501160&lt;br&gt;SB - AIM, IM&lt;br&gt;CP - UNITED STATES&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 02:37:00 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leer JA</AU>
<TI>Corticosteroids in bronchiolitis</TI>
<SO>JAMA</SO>
<YR>1969</YR>
<VL>208</VL>
<NO>6</NO>
<PG>1016-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-1991" MODIFIED="2010-06-27 02:37:10 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Lin 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-06-27 02:37:10 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 1688065&lt;br&gt;IN - Department of Pediatrics, Taipei Municipal Chung-Hsiao Hospital, Taiwan, R.O.C&lt;br&gt;AS - Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih. 32(6):333-40, 1991 Nov-Dec&lt;br&gt;JC - 1m6, 16210470r&lt;br&gt;SB - IM&lt;br&gt;CP - TAIWAN&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Controlled Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 02:37:10 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin YZ, Hsieh KH, Chen W, Wu KW</AU>
<TI>Clinical trial of corticosteroid and beta-2 bronchodilator in acute wheezing infants</TI>
<SO>Chung-Hua Min Kuo Hsiao Erh Ko i Hsueh Hui Tsa Chih</SO>
<YR>1991</YR>
<VL>32</VL>
<NO>6</NO>
<PG>333-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lukkarinen-2011" MODIFIED="2013-01-04 15:56:25 +1000" MODIFIED_BY="[Empty name]" NAME="Lukkarinen 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-04 15:56:25 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lukkarinen M, Lukkarinen H, Vuorinen T, Tuomas J</AU>
<TI>Prednisolone treatment of the first wheezing episode associated with rhinovirus infection reduces asthma in a 5-year follow-up</TI>
<SO>Allergy: European Journal of Allergy and Clinical Immunology</SO>
<YR>2011</YR>
<VL>66</VL>
<NO>Suppl 94</NO>
<PG>157</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mallol-1987" MODIFIED="2010-06-20 17:58:12 +1000" MODIFIED_BY="[Empty name]" NAME="Mallol 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-06-20 17:58:12 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 2954024&lt;br&gt;AS - Pediatr Pulmonol. 3(2):83-5, 1987 Mar-Apr&lt;br&gt;JC - owh, 8510590&lt;br&gt;SB - IM&lt;br&gt;CP - UNITED STATES&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-06-20 17:58:12 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mallol J, Munoz R, Puppo H, Ulloa V, Toro O, Girardi G, et al</AU>
<TI>Effects of nebulized fenoterol, associated with ipratropium or glucocorticoids, on the heart rate of infants under one year of age with acute wheezing</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1987</YR>
<VL>3</VL>
<NO>2</NO>
<PG>83-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martini-2009" MODIFIED="2013-01-07 10:34:48 +1000" MODIFIED_BY="[Empty name]" NAME="Martini 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-07 10:34:48 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martini ABC</AU>
<TI>Viral respiratory tract infection: oral glucocorticoids not effective in wheezing children</TI>
<SO>Virale Atemwegsinfektioneh: orale glucocorticoide bei kindern mit giemen nicht effektiv</SO>
<YR>2009</YR>
<VL>149</VL>
<PG>40-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Merkus-2005" MODIFIED="2010-06-27 02:37:41 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Merkus 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-06-27 02:37:41 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - EMBASE&lt;br&gt;UI - 2005469966&lt;br&gt;IN - (Merkus, De Jongste) Erasmus Medical Centre, Sophia Children's Hospital, Rotterdam, Netherlands. (Teper, Kofman, Vidaurreta) Ricardo Gutierrez Children's Hospital, Buenos Aires, Argentina&lt;br&gt;CP - United States&lt;br&gt;LG - English&lt;br&gt;PT - Journal: Letter&lt;br&gt;EM - 200500&lt;br&gt;DD - 20070409&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 02:37:41 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Merkus PJFM, de Jongste JC, Teper AM, Kofman CD, Vidaurreta SM</AU>
<TI>Inhaled corticosteroids in wheezy infants</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2005</YR>
<VL>172</VL>
<NO>8</NO>
<PG>1058-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Milner-1997" MODIFIED="2010-06-27 02:37:47 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Milner 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-06-27 02:37:47 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 9246128&lt;br&gt;CM - Comment on: Thorax. 1997 Jul;52(7):634-7; PMID: 9246136&lt;br&gt;NLM full journal name - Thorax&lt;br&gt;JC - vqw, 0417353&lt;br&gt;SB - IM&lt;br&gt;CP - ENGLAND&lt;br&gt;PT - Comment&lt;br&gt;PT - Editorial&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 02:37:47 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Milner AD</AU>
<TI>The role of corticosteroids in bronchiolitis and croup</TI>
<SO>Thorax</SO>
<YR>1997</YR>
<VL>52</VL>
<NO>7</NO>
<PG>595-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Callaghan-1989" MODIFIED="2010-06-20 17:58:12 +1000" MODIFIED_BY="[Empty name]" NAME="O'Callaghan 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-06-20 17:58:12 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 2567473&lt;br&gt;NLM full journal name - Lancet&lt;br&gt;JC - 2985213r, l0s, 0053266&lt;br&gt;SB - AIM, IM&lt;br&gt;CP - ENGLAND&lt;br&gt;PT - Letter&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-06-20 17:58:12 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Callaghan C, Milner AD</AU>
<TI>Inhaled glucocorticoids and recurrent wheeze after bronchiolitis</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>333</VL>
<NO>8652</NO>
<PG>1458</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oommen-2003" MODIFIED="2010-03-23 09:32:56 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Oommen 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-03-23 09:32:56 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 14602435&lt;br&gt;IN - Leicester Children's Asthma Centre, Institute for Lung Health, University of Leicester, Leicester, UK&lt;br&gt;CM - Comment in: Lancet. 2004 Jan 24;363(9405):330; author reply 330-1; PMID: 14751716&lt;br&gt;AS - Lancet. 362(9394):1433-8, 2003 Nov 1&lt;br&gt;JC - 2985213r, l0s, 0053266&lt;br&gt;SB - AIM, IM&lt;br&gt;CP - England&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Comparative Study&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-03-23 09:32:56 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oommen A, Lambert PC, Grigg J</AU>
<TI>Efficacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1-5 years: randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>362</VL>
<NO>9394</NO>
<PG>1433-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oski-1961" MODIFIED="2010-05-24 13:51:24 +1000" MODIFIED_BY="[Empty name]" NAME="Oski 1961" YEAR="1961">
<REFERENCE MODIFIED="2010-05-24 13:51:24 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Cited By (since 1996): 15&lt;br&gt;Export Date: 4 March 2009&lt;br&gt;Source: Scopus&lt;/p&gt;" NOTES_MODIFIED="2010-05-24 13:51:24 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oski FA, Salitsky S, Barness LA</AU>
<TI>Steroid therapy in bronchiolitis: a double-blind study</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1961</YR>
<VL>102</VL>
<PG>759-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Panickar-2009" MODIFIED="2010-03-23 09:32:56 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Panickar 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-03-23 09:32:56 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 19164186&lt;br&gt;IN - Division of Child Health, University of Leicester, Leicester, United Kingdom&lt;br&gt;CM - Comment in: N Engl J Med. 2009 Jan 22;360(4):409-10; PMID: 19164192&lt;br&gt;AS - N Engl J Med. 360(4):329-38, 2009 Jan 22&lt;br&gt;JC - 0255562, now&lt;br&gt;SB - AIM, IM&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Multicenter Study&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;SI - ISRCTN&lt;br&gt;SA - ISRCTN/ISRCTN58363576&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-03-23 09:32:56 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Panickar J, Lakhanpaul M, Lambert PC, Kenia P, Stephenson T, Smyth A, et al</AU>
<TI>Oral prednisolone for preschool children with acute virus-induced wheezing</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>4</NO>
<PG>329-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Park-1997" MODIFIED="2010-03-23 09:32:56 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Park 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-03-23 09:32:56 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - CCTR&lt;br&gt;AN - CN-00486799&lt;/p&gt;" NOTES_MODIFIED="2010-03-23 09:32:56 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Park J</AU>
<TI>The effect of salbutamol and budesonide inhalation therapy in infants with bronchiolitis</TI>
<SO>Journal of the Korean Pediatric Society</SO>
<YR>1997</YR>
<VL>40</VL>
<NO>1</NO>
<PG>45-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patel-2004" MODIFIED="2010-06-30 03:54:58 +1000" MODIFIED_BY="[Empty name]" NAME="Patel 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-06-30 03:54:58 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 15266547&lt;br&gt;NLM full journal name - Cochrane database of systematic reviews (Online)&lt;br&gt;JC - 100909747&lt;br&gt;SB - IM&lt;br&gt;CP - England&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-06-30 03:54:58 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="COCHRANE_REVIEW">
<AU>Patel H, Platt R, Lozano JM, Wang EE</AU>
<TI>Glucocorticoids for acute viral bronchiolitis in infants and young children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2010-06-30 03:54:58 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-06-30 03:54:58 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004878.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patel-2008" MODIFIED="2010-05-24 13:52:38 +1000" MODIFIED_BY="[Empty name]" NAME="Patel 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-24 13:52:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patel H, Plint AC, Johnson DW, Wiebe N, Correll R, Brant R, et al</AU>
<TI>A multicenter randomized controlled trial of nebulized epinephrine and dexamethasone in outpatients with bronchiolitis</TI>
<SO>Paediatrics and Child Health</SO>
<YR>2008</YR>
<VL>13</VL>
<NO>Suppl A</NO>
<PG>Abstract 136</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plint-2008" MODIFIED="2010-05-24 13:53:04 +1000" MODIFIED_BY="[Empty name]" NAME="Plint 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-24 13:53:04 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plint AC, Johnston DM, Patel H, Wiebe N, Correll R, Mitton C, et al</AU>
<TI>A multicenter randomized controlled trial of nebulized epinephrine and dexamethasone in outpatients with bronchiolitis</TI>
<SO>Academic Emergency Medicine</SO>
<YR>2008</YR>
<VL>15</VL>
<NO>5 Suppl 1</NO>
<PG>37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poets-2005" MODIFIED="2010-06-27 02:38:08 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Poets 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-06-27 02:38:08 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - EMBASE&lt;br&gt;UI - 2005085162&lt;br&gt;IN - (Patel) McGill University Health Centre, Montreal, Que., Canada. (Poets) University Hospital, Tubingen, Germany&lt;br&gt;CP - United Kingdom&lt;br&gt;LG - English&lt;br&gt;PT - Journal: Short Survey&lt;br&gt;EM - 200500&lt;br&gt;DD - 20070409&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 02:38:08 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poets CF</AU>
<TI>Review: corticosteroids do not reduce hospital length of stay or respiratory distress in infantile acute viral bronchiolitis</TI>
<SO>Evidence-Based Medicine</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>1</NO>
<PG>20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Principi-2011" MODIFIED="2012-12-21 09:13:21 +1000" MODIFIED_BY="[Empty name]" NAME="Principi 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-12-21 09:13:21 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Principi T, Komar L</AU>
<TI>KiDrug alert journal club</TI>
<SO>Canadian Journal of Clinical Pharmacology</SO>
<YR>2011</YR>
<VL>18</VL>
<PG>e273-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rajeshwari-2006" MODIFIED="2010-06-27 02:38:27 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Rajeshwari 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-06-27 02:38:27 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - EMBASE&lt;br&gt;UI - 2006423905&lt;br&gt;CP - India&lt;br&gt;LG - English&lt;br&gt;PT - Journal: Note&lt;br&gt;EM - 200600&lt;br&gt;DD - 20070403&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 02:38:27 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rajeshwari K</AU>
<TI>Corticosteroid therapy for wheezy infants</TI>
<SO>Indian Pediatrics</SO>
<YR>2006</YR>
<VL>4</VL>
<NO>7</NO>
<PG>662</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ranganathan-2003" MODIFIED="2010-06-27 02:38:34 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Ranganathan 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-06-27 02:38:34 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - EMBASE&lt;br&gt;UI - 2003468141&lt;br&gt;IN - (Ranganathan) Dept. of Paediat. Resp. Medicine, Great Ormond Street Hospital, London, United Kingdom. (McKenzie) Department of Child Health, Royal London Hospital, London, United Kingdom. (Ranganathan) Portex Unit, Cardiac Wing, Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, United Kingdom&lt;br&gt;CP - Italy&lt;br&gt;LG - English&lt;br&gt;PT - Journal: Review&lt;br&gt;EM - 200300&lt;br&gt;DD - 20070427&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 02:38:34 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ranganathan SC, McKenzie SA</AU>
<TI>The use of corticosteroids in syntomathic asthma in childhood</TI>
<SO>Minerva Pediatrica</SO>
<YR>2003</YR>
<VL>55</VL>
<NO>4</NO>
<PG>357-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Renzi-2003" MODIFIED="2010-06-11 01:53:38 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Renzi 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-06-11 01:53:38 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - CCTR&lt;br&gt;AN - CN-00447385&lt;/p&gt;" NOTES_MODIFIED="2010-06-11 01:53:38 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Renzi PM, Marcotte JE, Berube D, Bjornson C, Spier S</AU>
<TI>Effect of nebulized budesonide for 10 weeks on the development of asthma after acute bronchiolitis in infants</TI>
<SO>Proceedings of the American Thoracic Society 99th International Conference, 2003 May 16-21, Seattle WA</SO>
<YR>2003</YR>
<PG>B012</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sammartino-1995" MODIFIED="2010-05-24 13:54:44 +1000" MODIFIED_BY="[Empty name]" NAME="Sammartino 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-05-24 13:54:44 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - CCTR&lt;br&gt;AN - CN-00339319&lt;br&gt;PT - Clinical Trial. Letter. Randomized Controlled Trial&lt;/p&gt;" NOTES_MODIFIED="2010-05-24 13:54:44 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sammartino L</AU>
<TI>Budesonide in acute bronchiolitis</TI>
<SO>Journal of Paediatrics and Child Health</SO>
<YR>1995</YR>
<VL>31</VL>
<NO>1</NO>
<PG>61-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sano-2000" MODIFIED="2010-03-23 09:32:56 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Sano 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-03-23 09:32:56 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 10756218&lt;br&gt;IN - Hospital Nipo-brasileiro, Division of Allergy and Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of Sao Paulo, Sao Paulo, Brazil&lt;br&gt;AS - J Allergy Clin Immunol. 105(4):699-703, 2000 Apr&lt;br&gt;JC - h53, 1275002&lt;br&gt;SB - AIM, IM&lt;br&gt;CP - UNITED STATES&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-03-23 09:32:56 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sano F, Cortez GK, Sole D, Naspitz CK</AU>
<TI>Inhaled budesonide for the treatment of acute wheezing and dyspnea in children up to 24 months old receiving intravenous hydrocortisone</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>2000</YR>
<VL>105</VL>
<NO>4</NO>
<PG>699-703</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schuh-2004" MODIFIED="2010-06-27 03:56:53 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Schuh 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-06-27 03:56:53 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - EMBASE&lt;br&gt;UI - 2004399180&lt;br&gt;CP - Canada&lt;br&gt;LG - English&lt;br&gt;PT - Journal: Note&lt;br&gt;EM - 200400&lt;br&gt;DD - 20070402&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 03:56:53 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schuh S, Coates AL, Binnie R</AU>
<TI>Efficacy of oral dexamethasone in outpatients with acute bronchiolitis. In: Paediatric emergency research in Canada: using the iterative loop as a research paradigm for advancing the field</TI>
<SO>Paediatrics and Child Health</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>6</NO>
<PG>395-402</PG>
<ED>Johnson DW, Osmond MH, Hooton N, Klassen, TP</ED>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schuh-2008" MODIFIED="2010-05-24 13:56:13 +1000" MODIFIED_BY="[Empty name]" NAME="Schuh 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-24 13:56:13 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - EMBASE&lt;br&gt;UI - 2008417314&lt;br&gt;IN - (Schuh, Lalani, Nicota, Mokanski, Khaikin) Pediatric Emergency Medicine, Hospital for Sick Children, Toronto, ON, Canada. (Schuh, Coates, Dick, Stephens, Allen) Research Institute, Division of Child Health Evaluative Sciences, Hospital for Sick Children, Toronto, ON, Canada. (Coates) Division of Respirology, Hospital for Sick Children, Toronto, ON, Canada. (Dick) Division of Pediatric Medicine, Department of Pediatrics, Hospital for Sick Children, Toronto, ON, Canada. (Allen) Division of Infectious Diseases, Hospital for Sick Children, Toronto, ON, Canada. (Schuh) Division of Pediatric Emergency Medicine, Hospital for Sick Children, 555 University Avenue, Toronto, ON M5G 1X8, Canada&lt;br&gt;CP - United States&lt;br&gt;LG - English&lt;br&gt;PT - Journal: Article&lt;br&gt;EM - 200840&lt;br&gt;DD - 20080928&lt;/p&gt;" NOTES_MODIFIED="2010-05-24 13:56:13 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schuh S, Coates AL, Dick P, Stephens D, Lalani A, Nicota E, et al</AU>
<TI>A single versus multiple doses of dexamethasone in infants wheezing for the first time</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2008</YR>
<VL>43</VL>
<NO>9</NO>
<PG>844-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smart-2009" MODIFIED="2013-01-04 15:57:13 +1000" MODIFIED_BY="[Empty name]" NAME="Smart 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-04 15:57:13 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smart BA</AU>
<TI>Oral prednisolone for preschool children with acute virus-induced wheezing</TI>
<SO>Pediatrics</SO>
<YR>2009</YR>
<VL>124</VL>
<NO>Suppl</NO>
<PG>151</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2008" MODIFIED="2010-07-13 13:45:00 +1000" MODIFIED_BY="[Empty name]" NAME="Smith 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-07-13 13:45:00 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 18390234&lt;br&gt;NLM full journal name - The Journal of the Oklahoma State Medical Association&lt;br&gt;JC - jh3, 7503043&lt;br&gt;SB - IM&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-07-13 13:45:00 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith J, Salinas R</AU>
<TI>Do systemic corticosteroids improve acute outcomes in infants with RSV bronchiolitis?</TI>
<SO>Journal of the Oklahoma State Medical Association</SO>
<YR>2008</YR>
<VL>101</VL>
<NO>1</NO>
<PG>14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spencer-1989" MODIFIED="2010-05-24 13:57:05 +1000" MODIFIED_BY="[Empty name]" NAME="Spencer 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-05-24 13:57:05 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 2564474&lt;br&gt;AS - Lancet. 1(8639):665, 1989 Mar 25&lt;br&gt;JC - 2985213r, l0s, 0053266&lt;br&gt;SB - AIM, IM&lt;br&gt;CP - ENGLAND&lt;br&gt;PT - Letter&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-05-24 13:57:05 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spencer DA, Gleeson JG, Price JF</AU>
<TI>Inhaled budesonide for acute wheeze in infants</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>1</VL>
<NO>8639</NO>
<PG>665</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Springer-1990" MODIFIED="2010-06-27 02:38:56 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Springer 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-06-27 02:38:56 +1000" MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Springer C, Bar-Yishay E, Uwayyed K, Avital A, Vilozni D, Godfrey S</AU>
<TI>Corticosteroids do not affect the clinical or physiological status of infants with bronchiolitis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1990</YR>
<VL>9</VL>
<PG>181-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sussman-1964" MODIFIED="2010-05-24 13:57:30 +1000" MODIFIED_BY="[Empty name]" NAME="Sussman 1964" YEAR="1964">
<REFERENCE MODIFIED="2010-05-24 13:57:30 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 19650401&lt;br&gt;IS - 0031-4005 (Print)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;RN - 0 (Placebos)&lt;br&gt;RN - 50-02-2 (Dexamethasone)&lt;br&gt;SB - OM&lt;/p&gt;" NOTES_MODIFIED="2010-05-24 13:57:30 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sussman S, Grossman M, Magoffin R, Schieble J</AU>
<TI>Dexamethasone (16-alpha-methyl, 9-alpha-flouroprednisolone) in obstructive respiratory tract infections in children. A controlled study</TI>
<SO>Pediatrics</SO>
<YR>1964</YR>
<VL>34</VL>
<PG>851-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tal-1982" MODIFIED="2010-03-23 09:31:41 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Tal 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-03-23 04:40:54 +1000" MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tal A, Bavilski C, Yohai D, Bearman JE, Gorodischer R, Moses SW</AU>
<TI>Dexamethasone and salbutamol in the treatment of acute wheezing in infants</TI>
<SO>Pediatrics</SO>
<YR>1983</YR>
<VL>71</VL>
<NO>1</NO>
<PG>13-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tofts-2009" MODIFIED="2010-05-24 13:57:43 +1000" MODIFIED_BY="[Empty name]" NAME="Tofts 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-05-24 13:57:43 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - EMBASE&lt;br&gt;UI - 2009470599&lt;br&gt;IN - (Tofts) Internal Medicine, Cleveland Clinic, Weston, FL, United States&lt;br&gt;CP - United Kingdom&lt;br&gt;LG - English&lt;br&gt;PT - Journal: Article&lt;br&gt;EM - 200943&lt;br&gt;DD - 20091021&lt;/p&gt;" NOTES_MODIFIED="2010-05-24 13:57:43 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tofts RPH</AU>
<TI>Steroids do not improve RSV-related wheeze in children</TI>
<SO>Thorax</SO>
<YR>2009</YR>
<VL>64</VL>
<NO>9</NO>
<PG>769</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uhereczky-2001" MODIFIED="2010-06-27 02:39:08 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Uhereczky 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-06-27 02:39:08 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - CCTR&lt;br&gt;AN - CN-00361923&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 02:39:08 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Uhereczky G, Gács É, Jákly A, Göndöcs R</AU>
<TI>Inhaled corticosteroids in atopic wheezy infants</TI>
<SO>Proceedings of the International Paediatric Respiratory and Allergy Congress 2001, April 1-4, Prague</SO>
<YR>2001</YR>
<PG>84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Bever-1996" MODIFIED="2010-06-27 02:39:24 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Van Bever 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-06-27 02:39:24 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 8806308&lt;br&gt;CM - Comment on: Lancet. 1996 Aug 3;348(9023):292-5; PMID: 8709687&lt;br&gt;NLM full journal name - Lancet&lt;br&gt;JC - 2985213r, l0s, 0053266&lt;br&gt;SB - AIM, IM&lt;br&gt;CP - ENGLAND&lt;br&gt;PT - Comment&lt;br&gt;PT - Letter&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 02:39:24 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Bever HP</AU>
<TI>Corticosteroids for bronchiolitis</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>348</VL>
<NO>9029</NO>
<PG>753-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Woensel-1997" MODIFIED="2010-03-23 04:40:54 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="van Woensel 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-03-23 04:40:54 +1000" MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Woensel JBM, Wolfs TFW, van Aalderen WMC, Brand PLP, Kimpen JLL</AU>
<TI>Randomised double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis</TI>
<SO>Thorax</SO>
<YR>1997</YR>
<VL>52</VL>
<PG>634-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Woensel-2000" MODIFIED="2010-03-23 09:32:21 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="van Woensel 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-03-23 09:32:21 +1000" MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Woensel JB, Kimpen JL, Sprikkelman AB, Ouwehand A, van Aalderen WM</AU>
<TI>Long-term effects of prednisolone in the acute phase of bronchiolitis caused by respiratory syncytial virus</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2000</YR>
<VL>30</VL>
<NO>2</NO>
<PG>92-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Woensel-2003a" MODIFIED="2013-03-19 22:04:26 +1000" MODIFIED_BY="[Empty name]" NAME="van Woensel 2003a" YEAR="2003a">
<REFERENCE MODIFIED="2013-03-19 22:04:26 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Van Woensel JBM, Van-Aalderen WMC, DeWeerd W, Jansen NJG, Van-Gestel JPJ, Markhorst DG, et al</AU>
<TI>Dexamethasone for treatment of patients mechanically ventilated for lower respiratory tract infection caused by respiratory syncytial virus</TI>
<SO>Thorax</SO>
<YR>2003</YR>
<VL>58</VL>
<NO>5</NO>
<PG>383-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Woensel-2003b" MODIFIED="2010-07-15 14:10:37 +1000" MODIFIED_BY="[Empty name]" NAME="van Woensel 2003b" YEAR="2003b">
<REFERENCE MODIFIED="2010-03-23 09:32:56 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - EMBASE&lt;br&gt;UI - 2003336310&lt;br&gt;IN - (Van Woensel, Van Aalderen, Kuijpers) Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands. (Lutter, Dekker) Department of Pulmonology, Academic Medical Center, Amsterdam, Netherlands. (Biezeveld) Ctrl. L. NLD R. C. B. T. S., Amsterdam, Netherlands. (Nijhuis) Eijkman-Winkler Inst. M. M. I. D./I., University Medical Center, Utrecht (MN), Netherlands. (Van Woensel) Academic Medical Center, Emma Children's Hospital, Pediatric Intensive Care Unit G8ZW, P.O. Box 22660, 1100 DD Amsterdam, Netherlands&lt;br&gt;CP - United States&lt;br&gt;LG - English&lt;br&gt;PT - Journal: Article&lt;br&gt;EM - 200300&lt;br&gt;DD - 20070427&lt;/p&gt;" NOTES_MODIFIED="2010-03-23 09:32:56 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Woensel JBM, Lutter R, Biezeveld MH, Dekker T, Nijhuis M, Van Aalderen WMC, et al</AU>
<TI>Effect of dexamethasone on tracheal viral load and interleukin-8 tracheal concentration in children with respiratory syncytial virus infection</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>8</NO>
<PG>721-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Woensel-2011" MODIFIED="2013-01-04 15:57:31 +1000" MODIFIED_BY="[Empty name]" NAME="van Woensel 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-04 15:57:31 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Woensel JBM, Vyas H, Group Star Trial</AU>
<TI>Dexamethasone in children mechanically ventilated for lower respiratory tract infection caused by respiratory syncytial virus: a randomized controlled trial</TI>
<SO>Critical Care Medicine</SO>
<YR>2011</YR>
<VL>39</VL>
<PG>1779-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wardrope-2000" MODIFIED="2010-06-27 02:39:40 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Wardrope 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-06-27 02:39:40 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - CCTR&lt;br&gt;AN - CN-00274829&lt;br&gt;IN - Accident and Emergency Department, Northern General Hospital, Sheffield. jimwardrope@hotmail.com&lt;br&gt;PT - Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 02:39:40 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wardrope J</AU>
<TI>Journal scan: randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis</TI>
<SO>Journal of Accident and Emergency Medicine</SO>
<YR>2000</YR>
<VL>17</VL>
<NO>5</NO>
<PG>368-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Webb-1986" MODIFIED="2010-06-27 02:39:45 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Webb 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-06-27 02:39:45 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 3513715&lt;br&gt;AS - Arch Dis Child. 61(1):15-9, 1986 Jan&lt;br&gt;JC - 6xg, 0372434&lt;br&gt;SB - AIM, IM&lt;br&gt;CP - ENGLAND&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 02:39:45 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Webb MS, Henry RL, Milner AD</AU>
<TI>Oral corticosteroids for wheezing attacks under 18 months</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1986</YR>
<VL>61</VL>
<NO>1</NO>
<PG>15-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weinberger-2004" MODIFIED="2010-05-24 14:00:10 +1000" MODIFIED_BY="[Empty name]" NAME="Weinberger 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-05-24 14:00:10 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 14751716&lt;br&gt;CM - Comment on: Lancet. 2003 Nov 1;362(9394):1433-8; PMID: 14602435&lt;br&gt;AS - Lancet. 363(9405):330; author reply 330-1, 2004 Jan 24&lt;br&gt;JC - 2985213r, l0s, 0053266&lt;br&gt;SB - AIM, IM&lt;br&gt;CP - England&lt;br&gt;PT - Comment&lt;br&gt;PT - Comparative Study&lt;br&gt;PT - Letter&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-05-24 14:00:10 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weinberger M, Ahrens R</AU>
<TI>Oral prednisolone for viral wheeze in young children</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>363</VL>
<NO>9405</NO>
<PG>330-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weinberger-2007" MODIFIED="2010-06-27 02:39:53 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Weinberger 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-06-27 02:39:53 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 17403865&lt;br&gt;CM - Comment on: Pediatrics. 2006 Oct;118(4):1774-93; PMID: 17015575&lt;br&gt;NLM full journal name - Pediatrics&lt;br&gt;JC - oxv, 0376422&lt;br&gt;SB - AIM, IM&lt;br&gt;CP - United States&lt;br&gt;PT - Comment&lt;br&gt;PT - Letter&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 02:39:53 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weinberger MM</AU>
<TI>High-dose systemic corticosteroids may be effective early in the course of bronchiolitis</TI>
<SO>Pediatrics</SO>
<YR>2007</YR>
<VL>119</VL>
<NO>4</NO>
<PG>864-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wong-2000" MODIFIED="2010-06-20 17:58:12 +1000" MODIFIED_BY="[Empty name]" NAME="Wong 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-06-20 17:58:12 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 10706509&lt;br&gt;NLM full journal name - The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology&lt;br&gt;JC - 8803460, ery&lt;br&gt;SB - IM&lt;br&gt;CP - DENMARK&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-06-20 17:58:12 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wong JY, Moon S, Beardsmore C, O'Callaghan C, Simpson H</AU>
<TI>No objective benefit from glucocorticoids inhaled via a spacer in infants recovering from bronchiolitis</TI>
<SO>European Respiratory Journal</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>2</NO>
<PG>388-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yaffe-1970" MODIFIED="2010-06-20 17:58:12 +1000" MODIFIED_BY="[Empty name]" NAME="Yaffe 1970" YEAR="1970">
<REFERENCE MODIFIED="2010-06-20 17:58:12 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 5503700&lt;br&gt;NLM full journal name - Pediatrics&lt;br&gt;JC - oxv, 0376422&lt;br&gt;SB - AIM, IM&lt;br&gt;CP - UNITED STATES&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Controlled Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-06-20 17:58:12 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yaffe SJ, Weiss CF</AU>
<TI>Committee on drugs. Should glucocorticoids be used in treating bronchiolitis?</TI>
<SO>Pediatrics</SO>
<YR>1970</YR>
<VL>46</VL>
<NO>4</NO>
<PG>640-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2009" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]" NAME="Zhu 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu YF, Cai XH, Zhu JY, Jiang WP, Lan JH, Liu S</AU>
<TI>Study of CD4+ CD25+ regulatory T cells and expression of Foxp3 mRNA in bronchiolitis and glucocorticoid regulation</TI>
<SO>Chung-Hua i Hsueh Tsa Chih [Chinese Medical Journal]</SO>
<YR>2009</YR>
<VL>89</VL>
<PG>1563-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zuerlein-1990" MODIFIED="2010-06-27 02:40:01 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Zuerlein 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-06-27 02:40:01 +1000" MODIFIED_BY="Ricardo M Fernandes" NOTES="&lt;p&gt;DB - CCTR&lt;br&gt;AN - CN-00286160&lt;/p&gt;" NOTES_MODIFIED="2010-06-27 02:40:01 +1000" NOTES_MODIFIED_BY="Ricardo M Fernandes" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zuerlein N</AU>
<TI>Efficacy of combined corticosteroid (CS) and beta-agonist (BA) therapy for treatment of bronchiolitis in infants</TI>
<SO>Annals of Allergy</SO>
<YR>1990</YR>
<VL>64</VL>
<PG>85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-AAP-2006" MODIFIED="2010-06-27 04:30:06 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="AAP 2006" TYPE="JOURNAL_ARTICLE">
<AU>American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis</AU>
<TI>Diagnosis and management of bronchiolitis</TI>
<SO>Pediatrics</SO>
<YR>2006</YR>
<VL>118</VL>
<PG>1774-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Babl-2008" MODIFIED="2010-06-27 04:32:44 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Babl 2008" TYPE="JOURNAL_ARTICLE">
<AU>Babl FE, Sheriff N, Neutze J, Borland M, Oakley E</AU>
<TI>Bronchiolitis management in pediatric emergency departments in Australia and New Zealand: a PREDICT study</TI>
<SO>Pediatric Emergency Care</SO>
<YR>2008</YR>
<VL>24</VL>
<PG>656-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barben-2000" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Barben 2000" TYPE="JOURNAL_ARTICLE">
<AU>Barben JU, Robertson CF, Robinson PJ</AU>
<TI>Implementation of evidence-based management of acute bronchiolitis</TI>
<SO>Journal of Paediatrics and Child Health</SO>
<YR>2000</YR>
<VL>36</VL>
<PG>491-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barben-2003" MODIFIED="2010-06-27 04:33:35 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Barben 2003" TYPE="JOURNAL_ARTICLE">
<AU>Barben J, Hammer J</AU>
<TI>Current management of acute bronchiolitis in Switzerland</TI>
<SO>Swiss Medical Weekly</SO>
<YR>2003</YR>
<VL>133</VL>
<PG>9-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barben-2008" MODIFIED="2010-06-27 04:33:46 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Barben 2008" TYPE="JOURNAL_ARTICLE">
<AU>Barben J, Kuehni CE, Trachsel D, Hammer J</AU>
<TI>Management of acute bronchiolitis: can evidence based guidelines alter clinical practice?</TI>
<SO>Thorax</SO>
<YR>2008</YR>
<VL>63</VL>
<PG>1103-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baumer-2007" MODIFIED="2010-06-27 04:35:11 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Baumer 2007" TYPE="JOURNAL_ARTICLE">
<AU>Baumer JH</AU>
<TI>SIGN guideline on bronchiolitis in infants</TI>
<SO>Archives of Disease in Childhood Education and Practice</SO>
<YR>2007</YR>
<VL>92</VL>
<PG>ep149-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bialy-2011" MODIFIED="2013-01-04 15:59:34 +1000" MODIFIED_BY="[Empty name]" NAME="Bialy 2011" TYPE="JOURNAL_ARTICLE">
<AU>Bialy L, Foisy M, Smith M, Fernandes RM</AU>
<TI>The Cochrane Library and the treatment of bronchiolitis in children: an overview of reviews</TI>
<SO>Evidence-Based Child Health: A Cochrane Review Journal</SO>
<YR>2011</YR>
<VL>6</VL>
<NO>1</NO>
<PG>258-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bjornson-2008" MODIFIED="2010-06-27 04:35:16 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Bjornson 2008" TYPE="JOURNAL_ARTICLE">
<AU>Bjornson CL, Johnson DW</AU>
<TI>Croup</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>371</VL>
<NO>9609</NO>
<PG>329-39</PG>
<IDENTIFIERS MODIFIED="2010-06-25 04:04:21 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="18295000"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Black-2009" MODIFIED="2010-06-25 04:27:42 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Black 2009" TYPE="JOURNAL_ARTICLE">
<AU>Black JL, Oliver BG, Roth M</AU>
<TI>Molecular mechanisms of combination therapy with inhaled corticosteroids and long-acting beta-agonists</TI>
<SO>Chest</SO>
<YR>2009</YR>
<VL>136</VL>
<NO>4</NO>
<PG>1095-100</PG>
<IDENTIFIERS MODIFIED="2010-06-25 04:27:40 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="19809050"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Boluyt-2008" MODIFIED="2013-01-04 16:00:24 +1000" MODIFIED_BY="[Empty name]" NAME="Boluyt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Boluyt N, Tjosvold L, Lefebvre C, Klassen TP, Offringa M</AU>
<TI>Usefulness of systematic review search strategies in finding child health systematic reviews in MEDLINE</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>2008</YR>
<VL>162</VL>
<NO>2</NO>
<PG>111-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bont-2009" MODIFIED="2013-01-07 10:31:45 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Bont 2009" TYPE="JOURNAL_ARTICLE">
<AU>Bont L</AU>
<TI>Current concepts of the pathogenesis of RSV bronchiolitis</TI>
<SO>Advances in Experimental Medicine and Biology</SO>
<YR>2009</YR>
<VL>634</VL>
<PG>31-40</PG>
<IDENTIFIERS MODIFIED="2010-06-25 04:48:25 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="19280846"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brand-2000" MODIFIED="2010-06-27 04:36:45 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Brand 2000" TYPE="JOURNAL_ARTICLE">
<AU>Brand PL, Vaessen-Verberne AA</AU>
<TI>Differences in management of bronchiolitis between hospitals in The Netherlands. Dutch Paediatric Respiratory Society</TI>
<SO>European Journal of Pediatrics</SO>
<YR>2000</YR>
<VL>159</VL>
<PG>343-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brand-2008" MODIFIED="2010-06-27 04:37:23 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Brand 2008" TYPE="JOURNAL_ARTICLE">
<AU>Brand PL, Baraldi E, Bisgaard H, Boner AL, Castro-Rodriguez JA, Custovic A, et al</AU>
<TI>Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach</TI>
<SO>European Respiratory Journal</SO>
<YR>2008</YR>
<VL>32</VL>
<PG>1096-110</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bush-2007" MODIFIED="2010-06-27 04:37:38 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Bush 2007" TYPE="JOURNAL_ARTICLE">
<AU>Bush A, Thomson AH</AU>
<TI>Acute bronchiolitis</TI>
<SO>BMJ</SO>
<YR>2007</YR>
<VL>335</VL>
<PG>1037-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bush-2009" MODIFIED="2010-06-27 04:38:23 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Bush 2009" TYPE="JOURNAL_ARTICLE">
<AU>Bush A</AU>
<TI>Practice imperfect--treatment for wheezing in preschoolers</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<PG>409-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Calvo-2010" MODIFIED="2010-06-30 04:05:41 +1000" MODIFIED_BY="[Empty name]" NAME="Calvo 2010" TYPE="JOURNAL_ARTICLE">
<AU>Calvo C, Pozo F, Garcia-Garcia M, Sanchez M, Lopez-Valero M, Perez-Brena P, et al</AU>
<TI>Detection of new respiratory viruses in hospitalized infants with bronchiolitis: a three-year prospective study</TI>
<SO>Acta Paediatrica</SO>
<YR>2010</YR>
<VL>99</VL>
<PG>1651-2227 (Electronic)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carroll-2008" MODIFIED="2010-06-27 04:39:26 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Carroll 2008" TYPE="JOURNAL_ARTICLE">
<AU>Carroll KN, Gebretsadik T, Griffin MR, Wu P, Dupont WD, Mitchel EF, et al</AU>
<TI>Increasing burden and risk factors for bronchiolitis-related medical visits in infants enrolled in a state health care insurance plan</TI>
<SO>Pediatrics</SO>
<YR>2008</YR>
<VL>122</VL>
<PG>58-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Castro_x002d_Rodriguez-2000" MODIFIED="2013-01-07 10:30:48 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Castro-Rodriguez 2000" TYPE="JOURNAL_ARTICLE">
<AU>Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD</AU>
<TI>A clinical index to define risk of asthma in young children with recurrent wheezing</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2000</YR>
<VL>162</VL>
<PG>1403-6</PG>
<IDENTIFIERS MODIFIED="2010-06-25 02:39:12 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="11029352"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Christakis-2005" MODIFIED="2010-06-27 04:39:45 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Christakis 2005" TYPE="JOURNAL_ARTICLE">
<AU>Christakis DA, Cowan CA, Garrison MM, Molteni R, Marcuse E, Zerr DM</AU>
<TI>Variation in inpatient diagnostic testing and management of bronchiolitis</TI>
<SO>Pediatrics</SO>
<YR>2005</YR>
<VL>115</VL>
<PG>878-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collins-2008" MODIFIED="2013-01-07 10:30:22 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Collins 2008" TYPE="JOURNAL_ARTICLE">
<AU>Collins PL, Graham BS</AU>
<TI>Viral and host factors in human respiratory syncytial virus pathogenesis</TI>
<SO>Journal of Virology</SO>
<YR>2008</YR>
<VL>82</VL>
<NO>5</NO>
<PG>2040-55</PG>
<IDENTIFIERS MODIFIED="2010-06-25 04:12:31 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="17928346"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Colosia-2012" MODIFIED="2013-01-04 16:01:57 +1000" MODIFIED_BY="[Empty name]" NAME="Colosia 2012" TYPE="JOURNAL_ARTICLE">
<AU>Colosia AD, Masaquel A, Hall CB, Barrett AM, Mahadevia PJ, Yogev R</AU>
<TI>Residential crowding and severe respiratory syncytial virus disease among infants and young children: a systematic literature review</TI>
<SO>BMC Infectious Diseases</SO>
<YR>2012</YR>
<VL>12</VL>
<PG>95</PG>
<IDENTIFIERS MODIFIED="2012-10-27 21:12:51 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22520624"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Damore-2008" MODIFIED="2010-06-27 04:41:47 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Damore 2008" TYPE="JOURNAL_ARTICLE">
<AU>Damore D, Mansbach JM, Clark S, Ramundo M, Camargo CA Jr</AU>
<TI>Prospective multicenter bronchiolitis study: predicting intensive care unit admissions</TI>
<SO>Academic Emergency Medicine</SO>
<YR>2008</YR>
<VL>15</VL>
<PG>887-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-David-2010" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="David 2010" TYPE="JOURNAL_ARTICLE">
<AU>David M, Luc-Vanuxem C, Loundou A, Bosdure E, Auquier P, Dubus JC</AU>
<TI>Assessment of the French Consensus Conference for Acute Viral Bronchiolitis on outpatient management: progress between 2003 and 2008</TI>
<SO>Archives Pediatrie</SO>
<YR>2010</YR>
<VL>17</VL>
<PG>125-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DiFranza-2012" MODIFIED="2013-01-04 16:02:17 +1000" MODIFIED_BY="[Empty name]" NAME="DiFranza 2012" TYPE="JOURNAL_ARTICLE">
<AU>DiFranza JR, Masaquel A, Barrett AM, Colosia AD, Mahadevia PJ</AU>
<TI>Systematic literature review assessing tobacco smoke exposure as a risk factor for serious respiratory syncytial virus disease among infants and young children</TI>
<SO>BMC Pediatrics</SO>
<YR>2012</YR>
<VL>12</VL>
<PG>81</PG>
<IDENTIFIERS MODIFIED="2012-10-27 21:08:48 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22721493"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-DiTraglia-2004" MODIFIED="2013-03-19 22:08:04 +1000" MODIFIED_BY="[Empty name]" NAME="DiTraglia 2004" TYPE="OTHER">
<AU>DiTraglia J</AU>
<TI>Bronchiolitis</TI>
<SO>Archives of Pediatrics and Adolescent Medicine</SO>
<YR>2004</YR>
<VL>158</VL>
<NO>7</NO>
<PG>707; author reply 707-8</PG>
<IDENTIFIERS MODIFIED="2010-06-21 22:07:18 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15237074"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Doyle-2010" MODIFIED="2013-01-07 10:29:04 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Doyle 2010" TYPE="JOURNAL_ARTICLE">
<AU>Doyle LW, Ehrenkranz RA, Halliday HL</AU>
<TI>Dexamethasone treatment after the first week of life for bronchopulmonary dysplasia in preterm infants: a systematic review</TI>
<SO>Neonatology</SO>
<YR>2010</YR>
<VL>98</VL>
<NO>4</NO>
<PG>289-96</PG>
<IDENTIFIERS MODIFIED="2010-06-25 04:27:40 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="20453523"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ducharme-2009" MODIFIED="2010-06-27 04:42:57 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Ducharme 2009" TYPE="JOURNAL_ARTICLE">
<AU>Ducharme FM, Lemire C, Noya FJ, Davis GM, Alos N, Leblond H, et al</AU>
<TI>Preemptive use of high-dose fluticasone for virus-induced wheezing in young children</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<PG>339-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Everard-2009" MODIFIED="2010-06-27 04:43:44 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Everard 2009" TYPE="JOURNAL_ARTICLE">
<AU>Everard ML</AU>
<TI>Acute bronchiolitis and croup</TI>
<SO>Pediatric Clinics of North America</SO>
<YR>2009</YR>
<VL>56</VL>
<PG>119-xi</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Figueras_x002d_Aloy-2008" MODIFIED="2010-06-27 04:43:55 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Figueras-Aloy 2008" TYPE="JOURNAL_ARTICLE">
<AU>Figueras-Aloy J, Carbonell-Estrany X, Quero-Jimenez J, Fernandez-Colomer B, Guzman-Cabanas J, Echaniz-Urcelay I, et al</AU>
<TI>FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2008</YR>
<VL>27</VL>
<PG>788-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Flores-1997" MODIFIED="2010-06-27 04:44:03 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Flores 1997" TYPE="JOURNAL_ARTICLE">
<AU>Flores G, Horwitz RI</AU>
<TI>Efficacy of beta2-agonists in bronchiolitis: a reappraisal and meta-analysis</TI>
<SO>Pediatrics</SO>
<YR>1997</YR>
<VL>100</VL>
<PG>233-9</PG>
<IDENTIFIERS MODIFIED="2010-06-25 04:51:01 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="9240805"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Follmann-1992" MODIFIED="2010-06-27 04:44:22 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Follmann 1992" TYPE="JOURNAL_ARTICLE">
<AU>Follmann D, Elliott P, Suh I, Cutler J</AU>
<TI>Variance imputation for overviews of clinical trials with continuous response</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1992</YR>
<VL>45</VL>
<PG>769-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frey-2009" MODIFIED="2013-01-07 10:28:12 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Frey 2009" TYPE="OTHER">
<AU>Frey U, von Mutius E</AU>
<TI>The challenge of managing wheezing in infants</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>20</NO>
<PG>2130-3</PG>
<IDENTIFIERS MODIFIED="2010-06-25 04:27:40 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="19439749"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Giembycz-2008" MODIFIED="2013-01-07 10:27:50 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Giembycz 2008" TYPE="JOURNAL_ARTICLE">
<AU>Giembycz MA, Kaur M, Leigh R, Newton R</AU>
<TI>A holy grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids</TI>
<SO>British Journal of Pharmacology</SO>
<YR>2008</YR>
<VL>153</VL>
<NO>6</NO>
<PG>1090-104</PG>
<IDENTIFIERS MODIFIED="2010-06-25 04:27:40 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="18071293"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glanville-2006" MODIFIED="2010-06-27 04:46:04 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Glanville 2006" TYPE="JOURNAL_ARTICLE">
<AU>Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J</AU>
<TI>How to identify randomized controlled trials in MEDLINE: ten years on</TI>
<SO>Journal of the Medical Library Association</SO>
<YR>2006</YR>
<VL>94</VL>
<PG>130-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glasziou-2010" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Glasziou 2010" TYPE="JOURNAL_ARTICLE">
<AU>Glasziou PP, Shepperd S, Brassey J</AU>
<TI>Can we rely on the best trial? A comparison of individual trials and systematic reviews</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2010</YR>
<VL>10</VL>
<PG>23</PG>
<IDENTIFIERS MODIFIED="2010-06-25 04:04:21 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="20298582"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gonzalez-2010" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Gonzalez 2010" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez de Dios J, Ochoa Sangrador C</AU>
<TI>Study of variability in the management of acute bronchiolitis in Spain in relation to age of patients. National multicenter study (aBREVIADo project)</TI>
<SO>Anales de Pediatría (Barcelona, Spain: 2003)</SO>
<YR>2010</YR>
<VL>72</VL>
<PG>4-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADE-2009" MODIFIED="2013-01-07 10:27:13 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="GRADE 2009" TYPE="OTHER">
<AU>The GRADE Working Group</AU>
<TI>GRADE handbook for grading quality of evidence and strength of recommendation Version 3.2</TI>
<SO>Available from www.gradeworkinggroup.org</SO>
<YR>2009</YR>
<ED>Schünemann H, Brozek J, Oxman A</ED>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guilbert-2011" MODIFIED="2013-01-04 16:03:21 +1000" MODIFIED_BY="[Empty name]" NAME="Guilbert 2011" TYPE="JOURNAL_ARTICLE">
<AU>Guilbert TW, Bacharier LB</AU>
<TI>Controversies in the treatment of the acutely wheezing infant</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2011</YR>
<VL>183</VL>
<NO>10</NO>
<PG>1284-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gurusamy-2009" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]" NAME="Gurusamy 2009" TYPE="OTHER">
<AU>Gurusamy KS, Gluud C, Nikolova D, Davidson BR</AU>
<TI>Design of surgical randomized controlled trials involving multiple interventions</TI>
<SO>Journal of Surgical Research </SO>
<VL>2009 Oct 30 [E-pub ahead of print]</VL>
<IDENTIFIERS MODIFIED="2010-06-30 03:59:00 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-06-30 03:59:00 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20097373"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Halfhide-2008" MODIFIED="2013-01-07 10:26:43 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Halfhide 2008" TYPE="JOURNAL_ARTICLE">
<AU>Halfhide C, Smyth RL</AU>
<TI>Innate immune response and bronchiolitis and preschool recurrent wheeze</TI>
<SO>Paediatric Respiratory Reviews</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>4</NO>
<PG>251-62</PG>
<IDENTIFIERS MODIFIED="2010-06-25 04:12:31 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="19026366"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hall-2007" MODIFIED="2010-06-27 04:47:33 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Hall 2007" TYPE="JOURNAL_ARTICLE">
<AU>Hall CB</AU>
<TI>Therapy for bronchiolitis: when some become none</TI>
<SO>New England Journal of Medicine</SO>
<YR>2007</YR>
<VL>357</VL>
<PG>402-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hartling-2011a" MODIFIED="2013-01-04 16:05:23 +1000" MODIFIED_BY="[Empty name]" NAME="Hartling 2011a" TYPE="COCHRANE_REVIEW">
<AU>Hartling L, Bialy LM, Vandermeer B, Tjosvold L, Johnson DW, Plint AC, et al</AU>
<TI>Epinephrine for bronchiolitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2013-01-04 16:05:23 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-01-04 16:05:23 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003123.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hartling-2011b" MODIFIED="2013-01-04 16:05:28 +1000" MODIFIED_BY="[Empty name]" NAME="Hartling 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Hartling L, Fernandes RM, Bialy L, Milne A, Johnson D, Plint A, et al</AU>
<TI>Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>342</VL>
<PG>d1714</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-01-04 16:07:19 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jackson-2008" MODIFIED="2010-07-13 13:58:36 +1000" MODIFIED_BY="[Empty name]" NAME="Jackson 2008" TYPE="JOURNAL_ARTICLE">
<AU>Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE, et al</AU>
<TI>Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2008</YR>
<VL>178</VL>
<NO>7</NO>
<PG>667-72</PG>
<IDENTIFIERS MODIFIED="2010-06-25 02:53:31 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="18565953"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Karemaker-2008a" MODIFIED="2013-01-04 16:07:57 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Karemaker 2008a" TYPE="JOURNAL_ARTICLE">
<AU>Karemaker R, Karemaker JM, Kavelaars A, Tersteeg-Kamperman M, Baerts W, Veen S, et al</AU>
<TI>Effects of neonatal dexamethasone treatment on the cardiovascular stress response of children at school age</TI>
<SO>Pediatrics</SO>
<YR>2008</YR>
<VL>122</VL>
<NO>5</NO>
<PG>978-87</PG>
<IDENTIFIERS MODIFIED="2010-06-25 04:27:40 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="18977976"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Karemaker-2008b" MODIFIED="2013-01-04 16:07:51 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Karemaker 2008b" TYPE="JOURNAL_ARTICLE">
<AU>Karemaker R, Kavelaars A, ter Wolbeek M, Tersteeg-Kamperman M, Baerts W, Veen S, et al</AU>
<TI>Neonatal dexamethasone treatment for chronic lung disease of prematurity alters the hypothalamus-pituitary-adrenal axis and immune system activity at school age</TI>
<SO>Pediatrics</SO>
<YR>2008</YR>
<VL>121</VL>
<NO>4</NO>
<PG>e870-8</PG>
<IDENTIFIERS MODIFIED="2010-06-25 04:27:40 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="18381516"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kaur-2008" MODIFIED="2013-01-07 10:26:03 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Kaur 2008" TYPE="JOURNAL_ARTICLE">
<AU>Kaur M, Chivers JE, Giembycz MA, Newton R</AU>
<TI>Long-acting beta2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells</TI>
<SO>Molecular Pharmacology</SO>
<YR>2008</YR>
<VL>73</VL>
<NO>1</NO>
<PG>203-14</PG>
<IDENTIFIERS MODIFIED="2010-07-07 04:42:14 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="17901197"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-King-2004" MODIFIED="2010-06-27 04:48:11 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="King 2004" TYPE="JOURNAL_ARTICLE">
<AU>King VJ, Viswanathan M, Bordley WC, Jackman AM, Sutton SF, Lohr KN, et al</AU>
<TI>Pharmacologic treatment of bronchiolitis in infants and children: a systematic review</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>2004</YR>
<VL>158</VL>
<PG>127-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klassen-1996" MODIFIED="2010-07-13 13:59:03 +1000" MODIFIED_BY="[Empty name]" NAME="Klassen 1996" TYPE="OTHER">
<AU>Klassen TP</AU>
<TI>Determining the benefit of bronchodilators in bronchiolitis. When is there enough benefit to warrant adoption into clinical practice?</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>1996</YR>
<VL>150</VL>
<NO>11</NO>
<PG>1120-1</PG>
<IDENTIFIERS MODIFIED="2010-06-25 04:51:01 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="8904850"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Koehoorn-2008" MODIFIED="2010-06-27 04:48:30 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Koehoorn 2008" TYPE="JOURNAL_ARTICLE">
<AU>Koehoorn M, Karr CJ, Demers PA, Lencar C, Tamburic L, Brauer M</AU>
<TI>Descriptive epidemiological features of bronchiolitis in a population-based cohort</TI>
<SO>Pediatrics</SO>
<YR>2008</YR>
<VL>122</VL>
<PG>1196-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Korppi-2007" MODIFIED="2013-01-07 10:25:40 +1000" MODIFIED_BY="[Empty name]" NAME="Korppi 2007" TYPE="OTHER">
<AU>Korppi M</AU>
<TI>Are responses to treatment virus-specific in wheezing children?</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2007</YR>
<VL>119</VL>
<NO>6</NO>
<PG>1561-2</PG>
<IDENTIFIERS MODIFIED="2010-06-21 22:07:18 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17412400"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kusel-2006" MODIFIED="2010-06-27 04:48:53 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Kusel 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kusel MM, de Klerk NH, Holt PG, Kebadze T, Johnston SL, Sly PD</AU>
<TI>Role of respiratory viruses in acute upper and lower respiratory tract illness in the first year of life: a birth cohort study</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2006</YR>
<VL>25</VL>
<PG>680-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Langley-1997" MODIFIED="2010-06-27 04:49:17 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Langley 1997" TYPE="JOURNAL_ARTICLE">
<AU>Langley JM, Wang EE, Law BJ, Stephens D, Boucher FD, Dobson S, et al</AU>
<TI>Economic evaluation of respiratory syncytial virus infection in Canadian children: a Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study</TI>
<SO>Journal of Pediatrics</SO>
<YR>1997</YR>
<VL>131</VL>
<PG>113-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Langley-2003" MODIFIED="2010-06-27 04:49:57 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Langley 2003" TYPE="JOURNAL_ARTICLE">
<AU>Langley JM, LeBlanc JC, Smith B, Wang EE</AU>
<TI>Increasing incidence of hospitalization for bronchiolitis among Canadian children, 1980-2000</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2003</YR>
<VL>188</VL>
<PG>1764-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leer-1969" MODIFIED="2010-06-27 04:50:24 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Leer 1969" TYPE="JOURNAL_ARTICLE">
<AU>Leer JA Jr, Green JL, Heimlich EM, Hyde JS, Moffet HL, Young GA, et al</AU>
<TI>Corticoglucocorticoid treatment in bronchiolitis. A controlled, collaborative study in 297 infants and children</TI>
<SO>American Journal of Diseases of Children </SO>
<YR>1969</YR>
<VL>117</VL>
<PG>495-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2013-01-04 16:09:54 +1000" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="BOOK_SECTION">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org</SO>
<YR>2011</YR>
<ED>Higgins JPT, Green S</ED>
<PB>Wiley-Blackwell</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lehtinen-2007" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]" NAME="Lehtinen 2007" TYPE="JOURNAL_ARTICLE">
<AU>Lehtinen P, Ruohola A, Vanto T, Vuorinen T, Ruuskanen O, Jartti T</AU>
<TI>Prednisolone reduces recurrent wheezing after a first wheezing episode associated with rhinovirus infection or eczema</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2007</YR>
<VL>119</VL>
<NO>3</NO>
<PG>570-5</PG>
<IDENTIFIERS MODIFIED="2010-06-25 03:06:59 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="17196244"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lowell-1987" MODIFIED="2010-06-20 17:52:58 +1000" MODIFIED_BY="[Empty name]" NAME="Lowell 1987" TYPE="JOURNAL_ARTICLE">
<AU>Lowell DI, Lister G, Von Koss H, McCarthy P</AU>
<TI>Wheezing in infants: the response to epinephrine</TI>
<SO>Pediatrics</SO>
<YR>1987</YR>
<VL>79</VL>
<NO>6</NO>
<PG>939-45</PG>
<IDENTIFIERS MODIFIED="2010-06-20 17:52:55 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="3295741"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mallory-2003" MODIFIED="2010-06-27 04:51:06 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Mallory 2003" TYPE="JOURNAL_ARTICLE">
<AU>Mallory MD, Shay DK, Garrett J, Bordley WC</AU>
<TI>Bronchiolitis management preferences and the influence of pulse oximetry and respiratory rate on the decision to admit</TI>
<SO>Pediatrics</SO>
<YR>2003</YR>
<VL>111</VL>
<PG>e45-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mansbach-2005" MODIFIED="2010-06-27 04:51:12 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Mansbach 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mansbach JM, Emond JA, Camargo CA Jr</AU>
<TI>Bronchiolitis in US emergency departments 1992 to 2000: epidemiology and practice variation</TI>
<SO>Pediatric Emergency Care</SO>
<YR>2005</YR>
<VL>21</VL>
<PG>242-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mansbach-2007" MODIFIED="2010-06-27 04:51:34 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Mansbach 2007" TYPE="JOURNAL_ARTICLE">
<AU>Mansbach JM, Pelletier AJ, Camargo CA Jr</AU>
<TI>US outpatient office visits for bronchiolitis, 1993-2004</TI>
<SO>Ambulatory Pediatrics</SO>
<YR>2007</YR>
<VL>7</VL>
<PG>304-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mansbach-2008a" MODIFIED="2013-01-04 16:10:48 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Mansbach 2008a" TYPE="JOURNAL_ARTICLE">
<AU>Mansbach JM, Camargo CA Jr</AU>
<TI>Bronchiolitis: lingering questions about its definition and the potential role of vitamin D</TI>
<SO>Pediatrics</SO>
<YR>2008</YR>
<VL>122</VL>
<PG>177-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mansbach-2008b" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Mansbach 2008b" TYPE="JOURNAL_ARTICLE">
<AU>Mansbach JM, McAdam AJ, Clark S, Hain PD, Flood RG, Acholonu U, et al</AU>
<TI>Prospective multicenter study of the viral etiology of bronchiolitis in the emergency department</TI>
<SO>Academic Emergency Medicine</SO>
<YR>2008</YR>
<VL>15</VL>
<NO>2</NO>
<PG>111-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mansbach-2012" MODIFIED="2013-01-22 04:22:15 +1000" MODIFIED_BY="[Empty name]" NAME="Mansbach 2012" TYPE="OTHER">
<AU>Mansbach JM, Piedra PA, Teach SJ, Sullivan AF, Forgey T, Clark S, et al</AU>
<TI>Prospective multicenter study of viral etiology and hospital length of stay in children with severe bronchiolitis</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>2012</YR>
<VL>166</VL>
<PG>8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martinez-2005" MODIFIED="2010-06-27 04:52:09 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Martinez 2005" TYPE="JOURNAL_ARTICLE">
<AU>Martinez FD</AU>
<TI>Heterogeneity of the association between lower respiratory illness in infancy and subsequent asthma</TI>
<SO>Proceedings of the American Thoracic Society</SO>
<YR>2005</YR>
<VL>2</VL>
<PG>157-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McAlister-2003" MODIFIED="2010-06-27 04:52:17 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="McAlister 2003" TYPE="JOURNAL_ARTICLE">
<AU>McAlister FA, Straus SE, Sackett DL, Altman DG</AU>
<TI>Analysis and reporting of factorial trials: a systematic review</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<PG>2545-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meissner-2003" MODIFIED="2013-01-04 16:11:54 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Meissner 2003" TYPE="JOURNAL_ARTICLE">
<AU>Meissner HC</AU>
<TI>Selected populations at increased risk from respiratory syncytial virus infection</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>Suppl</NO>
<PG>40-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miyairi-2008" MODIFIED="2010-06-27 04:52:53 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Miyairi 2008" TYPE="JOURNAL_ARTICLE">
<AU>Miyairi I, DeVincenzo JP</AU>
<TI>Human genetic factors and respiratory syncytial virus disease severity</TI>
<SO>Clinical Microbiology Reviews</SO>
<YR>2008</YR>
<VL>21</VL>
<PG>686-703</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montgomery-2003" MODIFIED="2010-06-27 04:53:38 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Montgomery 2003" TYPE="JOURNAL_ARTICLE">
<AU>Montgomery AA, Peters TJ, Little P</AU>
<TI>Design, analysis and presentation of factorial randomised controlled trials</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2003</YR>
<VL>3</VL>
<PG>26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nair-2010" MODIFIED="2010-06-27 04:53:50 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Nair 2010" TYPE="JOURNAL_ARTICLE">
<AU>Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al</AU>
<TI>Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis</TI>
<SO>Lancet</SO>
<YR>2010</YR>
<VL>375</VL>
<PG>1545-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Onland-2008" MODIFIED="2010-06-25 04:27:42 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Onland 2008" TYPE="JOURNAL_ARTICLE">
<AU>Onland W, De Jaegere AP, Offringa M, van Kaam AH</AU>
<TI>Effects of higher versus lower dexamethasone doses on pulmonary and neurodevelopmental sequelae in preterm infants at risk for chronic lung disease: a meta-analysis</TI>
<SO>Pediatrics</SO>
<YR>2008</YR>
<VL>122</VL>
<NO>1</NO>
<PG>92-101</PG>
<IDENTIFIERS MODIFIED="2010-06-25 04:27:40 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="18595991"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Owens-2010" MODIFIED="2010-07-13 13:59:50 +1000" MODIFIED_BY="[Empty name]" NAME="Owens 2010" TYPE="JOURNAL_ARTICLE">
<AU>Owens DK, Lohr KN, Atkins D, Treadwell JR, Reston JT, Bass EB, et al</AU>
<TI>AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions-agency for healthcare research and quality and the effective health-care program</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2010</YR>
<VL>63</VL>
<PG>513-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Papadopoulos-2002" MODIFIED="2013-01-04 16:12:57 +1000" MODIFIED_BY="[Empty name]" NAME="Papadopoulos 2002" TYPE="JOURNAL_ARTICLE">
<AU>Papadopoulos NG, Moustaki M, Tsolia M, Bossios A, Astra E, Prezerakou A, et al</AU>
<TI>Association of rhinovirus infection with increased disease severity in acute bronchiolitis</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>9</NO>
<PG>1285-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paramore-2004" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Paramore 2004" TYPE="JOURNAL_ARTICLE">
<AU>Paramore LC, Ciuryla V, Ciesla G, Liu L</AU>
<TI>Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases</TI>
<SO>Pharmacoeconomics</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>275-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pelletier-2006" MODIFIED="2010-06-27 04:56:03 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Pelletier 2006" TYPE="JOURNAL_ARTICLE">
<AU>Pelletier AJ, Mansbach JM, Camargo CA Jr</AU>
<TI>Direct medical costs of bronchiolitis hospitalizations in the United States</TI>
<SO>Pediatrics</SO>
<YR>2006</YR>
<VL>118</VL>
<PG>2418-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perez_x002d_Yarza-2007" MODIFIED="2010-06-27 04:56:08 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Perez-Yarza 2007" TYPE="JOURNAL_ARTICLE">
<AU>Perez-Yarza EG, Moreno A, Lazaro P, Mejias A, Ramilo O</AU>
<TI>The association between respiratory syncytial virus infection and the development of childhood asthma: a systematic review of the literature</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2007</YR>
<VL>26</VL>
<PG>733-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Plint-2004" MODIFIED="2010-06-27 04:56:18 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Plint 2004" TYPE="JOURNAL_ARTICLE">
<AU>Plint AC, Johnson DW, Wiebe N, Bulloch B, Pusic M, Joubert G, et al</AU>
<TI>Practice variation among pediatric emergency departments in the treatment of bronchiolitis</TI>
<SO>Academic Emergency Medicine</SO>
<YR>2004</YR>
<VL>11</VL>
<PG>353-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robbins-2006" MODIFIED="2010-06-27 04:56:36 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Robbins 2006" TYPE="JOURNAL_ARTICLE">
<AU>Robbins JM, Kotagal UR, Kini NM, Mason WH, Parker JG, Kirschbaum MS</AU>
<TI>At-home recovery following hospitalization for bronchiolitis</TI>
<SO>Ambulatory Pediatrics</SO>
<YR>2006</YR>
<VL>6</VL>
<PG>8-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schuh-1990" MODIFIED="2013-01-04 16:13:40 +1000" MODIFIED_BY="[Empty name]" NAME="Schuh 1990" TYPE="JOURNAL_ARTICLE">
<AU>Schuh S, Canny G, Reisman JJ, Kerem E, Bentur L, Petric M, et al</AU>
<TI>Nebulized albuterol in acute bronchiolitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>1990</YR>
<VL>117</VL>
<NO>4</NO>
<PG>633-7</PG>
<IDENTIFIERS MODIFIED="2010-06-20 17:52:55 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="2213394"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schultz-2010" MODIFIED="2013-01-07 10:24:08 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Schultz 2010" TYPE="JOURNAL_ARTICLE">
<AU>Schultz A, Devadason SG, Savenije OE, Sly PD, Le Souef PN, Brand PL</AU>
<TI>The transient value of classifying preschool wheeze into episodic viral wheeze and multiple trigger wheeze</TI>
<SO>Acta Paediatrica</SO>
<YR>2010</YR>
<VL>99</VL>
<NO>1</NO>
<PG>56-60</PG>
<IDENTIFIERS MODIFIED="2010-06-25 02:39:12 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="19764920"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shay-1999" MODIFIED="2010-06-27 04:56:58 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Shay 1999" TYPE="JOURNAL_ARTICLE">
<AU>Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ</AU>
<TI>Bronchiolitis-associated hospitalizations among US children, 1980-1996</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>282</VL>
<PG>1440-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simoes-2003" MODIFIED="2010-06-27 04:57:26 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Simoes 2003" TYPE="JOURNAL_ARTICLE">
<AU>Simoes EA</AU>
<TI>Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease</TI>
<SO>Journal of Pediatrics</SO>
<YR>2003</YR>
<VL>143</VL>
<PG>S118-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simoes-2008" MODIFIED="2010-06-27 04:58:00 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Simoes 2008" TYPE="JOURNAL_ARTICLE">
<AU>Simoes EA</AU>
<TI>RSV disease in the pediatric population: epidemiology, seasonal variability, and long-term outcomes</TI>
<SO>Managed Care</SO>
<YR>2008</YR>
<VL>17</VL>
<PG>3-6, discussion</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-2010" MODIFIED="2013-01-04 16:14:15 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Simpson 2010" TYPE="JOURNAL_ARTICLE">
<AU>Simpson A, Tan VY, Winn J, Svensen M, Bishop CM, Heckerman DE, et al</AU>
<TI>Beyond atopy: multiple patterns of sensitization in relation to asthma in a birth cohort study</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2010</YR>
<VL>181</VL>
<NO>11</NO>
<PG>1200-6</PG>
<IDENTIFIERS MODIFIED="2010-06-25 03:48:59 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="20167852"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Singh-2007" MODIFIED="2013-01-04 16:14:41 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Singh 2007" TYPE="JOURNAL_ARTICLE">
<AU>Singh AM, Moore PE, Gern JE, Lemanske RF Jr, Hartert TV</AU>
<TI>Bronchiolitis to asthma: a review and call for studies of gene-virus interactions in asthma causation</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2007</YR>
<VL>175</VL>
<PG>108-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sly-2008" MODIFIED="2010-06-25 02:39:13 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Sly 2008" TYPE="JOURNAL_ARTICLE">
<AU>Sly PD, Boner AL, Bjorksten B, Bush A, Custovic A, Eigenmann PA, et al</AU>
<TI>Early identification of atopy in the prediction of persistent asthma in children</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>372</VL>
<NO>9643</NO>
<PG>1100-6</PG>
<IDENTIFIERS MODIFIED="2010-06-25 02:39:12 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="18805338"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sly-2010" MODIFIED="2010-06-27 04:58:51 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Sly 2010" TYPE="JOURNAL_ARTICLE">
<AU>Sly PD, Kusel M, Holt PG</AU>
<TI>Do early-life viral infections cause asthma?</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2010</YR>
<VL>125</VL>
<PG>1202-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smyth-2006" MODIFIED="2010-06-27 04:58:58 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Smyth 2006" TYPE="JOURNAL_ARTICLE">
<AU>Smyth RL, Openshaw PJ</AU>
<TI>Bronchiolitis</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>368</VL>
<PG>312-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Somers-2009" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Somers 2009" TYPE="JOURNAL_ARTICLE">
<AU>Somers CC, Ahmad N, Mejias A, Buckingham SC, Carubelli C, Katz K, et al</AU>
<TI>Effect of dexamethasone on respiratory syncytial virus-induced lung inflammation in children: results of a randomized, placebo controlled clinical trial</TI>
<SO>Pediatric Allergy and Immunology</SO>
<YR>2009</YR>
<VL>20</VL>
<NO>5</NO>
<PG>477-85</PG>
<IDENTIFIERS MODIFIED="2010-08-11 01:53:51 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER MODIFIED="2010-08-11 01:53:51 +1000" MODIFIED_BY="Ricardo M Fernandes" TYPE="PUBMED" VALUE="19397752"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stein-1999" MODIFIED="2010-06-25 02:53:31 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Stein 1999" TYPE="JOURNAL_ARTICLE">
<AU>Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, et al</AU>
<TI>Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9178</NO>
<PG>541-5</PG>
<IDENTIFIERS MODIFIED="2010-06-25 02:53:31 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="10470697"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tal-1983" MODIFIED="2010-06-20 17:52:58 +1000" MODIFIED_BY="[Empty name]" NAME="Tal 1983" TYPE="JOURNAL_ARTICLE">
<AU>Tal A, Bavilski C, Yohai D, Bearman JE, Gorodischer R, Moses SW</AU>
<TI>Dexamethasone and salbutamol in the treatment of acute wheezing in infants</TI>
<SO>Pediatrics</SO>
<YR>1983</YR>
<VL>71</VL>
<NO>1</NO>
<PG>13-8</PG>
<IDENTIFIERS MODIFIED="2010-06-20 17:52:55 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="6129609"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Taussig-2008" MODIFIED="2013-01-04 16:15:18 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Taussig 2008" TYPE="BOOK">
<AU>Taussig LM, Landau LI</AU>
<SO>Pediatric Respiratory Medicine</SO>
<YR>2008</YR>
<PB>Mosby - Elsevier</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turner-2008" MODIFIED="2010-06-27 04:59:55 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Turner 2008" TYPE="JOURNAL_ARTICLE">
<AU>Turner T, Wilkinson F, Harris C, Mazza D</AU>
<TI>Evidence based guideline for the management of bronchiolitis</TI>
<SO>Australian Family Physician</SO>
<YR>2008</YR>
<VL>37</VL>
<PG>6-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Woensel-2002" MODIFIED="2010-06-27 05:00:22 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="van Woensel 2002" TYPE="JOURNAL_ARTICLE">
<AU>van Woensel JB, van Aalderen WM, Kneyber MC, Heijnen ML, Kimpen JL</AU>
<TI>Bronchiolitis hospitalisations in the Netherlands from 1991 to 1999</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2002</YR>
<VL>86</VL>
<PG>370-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weinberger-2003" MODIFIED="2010-07-13 14:00:55 +1000" MODIFIED_BY="[Empty name]" NAME="Weinberger 2003" TYPE="OTHER">
<AU>Weinberger M</AU>
<TI>Corticosteroids for first-time young wheezers: current status of the controversy</TI>
<SO>Journal of Pediatrics</SO>
<YR>2003</YR>
<VL>143</VL>
<NO>6</NO>
<PG>700-2</PG>
<IDENTIFIERS MODIFIED="2010-06-21 22:07:18 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="14657809"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Westley-1978" MODIFIED="2013-03-19 22:17:41 +1000" MODIFIED_BY="[Empty name]" NAME="Westley 1978" TYPE="JOURNAL_ARTICLE">
<AU>Westley CR, Cotton EK, Brooks JG</AU>
<TI>Nebulized racemic epinephrine by IPPB for the treatment of croup: a double-blind study</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1978</YR>
<VL>132</VL>
<NO>5</NO>
<PG>484-7</PG>
<IDENTIFIERS MODIFIED="2010-06-20 17:52:55 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="347921"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wiebe-2006" MODIFIED="2010-06-27 05:01:27 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Wiebe 2006" TYPE="JOURNAL_ARTICLE">
<AU>Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, Barrowman NJ</AU>
<TI>A systematic review identifies a lack of standardization in methods for handling missing variance data</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<PG>342-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilson_x002d_Costello-2009" MODIFIED="2010-06-25 04:27:42 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Wilson-Costello 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wilson-Costello D, Walsh MC, Langer JC, Guillet R, Laptook AR, Stoll BJ, et al</AU>
<TI>Impact of postnatal corticosteroid use on neurodevelopment at 18 to 22 months' adjusted age: effects of dose, timing, and risk of bronchopulmonary dysplasia in extremely low birth weight infants</TI>
<SO>Pediatrics</SO>
<YR>2009</YR>
<VL>123</VL>
<NO>3</NO>
<PG>e430-7</PG>
<IDENTIFIERS MODIFIED="2010-06-25 04:27:40 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="19204058"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wright-1989" MODIFIED="2010-06-27 05:01:51 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Wright 1989" TYPE="JOURNAL_ARTICLE">
<AU>Wright AL, Taussig LM, Ray CG, Harrison HR, Holberg CJ</AU>
<TI>The Tucson Children's Respiratory Study. II. Lower respiratory tract illness in the first year of life</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1989</YR>
<VL>129</VL>
<PG>1232-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yusuf-2007" MODIFIED="2010-06-27 05:02:18 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Yusuf 2007" TYPE="JOURNAL_ARTICLE">
<AU>Yusuf S, Piedimonte G, Auais A, Demmler G, Krishnan S, Van Caeseele P, et al</AU>
<TI>The relationship of meteorological conditions to the epidemic activity of respiratory syncytial virus</TI>
<SO>Epidemiology and Infection</SO>
<YR>2007</YR>
<VL>135</VL>
<PG>1077-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2005" MODIFIED="2013-01-04 16:15:59 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Zhang 2005" TYPE="JOURNAL_ARTICLE">
<AU>Zhang L, Sanguebsche LS</AU>
<TI>The safety of nebulization with 3 to 5 ml of adrenaline (1:1000) in children: an evidence based review</TI>
<TO>Seguranca de nebulizacao com 3 a 5 ml de adrenalina (1:1000) em criancas: uma revisao baseada em evidencia</TO>
<SO>Jornal de Pediatria</SO>
<YR>2005</YR>
<VL>81</VL>
<NO>3</NO>
<PG>193-7</PG>
<IDENTIFIERS MODIFIED="2010-06-25 04:27:40 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER TYPE="PUBMED" VALUE="15951902"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2011" MODIFIED="2013-01-04 16:17:16 +1000" MODIFIED_BY="[Empty name]" NAME="Zhang 2011" TYPE="COCHRANE_REVIEW">
<AU>Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP</AU>
<TI>Nebulized hypertonic saline solution for acute bronchiolitis in infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2013-01-04 16:17:12 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-01-04 16:17:12 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006458.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-01-04 16:22:29 +1000" MODIFIED_BY="Ricardo M Fernandes">
<REFERENCE ID="REF-Fernandes-2010" MODIFIED="2013-01-04 16:22:29 +1000" MODIFIED_BY="[Empty name]" NAME="Fernandes 2010" TYPE="COCHRANE_REVIEW">
<AU>Fernandes RM, Bialy LM, Vandermeer B, Tjosvold L, Plint AC, Patel H, et al</AU>
<TI>Glucocorticoids for acute viral bronchiolitis in infants and young children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2013-01-04 16:22:29 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-01-04 16:22:29 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004878.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Patel-2004" MODIFIED="2010-06-27 04:07:10 +1000" MODIFIED_BY="Ricardo M Fernandes" NAME="Patel 2004" TYPE="COCHRANE_REVIEW">
<AU>Patel H, Platt R, Lozano JM, Wang EEL</AU>
<TI>Glucocorticoids for acute viral bronchiolitis in infants and young children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-06-27 04:07:10 +1000" MODIFIED_BY="Ricardo M Fernandes">
<IDENTIFIER MODIFIED="2010-06-27 04:07:10 +1000" MODIFIED_BY="Ricardo M Fernandes" TYPE="DOI" VALUE="10.1002/14651858.CD004878.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2013-01-04 16:21:09 +1000" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-05-06 11:52:03 +1000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-05-06 11:52:03 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Funding" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barlas-1998">
<CHAR_METHODS MODIFIED="2010-06-04 13:30:34 +1000" MODIFIED_BY="[Empty name]">
<P>Parallel design, multi-arm (6)<BR/>Single-centre, conducted in Turkey</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Outpatients (emergency department/outpatient clinic)</P>
<P>
<I>Inclusion/exclusion criteria</I>
<BR/>Inclusion criteria: age &lt; 24 months; 1st episode of wheezing; clinical score between 4 to 10 (mild-moderate)<BR/>Exclusion criteria: patients with history of premature heart disease, chronic heart and lung problems, prior diagnosis of bronchial asthma, used bronchodilators and anti-inflammatory medications</P>
<P>
<I>Participant characteristics (all groups)</I>
<BR/>Sample size: randomised (N): 90, analysed - all outcomes (N): 90 (unclear what type of analysis was performed regarding ITT and missing data)</P>
<P>Age, mean ± SD: 8.52 ± 0.59<BR/>Males, N (%): 50 (56)<BR/>RSV status: 19/57 positive<BR/>Atopic status: 4/86 (family)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>GROUP 1 </I>
<BR/>Drug name: placebo - mist tent<BR/>Dose: NR<BR/>Mode of administration: nebulised<BR/>Timing/duration: NR</P>
<P>
<I>GROUP 2 </I>
<BR/>Drug name: albuterol<BR/>Dose: 0.15 mg/kg<BR/>Mode of administration: nebulised<BR/>Timing/duration: every hour during the first 4h</P>
<P>
<I>GROUP 3 (with glucocorticoid)</I>
<BR/>Drug name: prednisolone<BR/>Dose: 2 mg/kg<BR/>Mode of administration: IV<BR/>Timing/duration: single dose</P>
<P>
<I>GROUP 4 (with glucocorticoid)</I>
<BR/>Drug name: albuterol + prednisolone<BR/>Dose: 0.15 mg/kg (alb) + 2 mg/kg (pre)<BR/>Mode of administration: nebulised + IV<BR/>Timing/duration: single dose for both interventions</P>
<P>
<I>GROUP 5 </I>
<BR/>Drug name: racaemic adrenaline (epinephrine)<BR/>Dose: 0.1 mL/kg<BR/>Mode of administration: nebulised<BR/>Timing/duration: every 2h during the first 4h</P>
<P>
<I>GROUP 6 (with glucocorticoid)</I>
<BR/>Drug name: budesonide<BR/>Dose: 0.5 mg<BR/>Mode of administration: nebulised<BR/>Timing/duration: single dose</P>
<P>Additional co-interventions for all groups: NR<BR/>Protocolised use of bronchodilators with glucocorticoids: yes (Group 4 - salbutamol)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>/<I>outcome used to calculate sample size</I>
<BR/>NR</P>
<P>
<I>Secondary outcomes</I>
<BR/>Hospital admission by day 1; SaO2*; heart rate*; clinical scale*: developed for this trial - 15-point score, based on respiratory rate, wheezing, retractions, nostril movement and general patient condition; length of observation period; improvement with initial therapy; additional therapy<BR/>*time points: baseline, 60, 120 minutes, 4 hours</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-03-23 20:42:42 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>NR</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Language of publication: Turkish</P>
<P>Study did not report any study-level subgroup analyses</P>
<P>Results from groups 3 and 6 were combined for some analyses</P>
<P>This study contributed to the following comparisons in this review: steroid versus placebo (with 2 comparisons: steroid versus placebo - 'Barlas 1998 (G versus P)'; and steroid + salbutamol versus salbutamol - 'Barlas 1998 (G + S versus S)'); steroid versus epinephrine; steroid versus salbutamol; prednisolone versus budesonide; steroid + salbutamol versus. Placebo; steroid + salbutamol versus epinephrine</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-14 09:54:36 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_">
<CHAR_METHODS MODIFIED="2010-06-10 07:44:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>(see Barlas 1998)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-10 07:47:57 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>(see Barlas 1998)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-14 09:54:36 +1000" MODIFIED_BY="[Empty name]">
<P>(see Barlas 1998)</P>
<P>This glucocorticoid versus placebo comparison includes pooled data from Groups 3 and 6 (prednisolone and budesonide) versus Group 1 (placebo)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-10 07:47:59 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>(see Barlas 1998)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-06-10 07:47:59 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>(see Barlas 1998)</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-06-10 07:48:00 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>(see Barlas 1998)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-01-05 09:27:24 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_">
<CHAR_METHODS MODIFIED="2010-06-25 08:01:01 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>(see Barlas 1998)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-25 08:01:02 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>(see Barlas 1998)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-05 09:27:24 +1000" MODIFIED_BY="[Empty name]">
<P>(see Barlas 1998)</P>
<P>This glucocorticoid + salbutamol versus salbutamol comparison includes data from Group 4 (prednisolone and albuterol) versus Group 2 (albuterol)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 08:01:02 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>(see Barlas 1998)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-06-25 08:01:02 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>(see Barlas 1998)</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-06-25 08:01:02 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>(see Barlas 1998)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-19 23:58:24 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bentur-2005">
<CHAR_METHODS MODIFIED="2013-01-07 10:38:17 +1000" MODIFIED_BY="[Empty name]">
<P>Parallel design, 2-arm</P>
<P>Centres: NR, conducted in Israel</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Inpatients</P>
<P>
<I>Inclusion/exclusion criteria</I>
<BR/>Inclusion criteria: age 3 to 12 months; 1st episode wheezing/dyspnoea; RSV present; parental consent<BR/>Exclusion criteria: previous therapy with systemic glucocorticoids; inhaled &#946;<SUB>2</SUB>-agonists prior to admission; other chronic diseases</P>
<P>
<I>Participant characteristics </I>
<BR/>
<I>All groups</I>
<BR/>Sample size: randomised (N): NR, analysed - trial/review primary outcomes (N): 61 (unclear what type of analysis was performed regarding ITT and missing data)</P>
<P>
<I>GROUP 1</I>
<BR/>Sample size: randomised (N): NR, analysed - trial/review primary outcomes (N): 29</P>
<P>Age, mean ± SD: 3.3 ± 2.5<BR/>Males, N (%): 14 (48.3)<BR/>RSV status: all positive</P>
<P>
<I>GROUP 2</I>
<BR/>Sample size: randomised (N): NR, analysed - trial/review primary outcomes (N): 32</P>
<P>Age, mean ± SD: 3.8 ± 2.0<BR/>Males, N (%): 14 (43.8)<BR/>RSV status: all positive</P>
<P>Atopic status: NR</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>GROUP 1 (with glucocorticoid)</I>
<BR/>Drug name: dexamethasone + epinephrine<BR/>Dose: 0.25 mg (dex) + 1 mL (epi)<BR/>Mode of administration: nebulised in 5 L/minute pre-specified 100% O<SUB>2</SUB>
<BR/>Timing/duration: every 6h until discharge</P>
<P>
<I>GROUP 2 </I>
<BR/>Drug name: placebo - 0.9% saline + epinephrine<BR/>Dose: 0.5 mL (0.9% sal) + 1 mL (epi)<BR/>Mode of administration: nebulised in 5 L/minute pre-specified 100% O<SUB>2</SUB>
<BR/>Timing/duration: every 6h until discharge</P>
<P>Additional co-interventions for all groups: O<SUB>2</SUB> therapy if SaO<SUB>2</SUB> &lt; 92%; IV fluids if respiratory rate &gt; 60 bpm<BR/>Protocolised use of bronchodilators with glucocorticoids: yes (epinephrine)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-19 23:58:24 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
</P>
<P>NR</P>
<P>
<I>Outcome used to calculate sample size</I>
<BR/>Clinical scale developed for this trial - 10-point score, based on respiratory rate, wheezing, retraction, general condition, oxygen saturation</P>
<P>
<I>Secondary outcomes</I>
<BR/>Length of stay (and time-to-discharge analysis); SaO<SUB>2</SUB>*; respiratory rate*; heart rate*; duration of O<SUB>2</SUB> and IV fluids; clinical status#; hospital re-admissions#; wheezing exacerbations#<BR/>*time points: baseline, every 8 hours<BR/>#time points: 1 week, 1 mo., 3 mo. post discharge</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-03-24 01:17:06 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>NR</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-07-14 14:25:13 +1000" MODIFIED_BY="[Empty name]">
<P>Study reported stratified results for premature and term infants; no specific interaction term</P>
<P>This study contributed to the following comparisons in this review: steroid versus placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-19 23:58:33 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berger-1998">
<CHAR_METHODS MODIFIED="2013-01-07 10:39:09 +1000" MODIFIED_BY="[Empty name]">
<P>Parallel design, 2-arm</P>
<P>Single-centre, conducted in Israel (affiliations: Shaare Zedek Medical Center, Jerusalem)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Outpatients (emergency department)</P>
<P>
<I>Inclusion/exclusion criteria</I>
<BR/>Inclusion criteria: age &#8804; 18 months; 1st episode of wheezing associated with low-grade fever, rhinitis, tachypnoea and increased respiratory effort; otherwise healthy infant<BR/>Exclusion criteria: chronic cardiopulmonary disease; asthma; proven or suspected acute bacterial infection; previous therapy with glucocorticoids; symptoms &gt; 7d; fever &gt; 38.5°C; severe bronchiolitis (clinical score &gt; 7)</P>
<P>
<I>Participant characteristics </I>
<BR/>
<I>All groups</I>
<BR/>Sample size: randomised (N): 42, analysed - trial/review primary outcomes (N): 38 (per protocol analysis was used)</P>
<P>
<I>GROUP 1</I>
<BR/>Sample size: randomised (N): NR, analysed - trial/review primary outcomes (N): 20</P>
<P>Age, mean ± SD: 5.2 ± 0.7<BR/>Males, N (%): NR<BR/>RSV status: 50% positive<BR/>Atopic status: 1/20 (infant), 3/20 (family)</P>
<P>
<I>GROUP 2</I>
<BR/>Sample size: randomised (N): NR, analysed - trial/review primary outcomes (N): 18</P>
<P>Age, mean ± SD: 4.8 ± 0.9<BR/>Males, N (%): NR<BR/>RSV status: 50% positive<BR/>Atopic status: 0 (infant), 4/20 (family)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>GROUP 1 (with glucocorticoid)</I>
<BR/>Drug name: prednisone<BR/>Dose: 1 mg/kg<BR/>Mode of administration: oral<BR/>Timing/duration: twice daily, 3 days</P>
<P>
<I>GROUP 2</I>
<BR/>Drug name: placebo (NR)<BR/>Dose: 1 mg/kg<BR/>Mode of administration: oral<BR/>Timing/duration: twice daily, 3 days</P>
<P>Additional co-interventions for all groups: inhaled albuterol solution 0.03 mL/kg/dose (0.15 mg/kg/dose) every 4 to 6 hours; O<SUB>2</SUB> and hydration as needed<BR/>Protocolised use of bronchodilators with glucocorticoids: yes (salbutamol)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-19 23:58:33 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>
<I>Primary outcome</I>
<BR/>NR</P>
<P>
<I>Outcome used to calculate sample size</I>
<BR/>Clinical scale developed for this trial - 9-point score, based on respiratory rate, wheezing, accessory muscle use</P>
<P>
<I>Secondary outcomes</I>
<BR/>Initial hospital admission (usually within 4 h); SaO<SUB>2</SUB>*; respiratory rate*; well-being#; return healthcare visits#; medications#; recurrent symptoms (by 2 years)<BR/>*time points: baseline, 3 days<BR/>#time points: 7 days<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-03-24 08:36:46 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>NR</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-07-14 14:25:08 +1000" MODIFIED_BY="[Empty name]">
<P>Study did not report any study-level subgroup analyses</P>
<P>This study contributed to the following comparisons in this review: steroid versus placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-05 00:57:10 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cade-2000">
<CHAR_METHODS MODIFIED="2013-01-07 10:40:23 +1000" MODIFIED_BY="[Empty name]">
<P>Parallel design, 2-arm</P>
<P>Multi-centre (5), conducted in the UK (West Yorkshire hospitals)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-05 00:57:10 +1000" MODIFIED_BY="[Empty name]">
<P>Inpatients</P>
<P>
<I>Inclusion/exclusion criteria</I>
<BR/>Inclusion criteria: age &lt; 12 mo.; confirmed RSV; informed consent; randomised within 12 hours admission<BR/>Exclusion criteria: history of hospitalisation with respiratory tract illness; chronic respiratory illness; congenital heart disease; prematurity; pre-existing immunodeficiencies; recent exposure to varicella or tuberculosis; prolonged exposure to systemic glucocorticoids</P>
<P>
<I>Participant characteristics </I>
<BR/>
<I>All groups</I>
<BR/>Sample size: randomised (N): 165, analysed - trial primary outcome (N): 155 (ITT with available case analysis was used), analysed - review primary outcome (N): 161 (ITT with available case analysis was used)</P>
<P>
<I>GROUP 1</I>
<BR/>Sample size: randomised (N): 83, analysed - trial primary outcome (N): 79, analysed - review primary outcome (N): 82</P>
<P>Age, mean ± SD: 4.3 ± 2.8<BR/>Males, N (%): 45 (54.9)<BR/>RSV status: all positive<BR/>Atopic status: 43/82 present (infant)</P>
<P>
<I>GROUP 2</I>
<BR/>Sample size: randomised (N): 82, analysed - trial primary outcome (N): 76, analysed - review primary outcome (N): 79</P>
<P>Age, mean ± SD: 4.0 ± 2.8<BR/>Males, N (%): 47 (59.5)<BR/>RSV status: all positive<BR/>Atopic status: 38/79 present (infant)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-19 21:32:07 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>GROUP 1 (with glucocorticoid)</I>
<BR/>Drug name: budesonide<BR/>Dose: 1 mg<BR/>Mode of administration: nebulised 10 minutes<BR/>Timing/duration: twice daily, 14 to 21 days</P>
<P>
<I>GROUP 2</I>
<BR/>Drug name: placebo (NR)<BR/>Dose: NR<BR/>Mode of administration: nebulised 10 minutes<BR/>Timing/duration: twice daily, 14 to 21 days</P>
<P>Additional co-interventions for all groups: 6.5 L/minute O<SUB>2</SUB> therapy; reported use of ipratropium bromide, B<SUB>2</SUB> agonists, oral/IV glucocorticoids, antibiotics<BR/>Protocolised use of bronchodilators with glucocorticoids: no</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-19 23:58:39 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome/outcome used to calculate sample size</I>
<BR/>Coughing or wheezing episodes (within 12 mo.; proportion with at least 1 episode)</P>
<P>
<I>Secondary outcomes</I>
<BR/>LOS; clinical scale developed for this trial - 11-point score, based on heart rate, respiratory rate, supplemental oxygen requirements, and the presence or absence of chest wall retractions*; additional medication use*#; hospital readmission#; return healthcare visits#; respiratory symptoms#<BR/>*time points: during hospitalisation<BR/>#time points: first 28 days, by 12 months (personal diaries, nurse visits, medical records)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-03-24 21:01:15 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Astra Foundation - full financial support grant</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Study reported analyses of some outcomes by initial severity score, duration of symptoms at presentation, atopic history and exposure to cigarette smoke or damp in the household; no specific interaction term</P>
<P>This study contributed to the following comparisons in this review: steroid versus placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-19 23:48:37 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Corneli-2007">
<CHAR_METHODS MODIFIED="2013-01-07 10:42:28 +1000" MODIFIED_BY="[Empty name]">
<P>Parallel design, 2-arm</P>
<P>Multi-centre (20), conducted in the US (centres from the Pediatric Emergency Care Applied Research Network - PECARN)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Outpatients (emergency department)</P>
<P>
<I>Inclusion/exclusion criteria</I>
<BR/>Inclusion criteria: age 2 to 12 mo.; 1st episode of bronchiolitis (no wheezing, asthma, no previous use of bronchodilators); within 7 days onset; moderate to severe (RDAI &#8805; 6)<BR/>Exclusion criteria: prior adverse event to dexamethasone; heart or lung disease; premature birth (&lt; 36 weeks); immunosuppression or immunodeficiency; therapy with glucocorticoids in previous 14 d; active or recent exposure to varicella; critically ill; parent inability to speak English/Spanish</P>
<P>
<I>Participant characteristics </I>
<BR/>
<I>All groups</I>
<BR/>Sample size: randomised (N): 600, analysed - review/trial primary outcome (N): 600 (ITT with all data used; also performed per protocol analysis)</P>
<P>
<I>GROUP 1</I>
<BR/>Sample size: randomised (N): 305, analysed - review/trial primary outcome (N): 305</P>
<P>Age, mean ± SD: 5.1 ± 2.6 months<BR/>Males, N (%): 190 (62.5)<BR/>RSV status: 85/127 positive<BR/>
<BR/>
<I>GROUP 2</I>
<BR/>Sample size: randomised (N): 295, analysed - review/trial primary outcome (N): 295</P>
<P>Age, mean ± SD: 5.1 ± 2.8 months<BR/>Males, N (%): 178 (60.5)<BR/>RSV status: 81/142 positive</P>
<P>Atopic status: NR (reported family history of wheezing)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-19 20:41:50 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>
<I>GROUP 1 (with glucocorticoid)</I>
<BR/>Drug name: dexamethasone<BR/>Dose: 1 mL/kg (max 12 mg); oral solution = 1 mg/mL of liquid from generic dexamethasone phosphate injection solution<BR/>Mode of administration: oral<BR/>Timing/duration: 1 dose</P>
<P>
<I>GROUP 2</I>
<BR/>Drug name: placebo (NR)<BR/>Dose: 1 mL/kg (max 12 mg)<BR/>Mode of administration: oral<BR/>Timing/duration: 1 dose</P>
<P>Additional co-interventions for all groups: reported use of albuterol, epinephrine<BR/>Protocolised use of bronchodilators with glucocorticoids: no</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-19 23:48:37 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome/outcome used to calculate sample size</I>
<BR/>Hospital admission (at 4 hours)</P>
<P>
<I>Secondary outcomes</I>
<BR/>Length of stay for admitted patients; SaO<SUB>2</SUB>*; respiratory rate *; heart rate *; temperature*; clinical scale: Respiratory Assessment Change Score, a change score based on RDAI and respiratory rate change from baseline*; hospital re-admission#; return healthcare visits#; adverse events#<BR/>*time points: 4 hours<BR/>#time points: within 7 to 10 days</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-01-07 10:43:24 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Grant from the Maternal and Child Health Research program and co-operative agreements with the Emergency Medical Services for Children program of the Maternal and Child Health Bureau, Health Resources and Services Administration</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Study reported subgroup analyses of patients with eczema or a family history of asthma (pre-specified), RSV positive and aged &lt; 6 months; adjusted analysis plan with interaction terms</P>
<P>This study contributed to the following comparisons in this review: steroid versus placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-19 23:58:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Boeck-1997">
<CHAR_METHODS MODIFIED="2013-01-07 10:43:40 +1000" MODIFIED_BY="[Empty name]">
<P>Parallel design, 2-arm</P>
<P>Single-centre, conducted in Belgium (affiliation: University Hospital Leuven)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Inpatients</P>
<P>
<I>Inclusion/exclusion criteria</I>
<BR/>Inclusion criteria: age &lt; 24 months; detection of RSV; 1st episode of wheezing or shortness of breath; onset of illness within the previous 5 days; informed consent<BR/>Exclusion criteria: heart, lung or immune disorder; premature infants born before 34 weeks</P>
<P>
<I>Participant characteristics </I>
<BR/>
<I>All groups</I>
<BR/>Sample size: randomised (N): 32, analysed - all trial outcomes (N): 29 (per protocol analysis was used)</P>
<P>
<I>GROUP 1</I>
<BR/>Sample size: randomised (N): NR, analysed - all trial outcomes (N): 14</P>
<P>Age: 6.2 (median), 3.7 to 7.5 (IQR) months<BR/>RSV status: all positive<BR/>
<BR/>
<I>GROUP 2</I>
<BR/>Sample size: randomised (N): NR, analysed - all trial outcomes (N): 15</P>
<P>Age: 7.1 (median), 4.4 to 8.9 (IQR)<BR/>RSV status: all positive</P>
<P>Males, N (%): NR<BR/>Atopic status: NR</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-19 20:41:51 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>
<I>GROUP 1 (with glucocorticoid)</I>
<BR/>Drug name: dexamethasone<BR/>Dose: 0.6 mg/kg<BR/>Mode of administration: IV<BR/>Timing/duration: day 1, 2 doses of 0.6 mg/kg; days 2 and 3, 0.15 mg/kg</P>
<P>
<I>GROUP 2</I>
<BR/>Drug name: placebo (NR)<BR/>Dose: NR<BR/>Mode of administration: IV<BR/>Timing/duration: day 1, 2 doses of 0.6 mg/kg; days 2 and 3, 0.15 mg/kg</P>
<P>Additional co-interventions for all groups: salbutamol (0.5%); 0.25 mL, ipratropium bromide (0.025%), 0.5 mL; both aerosolised every 6 h; also reported use of antibiotics<BR/>Protocolised use of bronchodilators with glucocorticoids: yes (salbutamol + ipratropium)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-19 23:58:46 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome/outcome used to calculate sample size</I>
<BR/>NR<BR/>
</P>
<P>
<I>Secondary outcomes</I>
<BR/>LOS; SaO<SUB>2</SUB>*; respiratory rate*; clinical scale modified from Tal et al - 12-point score; pulmonary function tests (minute ventilation, dynamic lung compliance, and airway resistance - PEDS, MAS, Inc., Hatfield, Pa.) (before/after aerosol and day 3)<BR/>*time points: every 12 hours until day 3<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-04-22 08:09:23 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>NR</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-07-14 14:24:45 +1000" MODIFIED_BY="[Empty name]">
<P>Study did not report any study-level subgroup analyses</P>
<P>This study contributed to the following comparisons in this review: steroid versus placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goebel-2000">
<CHAR_METHODS MODIFIED="2013-01-07 10:45:03 +1000" MODIFIED_BY="[Empty name]">
<P>Parallel design, 2-arm</P>
<P>Multi-centre (2), conducted in the US (University of South Alabama)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-19 20:58:47 +1000" MODIFIED_BY="[Empty name]">
<P>Outpatients (paediatric emergency department/children's clinic)</P>
<P>
<I>Inclusion/exclusion criteria</I>
<BR/>Inclusion criteria: age 23 months of age or younger; viral respiratory tract infection; 1st time wheeze that did not clear completely after 1 dose of nebulised albuterol<BR/>Exclusion criteria: history of immune defect; neurological disease with possible aspiration; gastroesophageal reflux; congenital or acquired chronic heart or lung disease; mechanical ventilation; birth &lt; 36 weeks; temp &gt; 38.5°C (rectal); antibiotic therapy &lt; 1 week or antipyretic therapy &lt; 8 hours before enrolment; concomitant bacterial infection; emesis precluding oral medications; initial bronchiolitis score &lt; 2 or &gt; 9</P>
<P>
<I>Participant characteristics </I>
<BR/>
<I>All groups</I>
<BR/>Sample size: randomised (N): 51, analysed - primary trial outcome (N): 32 (per protocol analysis was used), analysed - review primary outcome (N): 48 (per protocol analysis was used)</P>
<P>
<I>GROUP 1</I>
<BR/>Sample size: randomised (N): NR, analysed - primary trial outcome (N): 17, analysed - review primary outcome (N): 24</P>
<P>Age: 4.0 (median); 0 to 13 (range) months<BR/>Males, N (%): 6 (25)<BR/>RSV status: 11 positive</P>
<P>
<I>GROUP 2</I>
<BR/>Sample size: randomised (N): NR, analysed - primary trial outcome (N): 15, analysed - review primary outcome (N): 24</P>
<P>Age: 4.5 (median); 0 to 16 (range)<BR/>Males, N (%): 8 (33.3)<BR/>RSV status: 15 positive</P>
<P>Atopic status: NR</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>GROUP 1 (with glucocorticoid)</I>
<BR/>Drug name: prednisolone<BR/>Dose: 2 mg/kg/day<BR/>Mode of administration: oral<BR/>Timing/duration: twice per day for 5 days</P>
<P>
<I>GROUP 2</I>
<BR/>Drug name: placebo - similar in appearance and taste, 100 mL each of water and glycerin with 5 mL of cherry-flavoured Kool-Aid and 100 mg of quinine<BR/>Dose: equal volume per body weight<BR/>Mode of administration: oral<BR/>Timing/duration: twice per day for 5 days</P>
<P>Additional co-interventions for all groups: albuterol initially 1 dose (0.15 mg/kg), continued at 0.3 mg/kg/d 3 times a day by mouth or 0.15 mg/kg/dose qid by nebuliser</P>
<P>Protocolised use of bronchodilators with glucocorticoids: yes (salbutamol)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
<BR/>Clinical scale modified from Tal et al: 12-point score, based on respiratory rate, flaring or retractions, oxygen saturation on room air, and wheezing*</P>
<P>
<I>Outcome used to calculate sample size</I>
<BR/>NR<BR/>
</P>
<P>
<I>Secondary outcomes</I>
<BR/>Hospital admission - initial and later; adverse events<BR/>*time points: days 2, 3, 6, full convalescence</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-03-24 22:44:12 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>NR</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-07-14 10:05:29 +1000" MODIFIED_BY="[Empty name]">
<P>Study did not report any study-level subgroup analyses</P>
<P>This study contributed to the following comparisons in this review: steroid versus placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-19 23:58:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gomez-2007">
<CHAR_METHODS MODIFIED="2013-01-07 10:45:57 +1000" MODIFIED_BY="[Empty name]">
<P>Parallel design, 2-arm</P>
<P>Single-centre, conducted in Mexico (Hospital General de Zona 1, San Luis Potosi)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Inpatients (emergency department and infant paediatric department)</P>
<P>
<I>Inclusion/exclusion criteria</I>
<BR/>Inclusion criteria: age 1 to 18 mo.; observed in the ED of the centre; clinical and radiological diagnosis of bronchiolitis; &lt; 72 hours of evolution of symptoms; RDAI score &gt; 2, Silvermann-Andersen score &gt; 0; informed consent<BR/>Exclusion criteria: previous bronchospasm/bronchiolitis; congenital heart disease; chronic lung disease; possible bronchopneumonia; children treated with salbutamol/dexamethasone in the previous 48 hours</P>
<P>
<I>Participant characteristics </I>
<BR/>
<I>All groups</I>
<BR/>Sample size: randomised (N): NR, analysed - trial primary outcomes (N): 49 (unclear what type of analysis was performed regarding ITT and missing data)</P>
<P>
<I>GROUP 1</I>
<BR/>Sample size: randomised (N): NR, analysed - all trial outcomes (N): 24</P>
<P>Age, mean ± SD: 5.7 ± 1.3 months<BR/>Males, N (%): 12 (50)</P>
<P>
<I>GROUP 2</I>
<BR/>Sample size: randomised (N): NR, analysed - primary trial outcome (N): 25</P>
<P>Age, mean ± SD: 5.22 ± 1.6 months<BR/>Males, N (%): 13 (52)</P>
<P>RSV status: NR<BR/>Atopic status: NR</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>GROUP 1</I>
<BR/>Drug name: salbutamol<BR/>Dose: 0.3 mL/1.5 mg<BR/>Mode of administration: nebulised in 5 L/minute of O<SUB>2</SUB>
<BR/>Timing/duration: every 4 hours for 24 hours (total 6 doses)</P>
<P>
<I>GROUP 2 (with glucocorticoid)</I>
<BR/>Drug name: salbutamol + dexamethasone<BR/>Dose: 0.3 mL/1.5 mg (salb) + dexamethasone: 0.5 mL/2 mg<BR/>Mode of administration: nebulised<BR/>Timing/duration: every 4 hours for 24 hours (total 6 doses)</P>
<P>Additional co-interventions for all groups: NR<BR/>Protocolised use of bronchodilators with glucocorticoids: yes (salbutamol)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-19 23:58:52 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome/outcome used to calculate sample size</I>
<BR/>NR<BR/>
</P>
<P>
<I>Secondary outcomes</I>
<BR/>LOS; SaO<SUB>2</SUB>*; respiratory rate*; heart rate*; clinical scale: RDAI, 17-point score based on wheezing and retractions*<BR/>*time points: every 4 hours until 24 hours<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-03-24 22:52:21 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>NR</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-07-14 10:07:11 +1000" MODIFIED_BY="[Empty name]">
<P>Study did not report any study-level subgroup analyses</P>
<P>This study contributed to the following comparisons in this review: steroid versus placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-19 23:58:57 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klassen-1997">
<CHAR_METHODS MODIFIED="2013-01-07 10:47:34 +1000" MODIFIED_BY="[Empty name]">
<P>Parallel design, 2-arm</P>
<P>Single-centre, conducted in Canada (Children's Hospital of Eastern Ontario)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Inpatients (inpatient wards, paediatric tertiary hospital)</P>
<P>
<I>Inclusion/exclusion criteria</I>
<BR/>Inclusion criteria: age &gt; 6 weeks &lt; 15 mo.; 1st time wheeze; evidence of viral infection (rhinorrhoea/ temp &gt; 37.5°C); admitted to inpatient ward; SaO<SUB>2</SUB> &lt; 95%; RDAI score &gt; 6<BR/>Exclusion criteria: underlying disease that might affect cardiopulmonary status; asthma; wheezing/cough previously treated with bronchodilators; therapy with glucocorticoids within the past 2 weeks; history of adverse events with glucocorticoids<BR/>
</P>
<P>
<I>Participant characteristics </I>
<BR/>
<I>All groups</I>
<BR/>Sample size: randomised (N): 72 (5 ineligible), analysed - trial/review primary outcome (N): 67 (ITT with available case analysis was used)</P>
<P>
<I>GROUP 1</I>
<BR/>Sample size: randomised (N): 35, analysed - trial/review primary outcomes (N): 35</P>
<P>Age, mean: 4.68; 3.6 to 5.76 (95% CI)<BR/>Males, N (%): 22 (63)<BR/>RSV status: 30 (86%) positive</P>
<P>
<I>GROUP 2</I>
<BR/>Sample size: randomised (N): 37, analysed - trial/review primary trial outcome (N): 32</P>
<P>Age, mean: 4.68; 3.6 to 5.64 (95% CI)<BR/>Males, N (%): 15 (47)<BR/>RSV status: 28 (88%) positive</P>
<P>Atopic status: NR</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>GROUP 1 (with glucocorticoid)</I>
<BR/>Drug name: dexamethasone (clear 70% sucrose solution + dex sodium phosphate)<BR/>Dose: 1st: 0.5 mg/kg; 2nd and others: 0.3 mg/kg<BR/>Mode of administration: oral<BR/>Timing/duration: 3 doses max: at admission, once each of the following mornings or until discharge (if before)</P>
<P>
<I>GROUP 2</I>
<BR/>Drug name: placebo (70% sucrose solution)<BR/>Dose: NR<BR/>Mode of administration: oral<BR/>Timing/duration: 3 doses max: at admission, once each of the following mornings or until discharge (if before)</P>
<P>Additional co-interventions for all groups: salbutamol by nebulisation, 0.15 mg/kg every 4 hours for first 24 hours, O<SUB>2</SUB> concentration of 35% in a plastic tent; reported use of additional bronchodilators and antibiotics<BR/>Protocolised use of bronchodilators with glucocorticoids: yes (salbutamol)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-19 23:58:57 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome/outcome used to calculate sample size</I>
<BR/>Clinical scale: RDAI, 17-point score based on wheezing and retractions (at 24 h; other time points*)</P>
<P>
<I>Secondary outcomes</I>
<BR/>LOS; SaO<SUB>2</SUB>*; respiratory rate*; heart rate*; hospital readmission (1 week); return healthcare visits; adverse events, number of nebulisation; additional medications<BR/>*time points: 12, 24, 36, 48, 60 hours<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-03-24 23:32:29 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Grant from Physicians Services Inc, Toronto, Ontario, Canada</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-07-14 10:08:43 +1000" MODIFIED_BY="[Empty name]">
<P>Study did not report any study-level subgroup analyses</P>
<P>This study contributed to the following comparisons in this review: steroid versus placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-19 23:59:03 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuyucu-2004">
<CHAR_METHODS MODIFIED="2013-03-19 20:40:29 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Double-randomisation/factorial design, 4 arms</P>
<P>Single-centre, conducted in Turkey (Faculty of Medicine, Mersin University)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Outpatients (paediatric outpatient clinics and emergency department)</P>
<P>
<I>Inclusion/exclusion criteria</I>
<BR/>Inclusion criteria: age 2 to 21 mo.; admitted with 1st episode of wheezing; clinical findings compatible with acute bronchiolitis; RDAI &#8805; 4<BR/>Exclusion criteria: history of wheezing; previous therapy with bronchodilators; previous diagnosis of asthma or allergic bronchitis; personal history of atopic dermatitis or allergic rhinitis; chronic cardiac or pulmonary disease; any glucocorticoid therapy in the previous 2 week; signs of severe respiratory disease; bacterial infection; parental history of asthma or atopic disease</P>
<P>
<I>Participant characteristics </I>
<BR/>
<I>All groups</I>
<BR/>Sample size: randomised (N): 90, analysed - trial/review primary outcome (N): 69 (ITT with available case analysis was used)</P>
<P>
<I>GROUP 1</I>
<BR/>Sample size: randomised (N): 26, analysed - trial/review primary outcomes (N): 23</P>
<P>Age, mean ± SD: 7.2 ± 0.8 months</P>
<P>
<I>GROUP 2</I>
<BR/>Sample size: randomised (N): 24, analysed - trial/review primary trial outcome (N): 23</P>
<P>Age, mean ± SD: 7.9 ± 1.0 months</P>
<P>
<I>GROUP 3</I>
<BR/>Sample size: randomised (N): 19, analysed - trial/review primary trial outcome (N): 11</P>
<P>Age, mean ± SD: 9.6 ± 1.3 months</P>
<P>GROUP 4<BR/>Sample size: randomised (N): 21, analysed - trial/review primary trial outcome (N): 12<BR/>
</P>
<P>Age, mean ± SD: 9.9 ± 1.7 months<BR/>
<BR/>Males, N (%): NR<BR/>RSV status NR<BR/>Atopic status: NR</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-19 20:41:57 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>GROUP 1 (with glucocorticoid)</I>
<BR/>Drug name: epinephrine + dexamethasone<BR/>Dose: 3 mL (3 mg) of 1:1000 L-epinephrine + 0.6 mg/kg (dex)<BR/>Mode of administration: nebulised with O<SUB>2</SUB>, flow 5 to 6 L/minute for 10 minutes (epi) + IM (dex)<BR/>Timing/duration: epinephrine - initial dose, if no improvement at 120 minutes, then 2nd dose given; dexamethasone single dose</P>
<P>
<I>GROUP 2 (with glucocorticoid)</I>
<BR/>Drug name: salbutamol + dexamethasone<BR/>Dose: 0.15 mg/kg of 1 mg/mL solution of salbutamol added to 0.9% saline to total 3 mL+ 0.6 mg/kg (dex)<BR/>Mode of administration: nebulised with O<SUB>2</SUB>, flow 5 to 6 L/minute for 10 minutes (epi) + IM (dex)<BR/>Timing/duration: salbutamol - initial dose, if no improvement at 120 minutes, then 2nd dose given; dexamethasone single dose</P>
<P>
<I>GROUP 3</I>
<BR/>Drug name: epinephrine + placebo (NR)<BR/>Dose: 3 mL (3 mg) of 1:1000 L-epinephrine<BR/>Mode of administration: nebulised with O<SUB>2</SUB>, flow 5 to 6 L/minute for 10 minutes (epi) + IM (pla)<BR/>Timing/duration: epinephrine - initial dose, if no improvement at 120 minutes, then 2nd dose given; placebo single dose</P>
<P>
<I>GROUP 4</I>
<BR/>Drug name: salbutamol + placebo (NR)<BR/>Dose: 0.15 mg/kg of 1 mg/mL solution of salbutamol added to 0.9% saline solution to make a total of 3 mL<BR/>Mode of administration: nebulised with O2, flow 5 to 6 L/minute for 10 minutes (epi) + IM (pla)<BR/>Timing/duration: salbutamol - initial dose, if no improvement at 120 minutes, then 2nd dose given; placebo single dose</P>
<P>Additional co-interventions for all groups: NR<BR/>Protocolised use of bronchodilators with glucocorticoids: yes (epinephrine Group 1, salbutamol Group 2)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-19 23:59:03 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
<BR/>Respiratory rate*; heart rate*; clinical scale*: RDAI, 17-point score based on wheezing and retractions</P>
<P>
<I>Outcome used to calculate sample size</I>
<BR/>NR</P>
<P>
<I>Secondary outcomes</I>
<BR/>Admissions; additional medication; adverse events; respiratory complaints (2 months)<BR/>*time points: 30, 60, 90, 120 minutes, 24 hours, 5 days</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-03-25 01:16:44 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>NR</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2013-03-19 21:04:06 +1000" MODIFIED_BY="[Empty name]">
<P>Study did not report any study-level subgroup analyses</P>
<P>This study contributed to the following comparisons in this review: steroid versus. Placebo, steroids + epinephrine versus salbutamol, steroids + salbutamol versus epinephrine</P>
<P>Factorial design not reported explicitly; analysis was "inside the table", and did not aggregate group results</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-14 10:11:34 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<CHAR_METHODS MODIFIED="2010-06-25 23:50:56 +1000" MODIFIED_BY="[Empty name]">
<P>(see Kuyucu 2004)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-25 23:51:04 +1000" MODIFIED_BY="[Empty name]">
<P>(see Kuyucu 2004)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-14 10:11:34 +1000" MODIFIED_BY="[Empty name]">
<P>(see Kuyucu 2004)</P>
<P>This glucocorticoid versus placebo comparison includes data from Group 1 (epinephrine + dexamethasone) versus Group 3 (epinephrine + placebo)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 23:51:02 +1000" MODIFIED_BY="[Empty name]">
<P>(see Kuyucu 2004)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-06-25 23:51:02 +1000" MODIFIED_BY="[Empty name]">
<P>(see Kuyucu 2004)</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-06-25 23:51:00 +1000" MODIFIED_BY="[Empty name]">
<P>(see Kuyucu 2004)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-14 10:11:38 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_">
<CHAR_METHODS MODIFIED="2010-06-25 23:52:41 +1000" MODIFIED_BY="[Empty name]">
<P>(see Kuyucu 2004)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-25 23:52:41 +1000" MODIFIED_BY="[Empty name]">
<P>(see Kuyucu 2004)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-14 10:11:38 +1000" MODIFIED_BY="[Empty name]">
<P>(see Kuyucu 2004)</P>
<P>This glucocorticoid versus placebo comparison includes data from Group 1 (salbutamol + dexamethasone) versus Group 3 (salbutamol + placebo)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 23:52:41 +1000" MODIFIED_BY="[Empty name]">
<P>(see Kuyucu 2004)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-06-25 23:52:41 +1000" MODIFIED_BY="[Empty name]">
<P>(see Kuyucu 2004)</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-06-25 23:52:41 +1000" MODIFIED_BY="[Empty name]">
<P>(see Kuyucu 2004)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-19 23:59:08 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mesquita-2009">
<CHAR_METHODS MODIFIED="2013-01-07 10:52:50 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Parallel design, 2 arms</P>
<P>Single-centre, conducted in Paraguay (Hospital General Pediátrico &#8220;Niños de Acosta Ñu&#8221;, Asunción)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Outpatients (paediatric emergency department)</P>
<P>
<I>Inclusion/exclusion criteria</I>
<BR/>Inclusion criteria: age 2 to 24 mo.; 1st episode of bronchiolitis defined as respiratory distress, respiratory rate 40 to 80 bpm, wheezing; &lt; 7 d after onset of cold<BR/>Exclusion criteria: clinical or radiological pneumonia; cardiopulmonary congenital malformations; bronchopulmonary dysplasia; cystic fibrosis; foreign body aspirations;<BR/>neurological alteration; previous wheezing or asthma episode; inhaled or systemic glucocorticoid &lt; 15 d; &#946;<SUB>2</SUB>-agonists &lt; 4 hours; history of atopy in the child (dermatitis or allergic rhinitis) or parental asthma; severe wheezing attack (respiratory rate &#8805; 100/minute and/or heart rate &#8805; 200/minute and/or shock or lethargy)</P>
<P>
<I>Participant characteristics </I>
<BR/>
<I>All groups</I>
<BR/>Sample size: randomised (N): 80, analysed - trial/review primary outcomes (N): 65 (per protocol analysis was used)</P>
<P>
<I>GROUP 1</I>
<BR/>Sample size: randomised (N): NR, analysed - trial/review primary outcomes (N): 33</P>
<P>Age, mean ± SD: 7.3 ± 4 months<BR/>Males, N (%): 19 (58)<BR/>RSV status: 17/29 positive</P>
<P>
<I>GROUP 2</I>
<BR/>Sample size: randomised (N): NR, analysed - trial/review primary trial outcome (N): 32 (available case analysis was used)</P>
<P>Age, mean ± SD: 5.9 ± 3 months<BR/>Males, N (%): 15 (47)<BR/>RSV status: 19/23 positive</P>
<P>Atopic status: NR</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>GROUP 1 (with glucocorticoid)</I>
<BR/>Drug name: dexamethasone<BR/>Dose: 0.5 mg/kg (1 mL/kg)<BR/>Mode of administration: oral<BR/>Timing/duration: 1 dose<BR/>
<BR/>
<I>GROUP 2</I>
<BR/>Drug name: placebo (NR)<BR/>Dose: 1 mL/kg<BR/>Mode of administration: oral<BR/>Timing/duration: 1 dose<BR/>Co-interventions:</P>
<P>Additional co-interventions for all groups: all patients received 4 mL physiological solution during a 6-minute nebulisation with 0<SUB>2 </SUB>flow of 6 L/minute; after 30 minutes, a dose of 1 mL L-adrenaline solution (1:1000, 1 mL = 1 mg) was received by nebulisation<BR/>Protocolised use of bronchodilators with glucocorticoids: yes (epinephrine)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-19 23:59:08 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>
<I>Primary outcome/outcome used to calculate sample size</I>
<BR/>Clinical scale*: RDAI, 17-point score based on wheezing and retractions (at 4 h; other time points*)</P>
<P>
<I>Secondary outcomes</I>
<BR/>Hospital admission (at 4 hours); SaO<SUB>2</SUB>*; respiratory rate*; heart rate*<BR/>*time points: 60 minutes, 4 hours</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-03-25 01:40:51 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>NR (Lab. Formula Magistral, Asunción, Paraguay provided drugs)</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-07-14 10:12:57 +1000" MODIFIED_BY="[Empty name]">
<P>Study did not report any study-level subgroup analyses</P>
<P>This study contributed to the following comparisons in this review: steroid versus placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-19 23:59:14 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Plint-2009">
<CHAR_METHODS MODIFIED="2013-01-07 10:54:24 +1000" MODIFIED_BY="[Empty name]">
<P>Factorial design, 4 arms</P>
<P>Multi-centre (8), conducted in Canada (hospitals are members of the research group Paediatric Emergency Research Canada)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Outpatients (paediatric emergency department)</P>
<P>
<I>Inclusion/exclusion criteria</I>
<BR/>Inclusion criteria: age 6 to 12 mo.; RDAI: 4 to 15; 1st episode wheezing associated with upper respiratory tract infection; presenting bronchiolitis<BR/>Exclusion criteria: prior bronchodilator treatment in the emergency department; oral or inhaled glucocorticoid during previous 2 weeks; previous episode of wheezing or history of asthma; previous bronchodilator use; chronic cardiopulmonary disease; immunodeficiency; serious distress (defined as a pulse rate &gt; 200 beats per minute, a respiratory rate &gt; 80 breaths per minute, or an RDAI score &gt; 15); lethargy; exposed to varicella &lt; 3 weeks; &lt; 37-week gestation who had a corrected age of less than 6 weeks at presentation; communication barriers with family</P>
<P>
<I>Participant characteristics </I>
<BR/>
<I>All groups</I>
<BR/>Sample size: randomised (N): 800, analysed - trial/review primary outcome (N): 797 (ITT with available case analysis was performed)</P>
<P>
<I>GROUP 1</I>
<BR/>Sample size: randomised (N): 200, analysed - trial/review primary outcomes (N): 199</P>
<P>Age: 5 (median) 3 to 7 (interquartile range) months<BR/>Males, N (%): 124 (62)<BR/>RSV status: 128 (64) positive<BR/>Atopic status: 28 (14) present (infant)</P>
<P>
<I>GROUP 2</I>
<BR/>Sample size: randomised (N): 199, analysed - trial/review primary trial outcome (N): 198</P>
<P>Age: 5 (median) 3 to 7 (interquartile range) months<BR/>Males, N (%): 122 (61)<BR/>RSV status: 129 (65) positive<BR/>Atopic status: 20 (10) present (infant)</P>
<P>
<I>GROUP 3</I>
<BR/>Sample size: randomised (N): 200, analysed - trial/review primary trial outcome (N): 199</P>
<P>Age: 5 (median) 3 to 7 (interquartile range) months<BR/>Males, N (%): 127 (64)<BR/>RSV status: 127 (64) positive<BR/>Atopic status: 19 (9.5) present (infant)</P>
<P>GROUP 4<BR/>Sample size: randomised (N): 201, analysed - trial/review primary trial outcome (N): 201<BR/>
</P>
<P>Age: 5 (median) 3 to 7 (interquartile range) months<BR/>Males, N (%): 120 (60)<BR/>RSV status: 136 (68) positive<BR/>Atopic status: 22 (10.9) present (infant)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>GROUP 1 (with glucocorticoid)</I>
<BR/>Drug name: epinephrine + dexamethasone (generic dexamethasone phosphate injection solution mixed with Ora-Plus and Ora-Sweet - Paddock Laboratories)<BR/>Dose: 3 mL 1:1000 solution (epi)+ 1.0 mg/kg weight (max 10 mg) then 0.6 mg/kg (max 10 mg) after ED (dex)<BR/>Mode of administration: nebulised in O<SUB>2</SUB> flow 8L/minute (epi) + oral (dex)<BR/>Timing/duration: nebulise 2 doses 30 minutes apart (epi); oral after 1st nebulisation in ED, followed by 5, 1 x daily doses after leaving ED (dex)</P>
<P>
<I>GROUP 2</I>
<BR/>Drug name: epinephrine + placebo (Ora-Plus and Ora-Sweet)<BR/>Dose: 3 mL 1:1000 solution (epi) + placebo<BR/>Mode of administration: nebulised in O<SUB>2</SUB> flow 8 L/minute (epi) + oral (pla)<BR/>Timing/duration: nebulise 2 doses 30 minutes apart (epi); oral after 1st nebulisation in ED, followed by 5, 1 x daily doses after leaving ED (pla)</P>
<P>
<I>GROUP 3 (with glucocorticoid)</I>
<BR/>Drug name: dexamethasone + placebo (saline)<BR/>Dose: 1.0 mg/kg weight (max 10 mg) then 0.6 mg/kg (max 10 mg) after ED (dex) + 3 mL (pla)<BR/>Mode of administration: oral (dex) + nebulised in O<SUB>2</SUB> flow 8L/minute (pla)<BR/>Timing/duration: nebulise 2 doses 30 minutes apart (pla); oral after 1st nebulisation in ED, followed by 5, 1 x daily doses after leaving ED (dex)</P>
<P>
<I>GROUP 4</I>
<BR/>Drug name: placebo (saline) + placebo (Ora-Plus and Ora-Sweet)<BR/>Dose: 3 mL + oral<BR/>Mode of administration: nebulised in O<SUB>2</SUB> flow 8 L/minute + oral<BR/>Timing/duration: nebulise 2 doses 30 minutes apart; oral after 1st nebulisation in ED, followed by 5, 1 x daily doses after leaving ED</P>
<P>Additional co-interventions for all groups: O<SUB>2</SUB> if SaO<SUB>2</SUB> &lt; 92%; acetaminophen (15 mg/kg) if fever; additional interventions allowed after 90' - reported use of other bronchodilators and antibiotics<BR/>Protocolised use of bronchodilators with glucocorticoids: yes (epinephrine Group 1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-19 23:59:14 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome/outcome used to calculate sample size</I>
<BR/>Hospital admission by day 7</P>
<P>
<I>Secondary outcomes</I>
<BR/>Hospital admission by day 1 and day 22; SaO<SUB>2</SUB>*; respiratory rate*; heart rate*, temperature*; RDAI: 17-point score based on wheezing and retractions*; time to discharge (time between the triage time at the enrolment and the time of discharge from the last emergency department visit or from the last hospitalisation for each patient within the next 7 days); return healthcare visits#; symptoms (length/severity)#; adverse events<BR/>*time points: 30, 60, 120, 240 minutes<BR/>#time points: within 22 d</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-03-25 19:14:23 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Grants from the Canadian Institutes of Health Research and Alberta Children&#8217;s Hospital Foundation</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Study reported a priori subgroup analyses of presence or absence of atopy, RSV status and duration of illness at presentation; adjusted analysis plan with interaction terms</P>
<P>This study contributed to the following comparisons in this review: steroid versus placebo, steroids + epinephrine versus placebo</P>
<P>Analysis of factorial design was "inside the table", due to results suggesting unanticipated synergism between epinephrine and dexamethasone</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-14 10:11:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<CHAR_METHODS MODIFIED="2010-06-25 08:05:26 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>See Plint 2009</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-25 08:05:33 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>See Plint 2009</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-14 10:11:41 +1000" MODIFIED_BY="[Empty name]">
<P>See Plint 2009</P>
<P>This glucocorticoid and epinephrine versus placebo and epinephrine comparison includes data from Group 1 (glucocorticoid and epinephrine) versus Group 2 (placebo and epinephrine)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 08:05:33 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>See Plint 2009</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-06-25 08:05:32 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>See Plint 2009</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-06-25 08:05:30 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>See Plint 2009</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-14 10:11:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_">
<CHAR_METHODS MODIFIED="2010-06-25 08:05:37 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>See Plint 2009</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-25 08:05:38 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>See Plint 2009</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-14 10:11:42 +1000" MODIFIED_BY="[Empty name]">
<P>See Plint 2009</P>
<P>This glucocorticoid versus placebo comparison includes data from Group 3 (dexamethasone + placebo) versus Group 4 (placebo and placebo)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 08:05:39 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>See Plint 2009</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-06-25 08:05:39 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>See Plint 2009</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-06-25 08:05:40 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>See Plint 2009</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-19 23:59:20 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Richter-1998">
<CHAR_METHODS MODIFIED="2013-01-07 10:55:24 +1000" MODIFIED_BY="[Empty name]">
<P>Parallel design, 2 arms</P>
<P>Single-centre, conducted in the UK (affiliation: Royal Alexandra Children's Hospital Brighton)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Inpatients</P>
<P>
<I>Inclusion/exclusion criteria</I>
<BR/>Inclusion criteria: age &lt; 12 mo.; no history of wheezing; hospitalised with clinical features of bronchiolitis (tachypnoea, recession, wheezing, crepitations)<BR/>Exclusion criteria: congenital abnormality; pre-existing pulmonary disease; immune deficiency; need for assisted ventilation</P>
<P>
<I>Participant characteristics </I>
<BR/>
<I>All groups</I>
<BR/>Sample size: randomised (N): 40, analysed - trial primary outcomes (N): 39 (ITT with available case analysis was performed), analysed - review primary outcomes (N): 40 (ITT with all data was performed)</P>
<P>
<I>GROUP 1</I>
<BR/>Sample size: randomised (N): 21, analysed - trial primary outcomes (N): 20, analysed - review primary outcomes (N): 21</P>
<P>Age: 4.08 (median); 1.1 to 10.15 (range) months<BR/>Males, N (%): 12 (57)<BR/>RSV status: 16 (76) positive<BR/>Atopic status: 18 (86) present (family)</P>
<P>
<I>GROUP 2</I>
<BR/>Sample size: randomised (N): 19, analysed - trial primary outcomes (N): 19, analysed - review primary outcomes (N): 19</P>
<P>Age: 2.7 (median); 0.9 to 7.82 (range) months<BR/>Males, N (%): 10 (52.6)<BR/>RSV status: 17 (89) positive<BR/>Atopic status: 12 (63) present (family)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>GROUP 1 (with glucocorticoid)</I>
<BR/>Drug name: budesonide<BR/>Dose: 1 mg in 2 mL then 0.5 mg in 2 mL<BR/>Mode of administration: nebulised with O<SUB>2</SUB>, flow 6 L/minute<BR/>Timing/duration: 1 mg/2mL - twice daily for 5 d; 0.5 mg/2 mL - 2 x daily for 6 weeks</P>
<P>
<I>GROUP 2</I>
<BR/>Drug name: placebo<BR/>Dose: 2 mL 0.9% saline<BR/>Mode of administration: nebulised with O<SUB>2</SUB>, flow 6 L/minute<BR/>Timing/duration: twice daily for 6 weeks</P>
<P>Additional co-interventions for all groups: no restrictions on use of other drug treatments<BR/>Protocolised use of bronchodilators with glucocorticoids: no</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-19 23:59:20 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
<BR/>Clinical scale adapted from Wesley et al, based on respiratory rate, O<SUB>2 </SUB>concentration required to keep O<SUB>2</SUB> &gt; 92%, wheeze, degree of recession, and need for IV fluids or nasogastric tube feeding (at 48 hours; other time points*)</P>
<P>Clinical scale*: RDAI, 17-point score based on wheezing and retractions (at 4 hours; other time points*)</P>
<P>
<I>Outcome used to calculate sample size</I>
<BR/>Wheezing episodes in the early months after bronchiolitis (no specific time point or definition)</P>
<P>
<I>Secondary outcomes</I>
<BR/>Duration and maximum requirements of O<SUB>2</SUB> therapy; LOS; hospital re-admission (6 mo.); symptoms (diary; based on Noble et al, daytime and nighttime cough and wheeze)#¶; inhaled bronchodilators#¶; length and growth rate#<BR/>*time points: twice daily until discharge, 48 hours<BR/>#time points: daily until 6 weeks<BR/>¶time points: until 6 months, when symptomatic and by 6-week periods</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Astra Clinical Research Unit and Rockinghorse Appeal</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-07-14 10:15:41 +1000" MODIFIED_BY="[Empty name]">
<P>Study did not report any study-level subgroup analyses</P>
<P>This study contributed to the following comparisons in this review: steroid versus placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-19 23:59:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roosevelt-1996">
<CHAR_METHODS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Parallel design, 2 arms</P>
<P>Single-centre, conducted in the US (The Children's Memorial Hospital, Chicago)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Inpatients</P>
<P>
<I>Inclusion/exclusion criteria</I>
<BR/>Inclusion criteria: age &lt; 12 months; bronchiolitis (lower respiratory tract infection characterised by wheezing); 1st episode of wheezing; requiring inpatient management; examined in ED<BR/>Exclusion criteria: age: &lt; 4 weeks old; needing admission to ICU; history of congenital heart disease; history of intubation, ventilation, or O<SUB>2</SUB> therapy</P>
<P>
<I>Participant characteristics </I>
<BR/>
<I>All groups</I>
<BR/>Sample size: randomised (N): 122, analysed - trial primary outcomes (N): 118 (per protocol analysis was performed)</P>
<P>
<I>GROUP 1</I>
<BR/>Sample size: randomised (N): NR, analysed - trial primary outcomes (N): 65</P>
<P>Age, mean ± SD: 5.3 ± 3.7 months<BR/>Males, N (%): 41 (63)<BR/>RSV status: 39 (60) positive<BR/>Atopic status: 26 (40) present (family)</P>
<P>
<I>GROUP 2</I>
<BR/>Sample size: randomised (N): NR, analysed - trial primary outcomes (N): 53</P>
<P>Age, mean ± SD: 5.0 ± 2.5 months<BR/>Males, N (%): 33 (62)<BR/>RSV status: 40 (76) positive<BR/>Atopic status: 23 (43) present (family)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>GROUP 1 (with glucocorticoid)</I>
<BR/>Drug name: dexamethasone<BR/>Dose: 1 mg/kg<BR/>Mode of administration: IM<BR/>Timing/duration: every 24 hours for max 3 doses</P>
<P>
<I>GROUP 2</I>
<BR/>Drug name: placebo (saline)<BR/>Dose: equivalent volume<BR/>Mode of administration: IM<BR/>Timing/duration: every 24 hours for max 3 doses</P>
<P>Additional co-interventions for all groups: left at the discretion of physician<BR/>Protocolised use of bronchodilators with glucocorticoids: no</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-19 23:59:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
<BR/>Time to resolution (number of 12-hour periods needed for the following criteria to be met: SaO<SUB>2</SUB> &gt; 95% while receiving no supplemental oxygen, accessory muscle score of 0, a wheeze of 0 or 1, and resumption of normal feeding)</P>
<P>
<I>Outcomes used to calculate sample size</I>
<BR/>Time to resolution; duration of O<SUB>2 </SUB>therapy</P>
<P>
<I>Secondary outcomes</I>
<BR/>Use of co-interventions; clinical scale adapted from Schuh et al: 6-point score based on accessory muscle use and wheeze*; SaO<SUB>2</SUB>*; respiratory rate*; heart rate*; blood pressure*; temperature*; occult blood in the stool; return healthcare visits#; hospital re-admissions#; symptoms#<BR/>*time points: every 12 hours until resolution<BR/>#time points: 10 to 14 d<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Green Bay Foundation - James P Gorter Family Fund</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-07-14 10:16:28 +1000" MODIFIED_BY="[Empty name]">
<P>Study did not report any study-level subgroup analyses</P>
<P>This study contributed to the following comparisons in this review: steroid versus placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-20 00:00:36 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schuh-2002">
<CHAR_METHODS MODIFIED="2013-01-07 10:57:10 +1000" MODIFIED_BY="[Empty name]">
<P>Parallel design, 2 arms</P>
<P>Single-centre, conducted in Canada (Hospital for Sick Children, University of Toronto)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Outpatients (paediatric emergency department)</P>
<P>
<I>Inclusion/exclusion criteria</I>
<BR/>Inclusion criteria: age 8 weeks to 23 months, 1st wheezing episode associated with respiratory distress and URTI; RDAI &#8805; 6 at baseline<BR/>Exclusion criteria: history of wheezing or bronchodilator therapy; prematurity; neonatal ventilation; chronic lung/cardiac disease; aspiration, neurologic/neuromuscular problems; immunodeficiency; critically ill infants requiring immediate airway stabilisation; previous oral or inhaled glucocorticoids; exposed to varicella &lt; 21 days of arrival</P>
<P>
<I>Participant characteristics </I>
<BR/>
<I>All groups</I>
<BR/>Sample size: randomised (N): 71, analysed - trial primary outcomes (N): 70 (ITT with available case analysis was performed), analysed - review primary outcomes (N): 67 (ITT with available case analysis was performed)</P>
<P>
<I>GROUP 1</I>
<BR/>Sample size: randomised (N): NR, analysed - trial primary outcomes (N): 36, analysed - review primary outcomes (N): 35</P>
<P>Age, mean ± SD: 6.1 ± 3.5 months<BR/>Males, N (%): 20 (56)<BR/>RSV status: 15/28 positive<BR/>Atopic status: 30 (83) present (infant)</P>
<P>
<I>GROUP 2</I>
<BR/>Sample size: randomised (N): NR, analysed - trial primary outcomes (N): 34, analysed - review primary outcomes (N): 32</P>
<P>Age, mean ± SD: 6.9 ± 3.9 months<BR/>Males, N (%): 23 (68)<BR/>RSV status: 15/30 positive<BR/>Atopic status: 18 (53) present (infant)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-20 00:00:36 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>GROUP 1 (with glucocorticoid)</I>
<BR/>Drug name: dexamethasone (prepared from the intravenous dexamethasone solution flavoured with wild cherry syrup)<BR/>Dose: 1 mg/kg (first dose) and then 0.6 mg/kg/day (if discharged)<BR/>Mode of administration: oral<BR/>Timing/duration: single dose if admitted, 5 days if discharged</P>
<P>
<I>GROUP 2</I>
<BR/>Drug name: placebo<BR/>Dose: identical colour, texture, taste and smell<BR/>Mode of administration: oral<BR/>Timing/duration: single dose if admitted, 5 days if discharged</P>
<P>Additional co-interventions for all groups: nebulised albuterol 2.5 mg/dose in 3 mL normal saline with oxygen flow of 6 to 7 L/minute at 0, 30, 60 and 120 minutes during the observation period; albuterol (1.5 mg to 0.3 mL) 4 times daily with the same nebuliser if discharged home. All decisions regarding the need for further treatment and hospitalisation were made by the attending physicians not involved in the study; they were requested not to administer additional therapy (other than acetaminophen for fever) unless the patient&#8217;s condition deteriorated significantly; use of bronchodilators is reported. Hospitalised patients were given nebulised albuterol only and supportive treatment as indicated<BR/>Protocolised use of bronchodilators with glucocorticoids: yes (salbutamol)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-19 23:59:35 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome/outcome used to calculate sample size</I>
<BR/>Clinical scale: Respiratory Assessment Change Score, a change score based on RDAI and respiratory rate change from baseline (at 240'; other time points*)</P>
<P>
<I>Secondary outcomes</I>
<BR/>Hospital admission (at 4 hours, 7 days and 28 days); RDAI: 17-point score based on wheezing and retractions*; respiratory rate*; SaO<SUB>2</SUB> (4 hours)<SUB>; </SUB>heart rate (4 hours); additional treatments#; return healthcare visits#</P>
<P>*time points: 60', 120', 180', 240', 7 days<BR/>#time points: 7 days, 28 days</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-04-02 12:40:28 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Grants from the Medical Research Council of Canada and Merck Frosst, Canada</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-07-14 10:17:20 +1000" MODIFIED_BY="[Empty name]">
<P>Study did not report any study-level subgroup analyses</P>
<P>This study contributed to the following comparisons in this review: steroid versus placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-19 23:59:40 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Teeratakulpisarn-2007">
<CHAR_METHODS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Parallel design, 2 arms</P>
<P>Multi-centre (2), conducted in Thailand (2 tertiary hospitals in the northeast)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Inpatients</P>
<P>
<I>Inclusion/exclusion criteria</I>
<BR/>Inclusion criteria: age 4 week to 24 months; 1st episode wheezing with tachypnoea; increased respiratory effort; URTI; criteria for hospitalisation: &lt; 3 months, respiratory rate &gt; 60 bpm (&lt; 12 months) or &gt; 50 bpm (&#8805; 12 months), SaO<SUB>2</SUB> &lt; 95%, apathy/refusal to eat<BR/>Exclusion criteria: symptoms &gt; 7 d; admission to ICU with intubation; history of: intubation, asthma, atopy with good response to 1st dose &#946;<SUB>2</SUB>-agonist; therapy with glucocorticoid &lt; 2 weeks; contraindication to glucocorticoid therapy; premature birth</P>
<P>
<I>Participant characteristics </I>
<BR/>
<I>All groups</I>
<BR/>Sample size: randomised (N): 179, analysed - trial/review primary outcomes (N): 174 (per protocol analysis was performed)</P>
<P>
<I>GROUP 1</I>
<BR/>Sample size: randomised (N): 90, analysed - trial/review primary outcomes (N): 89</P>
<P>Age, mean ± SD: 10.2 ± 5.5 months<BR/>Males, N (%): 55 (62)<BR/>Atopic status: 26 (29) present (family)</P>
<P>
<I>GROUP 2</I>
<BR/>Sample size: randomised (N): 89, analysed - trial/review primary outcomes (N): 85</P>
<P>Age, mean ± SD: 11.2 ± 5.9 months<BR/>Males, N (%): 55 (65)<BR/>Atopic status: 24 (28) present (family)</P>
<P>RSV status: NR</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-19 21:32:11 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>GROUP 1 (with glucocorticoid)</I>
<BR/>Drug name: dexamethasone<BR/>Dose: 0.6 mg/kg<BR/>Mode of administration: intramuscular injection<BR/>Timing/duration: 1 dose</P>
<P>
<I>GROUP 2</I>
<BR/>Drug name: placebo<BR/>Dose: equivalent volume of saline<BR/>Mode of administration: intramuscular injection<BR/>Timing/duration: 1 dose</P>
<P>Additional co-interventions for all groups: use of epinephrine, &#946;<SUB>2</SUB>-agonist nebulisation, O<SUB>2</SUB> permitted and reported (both study groups were similarly treated following the National Treatment Guidelines for Acute Respiratory Infection in Children, Thailand); also reported use of antibiotics. The investigators monitored the treatment regimens in order to avoid any additional form of glucocorticoid being added to either group until the study endpoint was reached<BR/>Protocolised use of bronchodilators with glucocorticoids: no</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-19 23:59:40 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome/outcome used to calculate sample size</I>
<BR/>Time from the study entry to resolution of respiratory distress, recognised by a total clinical score of 3 and an oxygen saturation 95% at room air together with a respiratory rate score of 0 or 1, a wheezing score of 0 or 1, and a retraction muscle score of 0 or 1. Clinical scale developed for this trial, modified from De Boeck et al. and Tal et al - 12-point score based on respiratory rate, wheezing, accessory respiratory muscle retraction and oxygen saturation*</P>
<P>
<I>Secondary outcomes</I>
<BR/>Duration of O<SUB>2</SUB> therapy; LOS; hospital re-admission#, return healthcare visits#; duration of symptoms#; adverse events; additional medications</P>
<P>*time points: every 6 hours until the study endpoint was reached<BR/>#time points: 2-week intervals, until 1 month</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-08-17 09:58:00 +1000" MODIFIED_BY="[Empty name]">
<P>Grant sponsor: The National Research Council of Thailand</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-07-14 10:17:57 +1000" MODIFIED_BY="[Empty name]">
<P>Study reported subgroup analysis in children under 12 months; no specific interaction term</P>
<P>This study contributed to the following comparisons in this review: steroid versus placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2003">
<CHAR_METHODS MODIFIED="2013-01-07 10:36:46 +1000" MODIFIED_BY="[Empty name]">
<P>Parallel design, 2 arms</P>
<P>Single-centre, conducted in Brazil (teaching hospital of the Federal University of Rio Grande, Rio Grande)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Inpatients (30-bed paediatric inpatient ward)</P>
<P>
<I>Inclusion/exclusion criteria</I>
<BR/>Inclusion criteria: age &lt; 12 months, diagnosis of bronchiolitis, 1st episode of wheezing with respiratory distress, history of upper respiratory tract infection<BR/>Exclusion criteria: age &lt; 4 weeks; any chronic cardiac or pulmonary disease; congenital abnormality; immediate favourable response to administration of single dose nebulised fenoterol; received glucocorticoids &lt; 4 weeks; severe initial disease requiring intensive care</P>
<P>
<I>Participant characteristics </I>
<BR/>
<I>All groups</I>
<BR/>Sample size: randomised (N): 52, analysed - trial primary outcomes (N): 50 (ITT with available case analysis was performed), analysed - review primary outcomes (N): 52 (ITT with all data was performed)</P>
<P>
<I>GROUP 1</I>
<BR/>Sample size: randomised (N): 28, analysed - trial primary outcomes (N): 26 , analysed - review primary outcomes (N): 28</P>
<P>Age, mean ± SD: 4.0 ± 2.5 months<BR/>Males, N (%): 21 (75)<BR/>Atopic status: 23 (82.1) present (family)</P>
<P>
<I>GROUP 2</I>
<BR/>Sample size: randomised (N): 24, analysed - trial/review primary outcomes (N): 24</P>
<P>Age, mean ± SD: 3.4 ± 1.8 months<BR/>Males, N (%): 20 (83.3)<BR/>Atopic status: 21 (87.5) present (family)</P>
<P>RSV status: NR</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>GROUP 1 (with glucocorticoid)</I>
<BR/>Drug name: prednisolone + standard care (see below)<BR/>Dose: 1 mg/kg<BR/>Mode of administration: oral<BR/>Timing/duration: 1st at enrolment; once daily at 8:00 am for 4 days (total 5 days of treatment); if hospital stay &lt; 5 d, remaining doses given at home</P>
<P>
<I>GROUP 2</I>
<BR/>Drug name: standard care<BR/>Dose: judged by attending physician based on standard protocol: O<SUB>2</SUB> therapy, fluid replacement, nebulised fenoterol<BR/>Mode of administration: NR<BR/>Timing/duration: NR<BR/>
</P>
<P>Additional co-interventions for all groups: standard care as stated above; attending paediatricians were advised against prescribing any glucocorticoid for recruited patients (use of IV hydrocortisone was reported)<BR/>Protocolised use of bronchodilators with glucocorticoids: no</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome/outcome used to calculate sample size</I>
<BR/>prevalence of post bronchiolitic wheeze (at 1, 3, 6, 12 mo)</P>
<P>
<I>Secondary outcomes</I>
<BR/>LOS; duration of O<SUB>2 </SUB>therapy; time to clinical resolution - defined as the days needed for the following criteria to be met: pulse blood oxygen saturation above 95% without supplemental oxygen, absence of chest retractions and respiratory rate less than upper limits for age (&lt; 2 months 60 bpm; 2 to 12 months 50 bpm)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-04-04 09:28:06 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Research Support Foundation of Rio Grande do Sul</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-07-14 10:18:47 +1000" MODIFIED_BY="[Empty name]">
<P>Study did not report any study-level subgroup analyses</P>
<P>This study contributed to the following comparisons in this review: steroid versus placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>(Support for 'Risk of bias' judgement is shown for domains with unclear risk)</P>
<P>bpm = beats per minute<BR/>d = day<BR/>ED = emergency department<BR/>h = hour<BR/>ICU = intensive care unit<BR/>IM = intramuscular<BR/>IQR = interquartile range<BR/>ITT = intention-to-treat<BR/>IV = intravenous<BR/>LOS = length of stay<BR/>mo = month<BR/>NR = not reported<BR/>qid = four times a day<BR/>RDAI = Respiratory Distress Assessment Instrument<BR/>RSV = respiratory syncytial virus<BR/>SD = standard deviation<BR/>SaO<SUB>2</SUB> = oxygen saturation<BR/>tx = treatment<BR/>URTI = upper respiratory tract infection</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-04-09 01:54:59 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Anonymous-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 01:54:59 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-14 10:18:51 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bacharier-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-14 10:18:51 +1000" MODIFIED_BY="[Empty name]">
<P>Population: children aged 12 to 59 months with moderate-to-severe recurrent intermittent wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-24 06:13:16 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bai-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-24 06:13:16 +1000" MODIFIED_BY="[Empty name]">
<P>Outcome: reported outcomes were recurrent wheezing and asthma</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-04 09:43:08 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Berger-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-04 09:43:08 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type and duplicate: abstract of later published trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 01:41:20 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Bibi-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 01:41:20 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: clinical definition of bronchiolitis uncertain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-04 09:44:39 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Blom-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-04 09:44:39 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: Cochrane systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-04 09:45:17 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Bont-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-04 09:45:17 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: letter to editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-04 09:45:42 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Buckingham-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-04 09:45:42 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: intensive care unit patients who were intubated and mechanically ventilated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 01:41:41 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-B_x00fc_low-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 01:41:41 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: clinical definition of bronchiolitis uncertain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-27 02:27:44 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Callen-Blecua-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-27 02:27:44 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Intervention:inhaled glucocorticoid therapy given for 3 months after mild bronchiolitis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 01:41:56 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Chao-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 01:41:56 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: clinical definition of bronchiolitis uncertain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-04 09:52:04 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Chipps-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-04 09:52:04 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: letter to editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 01:42:05 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Connolly-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 01:42:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: clinical definition of bronchiolitis uncertain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-04 09:53:16 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Cornell-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-04 09:53:16 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: review </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Csonka-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: children aged 6 to 35 months, clinical definition of bronchiolitis uncertain and recurrent wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 01:42:45 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-da-Silva-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 01:42:45 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Article pending retrieval</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 01:43:02 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Dabbous-1966">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 01:43:02 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: clinical definition of bronchiolitis uncertain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 01:43:32 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Daugbjerg-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 01:43:32 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: history of recurrent wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-05 09:28:45 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dennis-1963">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-05 09:28:45 +1000" MODIFIED_BY="[Empty name]">
<P>Study design: not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-05 09:28:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Doornebal-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-05 09:28:46 +1000" MODIFIED_BY="[Empty name]">
<P>Study design: not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 01:44:20 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Ermers-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 01:44:20 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: clinical definition of bronchiolitis uncertain and some participants required mechanical ventilation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-24 05:58:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ermers-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-24 05:58:41 +1000" MODIFIED_BY="[Empty name]">
<P>Intervention: 3 months inhaled glucocorticoids</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 01:44:28 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Filippskii-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 01:44:28 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: children aged 0 months to 3 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 01:44:36 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Fox-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 01:44:36 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: clinical definition of bronchiolitis uncertain and history of recurrent wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:19:03 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Garrison-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:19:03 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: meta-analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-24 06:00:09 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gerasymov-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-24 06:00:09 +1000" MODIFIED_BY="[Empty name]">
<P>Intervention: same glucocorticoid, dose-comparison</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 01:44:54 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Hall-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 01:44:54 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:19:54 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Hoekstra-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:19:54 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: letter to editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:20:12 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Jartti-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:20:12 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:20:41 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Jartti-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:20:41 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: first or second episode of wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Jartti-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: children aged 3 months to 16 years, clinical definition of bronchiolitis uncertain and recurrent wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jartti-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Study design: post hoc analysis of previous RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 01:45:17 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Kajosaari-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 01:45:17 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: clinical definition of bronchiolitis uncertain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-24 06:01:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karaatmaca-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-24 06:01:13 +1000" MODIFIED_BY="[Empty name]">
<P>Population: first or second episode of wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 01:45:43 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Kelm_x002d_Kahl-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 01:45:43 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:22:27 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Kitowicz-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:22:27 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:22:33 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Koumbourlis-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:22:33 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: letter to editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Leer-1969a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: children aged 0 to 30 months, clinical definition of bronchiolitis uncertain and recurrent wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 01:57:53 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Leer-1969b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 01:57:53 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: letter to editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:23:58 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Lin-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:23:58 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: ages below 36 months</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lukkarinen-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Study design: post hoc analysis of previous RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 01:46:04 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Mallol-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 01:46:04 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: clinical definition of bronchiolitis uncertain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-24 06:01:59 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martini-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-24 06:01:59 +1000" MODIFIED_BY="[Empty name]">
<P>Unobtainable</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:24:39 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Merkus-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:24:39 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: letter to editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:28:04 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Milner-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:28:04 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: letter to editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:31:03 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-O_x0027_Callaghan-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:31:03 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: letter to editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Oommen-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: children aged 1 to 5 years with recurrent episodic viral wheeze</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-05 09:28:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oski-1961">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-05 09:28:46 +1000" MODIFIED_BY="[Empty name]">
<P>Study design: not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:32:49 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Panickar-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:32:49 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: children between the ages of 10 months and 60 months, possibly with recurrent wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 01:46:50 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Park-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 01:46:50 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: history of recurrent wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:34:01 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Patel-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:34:01 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: Cochrane systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:35:02 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Patel-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:35:02 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Duplicate: abstract of RCT by Plint et al (included)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:35:06 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Plint-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:35:06 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Duplicate: abstract of RCT by Plint et al (included)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:42:48 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Poets-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:42:48 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-24 06:03:02 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Principi-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-24 06:03:02 +1000" MODIFIED_BY="[Empty name]">
<P>Publication type: commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 02:23:36 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Rajeshwari-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 02:23:36 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:42:49 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Ranganathan-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:42:49 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 02:23:45 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Renzi-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 02:23:45 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Unobtainable (abstract from conference proceedings)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:44:02 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Sammartino-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:44:02 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: letter to editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 01:47:06 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Sano-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 01:47:06 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: history of recurrent wheeze</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 01:47:15 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Schuh-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 01:47:15 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:50:34 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Schuh-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:50:34 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Intervention: single versus multiple doses of the same glucocorticoid (dexamethasone)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-24 06:03:28 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smart-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-24 06:03:28 +1000" MODIFIED_BY="[Empty name]">
<P>Publication type: commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:50:54 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Smith-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:50:54 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:50:51 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Spencer-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:50:51 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: letter to editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-05 09:28:47 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Springer-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-05 09:28:47 +1000" MODIFIED_BY="[Empty name]">
<P>Study design: not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-05 09:28:48 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sussman-1964">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-05 09:28:48 +1000" MODIFIED_BY="[Empty name]">
<P>Study design: not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 01:55:34 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Tal-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 01:55:34 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: history of recurrent wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:53:39 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Tofts-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:53:39 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: letter to editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 01:48:27 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Uhereczky-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 01:48:27 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: children aged 3 to 36 months, history of recurrent wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:54:11 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Van-Bever-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:54:11 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: letter to editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:54:20 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-van-Woensel-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:54:20 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: letter to editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-van-Woensel-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population and intervention: not a study of acute effects of glucocorticoids; this study measured the follow-up incidence of recurrent wheezing in treated infants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:55:15 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-van-Woensel-2003a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:55:15 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: involved intensive care unit patients who were intubated and mechanically ventilated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:55:34 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-van-Woensel-2003b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:55:34 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: involved intensive care unit patients who were intubated and mechanically ventilated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-24 06:04:00 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Woensel-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-24 06:04:00 +1000" MODIFIED_BY="[Empty name]">
<P>Population: involved intensive care unit patients who were intubated and mechanically ventilated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:57:03 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Wardrope-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:57:03 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Duplicate: RCT by Cade et al (included)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 02:24:14 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Webb-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 02:24:14 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: history of recurrent wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:57:39 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Weinberger-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:57:39 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: letter to editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-06 02:58:14 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Weinberger-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-06 02:58:14 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: letter to editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-20 17:58:12 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wong-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-20 17:58:12 +1000" MODIFIED_BY="[Empty name]">
<P>Intervention: 3 months inhaled glucocorticoids</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 01:49:55 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Yaffe-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 01:49:55 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Publication type: commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-24 06:06:25 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhu-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-24 06:06:25 +1000" MODIFIED_BY="[Empty name]">
<P>Study design: uncertain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 01:50:11 +1000" MODIFIED_BY="Ricardo M Fernandes" STUDY_ID="STD-Zuerlein-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 01:50:11 +1000" MODIFIED_BY="Ricardo M Fernandes">
<P>Population: children aged 5 to 27 months, clinical definition of bronchiolitis uncertain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT = randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-05-23 04:29:38 +1000" MODIFIED_BY="Ricardo M Fernandes" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-05-06 11:52:03 +1000" MODIFIED_BY="Ricardo M Fernandes">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-05-06 11:51:18 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-29 03:00:58 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998">
<DESCRIPTION>
<P>Authors mention that the patients were assigned to groups randomly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-30 00:16:33 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_">
<DESCRIPTION>
<P>Authors mention that the patients were assigned to groups randomly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-30 00:16:51 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_">
<DESCRIPTION>
<P>Authors mention that the patients were assigned to groups randomly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:05:33 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Bentur-2005">
<DESCRIPTION>
<P>"Randomization was in blocks of 10 (five saline/five dexamethasone)." Sequence generation probably adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-30 01:29:03 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Berger-1998">
<DESCRIPTION>
<P>"Randomization was made according to a standardized statistical method"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:08:23 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Cade-2000">
<DESCRIPTION>
<P>"...infants were randomised to receive either treatment or placebo. Randomisation was stratified by sex and centre." No further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-03 00:16:20 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Corneli-2007">
<DESCRIPTION>
<P>"computerized randomization"; "random permuted blocks stratified by center"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:50:05 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-De-Boeck-1997">
<DESCRIPTION>
<P>"patients were randomised"; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-03 08:59:41 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Goebel-2000">
<DESCRIPTION>
<P>"computer-generated randomization list"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:50:20 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Gomez-2007">
<DESCRIPTION>
<P>Block randomisation (blocks of 4). Sequence generation probably adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:50:36 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Klassen-1997">
<DESCRIPTION>
<P>Computer generated randomisation, stratified by age</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:50:43 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004">
<DESCRIPTION>
<P>"randomised fashion"; randomised to the first treatment, "randomised fashion independent of the first randomization" for the second treatment; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:50:45 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>"randomised fashion"; randomised to the first treatment, "randomised fashion independent of the first randomization" for the second treatment; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:50:47 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_">
<DESCRIPTION>
<P>"randomised fashion"; randomised to the first treatment, "randomised fashion independent of the first randomization" for the second treatment; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-05 00:06:02 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Mesquita-2009">
<DESCRIPTION>
<P>"patients were randomised to a double-blind, placebo-control study using a table of random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:50:52 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009">
<DESCRIPTION>
<P>"computer-generated randomization sequence, stratified by center, used randomised permuted blocks of 8 and 12."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:51:11 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>"computer-generated randomization sequence, stratified by center, used randomised permuted blocks of 8 and 12."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:51:18 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_">
<DESCRIPTION>
<P>"computer-generated randomization sequence, stratified by center, used randomised permuted blocks of 8 and 12."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:21:50 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Richter-1998">
<DESCRIPTION>
<P>Randomised; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:22:36 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Roosevelt-1996">
<DESCRIPTION>
<P>Randomised; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 00:30:23 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Schuh-2002">
<DESCRIPTION>
<P>"A blocked randomization code was prepared by our pharmacy from a computer generated list of random numbers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 01:51:40 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Teeratakulpisarn-2007">
<DESCRIPTION>
<P>"Mixed, permuted, block randomization, using a computer-generated number, was performed for each site and prepared by an off-site investigator."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 02:04:13 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Zhang-2003">
<DESCRIPTION>
<P>"random-number table generated randomization list"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-05-06 11:51:30 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-05 01:04:35 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-05 01:15:21 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-05 01:15:35 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:05:35 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Bentur-2005">
<DESCRIPTION>
<P>"The hospital pharmacist prepared the treatment and placebo solutions, both of which were supplied in identical containers and were indistinguishable to the researchers." Allocation concealment probably adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:49:40 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Berger-1998">
<DESCRIPTION>
<P>"Upon enrolment, each patient was randomly assigned by a research pharmacist"; "neither the investigators nor the families were aware of treatment assignments."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:08:25 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Cade-2000">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-03 00:17:15 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Corneli-2007">
<DESCRIPTION>
<P>"randomization by telephone, using the keypad for data entry"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:09:21 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-De-Boeck-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:43:18 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Goebel-2000">
<DESCRIPTION>
<P>Treatment formulated by the hospital pharmacy; "identical medication bottles containing either prednisolone or placebo had been previously prepared and numbered consecutively according to the randomization list."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:10:02 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Gomez-2007">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:10:43 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Klassen-1997">
<DESCRIPTION>
<P>Randomisation performed by pharmacy; all packages of study medications were prepared and labelled with a study number; concealed until study complete and data analysis had begun</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-05 00:01:22 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004">
<DESCRIPTION>
<P>"Preparation and administration of nebulized solutions were performed by a trained emergency department nurse."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-05 00:04:29 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>"Preparation and administration of nebulized solutions were performed by a trained emergency department nurse."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-05 00:04:36 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_">
<DESCRIPTION>
<P>"Preparation and administration of nebulized solutions were performed by a trained emergency department nurse."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-05 00:06:52 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Mesquita-2009">
<DESCRIPTION>
<P>"The research pharmacy prepared the active drug ... and the placebo ...; their bottles were labelled only with the randomised numbers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:50:59 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009">
<DESCRIPTION>
<P>"Codes were secured at each center&#8217;s pharmacy until enrolment and data en- try were complete. In order to conceal the allocation sequence, the pharmacy at each site prepared the study drugs in sequentially numbered, visually identical packets."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:51:12 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>"Codes were secured at each center&#8217;s pharmacy until enrolment and data en- try were complete. In order to conceal the allocation sequence, the pharmacy at each site prepared the study drugs in sequentially numbered, visually identical packets."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:51:30 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_">
<DESCRIPTION>
<P>"Codes were secured at each center&#8217;s pharmacy until enrolment and data entry were complete. In order to conceal the allocation sequence, the pharmacy at each site prepared the study drugs in sequentially numbered, visually identical packets."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:21:53 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Richter-1998">
<DESCRIPTION>
<P>Randomisation details held by hospital pharmacy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-05 01:33:20 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Roosevelt-1996">
<DESCRIPTION>
<P>"The hospital pharmacy prepared and coded drug and placebo."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 00:30:41 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Schuh-2002">
<DESCRIPTION>
<P>"The pharmacy prepared sequential sealed packets containing the experimental drugs. The randomization code was revealed only after all patients had completed the study."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 01:52:34 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Teeratakulpisarn-2007">
<DESCRIPTION>
<P>"...randomization ... prepared by an off-site investigator. The study vials were prepared, numbered, and sealed by a pharmacist according to the randomization numbers. The treatment allocation was concealed from the investigators, the attending pediatricians and all of the health personnel involved in patient care."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 02:05:02 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Zhang-2003">
<DESCRIPTION>
<P>"The independent pharmacy staff members were responsible for group assignment and distribution of prednisolone"; "The randomization list was concealed until the study was complete."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-05-06 11:40:50 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Clinical parameters (severity scales, SpO<SUB>2</SUB>, respiratory and heart rate)</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.04" NO="4">
<NAME>Patient/parent-reported outcomes (symptoms, QoL)</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Health care use ((re)admissions, LOS, return visits)</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.05" NO="5">
<NAME>Other outcomes (adverse events, others)</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3">
<NAME>Pulmonary function</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-06 11:03:09 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Barlas-1998">
<DESCRIPTION>
<P>Different routes of administration for different interventions (e.g. nebulised versus IV), without blinding; no information provided regarding blinding of interventions with the same route of administration. Outcome likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-06 11:03:18 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Barlas-1998">
<DESCRIPTION>
<P>Different routes of administration for different interventions (e.g. nebulised versus IV), without blinding; no information provided regarding blinding of interventions with the same route of administration. Outcome likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2013-05-06 11:37:29 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2013-05-06 11:37:31 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2013-05-06 11:37:33 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-06 11:03:31 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_">
<DESCRIPTION>
<P>Different routes of administration for different interventions (e.g. nebulised versus IV), without blinding; no information provided regarding blinding of interventions with the same route of administration. Outcome likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-06 11:03:38 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_">
<DESCRIPTION>
<P>Different routes of administration for different interventions (e.g. nebulised versus IV), without blinding; no information provided regarding blinding of interventions with the same route of administration. Outcome likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2013-05-06 11:37:56 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2013-05-06 11:37:57 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2013-05-06 11:37:58 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-06 11:03:55 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_">
<DESCRIPTION>
<P>Different routes of administration for different interventions (e.g. nebulised versus IV), without blinding; no information provided regarding blinding of interventions with the same route of administration. Outcome likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-06 11:03:59 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_">
<DESCRIPTION>
<P>Different routes of administration for different interventions (e.g. nebulised versus IV), without blinding; no information provided regarding blinding of interventions with the same route of administration. Outcome likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2013-05-06 11:38:01 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2013-05-06 11:38:01 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2013-05-06 11:38:02 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-06 11:05:42 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Bentur-2005">
<DESCRIPTION>
<P>Double-blind; "treatment and placebo solutions (...) were supplied in identical containers and were indistinguishable to the researchers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-06 11:05:51 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Bentur-2005">
<DESCRIPTION>
<P>Double-blind; "treatment and placebo solutions (...) were supplied in identical containers and were indistinguishable to the researchers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2013-05-06 11:38:04 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Bentur-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2013-05-06 11:38:06 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Bentur-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2013-05-06 11:05:59 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Bentur-2005">
<DESCRIPTION>
<P>Double-blind; "treatment and placebo solutions (...) were supplied in identical containers and were indistinguishable to the researchers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-30 01:31:19 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Berger-1998">
<DESCRIPTION>
<P>"The solutions provided by the pharmacy appeared identical, and neither the investigators nor the families were aware of treatment assignments." "The examiner was blind to what treatment the patient had received."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-04-30 01:31:21 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Berger-1998">
<DESCRIPTION>
<P>"The solutions provided by the pharmacy appeared identical, and neither the investigators nor the families were aware of treatment assignments." "The examiner was blind to what treatment the patient had received."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2013-05-06 11:38:08 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Berger-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2013-04-30 01:31:45 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Berger-1998">
<DESCRIPTION>
<P>"The solutions provided by the pharmacy appeared identical, and neither the investigators nor the families were aware of treatment assignments." "The examiner was blind to what treatment the patient had received."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2013-05-06 11:38:09 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Berger-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-06 11:08:26 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Cade-2000">
<DESCRIPTION>
<P>"the trial solution and side stream nebulisers were manufactured and packaged to ensure the double-blind nature of the study"; as no further information provided, and both random sequence generation and allocation concealment were unclear, we considered blinding unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-06 11:38:11 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Cade-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2013-05-06 11:38:12 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Cade-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2013-05-06 11:08:30 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Cade-2000">
<DESCRIPTION>
<P>"the trial solution and side stream nebulisers were manufactured and packaged to ensure the double-blind nature of the study"; as no further information provided, and both random sequence generation and allocation concealment were unclear, we considered blinding unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2013-05-06 11:08:31 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Cade-2000">
<DESCRIPTION>
<P>"the trial solution and side stream nebulisers were manufactured and packaged to ensure the double-blind nature of the study"; as no further information provided, and both random sequence generation and allocation concealment were unclear, we considered blinding unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-03 00:18:39 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Corneli-2007">
<DESCRIPTION>
<P>"emergency department staff, study personnel, and parents and guardians were unaware of the group assignments."; "randomization codes were secured until all data entry was complete."; "research pharmacies prepared oral dexamethasone solutions ... and identical oral placebo solutions. The preparations were packaged in identical clear plastic vials labeled only with the randomization numbers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-03 00:18:43 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Corneli-2007">
<DESCRIPTION>
<P>"emergency department staff, study personnel, and parents and guardians were unaware of the group assignments."; "randomization codes were secured until all data entry was complete."; "research pharmacies prepared oral dexamethasone solutions ... and identical oral placebo solutions. The preparations were packaged in identical clear plastic vials labeled only with the randomization numbers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2013-05-06 11:38:15 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corneli-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2013-05-06 11:38:15 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corneli-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2013-05-03 00:18:46 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Corneli-2007">
<DESCRIPTION>
<P>"emergency department staff, study personnel, and parents and guardians were unaware of the group assignments."; "randomization codes were secured until all data entry was complete."; "research pharmacies prepared oral dexamethasone solutions ... and identical oral placebo solutions. The preparations were packaged in identical clear plastic vials labeled only with the randomization numbers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-06 11:09:23 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-De-Boeck-1997">
<DESCRIPTION>
<P>"double-blind"; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-06 11:09:26 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-De-Boeck-1997">
<DESCRIPTION>
<P>"double-blind"; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2013-05-06 11:09:27 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-De-Boeck-1997">
<DESCRIPTION>
<P>"double-blind"; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2013-05-06 11:38:19 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-De-Boeck-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2013-05-06 11:38:20 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-De-Boeck-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-03 09:02:05 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Goebel-2000">
<DESCRIPTION>
<P>"similar in appearance and taste"; "all study physicians, patients, and caregivers were blinded"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-03 09:02:29 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Goebel-2000">
<DESCRIPTION>
<P>"similar in appearance and taste"; "all study physicians, patients, and caregivers were blinded"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2013-05-06 11:38:23 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goebel-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2013-05-06 11:38:23 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goebel-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2013-05-06 11:38:24 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goebel-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-06 11:10:07 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Gomez-2007">
<DESCRIPTION>
<P>Patient, nurse and physician blinded to treatment group; drugs in opaque containers, similar organoleptic properties</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-06 11:10:11 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Gomez-2007">
<DESCRIPTION>
<P>Patient, nurse and physician blinded to treatment group; drugs in opaque containers, similar organoleptic properties</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2013-05-06 11:38:26 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gomez-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2013-05-06 11:38:27 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gomez-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2013-05-06 11:38:28 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gomez-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-06 11:10:48 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Klassen-1997">
<DESCRIPTION>
<P>Dexamethasone and placebo with identical appearance; research assistants, treating physicians, and parents were masked to the treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-06 11:10:53 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Klassen-1997">
<DESCRIPTION>
<P>Dexamethasone and placebo with identical appearance; research assistants, treating physicians, and parents were masked to the treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2013-05-06 11:38:30 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klassen-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2013-05-06 11:38:31 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klassen-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2013-05-06 11:10:59 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Klassen-1997">
<DESCRIPTION>
<P>Dexamethasone and placebo with identical appearance; research assistants, treating physicians, and parents were masked to the treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-05 00:01:29 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004">
<DESCRIPTION>
<P>Double-blind; "parents and investigators remained blinded to administered medications throughout study period"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-05 00:01:39 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004">
<DESCRIPTION>
<P>Double-blind; "parents and investigators remained blinded to administered medications throughout study period"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2013-05-06 11:38:34 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2013-05-06 11:38:35 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2013-05-05 00:01:45 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004">
<DESCRIPTION>
<P>Double-blind; "parents and investigators remained blinded to administered medications throughout study period"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-05 00:04:29 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>Double-blind; "parents and investigators remained blinded to administered medications throughout study period"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-05 00:04:28 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>Double-blind; "parents and investigators remained blinded to administered medications throughout study period"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2013-05-06 11:38:37 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2013-05-06 11:38:38 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2013-05-05 00:04:29 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>Double-blind; "parents and investigators remained blinded to administered medications throughout study period"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-05 00:04:36 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_">
<DESCRIPTION>
<P>Double-blind; "parents and investigators remained blinded to administered medications throughout study period"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-05 00:04:36 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_">
<DESCRIPTION>
<P>Double-blind; "parents and investigators remained blinded to administered medications throughout study period"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2013-05-06 11:38:48 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2013-05-06 11:38:48 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2013-05-05 00:04:36 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_">
<DESCRIPTION>
<P>Double-blind; "parents and investigators remained blinded to administered medications throughout study period"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-06 11:12:38 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Mesquita-2009">
<DESCRIPTION>
<P>Double-blind; "The research pharmacy prepared the active drug (dexamethasone, Lab. Formula Magistral, Paraguay) and the placebo in identical sweet syrups and their bottles were labelled only with the randomised numbers."; in the whole period of the trial, the investigators were blinded of the treatment administered."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-06 11:12:42 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Mesquita-2009">
<DESCRIPTION>
<P>Double-blind; "The research pharmacy prepared the active drug (dexamethasone, Lab. Formula Magistral, Paraguay) and the placebo in identical sweet syrups and their bottles were labelled only with the randomised numbers."; in the whole period of the trial, the investigators were blinded of the treatment administered."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2013-05-06 11:38:57 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mesquita-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2013-05-06 11:38:58 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mesquita-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2013-05-06 11:38:59 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mesquita-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-06 11:13:24 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009">
<DESCRIPTION>
<P>Double-blind; "The active drugs and placebo were identical in appearance, volume, weight, odor, and taste."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-06 11:13:29 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009">
<DESCRIPTION>
<P>Double-blind; "The active drugs and placebo were identical in appearance, volume, weight, odor, and taste."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2013-05-06 11:39:04 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Plint-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2013-05-06 11:13:33 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009">
<DESCRIPTION>
<P>Double-blind; "The active drugs and placebo were identical in appearance, volume, weight, odor, and taste."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2013-05-06 11:13:36 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009">
<DESCRIPTION>
<P>Double-blind; "The active drugs and placebo were identical in appearance, volume, weight, odor, and taste."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-06 11:14:02 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>Double-blind; "The active drugs and placebo were identical in appearance, volume, weight, odor, and taste."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-06 11:19:19 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>Double-blind; "The active drugs and placebo were identical in appearance, volume, weight, odor, and taste."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2013-05-06 11:39:06 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2013-05-06 11:20:28 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>Double-blind; "The active drugs and placebo were identical in appearance, volume, weight, odor, and taste."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2013-05-06 11:20:31 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>Double-blind; "The active drugs and placebo were identical in appearance, volume, weight, odor, and taste."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-06 11:20:48 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_">
<DESCRIPTION>
<P>Double-blind; "The active drugs and placebo were identical in appearance, volume, weight, odor, and taste."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-06 11:20:51 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_">
<DESCRIPTION>
<P>Double-blind; "The active drugs and placebo were identical in appearance, volume, weight, odor, and taste."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2013-05-06 11:39:08 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2013-05-06 11:20:55 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_">
<DESCRIPTION>
<P>Double-blind; "The active drugs and placebo were identical in appearance, volume, weight, odor, and taste."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2013-05-06 11:20:58 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_">
<DESCRIPTION>
<P>Double-blind; "The active drugs and placebo were identical in appearance, volume, weight, odor, and taste."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-06 11:22:01 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Richter-1998">
<DESCRIPTION>
<P>Double-blind; "Throughout the study, the investigators, nursing and medical staff, and parents were unaware to which treatment group infants had been assigned"; "both budesonide and placebo were supplied in plastic repsules prepared by Astra pharmaceuticals"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-06 11:22:05 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Richter-1998">
<DESCRIPTION>
<P>Double-blind; "Throughout the study, the investigators, nursing and medical staff, and parents were unaware to which treatment group infants had been assigned"; "both budesonide and placebo were supplied in plastic repsules prepared by Astra pharmaceuticals"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2013-05-06 11:39:09 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Richter-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2013-05-06 11:39:09 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Richter-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2013-05-06 11:22:10 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Richter-1998">
<DESCRIPTION>
<P>Double-blind; "Throughout the study, the investigators, nursing and medical staff, and parents were unaware to which treatment group infants had been assigned"; "both budesonide and placebo were supplied in plastic repsules prepared by Astra pharmaceuticals"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-06 11:22:57 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Roosevelt-1996">
<DESCRIPTION>
<P>Double-blind; "investigators were unaware of treatment allocation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-06 11:39:12 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Roosevelt-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2013-05-06 11:39:13 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roosevelt-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2013-05-06 11:23:19 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Roosevelt-1996">
<DESCRIPTION>
<P>Double-blind; "investigators were unaware of treatment allocation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2013-05-06 11:23:22 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Roosevelt-1996">
<DESCRIPTION>
<P>Double-blind; "investigators were unaware of treatment allocation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-06 00:31:57 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Schuh-2002">
<DESCRIPTION>
<P>"The experimental dexamethasone syrup was prepared from the intravenous dexamethasone solution flavored with wild cherry syrup; the latter flavoring was also given to the group taking the placebo. The active therapy and placebo were of identical color, texture, taste, and smell. The identity of the treatment assignment was completely masked to patients, family, clinicians, and research personnel with the exception of the research pharmacists."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-06 00:32:07 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Schuh-2002">
<DESCRIPTION>
<P>"The experimental dexamethasone syrup was prepared from the intravenous dexamethasone solution flavored with wild cherry syrup; the latter flavoring was also given to the group taking the placebo. The active therapy and placebo were of identical color, texture, taste, and smell. The identity of the treatment assignment was completely masked to patients, family, clinicians, and research personnel with the exception of the research pharmacists."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2013-05-06 11:39:15 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schuh-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2013-05-06 00:32:09 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Schuh-2002">
<DESCRIPTION>
<P>"The experimental dexamethasone syrup was prepared from the intravenous dexamethasone solution flavored with wild cherry syrup; the latter flavoring was also given to the group taking the placebo. The active therapy and placebo were of identical color, texture, taste, and smell. The identity of the treatment assignment was completely masked to patients, family, clinicians, and research personnel with the exception of the research pharmacists."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2013-05-06 11:39:16 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schuh-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-06 11:40:50 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Teeratakulpisarn-2007">
<DESCRIPTION>
<P>Double-blind; "container of identical appearance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-06 11:40:45 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Teeratakulpisarn-2007">
<DESCRIPTION>
<P>Double-blind; "container of identical appearance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2013-05-06 11:39:18 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Teeratakulpisarn-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2013-05-06 11:40:41 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Teeratakulpisarn-2007">
<DESCRIPTION>
<P>Double-blind; "container of identical appearance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2013-05-06 11:40:37 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Teeratakulpisarn-2007">
<DESCRIPTION>
<P>Double-blind; "container of identical appearance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-06 11:39:22 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Zhang-2003">
<DESCRIPTION>
<P>Authors report that "All study investigators were blinded to treatment assignment throughout the study." However, no blinded placebo comparator is used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-05-06 11:39:24 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Zhang-2003">
<DESCRIPTION>
<P>Authors report that "All study investigators were blinded to treatment assignment throughout the study." However, no blinded placebo comparator is used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2013-05-06 11:39:26 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2013-05-06 11:39:30 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Zhang-2003">
<DESCRIPTION>
<P>Authors report that "All study investigators were blinded to treatment assignment throughout the study." However, no blinded placebo comparator is used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2013-05-06 11:39:32 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Zhang-2003">
<DESCRIPTION>
<P>Authors report that "All study investigators were blinded to treatment assignment throughout the study." However, no blinded placebo comparator is used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="GROUP" NO="10">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="GROUP" NO="11">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-05-06 11:52:03 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>Health care use ((re)admissions, LOS, return visits)</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.05" NO="5">
<NAME>Other outcomes (adverse events, others)</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.04" NO="4">
<NAME>Pulmonary function</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>Clinical parameters (severity scales, SpO<SUB>2</SUB>, respiratory and heart rate)</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.03" NO="3">
<NAME>Patient/parent-reported outcomes (symptoms, QoL)</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-30 00:14:14 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Barlas-1998">
<DESCRIPTION>
<P>No missing outcome data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-04-30 00:14:20 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Barlas-1998">
<DESCRIPTION>
<P>No missing outcome data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-05-06 11:37:54 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2013-05-06 11:37:55 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2013-05-06 11:37:56 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-30 00:16:33 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_">
<DESCRIPTION>
<P>No missing outcome data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-04-30 00:16:33 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_">
<DESCRIPTION>
<P>No missing outcome data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-05-06 11:37:58 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2013-05-06 11:37:59 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2013-05-06 11:38:00 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-30 00:16:51 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_">
<DESCRIPTION>
<P>No missing outcome data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-04-30 00:16:51 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_">
<DESCRIPTION>
<P>No missing outcome data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-05-06 11:38:03 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2013-05-06 11:38:03 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2013-05-06 11:38:04 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-30 00:45:01 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Bentur-2005">
<DESCRIPTION>
<P>No missing outcome data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-04-30 00:45:06 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Bentur-2005">
<DESCRIPTION>
<P>No missing outcome data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-05-06 11:38:07 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Bentur-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2013-05-06 11:38:07 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Bentur-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2013-04-30 00:45:12 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Bentur-2005">
<DESCRIPTION>
<P>No missing outcome data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-06 11:07:47 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Berger-1998">
<DESCRIPTION>
<P>Number completing treatment specified for each group; total of 4 drop-outs, unclear what were the specific motives and to which arm they were assigned to</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-06 11:07:49 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Berger-1998">
<DESCRIPTION>
<P>Number completing treatment specified for each group; total of 4 drop-outs, unclear what were the specific motives and to which arm they were assigned to</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-05-06 11:07:52 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Berger-1998">
<DESCRIPTION>
<P>Number completing treatment specified for each group; total of 4 drop-outs, unclear what were the specific motives and to which arm they were assigned to</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2013-05-06 11:38:09 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Berger-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2013-05-06 11:38:10 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Berger-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-03 00:23:12 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Cade-2000">
<DESCRIPTION>
<P>3 exclusions post-randomisation, motives reported, balanced between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-06 11:38:12 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Cade-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-01-07 10:42:17 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Cade-2000">
<DESCRIPTION>
<P>Data on parental diaries reported in 79/83 and 76/82 participants, of which 96% and 98% were complete, respectively; apparently there is a mismatch with the absolute numbers presented; no motives for incomplete outcome data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2013-05-06 11:38:13 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Cade-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2013-05-03 00:23:16 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Cade-2000">
<DESCRIPTION>
<P>3 exclusions post-randomisation, motives reported, balanced between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-06 11:43:44 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Corneli-2007">
<DESCRIPTION>
<P>Primary outcome ITT, all analysed; no missing primary outcome data. For secondary outcomes, less than 10% follow-up data lost; balanced between groups; motives reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-06 11:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Corneli-2007">
<DESCRIPTION>
<P>Secondary outcomes were also assessed per protocol; less than 10% follow-up data lost; balanced between groups; motives reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-05-06 11:38:17 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corneli-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2013-05-06 11:38:18 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corneli-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2013-05-06 11:09:08 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Corneli-2007">
<DESCRIPTION>
<P>Secondary outcomes were also assessed per protocol; less than 10% follow-up data lost; balanced between groups; motives reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-03 08:56:22 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-De-Boeck-1997">
<DESCRIPTION>
<P>3 participants did not complete the study and were not included in the analysis; no report of motives or arm to which they had been assigned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-03 08:56:16 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-De-Boeck-1997">
<DESCRIPTION>
<P>3 participants did not complete the study and were not included in the analysis; no report of motives and arm to which they had been assigned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-05-06 11:38:21 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-De-Boeck-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2013-05-03 08:56:38 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-De-Boeck-1997">
<DESCRIPTION>
<P>3 participants did not complete the study and were not included in the analysis; no report of motives and arm to which they had been assigned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2013-05-06 11:38:22 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-De-Boeck-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-06 11:43:13 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Goebel-2000">
<DESCRIPTION>
<P>3 post-randomisation exclusions from all analyses with motives reported; 16 patients with missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-06 11:43:11 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Goebel-2000">
<DESCRIPTION>
<P>3 post-randomisation exclusions from all analyses with motives reported; 16 patients with missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-05-06 11:38:25 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goebel-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2013-05-06 11:38:25 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goebel-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2013-05-06 11:38:26 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goebel-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-07 12:56:18 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Gomez-2007">
<DESCRIPTION>
<P>No information reported on exclusions pre- or post-randomisation, nor on losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-04 23:47:49 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Gomez-2007">
<DESCRIPTION>
<P>No information reported on exclusions pre- or post-randomisation, nor on losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-05-06 11:38:29 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gomez-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2013-05-06 11:38:29 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gomez-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2013-05-06 11:38:30 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gomez-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-06 11:50:40 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Klassen-1997">
<DESCRIPTION>
<P>5 post-randomisation exclusions, motives reported; 1 patient discharged with missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-06 11:11:05 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Klassen-1997">
<DESCRIPTION>
<P>5 post-randomisation exclusions, motives reported; 1 patient discharged with missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-05-06 11:38:32 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klassen-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2013-05-06 11:38:33 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klassen-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2013-05-06 11:11:10 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Klassen-1997">
<DESCRIPTION>
<P>5 post-randomisation exclusions, motives reported; 1 patient discharged with missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-05 00:02:47 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Kuyucu-2004">
<DESCRIPTION>
<P>21 patients with missing outcome data, imbalanced between groups; no motives reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-06 11:42:33 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Kuyucu-2004">
<DESCRIPTION>
<P>21 patients with missing outcome data, imbalanced between groups; no motives reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-05-06 11:38:35 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2013-05-06 11:38:36 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2013-05-05 00:03:03 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Kuyucu-2004">
<DESCRIPTION>
<P>21 patients with missing outcome data, imbalanced between groups; no motives reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-05 00:04:29 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>21 patients with missing outcome data, imbalanced between groups; no motives reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-06 11:38:41 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>21 patients with missing outcome data, imbalanced between groups; no motives reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-05-06 11:38:45 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2013-05-06 11:38:46 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2013-05-05 00:04:29 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>21 patients with missing outcome data, imbalanced between groups; no motives reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-05 00:04:36 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_">
<DESCRIPTION>
<P>21 patients with missing outcome data, imbalanced between groups; no motives reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-06 11:38:52 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_">
<DESCRIPTION>
<P>21 patients with missing outcome data, imbalanced between groups; no motives reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-05-06 11:38:55 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2013-05-06 11:38:56 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2013-05-05 00:04:37 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_">
<DESCRIPTION>
<P>21 patients with missing outcome data, imbalanced between groups; no motives reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-05 00:10:32 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Mesquita-2009">
<DESCRIPTION>
<P>15 children excluded post-enrollment, motives reported (2 children quit the protocol before the first hour, 3 post-treatment)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-05 00:11:01 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Mesquita-2009">
<DESCRIPTION>
<P>15 children excluded post-enrollment, motives reported (2 children quit the protocol before the first hour, 3 post-treatment)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-05-06 11:39:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mesquita-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2013-05-06 11:39:02 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mesquita-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2013-05-06 11:39:03 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mesquita-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-05 00:56:27 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009">
<DESCRIPTION>
<P>3 patients with missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-05 00:56:53 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009">
<DESCRIPTION>
<P>3 patients with missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-05-05 00:56:54 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009">
<DESCRIPTION>
<P>3 patients with missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2013-05-06 11:39:05 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Plint-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2013-05-05 00:56:58 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009">
<DESCRIPTION>
<P>3 patients with missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-05 00:59:09 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>3 patients with missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-05 00:59:09 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>3 patients with missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-05-05 00:59:09 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>3 patients with missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2013-05-06 11:39:07 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2013-05-05 00:59:09 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>3 patients with missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-05 00:59:30 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_">
<DESCRIPTION>
<P>3 patients with missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-05 00:59:31 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_">
<DESCRIPTION>
<P>3 patients with missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-05-05 00:59:31 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_">
<DESCRIPTION>
<P>3 patients with missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2013-05-06 11:39:08 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2013-05-05 00:59:31 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_">
<DESCRIPTION>
<P>3 patients with missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-05 01:20:34 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Richter-1998">
<DESCRIPTION>
<P>1 participant with missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-05 01:20:45 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Richter-1998">
<DESCRIPTION>
<P>1 participant with missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-05-06 11:39:10 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Richter-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2013-05-06 11:39:11 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Richter-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2013-05-05 01:20:48 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Richter-1998">
<DESCRIPTION>
<P>1 participant with missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-06 00:27:06 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Roosevelt-1996">
<DESCRIPTION>
<P>Four participant exclusions, motives reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-06 11:39:14 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Roosevelt-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-05-06 00:25:28 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Roosevelt-1996">
<DESCRIPTION>
<P>Patient-reported data missing for 29 participants, no motives reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2013-05-06 11:39:14 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roosevelt-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2013-05-06 00:27:21 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Roosevelt-1996">
<DESCRIPTION>
<P>Four participant exclusions, motives reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-06 11:41:07 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Schuh-2002">
<DESCRIPTION>
<P>1 participant exclusion, 3 with missing outcome data, motives reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-06 11:52:03 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Schuh-2002">
<DESCRIPTION>
<P>1 participant exclusion, 3 with missing outcome data, motives reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-05-06 00:43:34 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Schuh-2002">
<DESCRIPTION>
<P>Missing symptom data by day 28 for 6 participants, imbalanced, no motives for attrition reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2013-05-06 11:39:16 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schuh-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2013-05-06 11:39:17 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schuh-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-06 01:57:53 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Teeratakulpisarn-2007">
<DESCRIPTION>
<P>Five participants with missing outcome data; some motives reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-06 01:57:59 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Teeratakulpisarn-2007">
<DESCRIPTION>
<P>Five participants with missing outcome data; some motives reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-05-06 01:58:02 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Teeratakulpisarn-2007">
<DESCRIPTION>
<P>Five participants with missing outcome data; some motives reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2013-05-06 11:39:18 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Teeratakulpisarn-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2013-05-06 01:58:04 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Teeratakulpisarn-2007">
<DESCRIPTION>
<P>Five participants with missing outcome data; some motives reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-06 11:39:34 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Zhang-2003">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-06 02:10:24 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Zhang-2003">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2013-05-06 11:39:36 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Zhang-2003">
<DESCRIPTION>
<P>Two participants with missing long-term symptom outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2013-05-06 11:39:38 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2013-05-06 02:10:56 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Zhang-2003">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-05-06 11:44:41 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:44:41 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Barlas-1998">
<DESCRIPTION>
<P>Published report includes all pre-specified and expected outcomes; the study protocol was not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:03:46 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_">
<DESCRIPTION>
<P>Published report includes all pre-specified and expected outcomes; the study protocol was not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:04:26 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_">
<DESCRIPTION>
<P>Published report includes all pre-specified and expected outcomes; the study protocol was not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-30 01:12:18 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Bentur-2005">
<DESCRIPTION>
<P>Some outcomes specified in methods not reported in results; LOS not prespecified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:07:54 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Berger-1998">
<DESCRIPTION>
<P>Published report includes all pre-specified and expected outcomes; the study protocol was not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:08:39 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Cade-2000">
<DESCRIPTION>
<P>Published report includes all pre-specified and expected outcomes; however, "length of time until symptom free" definition was changed due to incomplete outcome data; the study protocol was not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:09:09 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Corneli-2007">
<DESCRIPTION>
<P>Published report includes all pre-specified and expected outcomes; study protocol was available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-03 08:57:35 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-De-Boeck-1997">
<DESCRIPTION>
<P>Not all time points were reported and some outcomes with reported results were not mentioned in methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:09:51 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Goebel-2000">
<DESCRIPTION>
<P>Published report includes all pre-specified and expected outcomes; study protocol was not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-07 10:47:25 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Gomez-2007">
<DESCRIPTION>
<P>Hospitalisation-related outcomes not mentioned in methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:11:14 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Klassen-1997">
<DESCRIPTION>
<P>Published report includes all pre-specified and expected outcomes; study protocol was not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:11:42 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Kuyucu-2004">
<DESCRIPTION>
<P>Published report includes all pre-specified and expected outcomes; study protocol was not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:11:59 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>Published report includes all pre-specified and expected outcomes; study protocol was not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:12:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_">
<DESCRIPTION>
<P>Published report includes all pre-specified and expected outcomes; study protocol was not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:12:51 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Mesquita-2009">
<DESCRIPTION>
<P>Subgroups not defined in methods; published report includes all pre-specified and expected outcomes; study protocol was not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:13:42 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009">
<DESCRIPTION>
<P>Published report includes all pre-specified and expected outcomes; study protocol was available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:20:38 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>Published report includes all pre-specified and expected outcomes; study protocol was available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:21:05 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_">
<DESCRIPTION>
<P>Published report includes all pre-specified and expected outcomes; study protocol was available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-05 01:22:35 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Richter-1998">
<DESCRIPTION>
<P>Not all outcomes reported are specified in methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:23:32 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Roosevelt-1996">
<DESCRIPTION>
<P>Published report includes all pre-specified and expected outcomes; study protocol was not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 01:49:29 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Schuh-2002">
<DESCRIPTION>
<P>Some outcomes specified in methods not reported in results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-07 10:36:40 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Teeratakulpisarn-2007">
<DESCRIPTION>
<P>All outcomes specified in methods and results, subgroups not mentioned in methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 11:40:05 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Zhang-2003">
<DESCRIPTION>
<P>Published report includes all pre-specified and expected outcomes; study protocol was not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-05-06 02:11:30 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-05 01:14:26 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-05 01:15:48 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-05 01:15:58 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-30 01:14:13 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Bentur-2005">
<DESCRIPTION>
<P>No significant baseline imbalances; no other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-30 01:34:20 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Berger-1998">
<DESCRIPTION>
<P>No significant baseline imbalances; no other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-03 00:28:13 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Cade-2000">
<DESCRIPTION>
<P>No significant baseline imbalances; no other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-03 00:42:02 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Corneli-2007">
<DESCRIPTION>
<P>No significant baseline imbalances; no other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-03 08:57:49 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-De-Boeck-1997">
<DESCRIPTION>
<P>Few details on baseline characteristics</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-04 23:42:11 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Goebel-2000">
<DESCRIPTION>
<P>No significant baseline imbalances; no other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-04 23:48:32 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Gomez-2007">
<DESCRIPTION>
<P>No significant baseline imbalances; no other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-04 23:56:54 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Klassen-1997">
<DESCRIPTION>
<P>No significant baseline imbalances; no other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-05 00:03:32 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004">
<DESCRIPTION>
<P>Duration of illness was significantly different in G + S group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-05 00:04:29 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>Duration of illness was significantly different in G + S group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-05 00:04:37 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_">
<DESCRIPTION>
<P>Duration of illness was significantly different in G + S group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-05 00:12:36 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Mesquita-2009">
<DESCRIPTION>
<P>No significant baseline imbalances; no other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-05 00:58:53 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009">
<DESCRIPTION>
<P>No significant baseline imbalances; no other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-05 00:59:10 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>No significant baseline imbalances; no other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-05 00:59:32 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_">
<DESCRIPTION>
<P>No significant baseline imbalances; no other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-05 01:23:18 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Richter-1998">
<DESCRIPTION>
<P>No significant baseline imbalances; no other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 00:27:51 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Roosevelt-1996">
<DESCRIPTION>
<P>No significant baseline imbalances; no other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 01:49:35 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Schuh-2002">
<DESCRIPTION>
<P>Significant difference in baseline for family history of atopy; contamination - 22% of placebo received corticosteroids; 9 protocol violations (did not pursue therapy at home)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 01:58:35 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Teeratakulpisarn-2007">
<DESCRIPTION>
<P>No significant baseline imbalances; no other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 02:11:30 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="YES" STUDY_ID="STD-Zhang-2003">
<DESCRIPTION>
<P>No significant baseline imbalances; no other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2013-05-06 02:11:55 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="7">
<NAME>Overall risk of bias</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-29 03:10:57 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Barlas-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-30 00:16:33 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-30 01:14:25 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_">
<DESCRIPTION>
<P>&gt; 1 domain as high risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-05 01:27:45 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Bentur-2005">
<DESCRIPTION>
<P>&gt; 1 domain as high risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-03 00:28:52 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Berger-1998">
<DESCRIPTION>
<P>&gt; 1 domain as unclear risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-03 00:29:03 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Cade-2000">
<DESCRIPTION>
<P>&gt; 1 domain as high risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-03 08:51:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corneli-2007">
<DESCRIPTION>
<P>All applicable domains low risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-03 08:58:15 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-De-Boeck-1997">
<DESCRIPTION>
<P>&gt; 1 domain as unclear risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-04 23:42:39 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Goebel-2000">
<DESCRIPTION>
<P>&gt; 1 domain as high risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-04 23:48:35 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Gomez-2007">
<DESCRIPTION>
<P>&gt; 1 domain as unclear risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-04 23:57:26 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klassen-1997">
<DESCRIPTION>
<P>All applicable domains low risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-05 00:04:05 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Kuyucu-2004">
<DESCRIPTION>
<P>&gt; 1 domain as high risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-05 00:04:30 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>&gt; 1 domain as high risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-05 00:04:37 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_">
<DESCRIPTION>
<P>&gt; 1 domain as high risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-25 04:31:35 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mesquita-2009">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-05 00:58:53 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009">
<DESCRIPTION>
<P>All applicable domains low risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-05 00:59:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_">
<DESCRIPTION>
<P>All applicable domains low risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-05 00:59:32 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_">
<DESCRIPTION>
<P>All applicable domains low risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-05 01:23:34 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="UNKNOWN" STUDY_ID="STD-Richter-1998">
<DESCRIPTION>
<P>&gt; 1 domain as unclear risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 00:28:24 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Roosevelt-1996">
<DESCRIPTION>
<P>&gt; 1 domain as high risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 01:50:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schuh-2002">
<DESCRIPTION>
<P>&gt; 1 domain as unclear risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 01:58:46 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Teeratakulpisarn-2007">
<DESCRIPTION>
<P>&gt; 1 domain as unclear risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-06 02:11:55 +1000" MODIFIED_BY="Ricardo M Fernandes" RESULT="NO" STUDY_ID="STD-Zhang-2003">
<DESCRIPTION>
<P>&gt; 1 domain as high risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-03-19 23:52:07 +1000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-03-19 23:51:49 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-08-20 07:37:08 +1000" MODIFIED_BY="[Empty name]">Glucocorticoid versus placebo: summary of findings</TITLE>
<TABLE COLS="6" ROWS="12">
<TR>
<TD COLSPAN="6">
<P>
<B>Glucocorticoid versus placebo for acute viral bronchiolitis in infants and young children</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population: </B>infants and young children with acute viral bronchiolitis<BR/>
<B>Settings:</B> outpatients and inpatients<BR/>
<B>Intervention:</B> glucocorticoid versus placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="BOTTOM">
<P>
<B>Steroid versus placebo</B>
</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Assumed risk<SUP>1</SUP>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Placebo</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Steroid</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>
<B>Admissions (outpatients)</B>
</P>
<P>Follow-up: day 1</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>
<B>RR 0.92 </B>
</P>
<P>(0.78 to 1.08)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>1762<BR/>(8)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>high</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>
<B>162 per 1000</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>
<B>149 per 1000</B>
<BR/>(126 to 175)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>
<B>Admissions (outpatients)</B>
</P>
<P>Follow-up: day 7</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>
<B>RR 0.86 </B>
</P>
<P>(0.7 to 1.06)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>1530<BR/>(5)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>moderate</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>
<B>250 per 1000</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>
<B>215 per 1000</B>
<BR/>(175 to 265)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>Length of stay (inpatients) </B>
</P>
<P>days</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean length of stay ranged across control groups from<BR/>0.8 to 6.6 days</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean length of stay in the intervention groups was<BR/>
<B>0.18 lower</B>
<BR/>(0.39 lower to 0.04 higher)</P>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>633<BR/>(8)</P>
</TD>
<TD ALIGN="CENTER">
<P>high</P>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> (for example, the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>CI: confidence interval<BR/>RR: risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Assumed risk for admissions was based on the median control group risks across the studies included in the meta-analysis (medium risk).</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2013-03-19 23:52:07 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-08-20 07:35:58 +1000" MODIFIED_BY="[Empty name]">Glucocorticoid and epinephrine versus placebo: summary of findings</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>Glucocorticoid and epinephrine versus placebo for acute viral bronchiolitis in infants and young children</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>infants and young children with acute viral bronchiolitis<BR/>
<B>Settings:</B> outpatients<BR/>
<B>Intervention:</B> glucocorticoid and epinephrine versus placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="BOTTOM">
<P>
<B>Steroid versus placebo</B>
</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Assumed risk<SUP>1</SUP>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Placebo</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Steroid</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Admissions (outpatients)</B>
</P>
<P>Follow-up: day 1</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>
<B>179 per 1000</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>
<B>115 per 1000</B>
<BR/>(72 to 186)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>RR 0.65 </B>
<BR/>(0.4 to 1.05)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>400<BR/>(1)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Low</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>NNT: not calculated for non-significant findings</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Admissions (outpatients)</B>
</P>
<P>Follow-up: day 7</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>
<B>264 per 1000</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>
<B>169 per 1000</B>
<BR/>(116 to 251)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>RR 0.65 </B>
</P>
<P>(0.44 to 0.95)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>400<BR/>(1)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Low</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>NNT: 11 (95% CI 7 to 76) (based on unadjusted analysis results)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (for example, the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>CI: confidence interval<BR/>NNT: number needed to treat<BR/>RR: risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Assumed risk for admissions was based on the control group risk in the single study included (<LINK REF="STD-Plint-2009" TYPE="STUDY">Plint 2009</LINK>).</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-03-20 00:05:09 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1">
<TITLE MODIFIED="2010-05-20 07:28:48 +1000" MODIFIED_BY="Ricardo M Fernandes">Placebo group risk of admission/length of stay</TITLE>
<TABLE COLS="4" ROWS="19">
<TR>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Study</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Placebo group - participants</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Placebo group - primary outcomes</P>
</TH>
</TR>
<TR>
<TH COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>OUTPATIENT STUDIES</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>
<B>Risk of admission day 1 (%)</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>
<B>Risk of admission day 7 (%)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Barlas 1998</P>
</TD>
<TD ALIGN="CENTER">
<P>30</P>
</TD>
<TD ALIGN="CENTER">
<P>17%</P>
</TD>
<TD ALIGN="CENTER">
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Berger 1998</P>
</TD>
<TD ALIGN="CENTER">
<P>18</P>
</TD>
<TD ALIGN="CENTER">
<P>11%</P>
</TD>
<TD ALIGN="CENTER">
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Corneli 2007</P>
</TD>
<TD ALIGN="CENTER">
<P>295</P>
</TD>
<TD ALIGN="CENTER">
<P>41%</P>
</TD>
<TD ALIGN="CENTER">
<P>49%</P>
</TD>
</TR>
<TR>
<TD>
<P>Goebel 2000</P>
</TD>
<TD ALIGN="CENTER">
<P>24</P>
</TD>
<TD ALIGN="CENTER">
<P>8%</P>
</TD>
<TD ALIGN="CENTER">
<P>21%</P>
</TD>
</TR>
<TR>
<TD>
<P>Kuyucu 2004</P>
</TD>
<TD ALIGN="CENTER">
<P>11</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
</TR>
<TR>
<TD>
<P>Mesquita 2009</P>
</TD>
<TD ALIGN="CENTER">
<P>32</P>
</TD>
<TD ALIGN="CENTER">
<P>22%</P>
</TD>
<TD ALIGN="CENTER">
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Plint 2009</P>
</TD>
<TD ALIGN="CENTER">
<P>201</P>
</TD>
<TD ALIGN="CENTER">
<P>18%</P>
</TD>
<TD ALIGN="CENTER">
<P>26%</P>
</TD>
</TR>
<TR>
<TD>
<P>Schuh 2002</P>
</TD>
<TD ALIGN="CENTER">
<P>34</P>
</TD>
<TD ALIGN="CENTER">
<P>44%</P>
</TD>
<TD ALIGN="CENTER">
<P>47%</P>
</TD>
</TR>
<TR>
<TH COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>INPATIENT STUDIES</B>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>Length of stay (mean ± SD days)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Bentur 2005</P>
</TD>
<TD ALIGN="CENTER">
<P>32</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>6.3 ± 8.8</P>
</TD>
</TR>
<TR>
<TD>
<P>Cade 2000</P>
</TD>
<TD ALIGN="CENTER">
<P>79</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>2 ± 2.2</P>
</TD>
</TR>
<TR>
<TD>
<P>De Boeck 1997</P>
</TD>
<TD ALIGN="CENTER">
<P>15</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>6.6 ± 1.2</P>
</TD>
</TR>
<TR>
<TD>
<P>Gomez 2007</P>
</TD>
<TD ALIGN="CENTER">
<P>25</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>0.8 ± 0.2</P>
</TD>
</TR>
<TR>
<TD>
<P>Klassen 1997</P>
</TD>
<TD ALIGN="CENTER">
<P>32</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>2 ± 0.7</P>
</TD>
</TR>
<TR>
<TD>
<P>Richter 1998</P>
</TD>
<TD ALIGN="CENTER">
<P>19</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>3 ± 1.6</P>
</TD>
</TR>
<TR>
<TD>
<P>Teeratakulpisarn 2007</P>
</TD>
<TD ALIGN="CENTER">
<P>85</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>2.8 ± 1.7</P>
</TD>
</TR>
<TR>
<TD>
<P>Zhang 2003</P>
</TD>
<TD ALIGN="CENTER">
<P>24</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>5 ± 3.3</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>NR = not reported<BR/>SD = standard deviation<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2013-03-19 23:52:24 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2">
<TITLE MODIFIED="2010-07-14 10:22:27 +1000" MODIFIED_BY="[Empty name]">GRADE assessments: glucocorticoid versus placebo</TITLE>
<TABLE COLS="10" ROWS="16">
<TR>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>Population</P>
</TH>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>Outcome</P>
</TH>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>Number of studies</P>
</TH>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>Number of participants</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="4" VALIGN="BOTTOM">
<P>GRADE domains</P>
</TH>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>Strength of evidence</P>
</TH>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>Intervention favoured</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Risk of bias</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Consistency</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Directness</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Precision</P>
</TH>
</TR>
<TR>
<TH COLSPAN="10" VALIGN="BOTTOM">
<P>GLUCOCORTICOID versus PLACEBO</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="5">
<P>Inpatients</P>
</TD>
<TD>
<P>Length of stay</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>633</P>
</TD>
<TD>
<P>Medium</P>
</TD>
<TD>
<P>Consistent</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD>
<P>Precise</P>
</TD>
<TD>
<P>High</P>
</TD>
<TD>
<P>No difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical score : 3 to 6 hours</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>Medium</P>
</TD>
<TD>
<P>Unknown</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD>
<P>Imprecise</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>Glucocorticoid</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical score : 6 to 12 hours</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>175</P>
</TD>
<TD>
<P>Medium</P>
</TD>
<TD>
<P>Consistent</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD>
<P>Imprecise</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
<TD>
<P>Glucocorticoid</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical score : 12 to 24 hours</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>230</P>
</TD>
<TD>
<P>Medium</P>
</TD>
<TD>
<P>Consistent</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD>
<P>Imprecise</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
<TD>
<P>No difference (glucocorticoid favoured)</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical score : 24 to 72 hours</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>113</P>
</TD>
<TD>
<P>Medium</P>
</TD>
<TD>
<P>Inconsistent</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD>
<P>Imprecise</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>No difference (glucocorticoid favoured; very close to significant)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="7">
<P>Outpatients</P>
</TD>
<TD>
<P>Admissions day 1</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>1762</P>
</TD>
<TD>
<P>Medium</P>
</TD>
<TD>
<P>Consistent</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD>
<P>Precise</P>
</TD>
<TD>
<P>High</P>
</TD>
<TD>
<P>No difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Admissions up to day 7</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>1530</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>Consistent</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD>
<P>Imprecise</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
<TD>
<P>No difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical score: 60 minutes</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>1006</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>Consistent</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD>
<P>Precise</P>
</TD>
<TD>
<P>High</P>
</TD>
<TD>
<P>No difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical score: 120 minutes</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>214</P>
</TD>
<TD>
<P>Medium</P>
</TD>
<TD>
<P>Consistent</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD>
<P>Imprecise</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
<TD>
<P>No difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical score: 3 to 6 hours</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>808</P>
</TD>
<TD>
<P>Medium</P>
</TD>
<TD>
<P>Inconsistent</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD>
<P>Precise</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
<TD>
<P>No difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical score: 12 to 24 hours</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>69</P>
</TD>
<TD>
<P>Medium</P>
</TD>
<TD>
<P>Unknown</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD>
<P>Imprecise</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>No difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical score: 3 to 10 days</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>224</P>
</TD>
<TD>
<P>Medium</P>
</TD>
<TD>
<P>Inconsistent</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD>
<P>Imprecise</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>No difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Inpatients/outpatients</P>
</TD>
<TD>
<P>Adverse events</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>1123</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>Consistent</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD>
<P>Precise</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
<TD>
<P>No difference</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3">
<TITLE MODIFIED="2010-07-14 10:22:37 +1000" MODIFIED_BY="[Empty name]">GRADE assessments: glucocorticoid and epinephrine versus placebo</TITLE>
<TABLE COLS="10" ROWS="7">
<TR>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>Population</P>
</TH>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>Outcome</P>
</TH>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>Number of studies</P>
</TH>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>Number of participants</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="4" VALIGN="BOTTOM">
<P>GRADE domains</P>
</TH>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>Strength of evidence</P>
</TH>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>Intervention favoured</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Risk of bias</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Consistency</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Directness</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Precision</P>
</TH>
</TR>
<TR>
<TH COLSPAN="10">
<P>GLUCOCORTICOID AND EPINEPHRINE versus PLACEBO</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="4">
<P>Outpatients</P>
</TD>
<TD>
<P>Admissions day 1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>400</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>Unknown</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD>
<P>Imprecise</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>Favours epi + dex but NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Admissions day 7</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>400</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>Unknown</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD>
<P>Imprecise</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>Epi + dex</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical score: 60 minutes</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>400</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>Unknown</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD>
<P>Precise</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
<TD>
<P>Epi + dex</P>
</TD>
</TR>
<TR>
<TD>
<P>Adverse events</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>400</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>Unknown</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD>
<P>Imprecise</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>No difference</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>dex = dexamethasone<BR/>epi = epinephrine<BR/>NS = non-significant</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2013-03-20 00:05:09 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="4">
<TITLE MODIFIED="2010-05-03 20:10:56 +1000" MODIFIED_BY="Ricardo M Fernandes">Hospital re-admissions and return healthcare visits (in- and outpatients)</TITLE>
<TABLE COLS="6" ROWS="16">
<TR>
<TH VALIGN="BOTTOM">
<P>Study</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Population</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Duration of follow-up</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Glucocorticoid-including group</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Placebo or comparator group</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Notes</P>
</TH>
</TR>
<TR>
<TH COLSPAN="6" VALIGN="BOTTOM">
<P>GLUCOCORTICOID AND EPINEPHRINE versus PLACEBO: HOSPITAL RE-ADMISSIONS</P>
</TH>
</TR>
<TR>
<TD>
<P>Roosevelt 1996</P>
</TD>
<TD>
<P>Inpatients</P>
</TD>
<TD>
<P>Days 1 to 14</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>(No events in either group)</P>
</TD>
</TR>
<TR>
<TD>
<P>Klassen 1997</P>
</TD>
<TD>
<P>Inpatients</P>
</TD>
<TD>
<P>Days 1 to 7</P>
</TD>
<TD>
<P>4/35 (11%)</P>
</TD>
<TD>
<P>1/32 (3%)</P>
</TD>
<TD>
<P>P = 0.36</P>
</TD>
</TR>
<TR>
<TD>
<P>Teeratakulpisarn 2007</P>
</TD>
<TD>
<P>Inpatients</P>
</TD>
<TD>
<P>Days 1 to 30</P>
</TD>
<TD>
<P>3/89 (3%)</P>
</TD>
<TD>
<P>7/85 (8%)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TH COLSPAN="6">
<P>GLUCOCORTICOID versus PLACEBO: RETURN HEALTHCARE VISITS*</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Plint 2009</P>
<P>(epinephrine - E; dexamethasone - D; placebo - P)</P>
</TD>
<TD ROWSPAN="2">
<P>Outpatients</P>
</TD>
<TD ROWSPAN="2">
<P>Days 1 to 22</P>
</TD>
<TD>
<P>D + E</P>
<P>95/199 (48%)</P>
</TD>
<TD>
<P>P + E</P>
<P>93/198 (47%)</P>
</TD>
<TD ROWSPAN="2">
<P>Return to the health care provider for bronchiolitis symptoms</P>
<P>Difference between dexamethasone + placebo versus placebo + placebo, was significant in the unadjusted analysis (P = 0.04)</P>
</TD>
</TR>
<TR>
<TD>
<P>D + P</P>
<P>106/199 (53%)</P>
</TD>
<TD>
<P>P + P</P>
<P>86/201 (43%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Schuh 2002</P>
</TD>
<TD>
<P>Outpatients</P>
</TD>
<TD>
<P>Days 7 to 28</P>
</TD>
<TD>
<P>9/35 (26%)</P>
</TD>
<TD>
<P>14/32 (44%)</P>
</TD>
<TD>
<P>Medical visits for continuing symptoms; P = 0.069</P>
</TD>
</TR>
<TR>
<TD>
<P>Klassen 1997</P>
</TD>
<TD>
<P>Inpatients</P>
</TD>
<TD>
<P>Days 1 to 7</P>
</TD>
<TD>
<P>29/35 (83%)</P>
</TD>
<TD>
<P>24/32 (75%)</P>
</TD>
<TD>
<P>P = 0.77</P>
</TD>
</TR>
<TR>
<TD>
<P>Roosevelt 1996</P>
</TD>
<TD>
<P>Inpatients</P>
</TD>
<TD>
<P>Days 1 to 14</P>
</TD>
<TD>
<P>16/65 (25%)</P>
</TD>
<TD>
<P>5/53 (9%)</P>
</TD>
<TD>
<P>P = 0.01; reported on visits made by the physician; 69% were for non-respiratory difficulties</P>
</TD>
</TR>
<TR>
<TD>
<P>Teeratakulpisarn 2007</P>
</TD>
<TD>
<P>Inpatients</P>
</TD>
<TD>
<P>Days 1 to 30</P>
</TD>
<TD>
<P>17/89 (19%)</P>
</TD>
<TD>
<P>26/85 (31%)</P>
</TD>
<TD>
<P>Visit to emergency room or a private clinic because of respiratory symptoms</P>
</TD>
</TR>
<TR>
<TH COLSPAN="6">
<P>GLUCOCORTICOID versus EPINEPHRINE: RETURN HEALTHCARE VISITS</P>
</TH>
</TR>
<TR>
<TD>
<P>Plint 2009</P>
<P>(dexamethasone + placebo versus epinephrine + placebo)</P>
</TD>
<TD>
<P>Outpatients</P>
</TD>
<TD>
<P>Days 1 to 22</P>
</TD>
<TD>
<P>106/199 (53%)</P>
</TD>
<TD>
<P>93/198 (47%)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH COLSPAN="6">
<P>GLUCOCORTICOID AND EPINEPHRINE versus PLACEBO: RETURN HEALTHCARE VISITS</P>
</TH>
</TR>
<TR>
<TD>
<P>Plint 2009</P>
<P>(dexamethasone + epinephrine versus placebo + placebo)</P>
</TD>
<TD>
<P>Outpatients</P>
</TD>
<TD>
<P>Days 1 to 22</P>
</TD>
<TD>
<P>95/198 (48%)</P>
</TD>
<TD>
<P>86/201 (43%)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*Berger 1998: no difference between groups, but did not report quantitative data.<BR/>Data presented as n/N (%)</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2010-07-14 10:22:00 +1000" MODIFIED_BY="[Empty name]">Symptoms and quality of life (in- and outpatients)*</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TH VALIGN="BOTTOM">
<P>Study</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Population</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Duration of follow-up</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Parameter</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Glucocorticoid-including group</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Placebo or comparator group</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Notes</P>
</TH>
</TR>
<TR>
<TH COLSPAN="7" VALIGN="BOTTOM">
<P>GLUCOCORTICOID versus PLACEBO</P>
</TH>
</TR>
<TR>
<TD>
<P>Teeratakulpisarn 2007</P>
</TD>
<TD>
<P>Inpatients</P>
</TD>
<TD>
<P>Days 1 to 30</P>
</TD>
<TD>
<P>Time from treatment to being symptom free - mean ± SD</P>
</TD>
<TD>
<P>7.0 ± 5.9</P>
</TD>
<TD>
<P>9.0 ± 6.4</P>
</TD>
<TD>
<P>P = 0.035</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Cade 2000</P>
</TD>
<TD ROWSPAN="2">
<P>Inpatients</P>
</TD>
<TD ROWSPAN="2">
<P>Days 1 to 28</P>
</TD>
<TD>
<P>Time taken for half of infants to become asymptomatic for 48 hours (95% CI) - time to event analysis</P>
</TD>
<TD>
<P>10 (10 to 13)</P>
</TD>
<TD>
<P>12 (10 to 16)</P>
</TD>
<TD>
<P>HR 1.41 (95% CI 0.98 to 2.04), P = 0.07</P>
</TD>
</TR>
<TR>
<TD>
<P>Days with coughing or wheezing episodes - mean ± SD</P>
</TD>
<TD>
<P>17.0 ± 7.6 days</P>
</TD>
<TD>
<P>17.1 ± 8.5</P>
</TD>
<TD>
<P>Mean difference: 0.91 days (95% CI -2.72 to 2.41), P = 0.91</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Roosevelt 1996#</P>
</TD>
<TD ROWSPAN="2">
<P>Inpatients</P>
</TD>
<TD ROWSPAN="2">
<P>Day 10 to 14</P>
</TD>
<TD>
<P>No current difficulty breathing - n/N (%)</P>
</TD>
<TD>
<P>45/45 (100)</P>
</TD>
<TD>
<P>37/42 (88)</P>
</TD>
<TD>
<P>P = 0.07</P>
</TD>
</TR>
<TR>
<TD>
<P>Feeding and drinking well - n/N (%)</P>
</TD>
<TD>
<P>45/45 (100)</P>
</TD>
<TD>
<P>40/42 (95)</P>
</TD>
<TD>
<P>P = 0.57</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>GLUCOCORTICOID versus PLACEBO, GLUCOCORTICOID versus EPINEPHRINE, GLUCOCORTICOID AND EPINEPHRINE versus PLACEBO</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="4">
<P>Plint 2009<BR/>(epinephrine - E; dexamethasone - D; placebo - P)</P>
</TD>
<TD ROWSPAN="4">
<P>Outpatients</P>
</TD>
<TD ROWSPAN="4">
<P>Days 1 to 22</P>
</TD>
<TD>
<P>Time to return to normal feeding - median (IQR)</P>
</TD>
<TD COLSPAN="2">
<P>D + E: 0.6 (0.2 to 1.3)<BR/>D + P: 0.8 (0.3 to 1.9)<BR/>P + E: 0.5 (0.2 to 1.2)<BR/>P + P: 0.9 (0.3 to 2.1)</P>
</TD>
<TD ROWSPAN="4">
<P>Time to return to normal feeding - mean symptom duration ratio D + E versus P + P: 0.63 (unadjusted 95% CI 0.5 to 0.8)¶</P>
<P>Time to return to quiet breathing - mean symptom duration ratio D + E versus P + P: 0.83 (unadjusted 95% CI 0.69 to 1.00)</P>
<P>No other reported comparison was statistically significant in adjusted analysis</P>
</TD>
</TR>
<TR>
<TD>
<P>Time to return to normal sleeping - median (IQR)</P>
</TD>
<TD COLSPAN="2">
<P>D + E: 0.7 (0.2 to 1.7)<BR/>D + P: 0.8 (0.3 to 1.9)<BR/>P + E: 0.8 (0.3 to 1.9)<BR/>P + P: 0.8 (0.3 to 1.8)</P>
</TD>
</TR>
<TR>
<TD>
<P>Time to no coughing - median (IQR)</P>
</TD>
<TD COLSPAN="2">
<P>D + E: 12.6 (7.8 to 18.5)<BR/>D + P: 13.8 (8.5 to 20.2)<BR/>P + E: 13.2 (8.1 to 19.3)<BR/>P + P: 13.3 (8.2 to 19.5)</P>
</TD>
</TR>
<TR>
<TD>
<P>Time to quiet breathing - median (IQR)</P>
</TD>
<TD COLSPAN="2">
<P>D + E: 3.1 (1.4 to 6.1)<BR/>D + P: 3.7 (1.6 to 7.1)<BR/>P + E: 3.6 (1.5 to 6.9)<BR/>P + P: 3.7 (1.6 to 7.2)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*Units in days unless otherwise stated; no study assessed or reported data from generic or disease-specific quality of life instruments; Richter 1998 also reported number of symptom-free days for a 6-week follow-up period</P>
<P>#Roosevelt 1996 primary outcome was time to resolution (defined as number of 12 h periods needed to achieve: O<SUB>2</SUB> saturation &gt; 95% at room air, accessory muscle score = 0, wheeze = 0 or 1, and normal feeding); only association measures were reported: HR 1.3 (95% CI 0.9 to 1.3), P = 0.22</P>
<P>¶time to symptom relief was analysed by means of parametric survival models with Weibull distributions assumed; 95% CI adjusted for multiple analysis in a factorial trial.</P>
<P>CI = confidence interval<BR/>HR = hazard ratio<BR/>IQR = interquartile range<BR/>SD = standard deviation</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2013-03-19 23:09:05 +1000" MODIFIED_BY="Liz Dooley" NO="6">
<TITLE MODIFIED="2010-07-14 10:22:16 +1000" MODIFIED_BY="[Empty name]">Harms - adverse events</TITLE>
<TABLE COLS="7" ROWS="19">
<TR>
<TH COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>Adverse event </B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Number of participants</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Study</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Glucocorticoid-including group, N (%)</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Placebo or comparator group, N (%)</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Notes</B>
</P>
</TH>
</TR>
<TR>
<TH COLSPAN="7" VALIGN="BOTTOM">
<P>GLUCOCORTICOID versus PLACEBO, GLUCOCORTICOID versus EPINEPHRINE, GLUCOCORTICOID AND EPINEPHRINE versus PLACEBO</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="6">
<P>
<B>Gastrointestinal</B>
</P>
</TD>
<TD ROWSPAN="3">
<P>Vomiting</P>
</TD>
<TD ROWSPAN="3">
<P>1466</P>
</TD>
<TD>
<P>Plint 2009*  </P>
</TD>
<TD>
<P>D + E: 2/199 (1)<BR/>D + P: 5/199 (2.5)<BR/>
</P>
</TD>
<TD>
<P>P + E: 4/198 (2)<BR/>P + P: 3/201 (1.5)</P>
</TD>
<TD>
<P>Observed in the emergency department by research nurse</P>
</TD>
</TR>
<TR>
<TD>
<P>Kuyucu 2004*</P>
</TD>
<TD COLSPAN="2">
<P>No events in either group (D + E, D + S, P + E, P + S)</P>
</TD>
<TD>
<P>Methods/timings NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Corneli 2007</P>
</TD>
<TD>
<P>16/305 (5.2)</P>
</TD>
<TD>
<P>14/295 (4.7)</P>
</TD>
<TD>
<P>Within 20 minutes after administration of the study medication</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>Bleeding</P>
</TD>
<TD ROWSPAN="3">
<P>1576</P>
</TD>
<TD>
<P>Corneli 2007</P>
</TD>
<TD COLSPAN="2">
<P>No events in either group</P>
</TD>
<TD>
<P>#</P>
</TD>
</TR>
<TR>
<TD>
<P>Teeratakulpisarn 2007</P>
</TD>
<TD>
<P>2/90 (2) </P>
</TD>
<TD>
<P>1/89 (1)</P>
</TD>
<TD>
<P>Occult blood; also assessed diarrhoea separately. Methods/timings NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Plint 2009</P>
</TD>
<TD>
<P>D + E: 17/199 (8.5)<BR/>D + P: 12/199 (6)<BR/>
</P>
</TD>
<TD>
<P>P + E: 14/198 (7)<BR/>P+P: 16/201 (8)</P>
</TD>
<TD>
<P>Dark stools; reported by families during the 22-day telephone follow-up. No patient had more than 1 episode</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Endocrine</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>Hypertension</P>
</TD>
<TD ROWSPAN="2">
<P>1397</P>
</TD>
<TD>
<P>Plint 2009</P>
</TD>
<TD>
<P>D + E: 0/199 (0)<BR/>D + P: 1/199 (0.5)<BR/>
</P>
</TD>
<TD>
<P>P + E: 1/198 (0.5)<BR/>P + P: 0/201 (0)</P>
</TD>
<TD>
<P>Observed in infants admitted to hospital</P>
</TD>
</TR>
<TR>
<TD>
<P>Corneli 2007</P>
</TD>
<TD COLSPAN="2">
<P>No events in either group</P>
</TD>
<TD>
<P>#</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="5">
<P>
<B>Infectious</B>
</P>
</TD>
<TD ROWSPAN="3">
<P>Pneumonia</P>
</TD>
<TD ROWSPAN="3">
<P>851</P>
</TD>
<TD>
<P>Corneli 2007</P>
</TD>
<TD>
<P>1/305 (3.3)</P>
</TD>
<TD>
<P>2/295 (7)</P>
</TD>
<TD>
<P>Also assessed empyema separately</P>
</TD>
</TR>
<TR>
<TD>
<P>Teeratakulpisarn 2007</P>
</TD>
<TD>
<P>0/90 (0)</P>
</TD>
<TD>
<P>3/89 (3.4)</P>
</TD>
<TD>
<P>Methods/timings NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Klassen 1997</P>
</TD>
<TD>
<P>1/35 (3)</P>
</TD>
<TD>
<P>1/37 (3)</P>
</TD>
<TD>
<P>Methods/timings NR</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Varicella</P>
</TD>
<TD ROWSPAN="2">
<P>1397</P>
</TD>
<TD>
<P>Corneli 2007</P>
</TD>
<TD COLSPAN="2">
<P>No events in either group</P>
</TD>
<TD>
<P>#</P>
</TD>
</TR>
<TR>
<TD>
<P>Plint 2009</P>
</TD>
<TD COLSPAN="2">
<P>No events in either group</P>
</TD>
<TD>
<P>Reported by families during the 22-day telephone follow-up</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>
<B>General</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>Tremor</P>
</TD>
<TD ROWSPAN="2">
<P>866</P>
</TD>
<TD>
<P>Kuyucu 2004</P>
</TD>
<TD COLSPAN="2">
<P>No events in either group</P>
</TD>
<TD>
<P>Methods/timings NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Plint 2009</P>
</TD>
<TD>
<P>D + E: 4/199 (2)<BR/>D + P: 5/199 (2.5)<BR/>
</P>
</TD>
<TD>
<P>P + E: 4/198 (2)<BR/>P + P: 2/201 (1)</P>
</TD>
<TD>
<P>Observed in the emergency department by research nurse</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Pallor/flushing</P>
</TD>
<TD ROWSPAN="2">
<P>866</P>
</TD>
<TD>
<P>Kuyucu 2004</P>
</TD>
<TD COLSPAN="2">
<P>No events in either group</P>
</TD>
<TD>
<P>Methods/timings NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Plint 2009</P>
</TD>
<TD>
<P>D + E: 23/199 (11.5)<BR/>D + P: 15/199 (7.5)<BR/>
</P>
</TD>
<TD>
<P>P + E: 22/198 (11.1)<BR/>P + P: 16/201 (8)</P>
</TD>
<TD>
<P>Observed in the emergency department by research nurse</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Additional reported adverse events: Goebel 2000 reported toxicity data: one patient was "jittery"; no evidence of further treatment complications. Plint 2009 also reported hyperkalaemia observed in infants admitted to hospital (only one case was noted in the dexamethasone group).</P>
<P>*epinephrine - E; dexamethasone - D; salbutamol - S; placebo - P</P>
<P>#Corneli 2007: Study clinicians and research assistants monitored the infants for adverse events during observation in the emergency department. Subsequent adverse events were determined at follow-up. A patient safety committee, made up of people not involved with patient enrolment, tracked all adverse events.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-05-03 00:51:48 +1000" MODIFIED_BY="Ricardo M Fernandes">
<COMPARISON ID="CMP-001" MODIFIED="2013-05-03 00:51:48 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1">
<NAME>Glucocorticoid versus placebo</NAME>
<DICH_OUTCOME CHI2="12.73918294543213" CI_END="1.0191847744518552" CI_START="0.7920522511566397" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8984695848770641" ESTIMABLE="YES" EVENTS_1="436" EVENTS_2="468" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.008252927137140657" LOG_CI_START="-0.10124616734928887" LOG_EFFECT_SIZE="-0.04649662010607414" METHOD="MH" MODIFIED="2010-08-15 03:20:29 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="0.4681539790891217" P_Q="0.6388618435193745" P_Z="0.09600861442592687" Q="0.22023380750806065" RANDOM="YES" SCALE="10.45" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1694" TOTAL_2="1598" WEIGHT="200.0" Z="1.6645197156774727">
<NAME>Admissions (days 1 and 7) (outpatients) - review primary outcome</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.868751405784378" CI_END="1.076476544701088" CI_START="0.7848709984662657" DF="8" EFFECT_SIZE="0.9191818212220358" ESTIMABLE="YES" EVENTS_1="205" EVENTS_2="217" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.03200457143970596" LOG_CI_START="-0.10520171810585138" LOG_EFFECT_SIZE="-0.03659857333307271" MODIFIED="2010-08-15 03:20:16 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="0.5508576370903966" P_Z="0.29574281921299106" STUDIES="10" TAU2="0.0" TOTAL_1="907" TOTAL_2="855" WEIGHT="100.00000000000001" Z="1.0456063764417016">
<NAME>Admissions day 1</NAME>
<DICH_DATA CI_END="2.6042495575339197" CI_START="0.17066123450369663" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.4156825990462294" LOG_CI_START="-0.7678651171575919" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2010-08-13 02:13:15 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="533" O_E="0.0" SE="0.695221787153807" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_" TOTAL_1="30" TOTAL_2="15" VAR="0.4833333333333333" WEIGHT="1.3439295287726096">
<FOOTNOTE>Plint 2009 (factorial trial) and Barlas 1998 (parallel multiarm study) contribute two independent comparisons which are shown separately; sensitivity analysis did not show relevant differences when pooling results</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="6.20048286508611" CI_START="0.16127776203218527" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7924255116719207" LOG_CI_START="-0.7924255116719207" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-13 02:13:20 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="535" O_E="0.0" SE="0.9309493362512627" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_" TOTAL_1="15" TOTAL_2="15" VAR="0.8666666666666667" WEIGHT="0.7494991602770322">
<FOOTNOTE>G: Glucocorticoid, S:Salbutamol, E: Epinephrine, P: Placebo</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="10.19672740704177" CI_START="0.4964828221752679" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0084608092997827" LOG_CI_START="-0.30409577307705765" LOG_EFFECT_SIZE="0.3521825181113625" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1009" O_E="0.0" SE="0.7710022337480251" STUDY_ID="STD-Berger-1998" TOTAL_1="20" TOTAL_2="18" VAR="0.5944444444444443" WEIGHT="1.0927277476936175"/>
<DICH_DATA CI_END="1.17502236352059" CI_START="0.7961560889355206" EFFECT_SIZE="0.9672131147540983" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="121" LOG_CI_END="0.07004613236193619" LOG_CI_START="-0.09900177909918194" LOG_EFFECT_SIZE="-0.01447782336862286" MODIFIED="2010-08-12 08:05:48 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1008" O_E="0.0" SE="0.09929957999291825" STUDY_ID="STD-Corneli-2007" TOTAL_1="305" TOTAL_2="295" VAR="0.00986040658676997" WEIGHT="65.87618200027423"/>
<DICH_DATA CI_END="9.909075681283461" CI_START="0.4036703451115336" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9960331453793151" LOG_CI_START="-0.3939731540513527" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1004" O_E="0.0" SE="0.816496580927726" STUDY_ID="STD-Goebel-2000" TOTAL_1="24" TOTAL_2="24" VAR="0.6666666666666667" WEIGHT="0.9743489083601418"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-12 07:15:22 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1005" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="46" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.699291526026783" CI_START="0.45499453417999086" EFFECT_SIZE="1.1082251082251082" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.43124979130257723" LOG_CI_START="-0.3419938204631667" LOG_EFFECT_SIZE="0.04462798541970525" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1002" O_E="0.0" SE="0.45420712516880724" STUDY_ID="STD-Mesquita-2009" TOTAL_1="33" TOTAL_2="32" VAR="0.20630411255411255" WEIGHT="3.148584537966413"/>
<DICH_DATA CI_END="1.3149856743021993" CI_START="0.47354677401404854" EFFECT_SIZE="0.7891180038121642" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="29" LOG_CI_END="0.1189210215669222" LOG_CI_START="-0.3246371176259998" LOG_EFFECT_SIZE="-0.10285804802953877" MODIFIED="2010-08-15 03:20:11 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="538" O_E="0.0" SE="0.2605482466101223" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" TOTAL_1="199" TOTAL_2="198" VAR="0.06788538881160912" WEIGHT="9.568567703271055"/>
<DICH_DATA CI_END="1.348355334634231" CI_START="0.5610479636639762" EFFECT_SIZE="0.8697654941373534" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" LOG_CI_END="0.12980435772970553" LOG_CI_START="-0.2510000095741703" LOG_EFFECT_SIZE="-0.06059782592223239" MODIFIED="2010-08-15 03:20:16 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="539" O_E="0.0" SE="0.22368637036631592" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_" TOTAL_1="199" TOTAL_2="201" VAR="0.05003559228765665" WEIGHT="12.982077541370558"/>
<DICH_DATA CI_END="0.9471251141566177" CI_START="0.2050968743677248" EFFECT_SIZE="0.44074074074074077" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.0235926473971687" LOG_CI_START="-0.6880409581357444" LOG_EFFECT_SIZE="-0.35581680276645655" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1007" O_E="0.0" SE="0.39030022680002296" STUDY_ID="STD-Schuh-2002" TOTAL_1="36" TOTAL_2="34" VAR="0.15233426704014935" WEIGHT="4.2640828720143515"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.842797338900415" CI_END="1.0641445016670419" CI_START="0.7002968697439977" DF="4" EFFECT_SIZE="0.8632595574175335" ESTIMABLE="YES" EVENTS_1="231" EVENTS_2="251" I2="31.539641579408613" ID="CMP-001.01.02" LOG_CI_END="0.02700060541725122" LOG_CI_START="-0.1547178148999694" LOG_EFFECT_SIZE="-0.06385860474135911" MODIFIED="2010-08-15 03:20:29 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="0.21119997140734348" P_Z="0.1683509024865236" STUDIES="6" TAU2="0.01747185151517307" TOTAL_1="787" TOTAL_2="743" WEIGHT="100.0" Z="1.3775220495264417">
<NAME>Admissions day 7</NAME>
<DICH_DATA CI_END="1.1270972176819116" CI_START="0.796259048706326" EFFECT_SIZE="0.9473443715729492" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="131" LOG_CI_END="0.051961377698152976" LOG_CI_START="-0.09894561929596962" LOG_EFFECT_SIZE="-0.023492120798908292" MODIFIED="2010-04-23 04:06:52 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1694" O_E="0.0" SE="0.08864351703603024" STUDY_ID="STD-Corneli-2007" TOTAL_1="284" TOTAL_2="265" VAR="0.007857673112516984" WEIGHT="44.98275705753927"/>
<DICH_DATA CI_END="3.4061821332564044" CI_START="0.42276071673927784" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.532267866572387" LOG_CI_START="-0.37390537447713734" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2010-04-23 04:06:52 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1698" O_E="0.0" SE="0.5322906474223771" STUDY_ID="STD-Goebel-2000" TOTAL_1="24" TOTAL_2="24" VAR="0.2833333333333333" WEIGHT="3.7878065608615357"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-12 07:15:24 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1695" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="46" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0683964036649523" CI_START="0.4849019475898856" EFFECT_SIZE="0.7197690580562386" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="47" LOG_CI_END="0.028732417470736377" LOG_CI_START="-0.31434607155401223" LOG_EFFECT_SIZE="-0.1428068270416379" MODIFIED="2010-08-15 03:20:27 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="540" O_E="0.0" SE="0.20152600271904728" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" TOTAL_1="199" TOTAL_2="198" VAR="0.04061272977191745" WEIGHT="19.6160810229267"/>
<DICH_DATA CI_END="1.3529287095339466" CI_START="0.6982318611196237" EFFECT_SIZE="0.9719351474352896" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="53" LOG_CI_END="0.13127491273086228" LOG_CI_START="-0.15600033771500318" LOG_EFFECT_SIZE="-0.012362712492070467" MODIFIED="2010-08-15 03:20:29 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="541" O_E="0.0" SE="0.1687469041473254" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_" TOTAL_1="199" TOTAL_2="201" VAR="0.02847551765930663" WEIGHT="24.797760419832393"/>
<DICH_DATA CI_END="0.9108155575186726" CI_START="0.19986971340321266" EFFECT_SIZE="0.4266666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.04056955986760247" LOG_CI_START="-0.6992530102759856" LOG_EFFECT_SIZE="-0.36991128507179405" MODIFIED="2010-04-23 04:06:52 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1697" O_E="0.0" SE="0.386913919305549" STUDY_ID="STD-Schuh-2002" TOTAL_1="35" TOTAL_2="32" VAR="0.14970238095238092" WEIGHT="6.8155949388401"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="8.33019574811678" CI_END="0.04289960696091927" CI_START="-0.3948879622927039" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.17599417766589232" ESTIMABLE="YES" I2="15.968361228696216" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2010-06-26 21:12:45 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="0.304380061366882" P_Q="1.0" P_Z="0.1150619777791252" Q="0.0" RANDOM="YES" SCALE="7.8" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.017841785359773217" TOTALS="YES" TOTAL_1="322" TOTAL_2="311" UNITS="" WEIGHT="99.99999999999999" Z="1.5758430523825924">
<NAME>Length of stay (inpatients) - review primary outcome</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.3588370411405615" CI_START="-4.996837041140561" EFFECT_SIZE="-0.819" ESTIMABLE="YES" MEAN_1="5.469" MEAN_2="6.288" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1019" SD_1="7.87" SD_2="8.778" SE="2.1315886792281935" STUDY_ID="STD-Bentur-2005" TOTAL_1="29" TOTAL_2="32" WEIGHT="0.2734398761927848"/>
<CONT_DATA CI_END="0.5850320304986812" CI_START="-0.5850320304986812" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.0" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1018" SD_1="1.48" SD_2="2.22" SE="0.2984912146923817" STUDY_ID="STD-Cade-2000" TOTAL_1="82" TOTAL_2="79" WEIGHT="11.663675005771099"/>
<CONT_DATA CI_END="0.892607915895336" CI_START="-2.0926079158953352" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="6.6" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1021" SD_1="2.619" SD_2="1.162" SE="0.7615486446020623" STUDY_ID="STD-De-Boeck-1997" TOTAL_1="14" TOTAL_2="15" WEIGHT="2.0864891511479704"/>
<CONT_DATA CI_END="-0.008630944936559248" CI_START="-0.24136905506344075" EFFECT_SIZE="-0.125" ESTIMABLE="YES" MEAN_1="0.654" MEAN_2="0.779" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1020" SD_1="0.192" SD_2="0.223" SE="0.059373057862973505" STUDY_ID="STD-Gomez-2007" TOTAL_1="24" TOTAL_2="25" WEIGHT="58.37518083018746"/>
<CONT_DATA CI_END="1.2053703387678127" CI_START="-0.45537033876781263" EFFECT_SIZE="0.375" ESTIMABLE="YES" MEAN_1="2.375" MEAN_2="2.0" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1023" SD_1="2.39" SD_2="0.722" SE="0.4236661210704216" STUDY_ID="STD-Klassen-1997" TOTAL_1="35" TOTAL_2="32" WEIGHT="6.320727538034425"/>
<CONT_DATA CI_END="0.3476792968530291" CI_START="-2.347679296853029" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.0" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1022" SD_1="2.647" SD_2="1.626" SE="0.6876041128731708" STUDY_ID="STD-Richter-1998" TOTAL_1="21" TOTAL_2="19" WEIGHT="2.54218213963027"/>
<CONT_DATA CI_END="-0.1071666458089971" CI_START="-1.0108333541910033" EFFECT_SIZE="-0.5590000000000002" ESTIMABLE="YES" MEAN_1="2.258" MEAN_2="2.817" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1025" SD_1="1.246" SD_2="1.742" SE="0.23053145759565324" STUDY_ID="STD-Teeratakulpisarn-2007" TOTAL_1="89" TOTAL_2="85" WEIGHT="17.570927235210867"/>
<CONT_DATA CI_END="3.008958531386528" CI_START="-1.008958531386528" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="5.0" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1024" SD_1="4.05" SD_2="3.34" SE="1.0249976771169962" STUDY_ID="STD-Zhang-2003" TOTAL_1="28" TOTAL_2="24" WEIGHT="1.167378223825112"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.2861035472632656" CI_END="1.0064138749764862" CI_START="-0.8080893157156118" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.09916227963043722" ESTIMABLE="YES" I2="12.514898881363669" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2010-06-20 17:59:13 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.31884486728822825" P_Q="1.0" P_Z="0.8303728704528395" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.217999717184578" TOTALS="YES" TOTAL_1="130" TOTAL_2="125" UNITS="" WEIGHT="100.0" Z="0.21422337276399608">
<NAME>Length of stay (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3319181449693094" CI_START="-7.331918144969309" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="8.0" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1027" SD_1="2.105" SD_2="2.828" SE="2.2102029318594254" STUDY_ID="STD-Berger-1998" TOTAL_1="5" TOTAL_2="2" WEIGHT="4.198885288831495"/>
<CONT_DATA CI_END="0.6126169178439225" CI_START="-0.05261691784392292" EFFECT_SIZE="0.2799999999999998" ESTIMABLE="YES" MEAN_1="2.55" MEAN_2="2.27" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1026" SD_1="1.32" SD_2="1.32" SE="0.16970562748477142" STUDY_ID="STD-Corneli-2007" TOTAL_1="121" TOTAL_2="121" WEIGHT="86.81897244119152"/>
<CONT_DATA CI_END="2.6855436218942375" CI_START="-3.085543621894238" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="2.5" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1028" SD_1="1.7" SD_2="1.7" SE="1.4722431864335455" STUDY_ID="STD-Goebel-2000" TOTAL_1="4" TOTAL_2="2" WEIGHT="8.982142269976984"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="35.8878285711866" CI_END="0.04416006745438603" CI_START="-0.16859690518047826" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.06221841886304611" ESTIMABLE="YES" I2="38.69787926466183" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2013-01-07 12:42:19 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="4" P_CHI2="0.031217280383581736" P_Q="0.8325180098896101" P_Z="0.2516547270295917" Q="1.4667306384314096" RANDOM="YES" SCALE="2.76" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.028566397505658078" TOTALS="SUB" TOTAL_1="1228" TOTAL_2="1093" UNITS="" WEIGHT="500.0" Z="1.146339493708464">
<NAME>Clinical scores (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.4389699135592533" CI_END="0.08864816117770995" CI_START="-0.1594066649947702" DF="5" EFFECT_SIZE="-0.03537925190853011" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" MODIFIED="2013-01-07 12:41:56 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="0.6326418102515348" P_Z="0.5761026503321962" STUDIES="6" TAU2="0.0" TOTAL_1="512" TOTAL_2="494" WEIGHT="100.0" Z="0.5590865584890765">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="0.2992967172296698" CI_START="-0.948213470315929" EFFECT_SIZE="-0.3244583765431296" ESTIMABLE="YES" MEAN_1="-1.135" MEAN_2="-0.54" MODIFIED="2010-08-13 02:14:09 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="267" SD_1="1.72" SD_2="1.96" SE="0.31824824266818164" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_" TOTAL_1="30" TOTAL_2="15" WEIGHT="3.9537313875415396">
<FOOTNOTE>Kuyucu 2004 and Plint 2009 (factorial trials) and Barlas 1998 (parallel multiarm study) contribute two independent comparisons which are shown separately; sensitivity analysis did not show relevant differences when pooling results</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="1.2436033065002485" CI_START="-0.21475077163644485" EFFECT_SIZE="0.5144262674319019" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="-2.27" MODIFIED="2010-08-13 02:14:27 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="268" SD_1="2.28" SD_2="1.73" SE="0.3720359378131446" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_" TOTAL_1="15" TOTAL_2="15" WEIGHT="2.893139677264892">
<FOOTNOTE>G: Glucocorticoid, S:Salbutamol, E: Epinephrine, P: Placebo</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.48626477478635916" CI_START="-0.48626477478635916" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-2.0" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1030" SD_1="2.0" SD_2="2.0" SE="0.24809883172443659" STUDY_ID="STD-Mesquita-2009" TOTAL_1="33" TOTAL_2="32" WEIGHT="6.505635853506312"/>
<CONT_DATA CI_END="0.17640325603222395" CI_START="-0.21707935665696726" EFFECT_SIZE="-0.020338050312371656" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-2.45" MODIFIED="2010-06-25 08:20:15 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="543" SD_1="2.58" SD_2="2.32" SE="0.10038006202994847" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" TOTAL_1="199" TOTAL_2="198" WEIGHT="39.74150131522745"/>
<CONT_DATA CI_END="0.15484916747595504" CI_START="-0.2376782643147037" EFFECT_SIZE="-0.04141454841937433" ESTIMABLE="YES" MEAN_1="-1.75" MEAN_2="-1.65" MODIFIED="2010-06-25 08:19:57 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="542" SD_1="2.4" SD_2="2.42" SE="0.10013638895583414" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_" TOTAL_1="199" TOTAL_2="200" WEIGHT="39.93515152362942"/>
<CONT_DATA CI_END="0.2859576331360129" CI_START="-0.6535603910868324" EFFECT_SIZE="-0.18380137897540977" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="-1.5" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1033" SD_1="3.673" SD_2="2.677" SE="0.23967736949087934" STUDY_ID="STD-Schuh-2002" TOTAL_1="36" TOTAL_2="34" WEIGHT="6.970840242830371"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.977229618976304" CI_END="0.205704789009458" CI_START="-0.5501044664961434" DF="4" EFFECT_SIZE="-0.17219983874334271" ESTIMABLE="YES" I2="42.670655569067" ID="CMP-001.04.02" MODIFIED="2013-01-07 12:42:01 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.13709661809431084" P_Z="0.37180524950879923" STUDIES="5" TAU2="0.0785707353926471" TOTAL_1="127" TOTAL_2="87" WEIGHT="100.0" Z="0.8930969808110678">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="0.1391639111973778" CI_START="-1.118388733029231" EFFECT_SIZE="-0.48961241091592655" ESTIMABLE="YES" MEAN_1="-2.65" MEAN_2="-1.47" MODIFIED="2010-06-25 23:28:58 +1000" MODIFIED_BY="[Empty name]" ORDER="269" SD_1="2.28" SD_2="2.54" SE="0.3208101409377987" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_" TOTAL_1="30" TOTAL_2="15" WEIGHT="20.484049675243"/>
<CONT_DATA CI_END="1.3001056461005023" CI_START="-0.16409860565230305" EFFECT_SIZE="0.5680035202240996" ESTIMABLE="YES" MEAN_1="-2.07" MEAN_2="-3.42" MODIFIED="2010-06-25 23:29:10 +1000" MODIFIED_BY="[Empty name]" ORDER="270" SD_1="2.75" SD_2="1.77" SE="0.37352835646528754" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_" TOTAL_1="15" TOTAL_2="15" WEIGHT="17.046066764647463"/>
<CONT_DATA CI_END="0.42069075464970285" CI_START="-1.0243909913084925" EFFECT_SIZE="-0.3018501183293948" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="-3.2" MODIFIED="2010-06-26 00:11:05 +1000" MODIFIED_BY="[Empty name]" ORDER="299" SD_1="0.959" SD_2="0.995" SE="0.36865007657202264" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" TOTAL_1="23" TOTAL_2="11" WEIGHT="17.333823408106145"/>
<CONT_DATA CI_END="0.7668991409442273" CI_START="-0.629429866039703" EFFECT_SIZE="0.0687346374522622" ESTIMABLE="YES" MEAN_1="-3.2" MEAN_2="-3.3" MODIFIED="2010-06-26 00:11:20 +1000" MODIFIED_BY="[Empty name]" ORDER="300" SD_1="1.439" SD_2="1.386" SE="0.35621292482872013" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_" TOTAL_1="23" TOTAL_2="12" WEIGHT="18.09440772766894"/>
<CONT_DATA CI_END="-7.655962580764841E-4" CI_START="-0.9521688296318309" EFFECT_SIZE="-0.4764672129449537" ESTIMABLE="YES" MEAN_1="-3.7" MEAN_2="-2.2" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1039" SD_1="3.673" SD_2="2.38" SE="0.24270936631445825" STUDY_ID="STD-Schuh-2002" TOTAL_1="36" TOTAL_2="34" WEIGHT="27.041652424334462"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="12.457220830655679" CI_END="0.21469569807482947" CI_START="-0.4966733997373396" DF="4" EFFECT_SIZE="-0.14098885083125506" ESTIMABLE="YES" I2="67.89010924365654" ID="CMP-001.04.03" MODIFIED="2013-01-07 12:42:06 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.014256245943375379" P_Z="0.4372148851686939" STUDIES="5" TAU2="0.10188158850857218" TOTAL_1="418" TOTAL_2="390" WEIGHT="100.0" Z="0.7769049026751887">
<NAME>3 to 6 hours</NAME>
<CONT_DATA CI_END="-0.0700557637068433" CI_START="-1.346971329044783" EFFECT_SIZE="-0.7085135463758131" ESTIMABLE="YES" MEAN_1="-2.915" MEAN_2="-1.07" MODIFIED="2010-06-25 23:29:44 +1000" MODIFIED_BY="[Empty name]" ORDER="271" SD_1="2.67" SD_2="2.31" SE="0.32574975239598447" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_" TOTAL_1="30" TOTAL_2="15" WEIGHT="15.833684526426252"/>
<CONT_DATA CI_END="1.585740414800982" CI_START="0.08429443147434013" EFFECT_SIZE="0.835017423137661" ESTIMABLE="YES" MEAN_1="-2.39" MEAN_2="-4.63" MODIFIED="2010-06-25 23:30:07 +1000" MODIFIED_BY="[Empty name]" ORDER="272" SD_1="3.25" SD_2="1.75" SE="0.3830289727693611" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_" TOTAL_1="15" TOTAL_2="15" WEIGHT="13.247846941014949"/>
<CONT_DATA CI_END="0.05307044908664327" CI_START="-0.26780232933966414" EFFECT_SIZE="-0.10736594012651043" ESTIMABLE="YES" MEAN_1="-5.3" MEAN_2="-4.8" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1043" SD_1="4.7" SD_2="4.6" SE="0.08185680475695241" STUDY_ID="STD-Corneli-2007" TOTAL_1="304" TOTAL_2="294" WEIGHT="30.33021441838612"/>
<CONT_DATA CI_END="0.48626477478635916" CI_START="-0.48626477478635916" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-3.0" MEAN_2="-3.0" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1044" SD_1="3.0" SD_2="2.0" SE="0.24809883172443659" STUDY_ID="STD-Mesquita-2009" TOTAL_1="33" TOTAL_2="32" WEIGHT="20.150682621629425"/>
<CONT_DATA CI_END="-0.04575631772311506" CI_START="-0.9999898601483717" EFFECT_SIZE="-0.5228730889357434" ESTIMABLE="YES" MEAN_1="-5.0" MEAN_2="-3.2" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1040" SD_1="3.1" SD_2="3.7" SE="0.24343139719712428" STUDY_ID="STD-Schuh-2002" TOTAL_1="36" TOTAL_2="34" WEIGHT="20.437571492543263"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.572689573966727" CI_END="0.7581738751677626" CI_START="-0.5071531468580036" DF="1" EFFECT_SIZE="0.12551036415487946" ESTIMABLE="YES" I2="36.41466081079541" ID="CMP-001.04.04" MODIFIED="2013-01-07 12:42:13 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="4" P_CHI2="0.20981689617667332" P_Z="0.6974051346567423" STUDIES="2" TAU2="0.07589617897192312" TOTAL_1="46" TOTAL_2="23" WEIGHT="100.00000000000001" Z="0.38882563819151794">
<NAME>12 to 24 hours</NAME>
<CONT_DATA CI_END="0.5190658035311916" CI_START="-0.9215326279703843" EFFECT_SIZE="-0.20123341221959637" ESTIMABLE="YES" MEAN_1="-3.9" MEAN_2="-3.7" MODIFIED="2010-06-26 00:19:07 +1000" MODIFIED_BY="[Empty name]" ORDER="302" SD_1="0.959" SD_2="0.995" SE="0.3675063528883266" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" TOTAL_1="23" TOTAL_2="11" WEIGHT="49.39184496910855"/>
<CONT_DATA CI_END="1.151051288025907" CI_START="-0.2622488449921804" EFFECT_SIZE="0.44440122151686334" ESTIMABLE="YES" MEAN_1="-3.3" MEAN_2="-3.9" MODIFIED="2010-06-26 00:12:07 +1000" MODIFIED_BY="[Empty name]" ORDER="301" SD_1="1.439" SD_2="1.039" SE="0.3605423732696158" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_" TOTAL_1="23" TOTAL_2="12" WEIGHT="50.60815503089147"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.807010331153586" CI_END="0.20970159666698163" CI_START="-0.6098882756918118" DF="4" EFFECT_SIZE="-0.2000933395124151" ESTIMABLE="YES" I2="54.58163611037732" ID="CMP-001.04.05" MODIFIED="2013-01-07 12:42:19 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="5" P_CHI2="0.06610858929261632" P_Z="0.33856482191835247" STUDIES="5" TAU2="0.11754879389782417" TOTAL_1="125" TOTAL_2="99" WEIGHT="100.0" Z="0.9570048440495991">
<NAME>3 to 10 days</NAME>
<CONT_DATA CI_END="0.6367788626848081" CI_START="-0.6367788626848081" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-2.45" MEAN_2="-2.45" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1049" SD_1="1.9" SD_2="2.0" SE="0.32489314482696546" STUDY_ID="STD-Berger-1998" TOTAL_1="20" TOTAL_2="18" WEIGHT="19.594264039979432"/>
<CONT_DATA CI_END="0.7948832717779527" CI_START="-0.34066948125330543" EFFECT_SIZE="0.22710689526232367" ESTIMABLE="YES" MEAN_1="-3.1" MEAN_2="-3.5" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1048" SD_1="1.47" SD_2="1.96" SE="0.28968714782219296" STUDY_ID="STD-Goebel-2000" TOTAL_1="24" TOTAL_2="24" WEIGHT="21.698620807716114"/>
<CONT_DATA CI_END="-0.1441855464876558" CI_START="-1.651144689149961" EFFECT_SIZE="-0.8976651178188084" ESTIMABLE="YES" MEAN_1="-5.0" MEAN_2="-4.5" MODIFIED="2010-06-26 00:19:35 +1000" MODIFIED_BY="[Empty name]" ORDER="303" SD_1="0.48" SD_2="0.663" SE="0.3844354168109737" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" TOTAL_1="23" TOTAL_2="11" WEIGHT="16.475373811473006"/>
<CONT_DATA CI_END="0.02136922341328129" CI_START="-1.4170405929456371" EFFECT_SIZE="-0.6978356847661779" ESTIMABLE="YES" MEAN_1="-4.7" MEAN_2="-4.3" MODIFIED="2010-06-26 00:19:47 +1000" MODIFIED_BY="[Empty name]" ORDER="304" SD_1="0.48" SD_2="0.693" SE="0.36694802243942015" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_" TOTAL_1="23" TOTAL_2="12" WEIGHT="17.33374973800443"/>
<CONT_DATA CI_END="0.5503936716830177" CI_START="-0.39389613820380154" EFFECT_SIZE="0.07824876673960808" ESTIMABLE="YES" MEAN_1="-8.9" MEAN_2="-9.3" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1050" SD_1="5.2" SD_2="4.9" SE="0.24089468412053913" STUDY_ID="STD-Schuh-2002" TOTAL_1="35" TOTAL_2="34" WEIGHT="24.89799160282702"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="12.540174155478441" CI_END="-0.26572924031642614" CI_START="-0.7392833933935898" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_SIZE="-0.502506316855008" ESTIMABLE="YES" I2="20.256290893445943" I2_Q="5.326449741167255" ID="CMP-001.05" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2013-01-07 12:30:00 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="5" P_CHI2="0.25052890116192406" P_Q="0.3663273047603376" P_Z="3.188269035866911E-5" Q="3.1687836695657343" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.028434959932399886" TOTALS="SUB" TOTAL_1="504" TOTAL_2="474" WEIGHT="400.0" Z="4.159584607757432">
<NAME>Clinical scores (inpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.18638648754816323" CI_START="-1.8720535124518367" DF="0" EFFECT_SIZE="-1.02922" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2013-01-07 12:30:00 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.016693225273222968" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="85" WEIGHT="100.0" Z="2.3933957328062325">
<NAME>3 to 6 hours</NAME>
<IV_DATA CI_END="-0.18638648754816323" CI_START="-1.8720535124518367" EFFECT_SIZE="-1.02922" ESTIMABLE="YES" ESTIMATE="-1.02922" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-02 17:38:31 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="271" SE="0.430025" STUDY_ID="STD-Teeratakulpisarn-2007" TOTAL_1="89" TOTAL_2="85" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.1254794236023368" CI_END="-0.22662244245159674" CI_START="-1.0048342120774192" DF="2" EFFECT_SIZE="-0.615728327264508" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2013-01-07 12:29:27 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="0.939187909092658" P_Z="0.0019255383010788507" STUDIES="3" TAU2="0.0" TOTAL_1="138" TOTAL_2="131" WEIGHT="99.99999999999999" Z="3.1014831509931553">
<NAME>6 to 12 hours</NAME>
<IV_DATA CI_END="0.22998640232634693" CI_START="-1.249986402326347" EFFECT_SIZE="-0.51" ESTIMABLE="YES" ESTIMATE="-0.51" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-27 00:42:26 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="272" SE="0.37755102040816324" STUDY_ID="STD-De-Boeck-1997" TOTAL_1="14" TOTAL_2="15" WEIGHT="27.64955330442516"/>
<IV_DATA CI_END="7.292567054815102" CI_START="-7.612567054815102" EFFECT_SIZE="-0.16" ESTIMABLE="YES" ESTIMATE="-0.16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-27 00:42:33 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="273" SE="3.8024" STUDY_ID="STD-Klassen-1997" TOTAL_1="35" TOTAL_2="31" WEIGHT="0.27259872083137227"/>
<IV_DATA CI_END="-0.19969202185515372" CI_START="-1.1163279781448463" EFFECT_SIZE="-0.65801" ESTIMABLE="YES" ESTIMATE="-0.65801" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-02 17:38:46 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="274" SE="0.23384" STUDY_ID="STD-Teeratakulpisarn-2007" TOTAL_1="89" TOTAL_2="85" WEIGHT="72.07784797474346"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="3.4071160485418055" CI_END="0.09248562168751384" CI_START="-0.6563506075103142" DF="2" EFFECT_SIZE="-0.28193249291140016" ESTIMABLE="YES" I2="41.29932847881803" ID="CMP-001.05.03" LOG_CI_END="-1.0339257797706147" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2013-01-07 12:29:36 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="0.1820349474852868" P_Z="0.1399895018999849" STUDIES="3" TAU2="0.04617892392674391" TOTAL_1="136" TOTAL_2="128" WEIGHT="100.00000000000001" Z="1.4758301231495523">
<NAME>12 to 24 hours</NAME>
<IV_DATA CI_END="0.08998621857400024" CI_START="-1.4099862185740002" EFFECT_SIZE="-0.66" ESTIMABLE="YES" ESTIMATE="-0.66" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-27 00:42:46 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="275" SE="0.3826530612244898" STUDY_ID="STD-De-Boeck-1997" TOTAL_1="14" TOTAL_2="15" WEIGHT="18.94768156507082"/>
<IV_DATA CI_END="0.5949907205064935" CI_START="-0.41499072050649355" EFFECT_SIZE="0.09" ESTIMABLE="YES" ESTIMATE="0.09" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-27 00:42:46 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="276" SE="0.2576530612244898" STUDY_ID="STD-Klassen-1997" TOTAL_1="33" TOTAL_2="28" WEIGHT="32.420365924588275"/>
<IV_DATA CI_END="-0.049607598558443766" CI_START="-0.7155524014415562" EFFECT_SIZE="-0.38258" ESTIMABLE="YES" ESTIMATE="-0.38258" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-02 17:38:54 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="277" SE="0.169887" STUDY_ID="STD-Teeratakulpisarn-2007" TOTAL_1="89" TOTAL_2="85" WEIGHT="48.63195251034091"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="5.078162936616939" CI_END="0.0758175392944832" CI_START="-1.1433478264300918" DF="3" EFFECT_SIZE="-0.5337651435678042" ESTIMABLE="YES" I2="40.92351825956587" ID="CMP-001.05.04" LOG_CI_END="-1.1202303149790849" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2013-01-07 12:29:42 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="4" P_CHI2="0.16616253803853065" P_Z="0.0861270468384574" STUDIES="4" TAU2="0.15404037853872238" TOTAL_1="141" TOTAL_2="130" WEIGHT="99.99999999999999" Z="1.7161912354260378">
<NAME>24 to 72 hours</NAME>
<IV_DATA CI_END="-0.0050307785180658815" CI_START="-3.3549692214819338" EFFECT_SIZE="-1.68" ESTIMABLE="YES" ESTIMATE="-1.68" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-27 00:42:56 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="278" SE="0.8545918367346939" STUDY_ID="STD-De-Boeck-1997" TOTAL_1="14" TOTAL_2="15" WEIGHT="10.937957803072768"/>
<IV_DATA CI_END="0.5999860348216537" CI_START="-0.9199860348216538" EFFECT_SIZE="-0.16" ESTIMABLE="YES" ESTIMATE="-0.16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-27 00:42:56 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="279" SE="0.3877551020408163" STUDY_ID="STD-Klassen-1997" TOTAL_1="17" TOTAL_2="11" WEIGHT="31.778427627855155"/>
<IV_DATA CI_END="0.44998860735450696" CI_START="-0.789988607354507" EFFECT_SIZE="-0.17" ESTIMABLE="YES" ESTIMATE="-0.17" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-27 00:42:56 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="281" SE="0.3163265306122449" STUDY_ID="STD-Richter-1998" TOTAL_1="21" TOTAL_2="19" WEIGHT="38.0679525714918"/>
<IV_DATA CI_END="-0.06160996754986381" CI_START="-2.3785500324501365" EFFECT_SIZE="-1.22008" ESTIMABLE="YES" ESTIMATE="-1.22008" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-02 17:39:03 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="280" SE="0.591067" STUDY_ID="STD-Teeratakulpisarn-2007" TOTAL_1="89" TOTAL_2="85" WEIGHT="19.215661997580273"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="13.556155980337635" CI_END="-0.02318676556958177" CI_START="-0.6066218812580094" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3149043234137956" ESTIMABLE="YES" I2="11.479330737966894" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2013-01-07 12:41:45 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="6" P_CHI2="0.32994405663842896" P_Q="0.7756463903389521" P_Z="0.03436616037672853" Q="1.1059150717363142" RANDOM="YES" SCALE="3.332307989116978" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.028464091189068227" TOTALS="SUB" TOTAL_1="959" TOTAL_2="898" UNITS="" WEIGHT="400.0" Z="2.1157490040301146">
<NAME>O<SUB>2</SUB> saturation (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glucocorticoid</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.385555788660863" CI_END="0.1909805268147322" CI_START="-0.7308603562142206" DF="4" EFFECT_SIZE="-0.2699399146997442" ESTIMABLE="YES" I2="37.358624176410906" ID="CMP-001.06.01" MODIFIED="2013-01-07 12:41:41 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="0.172145695239024" P_Z="0.2510260487543968" STUDIES="5" TAU2="0.0975561891455724" TOTAL_1="476" TOTAL_2="460" WEIGHT="100.0" Z="1.14786080882615">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="1.90920387214515" CI_START="-0.5692038721451502" EFFECT_SIZE="0.6699999999999999" ESTIMABLE="YES" MEAN_1="0.87" MEAN_2="0.2" MODIFIED="2010-08-13 02:14:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="273" SD_1="2.018" SD_2="1.99" SE="0.6322584914415939" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_" TOTAL_1="30" TOTAL_2="15" WEIGHT="11.120676147549913">
<FOOTNOTE>Plint 2009 (factorial trial) and Barlas 1998 (parallel multiarm study) contribute two independent comparisons which are shown separately; sensitivity analysis did not show relevant differences when pooling results</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="1.7835468393723959" CI_START="-1.943546839372396" EFFECT_SIZE="-0.08000000000000002" ESTIMABLE="YES" MEAN_1="-0.14" MEAN_2="-0.06" MODIFIED="2010-08-13 02:15:01 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="274" SD_1="1.94" SD_2="3.13" SE="0.9508066750572028" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_" TOTAL_1="15" TOTAL_2="15" WEIGHT="5.52161324383014">
<FOOTNOTE>G: Glucocorticoid, S:Salbutamol, E: Epinephrine, P: Placebo</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.8270032503605833" CI_START="-0.8270032503605833" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.0" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1119" SD_1="1.323" SD_2="2.0" SE="0.42194818725439825" STUDY_ID="STD-Mesquita-2009" TOTAL_1="33" TOTAL_2="32" WEIGHT="20.06698465799842"/>
<CONT_DATA CI_END="-0.2823659600704259" CI_START="-1.3176340399295743" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="-0.73" MEAN_2="0.07" MODIFIED="2010-06-25 23:33:37 +1000" MODIFIED_BY="[Empty name]" ORDER="280" SD_1="2.56" SD_2="2.7" SE="0.26410385293434235" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" TOTAL_1="199" TOTAL_2="198" WEIGHT="33.055334439401946"/>
<CONT_DATA CI_END="0.322614647257754" CI_START="-0.822614647257754" EFFECT_SIZE="-0.25" ESTIMABLE="YES" MEAN_1="-1.02" MEAN_2="-0.77" MODIFIED="2010-06-25 23:33:24 +1000" MODIFIED_BY="[Empty name]" ORDER="279" SD_1="2.57" SD_2="3.23" SE="0.29215569866306995" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_" TOTAL_1="199" TOTAL_2="200" WEIGHT="30.23539151121958"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.9198772268950295" CI_END="1.36576227082598" CI_START="-1.5638972323221298" DF="1" EFFECT_SIZE="-0.09906748074807488" ESTIMABLE="YES" I2="47.91333602007064" ID="CMP-001.06.02" MODIFIED="2013-01-07 12:41:45 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.16587044737503243" P_Z="0.8945463022080292" STUDIES="2" TAU2="0.549859433333333" TOTAL_1="45" TOTAL_2="30" WEIGHT="100.0" Z="0.13255376203049882">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="1.7911409024010045" CI_START="-0.7211409024010047" EFFECT_SIZE="0.5349999999999999" ESTIMABLE="YES" MEAN_1="1.005" MEAN_2="0.47" MODIFIED="2010-06-25 23:31:22 +1000" MODIFIED_BY="[Empty name]" ORDER="275" SD_1="2.172" SD_2="1.95" SE="0.6408999921984708" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_" TOTAL_1="30" TOTAL_2="15" WEIGHT="58.147361006727735"/>
<CONT_DATA CI_END="0.7562596621480473" CI_START="-2.7162596621480475" EFFECT_SIZE="-0.98" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="0.78" MODIFIED="2010-06-25 23:31:33 +1000" MODIFIED_BY="[Empty name]" ORDER="276" SD_1="1.88" SD_2="2.87" SE="0.8858630443433868" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_" TOTAL_1="15" TOTAL_2="15" WEIGHT="41.852638993272265"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.8241955584279625" CI_END="-0.015805347056983887" CI_START="-0.8396903146358897" DF="4" EFFECT_SIZE="-0.4277478308464368" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.03" MODIFIED="2013-01-07 12:30:18 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4303210245176411" P_Z="0.0418344155967025" STUDIES="5" TAU2="0.0" TOTAL_1="418" TOTAL_2="390" WEIGHT="100.00000000000003" Z="2.0351635869454174">
<NAME>3 to 6 hours</NAME>
<CONT_DATA CI_END="1.484208765525807" CI_START="-0.8742087655258067" EFFECT_SIZE="0.30500000000000005" ESTIMABLE="YES" MEAN_1="0.795" MEAN_2="0.49" MODIFIED="2010-06-25 23:31:56 +1000" MODIFIED_BY="[Empty name]" ORDER="277" SD_1="1.804" SD_2="1.95" SE="0.6016481806947755" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_" TOTAL_1="30" TOTAL_2="15" WEIGHT="12.203706908825533"/>
<CONT_DATA CI_END="0.3083652471625058" CI_START="-3.1483652471625057" EFFECT_SIZE="-1.42" ESTIMABLE="YES" MEAN_1="-0.59" MEAN_2="0.83" MODIFIED="2010-06-25 23:32:07 +1000" MODIFIED_BY="[Empty name]" ORDER="278" SD_1="1.82" SD_2="2.89" SE="0.8818352075832159" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_" TOTAL_1="15" TOTAL_2="15" WEIGHT="5.680703419135433"/>
<CONT_DATA CI_END="-0.0790317643557773" CI_START="-1.1209682356442228" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.9" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1124" SD_1="3.3" SD_2="3.2" SE="0.2658050044559766" STUDY_ID="STD-Corneli-2007" TOTAL_1="304" TOTAL_2="294" WEIGHT="62.52456481778466"/>
<CONT_DATA CI_END="1.2752191733625708" CI_START="-1.2752191733625708" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.0" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1127" SD_1="2.598" SD_2="2.646" SE="0.6506339827779168" STUDY_ID="STD-Mesquita-2009" TOTAL_1="33" TOTAL_2="32" WEIGHT="10.435265394330878"/>
<CONT_DATA CI_END="1.261411441133773" CI_START="-1.461411441133773" EFFECT_SIZE="-0.10000000000000003" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.3" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1128" SD_1="2.8" SD_2="3.0" SE="0.6946104376776373" STUDY_ID="STD-Schuh-2002" TOTAL_1="36" TOTAL_2="34" WEIGHT="9.155759459923512"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.0272946783023537E-33" CI_END="1.408202943161358" CI_START="-1.0082029431613582" DF="0" EFFECT_SIZE="0.19999999999999998" ESTIMABLE="YES" I2="100.0" ID="CMP-001.06.04" MODIFIED="2013-01-07 12:30:27 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="4" P_CHI2="0.0" P_Z="0.7456027894488407" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="0.32444284226152503">
<NAME>24 to 72 hours</NAME>
<CONT_DATA CI_END="1.408202943161358" CI_START="-1.0082029431613582" EFFECT_SIZE="0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="0.8" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1129" SD_1="2.0" SD_2="1.8" SE="0.6164414002968976" STUDY_ID="STD-Berger-1998" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.725660553038966" CI_END="0.6582810185708876" CI_START="-1.1024039262112328" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.22206145382017267" ESTIMABLE="YES" I2="19.477366300777337" I2_Q="20.729433792303873" ID="CMP-001.07" MODIFIED="2013-01-07 12:41:33 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="7" P_CHI2="0.2926525220006986" P_Q="0.28322832066470816" P_Z="0.6210308273576861" Q="2.5230045598006923" RANDOM="YES" SCALE="5.407522122194801" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.19977376552344486" TOTALS="SUB" TOTAL_1="129" TOTAL_2="121" UNITS="" WEIGHT="300.0" Z="0.49438992834234935">
<NAME>O<SUB>2</SUB> saturation (inpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glucocorticoid</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5755909220748343" CI_START="-1.9755909220748342" DF="0" EFFECT_SIZE="-0.7" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" MODIFIED="2013-01-07 12:41:22 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.2821240249488576" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="32" WEIGHT="100.0" Z="1.0755601701417166">
<NAME>6 to 12 hours</NAME>
<CONT_DATA CI_END="0.5755909220748343" CI_START="-1.9755909220748342" EFFECT_SIZE="-0.7" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="1.4" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1130" SD_1="2.5" SD_2="2.8" SE="0.650823653973508" STUDY_ID="STD-Klassen-1997" TOTAL_1="35" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.13286359816442" CI_END="1.164656158886403" CI_START="-2.035929028560589" DF="1" EFFECT_SIZE="-0.4356364348370928" ESTIMABLE="YES" I2="11.72811964120826" ID="CMP-001.07.02" MODIFIED="2013-01-07 12:41:28 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="0.28716539184470713" P_Z="0.5936548101661611" STUDIES="2" TAU2="0.21169255952380903" TOTAL_1="59" TOTAL_2="57" WEIGHT="99.99999999999997" Z="0.5335472562848467">
<NAME>12 to 24 hours</NAME>
<CONT_DATA CI_END="4.108886362860519" CI_START="-2.108886362860518" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="87.0" MEAN_2="86.0" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1131" SD_1="5.3" SD_2="5.8" SE="1.5861956583809789" STUDY_ID="STD-Gomez-2007" TOTAL_1="24" TOTAL_2="25" WEIGHT="24.440187640153006"/>
<CONT_DATA CI_END="0.7050157087734648" CI_START="-2.5050157087734646" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="1.9" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1132" SD_1="3.6" SD_2="3.1" SE="0.818900613191683" STUDY_ID="STD-Klassen-1997" TOTAL_1="35" TOTAL_2="32" WEIGHT="75.55981235984697"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.972326243954069" CI_START="-0.7723262439540697" DF="0" EFFECT_SIZE="1.0999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.03" MODIFIED="2013-01-07 12:41:33 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="1.0" P_Z="0.24953172866776085" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="32" WEIGHT="100.00000000000001" Z="1.1514875625740295">
<NAME>24 to 72 hours</NAME>
<CONT_DATA CI_END="2.972326243954069" CI_START="-0.7723262439540697" EFFECT_SIZE="1.0999999999999999" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="1.2" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1133" SD_1="3.8" SD_2="4.0" SE="0.9552860454185587" STUDY_ID="STD-Klassen-1997" TOTAL_1="35" TOTAL_2="32" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="37.20853100246208" CI_END="0.4775617204181485" CI_START="-1.57807358875591" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5502559341688807" ESTIMABLE="YES" I2="65.0617757547596" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2013-03-19 22:19:14 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="8" P_CHI2="3.842384216493633E-4" P_Q="0.9313015068060639" P_Z="0.29404332752847673" Q="0.8523048669276371" RANDOM="YES" SCALE="17.44478343430271" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="5.933718569238987" TOTALS="SUB" TOTAL_1="997" TOTAL_2="909" UNITS="" WEIGHT="500.0" Z="1.0492929445581247">
<NAME>Respiratory rate (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.7827880875823415" CI_END="1.0295752067003743" CI_START="-1.5113941750284094" DF="2" EFFECT_SIZE="-0.2409094841640176" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" MODIFIED="2013-01-07 12:41:11 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="0.6761138835455032" P_Z="0.7101544672692426" STUDIES="3" TAU2="0.0" TOTAL_1="431" TOTAL_2="430" WEIGHT="100.0" Z="0.37164864393159036">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="7.130348749715828" CI_START="-3.1303487497158278" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="-5.0" MEAN_2="-7.0" MODIFIED="2010-04-30 23:20:51 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1061" SD_1="11.5" SD_2="9.54" SE="2.6175729708215885" STUDY_ID="STD-Mesquita-2009" TOTAL_1="33" TOTAL_2="32" WEIGHT="6.132606450797224"/>
<CONT_DATA CI_END="1.4166717378335059" CI_START="-2.1366717378335056" EFFECT_SIZE="-0.3599999999999999" ESTIMABLE="YES" MEAN_1="-4.04" MEAN_2="-3.68" MODIFIED="2010-08-13 02:16:07 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="283" SD_1="9.17" SD_2="8.89" SE="0.9064818291803654" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" TOTAL_1="199" TOTAL_2="198" WEIGHT="51.13573287781576">
<FOOTNOTE>Kuyucu 2004 and Plint 2009 (factorial trials) contribute two independent comparisons which are shown separately; sensitivity analysis did not show relevant differences when pooling results</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="1.523544777001384" CI_START="-2.3635447770013838" EFFECT_SIZE="-0.41999999999999993" ESTIMABLE="YES" MEAN_1="-3.3" MEAN_2="-2.88" MODIFIED="2010-08-13 02:15:41 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="282" SD_1="9.6" SD_2="10.2" SE="0.9916226993617316" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_" TOTAL_1="199" TOTAL_2="200" WEIGHT="42.73166067138702">
<FOOTNOTE>G: Glucocorticoid, S:Salbutamol, E: Epinephrine, P: Placebo</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.4789322763801893" CI_END="5.3920232297140345" CI_START="-9.301947393086895" DF="1" EFFECT_SIZE="-1.9549620816864306" ESTIMABLE="YES" I2="59.66005164690382" ID="CMP-001.08.02" MODIFIED="2013-01-07 12:41:14 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.11538081574558012" P_Z="0.6019993188026398" STUDIES="2" TAU2="16.7793895256917" TOTAL_1="46" TOTAL_2="23" WEIGHT="100.0" Z="0.5215275529816562">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="0.7686449951065448" CI_START="-11.968644995106548" EFFECT_SIZE="-5.600000000000001" ESTIMABLE="YES" MEAN_1="-24.0" MEAN_2="-18.4" MODIFIED="2010-06-26 00:21:36 +1000" MODIFIED_BY="[Empty name]" ORDER="305" SD_1="8.21" SD_2="9.16" SE="3.2493683788792063" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" TOTAL_1="23" TOTAL_2="11" WEIGHT="51.39949442248573"/>
<CONT_DATA CI_END="8.726987021496885" CI_START="-4.926987021496887" EFFECT_SIZE="1.8999999999999986" ESTIMABLE="YES" MEAN_1="-19.0" MEAN_2="-20.9" MODIFIED="2010-06-26 00:21:47 +1000" MODIFIED_BY="[Empty name]" ORDER="306" SD_1="10.01" SD_2="9.66" SE="3.4832206486176727" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_" TOTAL_1="23" TOTAL_2="12" WEIGHT="48.60050557751428"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.26960669876701" CI_END="0.8240461240362582" CI_START="-3.069133899959871" DF="2" EFFECT_SIZE="-1.1225438879618064" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.03" MODIFIED="2013-01-07 12:30:36 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="0.5300397368032221" P_Z="0.25836826850393935" STUDIES="3" TAU2="0.0" TOTAL_1="373" TOTAL_2="360" WEIGHT="99.99999999999999" Z="1.1302562829922165">
<NAME>3 to 6 hours</NAME>
<CONT_DATA CI_END="1.3246843935362618" CI_START="-3.3246843935362618" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-8.0" MEAN_2="-7.0" MODIFIED="2010-04-30 23:20:51 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1068" SD_1="15.0" SD_2="14.0" SE="1.1860852606849286" STUDY_ID="STD-Corneli-2007" TOTAL_1="304" TOTAL_2="294" WEIGHT="70.11662139918056"/>
<CONT_DATA CI_END="6.5464830878109295" CI_START="-4.5464830878109295" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="-23.0" MEAN_2="-24.0" MODIFIED="2010-04-30 23:20:51 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1067" SD_1="13.75" SD_2="8.54" SE="2.829890310006143" STUDY_ID="STD-Mesquita-2009" TOTAL_1="33" TOTAL_2="32" WEIGHT="12.31724543061955"/>
<CONT_DATA CI_END="1.5444726014645798" CI_START="-7.7444726014645795" EFFECT_SIZE="-3.1" ESTIMABLE="YES" MEAN_1="-6.5" MEAN_2="-3.4" MODIFIED="2010-04-30 23:20:51 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1066" SD_1="9.58" SD_2="10.21" SE="2.3696724215850837" STUDY_ID="STD-Schuh-2002" TOTAL_1="36" TOTAL_2="34" WEIGHT="17.56613317019988"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.9656391517582468" CI_END="7.399126209714184" CI_START="-7.103173538169123" DF="1" EFFECT_SIZE="0.14797633577253028" ESTIMABLE="YES" I2="49.12596245829206" ID="CMP-001.08.04" MODIFIED="2013-01-07 12:30:41 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="4" P_CHI2="0.16091181195643744" P_Z="0.9680950730549952" STUDIES="2" TAU2="13.450688521080362" TOTAL_1="46" TOTAL_2="23" WEIGHT="100.0" Z="0.03999755814186597">
<NAME>12 to 24 hours</NAME>
<CONT_DATA CI_END="3.7131830972559614" CI_START="-10.71318309725596" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="-27.3" MEAN_2="-23.8" MODIFIED="2010-06-26 00:22:20 +1000" MODIFIED_BY="[Empty name]" ORDER="307" SD_1="10.58" SD_2="9.77" SE="3.6802630834814463" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" TOTAL_1="23" TOTAL_2="11" WEIGHT="50.70302248956039"/>
<CONT_DATA CI_END="11.315372040514514" CI_START="-3.5153720405145163" EFFECT_SIZE="3.8999999999999986" ESTIMABLE="YES" MEAN_1="-20.6" MEAN_2="-24.5" MODIFIED="2010-06-26 00:22:31 +1000" MODIFIED_BY="[Empty name]" ORDER="308" SD_1="11.58" SD_2="10.09" SE="3.7834226031733356" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_" TOTAL_1="23" TOTAL_2="12" WEIGHT="49.29697751043961"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="23.059205656565148" CI_END="4.6091097709691535" CI_START="-7.885357073653685" DF="3" EFFECT_SIZE="-1.6381236513422655" ESTIMABLE="YES" I2="86.99001151782575" ID="CMP-001.08.05" MODIFIED="2013-03-19 22:19:14 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="5" P_CHI2="3.925194106602081E-5" P_Z="0.6072983951220143" STUDIES="4" TAU2="34.02287592129377" TOTAL_1="101" TOTAL_2="73" WEIGHT="100.0" Z="0.5139336313875356">
<NAME>3 to 10 days</NAME>
<CONT_DATA CI_END="7.262719260174563" CI_START="2.737280739825437" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="-8.0" MEAN_2="-13.0" MODIFIED="2010-04-30 23:20:51 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1074" SD_1="1.83" SD_2="4.58" SE="1.154469815783659" STUDY_ID="STD-Berger-1998" TOTAL_1="20" TOTAL_2="18" WEIGHT="28.735590978030345"/>
<CONT_DATA CI_END="-1.7391308431185228" CI_START="-13.46086915688148" EFFECT_SIZE="-7.600000000000001" ESTIMABLE="YES" MEAN_1="-39.1" MEAN_2="-31.5" MODIFIED="2010-06-26 00:22:48 +1000" MODIFIED_BY="[Empty name]" ORDER="309" SD_1="8.13" SD_2="8.17" SE="2.990294313115581" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" TOTAL_1="23" TOTAL_2="11" WEIGHT="23.646514620319074"/>
<CONT_DATA CI_END="0.5375816559376805" CI_START="-13.53758165593768" EFFECT_SIZE="-6.5" ESTIMABLE="YES" MEAN_1="-31.9" MEAN_2="-25.4" MODIFIED="2010-06-26 00:22:59 +1000" MODIFIED_BY="[Empty name]" ORDER="310" SD_1="9.01" SD_2="10.6" SE="3.5906688650654943" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_" TOTAL_1="23" TOTAL_2="12" WEIGHT="21.65510801582551"/>
<CONT_DATA CI_END="4.930020801876831" CI_START="-3.9300208018768306" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-10.3" MEAN_2="-10.8" MODIFIED="2010-04-30 23:20:51 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1071" SD_1="9.76" SD_2="8.74" SE="2.260256227573705" STUDY_ID="STD-Schuh-2002" TOTAL_1="35" TOTAL_2="32" WEIGHT="25.962786385825083"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0533047844952856" CI_END="1.5103370936255769" CI_START="-5.1326639980024495" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.811163452188436" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2013-01-07 12:31:03 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="9" P_CHI2="0.7883567566599138" P_Q="0.8092017323786158" P_Z="0.2851875850627046" Q="0.4234143235420056" RANDOM="YES" SCALE="17.44478343430271" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="109" TOTAL_2="95" UNITS="" WEIGHT="300.0" Z="1.0687383871962002">
<NAME>Respiratory rate (inpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.4471595555821493" CI_START="-11.44715955558215" DF="0" EFFECT_SIZE="-4.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.01" MODIFIED="2013-01-07 12:30:50 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.2924642989561914" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="31" WEIGHT="100.00000000000001" Z="1.0527310284743012">
<NAME>6 to 12 hours</NAME>
<CONT_DATA CI_END="3.4471595555821493" CI_START="-11.44715955558215" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="-3.2" MEAN_2="0.8" MODIFIED="2010-04-30 23:20:51 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1075" SD_1="14.2" SD_2="16.4" SE="3.799641021123038" STUDY_ID="STD-Klassen-1997" TOTAL_1="35" TOTAL_2="31" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.62989046095328" CI_END="2.6447111702241677" CI_START="-5.076117028396743" DF="1" EFFECT_SIZE="-1.2157029290862877" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.02" MODIFIED="2013-01-07 12:30:59 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="0.4273957193006883" P_Z="0.5370880630793158" STUDIES="2" TAU2="0.0" TOTAL_1="57" TOTAL_2="53" WEIGHT="99.99999999999999" Z="0.6172223744946372">
<NAME>12 to 24 hours</NAME>
<CONT_DATA CI_END="2.3190494391248118" CI_START="-6.319049439124812" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="54.0" MEAN_2="56.0" MODIFIED="2010-04-30 23:20:51 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1076" SD_1="7.1" SD_2="8.3" SE="2.203637144964358" STUDY_ID="STD-Gomez-2007" TOTAL_1="24" TOTAL_2="25" WEIGHT="79.88981869452019"/>
<CONT_DATA CI_END="10.508468608134503" CI_START="-6.7084686081345035" EFFECT_SIZE="1.8999999999999995" ESTIMABLE="YES" MEAN_1="-2.2" MEAN_2="-4.1" MODIFIED="2010-04-30 23:20:51 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1077" SD_1="18.3" SD_2="16.0" SE="4.392156527383668" STUDY_ID="STD-Klassen-1997" TOTAL_1="33" TOTAL_2="28" WEIGHT="20.110181305479802"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="11.571831187619132" CI_START="-15.37183118761913" DF="0" EFFECT_SIZE="-1.8999999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.03" MODIFIED="2013-01-07 12:31:03 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="1.0" P_Z="0.7822227615196777" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="11" WEIGHT="100.0" Z="0.2764235625256696">
<NAME>24 to 72 hours</NAME>
<CONT_DATA CI_END="11.571831187619132" CI_START="-15.37183118761913" EFFECT_SIZE="-1.8999999999999995" ESTIMABLE="YES" MEAN_1="-5.6" MEAN_2="-3.7" MODIFIED="2010-04-30 23:20:51 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1078" SD_1="16.9" SD_2="18.3" SE="6.873509561340522" STUDY_ID="STD-Klassen-1997" TOTAL_1="17" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="44.27748808257261" CI_END="1.7364101865481854" CI_START="-1.8630678267156886" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.0633288200837517" ESTIMABLE="YES" I2="59.34728734739424" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2013-01-07 12:41:01 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="10" P_CHI2="5.264892988963155E-4" P_Q="0.7298051344275995" P_Z="0.945016061163985" Q="2.0323700323736658" RANDOM="YES" SCALE="21.74504014745838" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="15.03906129108504" TOTALS="SUB" TOTAL_1="1112" TOTAL_2="981" UNITS="" WEIGHT="500.0" Z="0.06896678134450987">
<NAME>Heart rate (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.468880921870507" CI_END="2.552553696509534" CI_START="-1.6239360699125012" DF="4" EFFECT_SIZE="0.46430881329851637" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.01" MODIFIED="2013-01-07 12:41:01 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="0.4826258589766814" P_Z="0.6629917717815049" STUDIES="5" TAU2="0.0" TOTAL_1="476" TOTAL_2="460" WEIGHT="99.99999999999999" Z="0.43578631945229845">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="8.989483289100113" CI_START="-0.6494832891001128" EFFECT_SIZE="4.17" ESTIMABLE="YES" MEAN_1="2.57" MEAN_2="-1.6" MODIFIED="2010-08-13 02:16:39 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="318" SD_1="10.55" SD_2="5.92" SE="2.4589652295223696" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_" TOTAL_1="30" TOTAL_2="15" WEIGHT="18.774219639322677">
<FOOTNOTE>Kuyucu 2004 and Plint 2009 (factorial trials) and Barlas 1998 (parallel multiarm study) contribute two independent comparisons which are shown separately; sensitivity analysis did not show relevant differences when pooling results</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="4.828962698930351" CI_START="-10.428962698930352" EFFECT_SIZE="-2.8000000000000003" ESTIMABLE="YES" MEAN_1="3.07" MEAN_2="5.87" MODIFIED="2010-08-13 02:16:46 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="319" SD_1="11.54" SD_2="9.7" SE="3.8923994313704924" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_" TOTAL_1="15" TOTAL_2="15" WEIGHT="7.492588285352275">
<FOOTNOTE>G: Glucocorticoid, S:Salbutamol, E: Epinephrine, P: Placebo</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="8.714049225454948" CI_START="-12.714049225454948" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="-6.0" MEAN_2="-4.0" MODIFIED="2010-04-30 23:20:51 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1082" SD_1="21.52" SD_2="22.52" SE="5.46645209298028" STUDY_ID="STD-Mesquita-2009" TOTAL_1="33" TOTAL_2="32" WEIGHT="3.7988800167069847"/>
<CONT_DATA CI_END="3.8822362175997633" CI_START="-3.0822362175997626" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="4.8" MODIFIED="2010-06-25 23:36:21 +1000" MODIFIED_BY="[Empty name]" ORDER="285" SD_1="17.8" SD_2="17.6" SE="1.7766837784098064" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" TOTAL_1="199" TOTAL_2="198" WEIGHT="35.96221188778017"/>
<CONT_DATA CI_END="3.0627807155540587" CI_START="-4.102780715554058" EFFECT_SIZE="-0.5199999999999996" ESTIMABLE="YES" MEAN_1="-3.76" MEAN_2="-3.24" MODIFIED="2010-06-25 23:36:10 +1000" MODIFIED_BY="[Empty name]" ORDER="284" SD_1="17.7" SD_2="18.8" SE="1.8279829342858211" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_" TOTAL_1="199" TOTAL_2="200" WEIGHT="33.97210017083788"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.208063704789687" CI_END="1.749449486119381" CI_START="-8.829786274566853" DF="3" EFFECT_SIZE="-3.5401683942237363" ESTIMABLE="YES" I2="28.708303617520077" ID="CMP-001.10.02" MODIFIED="2013-01-07 12:40:57 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.23985593619263657" P_Z="0.18960792697588738" STUDIES="4" TAU2="8.374237956414389" TOTAL_1="91" TOTAL_2="53" WEIGHT="99.99999999999999" Z="1.311739847536102">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="7.683163292714067" CI_START="-15.483163292714067" EFFECT_SIZE="-3.9" ESTIMABLE="YES" MEAN_1="0.57" MEAN_2="4.47" MODIFIED="2010-06-26 00:37:20 +1000" MODIFIED_BY="[Empty name]" ORDER="320" SD_1="11.85" SD_2="21.3" SE="5.909885785698401" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_" TOTAL_1="30" TOTAL_2="15" WEIGHT="16.821108513463354"/>
<CONT_DATA CI_END="2.313504033590811" CI_START="-13.31350403359081" EFFECT_SIZE="-5.5" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="8.1" MODIFIED="2010-06-26 00:37:34 +1000" MODIFIED_BY="[Empty name]" ORDER="321" SD_1="11.43" SD_2="10.38" SE="3.986554903673095" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_" TOTAL_1="15" TOTAL_2="15" WEIGHT="30.01503608185451"/>
<CONT_DATA CI_END="0.18227339244621987" CI_START="-16.38227339244622" EFFECT_SIZE="-8.1" ESTIMABLE="YES" MEAN_1="-14.0" MEAN_2="-5.9" MODIFIED="2010-06-26 00:27:46 +1000" MODIFIED_BY="[Empty name]" ORDER="312" SD_1="14.6" SD_2="9.72" SE="4.225727338755067" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" TOTAL_1="23" TOTAL_2="11" WEIGHT="27.767540445321917"/>
<CONT_DATA CI_END="12.83200994998283" CI_START="-4.832009949982829" EFFECT_SIZE="4.000000000000001" ESTIMABLE="YES" MEAN_1="-6.8" MEAN_2="-10.8" MODIFIED="2010-06-26 00:27:57 +1000" MODIFIED_BY="[Empty name]" ORDER="313" SD_1="13.97" SD_2="11.91" SE="4.506210328173679" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_" TOTAL_1="23" TOTAL_2="12" WEIGHT="25.3963149593602"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="18.687251131991797" CI_END="5.71109629990552" CI_START="-7.0078371246127045" DF="4" EFFECT_SIZE="-0.6483704123535919" ESTIMABLE="YES" I2="78.59503266827636" ID="CMP-001.10.03" MODIFIED="2013-01-07 12:31:18 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="9.052953522840079E-4" P_Z="0.8416171754181618" STUDIES="5" TAU2="39.12049561781928" TOTAL_1="418" TOTAL_2="390" WEIGHT="100.00000000000001" Z="0.19982534925526738">
<NAME>3 to 6 hours</NAME>
<CONT_DATA CI_END="7.657234130649915" CI_START="-2.5772341306499147" EFFECT_SIZE="2.54" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="-1.34" MODIFIED="2010-06-26 00:37:50 +1000" MODIFIED_BY="[Empty name]" ORDER="322" SD_1="12.17" SD_2="5.31" SE="2.610881715691719" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_" TOTAL_1="30" TOTAL_2="15" WEIGHT="22.918210523973972"/>
<CONT_DATA CI_END="5.087546333149214" CI_START="-11.807546333149215" EFFECT_SIZE="-3.3600000000000003" ESTIMABLE="YES" MEAN_1="2.96" MEAN_2="6.32" MODIFIED="2010-06-26 00:38:02 +1000" MODIFIED_BY="[Empty name]" ORDER="323" SD_1="12.09" SD_2="11.51" SE="4.310051817167245" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_" TOTAL_1="15" TOTAL_2="15" WEIGHT="18.247008074576417"/>
<CONT_DATA CI_END="-4.069997443309909" CI_START="-11.930002556690091" EFFECT_SIZE="-8.0" ESTIMABLE="YES" MEAN_1="-13.0" MEAN_2="-5.0" MODIFIED="2010-04-30 23:20:51 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1089" SD_1="24.0" SD_2="25.0" SE="2.0051401901715793" STUDY_ID="STD-Corneli-2007" TOTAL_1="304" TOTAL_2="294" WEIGHT="24.403615489287468"/>
<CONT_DATA CI_END="8.22791559319949" CI_START="-12.22791559319949" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="-18.0" MEAN_2="-16.0" MODIFIED="2010-04-30 23:20:51 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1088" SD_1="20.52" SD_2="21.52" SE="5.218420171939885" STUDY_ID="STD-Mesquita-2009" TOTAL_1="33" TOTAL_2="32" WEIGHT="15.866770783451361"/>
<CONT_DATA CI_END="17.120203555117502" CI_START="0.6797964448824985" EFFECT_SIZE="8.9" ESTIMABLE="YES" MEAN_1="22.3" MEAN_2="13.4" MODIFIED="2010-04-30 23:20:51 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1092" SD_1="18.06" SD_2="17.03" SE="4.1940584724808305" STUDY_ID="STD-Schuh-2002" TOTAL_1="36" TOTAL_2="34" WEIGHT="18.564395128710803"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.96361087557324" CI_END="14.880103553196076" CI_START="-11.184343651960777" DF="1" EFFECT_SIZE="1.8478799506176498" ESTIMABLE="YES" I2="79.85337640141842" ID="CMP-001.10.04" MODIFIED="2013-01-07 12:31:23 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="4" P_CHI2="0.02588625662492161" P_Z="0.7810818664543251" STUDIES="2" TAU2="70.62631875823455" TOTAL_1="46" TOTAL_2="23" WEIGHT="100.0" Z="0.2779094543963839">
<NAME>12 to 24 hours</NAME>
<CONT_DATA CI_END="3.2518723393847306" CI_START="-12.651872339384733" EFFECT_SIZE="-4.700000000000001" ESTIMABLE="YES" MEAN_1="-17.6" MEAN_2="-12.9" MODIFIED="2010-06-26 00:28:32 +1000" MODIFIED_BY="[Empty name]" ORDER="314" SD_1="11.93" SD_2="10.63" SE="4.057152275301019" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" TOTAL_1="23" TOTAL_2="11" WEIGHT="50.767819920168044"/>
<CONT_DATA CI_END="17.18295909094072" CI_START="0.017040909059280906" EFFECT_SIZE="8.6" ESTIMABLE="YES" MEAN_1="-7.6" MEAN_2="-16.2" MODIFIED="2010-06-26 00:28:43 +1000" MODIFIED_BY="[Empty name]" ORDER="315" SD_1="14.3" SD_2="11.11" SE="4.379141228431749" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_" TOTAL_1="23" TOTAL_2="12" WEIGHT="49.23218007983196"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.594775982727415" CI_END="9.183042333075216" CI_START="-8.317724251249627" DF="2" EFFECT_SIZE="0.4326590409127936" ESTIMABLE="YES" I2="73.66610938165202" ID="CMP-001.10.05" MODIFIED="2013-01-07 12:31:28 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="5" P_CHI2="0.022429304128417926" P_Z="0.9227981856314311" STUDIES="3" TAU2="44.00942480597833" TOTAL_1="81" TOTAL_2="55" WEIGHT="99.99999999999999" Z="0.09690959920970021">
<NAME>3 to 10 days</NAME>
<CONT_DATA CI_END="-0.3131669943657007" CI_START="-15.086833005634297" EFFECT_SIZE="-7.699999999999999" ESTIMABLE="YES" MEAN_1="-26.8" MEAN_2="-19.1" MODIFIED="2010-06-26 00:29:01 +1000" MODIFIED_BY="[Empty name]" ORDER="316" SD_1="11.22" SD_2="9.8" SE="3.768861603529807" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" TOTAL_1="23" TOTAL_2="11" WEIGHT="34.239897061384184"/>
<CONT_DATA CI_END="10.834877459585865" CI_START="-6.034877459585868" EFFECT_SIZE="2.3999999999999986" ESTIMABLE="YES" MEAN_1="-18.1" MEAN_2="-20.5" MODIFIED="2010-06-26 00:29:12 +1000" MODIFIED_BY="[Empty name]" ORDER="317" SD_1="13.3" SD_2="11.4" SE="4.303587987391148" STUDY_ID="STD-Kuyucu-2004-_x0028_G_x002b_S-vs-P_x002b_S_x0029_" TOTAL_1="23" TOTAL_2="12" WEIGHT="31.876270117874974"/>
<CONT_DATA CI_END="14.344219373821602" CI_START="-0.7442193738216032" EFFECT_SIZE="6.799999999999999" ESTIMABLE="YES" MEAN_1="-7.4" MEAN_2="-14.2" MODIFIED="2010-04-30 23:20:51 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1095" SD_1="15.4" SD_2="16.04" SE="3.8491622465154673" STUDY_ID="STD-Schuh-2002" TOTAL_1="35" TOTAL_2="32" WEIGHT="33.883832820740835"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9930689515882314" CI_START="-18.99306895158823" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2013-03-19 22:19:27 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.07753166253276444" Q="0.0" RANDOM="YES" SCALE="21.74504014745838" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="25" UNITS="" WEIGHT="100.0" Z="1.765191048547399">
<NAME>Heart rate (inpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9930689515882314" CI_START="-18.99306895158823" DF="0" EFFECT_SIZE="-9.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.01" MODIFIED="2013-03-19 22:19:27 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.07753166253276444" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="25" WEIGHT="100.0" Z="1.765191048547399">
<NAME>12 to 24 hours</NAME>
<CONT_DATA CI_END="0.9930689515882314" CI_START="-18.99306895158823" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="11.0" MODIFIED="2010-04-30 23:20:51 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1098" SD_1="22.87" SD_2="10.25" SE="5.098598255076259" STUDY_ID="STD-Gomez-2007" TOTAL_1="24" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.945491487233265" CI_END="2.3013690479041933" CI_START="0.2436014571650534" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7487435165288665" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="66.04980851805782" I2_Q="65.73422882226569" ID="CMP-001.12" LOG_CI_END="0.36198626778501125" LOG_CI_START="-0.6133201181867437" LOG_EFFECT_SIZE="-0.12566692520086625" METHOD="MH" MODIFIED="2013-01-07 12:31:46 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="12" P_CHI2="0.08611766138518318" P_Q="0.08757675149276734" P_Z="0.6135044174946764" Q="2.9183642031958534" RANDOM="YES" SCALE="41.1" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.598579603337603" TOTALS="SUB" TOTAL_1="189" TOTAL_2="170" WEIGHT="200.0" Z="0.5050774833103978">
<NAME>Hospital readmissions (inpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="31.028647850095165" CI_START="0.43104340034946126" DF="0" EFFECT_SIZE="3.6571428571428575" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="1.4917628505426828" LOG_CI_START="-0.36547899994749733" LOG_EFFECT_SIZE="0.5631419252975928" MODIFIED="2013-01-07 12:31:41 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.2346060069506799" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="32" WEIGHT="100.0" Z="1.188577450455921">
<NAME>2 to 10 days</NAME>
<DICH_DATA CI_END="31.028647850095165" CI_START="0.43104340034946115" EFFECT_SIZE="3.657142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.4917628505426828" LOG_CI_START="-0.36547899994749744" LOG_EFFECT_SIZE="0.5631419252975928" MODIFIED="2010-05-01 07:28:16 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1141" O_E="0.0" SE="1.0909530564733625" STUDY_ID="STD-Klassen-1997" TOTAL_1="35" TOTAL_2="32" VAR="1.1901785714285715" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5313543144930155" CI_START="0.1094028362312261" DF="0" EFFECT_SIZE="0.40930979133226325" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="0.1850756864698531" LOG_CI_START="-0.9609714189202819" LOG_EFFECT_SIZE="-0.38794786622521443" MODIFIED="2013-01-07 12:31:46 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="1.0" P_Z="0.18453085626864071" STUDIES="2" TAU2="0.0" TOTAL_1="154" TOTAL_2="138" WEIGHT="100.0" Z="1.3269329717852072">
<NAME>10 to 30 days</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-01 07:33:31 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1149" O_E="0.0" SE="0.0" STUDY_ID="STD-Roosevelt-1996" TOTAL_1="65" TOTAL_2="53" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.5313543144930155" CI_START="0.1094028362312261" EFFECT_SIZE="0.40930979133226325" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.1850756864698531" LOG_CI_START="-0.9609714189202819" LOG_EFFECT_SIZE="-0.38794786622521443" MODIFIED="2010-05-01 07:28:16 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1142" O_E="0.0" SE="0.6731937427308303" STUDY_ID="STD-Teeratakulpisarn-2007" TOTAL_1="89" TOTAL_2="85" VAR="0.4531898152519434" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.469917445149749" CI_END="1.417676346847039" CI_START="0.8657500614414698" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1078598216322055" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="55" I2="73.225942392461" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.15157709345490622" LOG_CI_START="-0.06260746895702844" LOG_EFFECT_SIZE="0.04448481224893885" METHOD="MH" MODIFIED="2013-01-07 12:31:57 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="13" P_CHI2="0.023874249099422817" P_Q="0.9002490217190855" P_Z="0.41556197915936866" Q="0.015711815592706572" RANDOM="YES" SCALE="3.61" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.18779983473616613" TOTALS="SUB" TOTAL_1="189" TOTAL_2="170" WEIGHT="200.0" Z="0.814144856054184">
<NAME>Return healthcare visits (inpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.419175539028113" CI_START="0.8600055684788509" DF="0" EFFECT_SIZE="1.1047619047619048" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="24" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="0.1520361170334069" LOG_CI_START="-0.06549873671944603" LOG_EFFECT_SIZE="0.043268690156980434" MODIFIED="2013-01-07 12:31:53 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.4355722942326964" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="32" WEIGHT="100.0" Z="0.7796918323925568">
<NAME>2 to 10 days</NAME>
<DICH_DATA CI_END="1.419175539028113" CI_START="0.8600055684788509" EFFECT_SIZE="1.1047619047619048" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="24" LOG_CI_END="0.1520361170334069" LOG_CI_START="-0.06549873671944603" LOG_EFFECT_SIZE="0.043268690156980434" MODIFIED="2010-05-01 07:28:16 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1146" O_E="0.0" SE="0.12778104990931854" STUDY_ID="STD-Klassen-1997" TOTAL_1="35" TOTAL_2="32" VAR="0.01632799671592776" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.884832800660927" CI_END="4.961481260718292" CI_START="0.29546209356178116" DF="1" EFFECT_SIZE="1.2107558137210708" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="31" I2="85.47531902439225" ID="CMP-001.13.02" LOG_CI_END="0.6956113553847273" LOG_CI_START="-0.5294982292089098" LOG_EFFECT_SIZE="0.08305656308790879" MODIFIED="2013-01-07 12:31:57 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="0.008693084874527801" P_Z="0.7904299474087746" STUDIES="2" TAU2="0.8901747271476959" TOTAL_1="154" TOTAL_2="138" WEIGHT="100.0" Z="0.26575234473571757">
<NAME>10 to 30 days</NAME>
<DICH_DATA CI_END="6.655430680635026" CI_START="1.0229368366662934" EFFECT_SIZE="2.609230769230769" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.8231761644194489" LOG_CI_START="0.009848818136229875" LOG_EFFECT_SIZE="0.4165124912778394" MODIFIED="2010-05-01 07:32:17 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1148" O_E="0.0" SE="0.47775250924205803" STUDY_ID="STD-Roosevelt-1996" TOTAL_1="65" TOTAL_2="53" VAR="0.22824746008708274" WEIGHT="46.30408483727379"/>
<DICH_DATA CI_END="1.0653710356391453" CI_START="0.3660227667892139" EFFECT_SIZE="0.6244598098530683" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="26" LOG_CI_END="0.027500885396920766" LOG_CI_START="-0.436491900443249" LOG_EFFECT_SIZE="-0.2044955075231641" MODIFIED="2010-05-01 07:28:16 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1147" O_E="0.0" SE="0.2725516592038479" STUDY_ID="STD-Teeratakulpisarn-2007" TOTAL_1="89" TOTAL_2="85" VAR="0.07428440693477045" WEIGHT="53.69591516272621"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.041080856219731" CI_END="1.353011233430749" CI_START="0.7985946932004773" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0394746706189757" ESTIMABLE="YES" EVENTS_1="210" EVENTS_2="193" I2="60.325968635627376" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.13130140236017626" LOG_CI_START="-0.09767358009385615" LOG_EFFECT_SIZE="0.016813911133159998" METHOD="MH" MODIFIED="2013-01-07 12:32:04 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="14" P_CHI2="0.08041621257197318" P_Q="1.0" P_Z="0.7734653339359481" Q="0.0" RANDOM="YES" SCALE="3.61" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.029925665694031742" TOTALS="SUB" TOTAL_1="433" TOTAL_2="430" WEIGHT="99.99999999999999" Z="0.2878450729163521">
<NAME>Return healthcare visits (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.041080856219731" CI_END="1.353011233430749" CI_START="0.7985946932004773" DF="2" EFFECT_SIZE="1.0394746706189757" ESTIMABLE="YES" EVENTS_1="210" EVENTS_2="193" I2="60.325968635627376" ID="CMP-001.14.01" LOG_CI_END="0.13130140236017626" LOG_CI_START="-0.09767358009385615" LOG_EFFECT_SIZE="0.016813911133159998" MODIFIED="2013-01-07 12:32:04 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="0.08041621257197318" P_Z="0.7734653339359481" STUDIES="3" TAU2="0.029925665694031742" TOTAL_1="433" TOTAL_2="430" WEIGHT="99.99999999999999" Z="0.2878450729163521">
<NAME>10 to 30 days</NAME>
<DICH_DATA CI_END="1.2506881624618618" CI_START="0.8259552192093838" EFFECT_SIZE="1.0163721834981359" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="93" LOG_CI_END="0.09714903934638207" LOG_CI_START="-0.08304349817290782" LOG_EFFECT_SIZE="0.0070527705867371145" MODIFIED="2010-08-13 02:17:15 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="287" O_E="0.0" SE="0.10584598850627709" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" TOTAL_1="199" TOTAL_2="198" VAR="0.011203373282870941" WEIGHT="43.98480905508967">
<FOOTNOTE>Plint 2009 (factorial trial) contributes two independent comparisons which are shown separately; sensitivity analysis did not show relevant differences when pooling results</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.521976979141622" CI_START="1.0082322455468147" EFFECT_SIZE="1.238751899030034" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="86" LOG_CI_END="0.18240808350723892" LOG_CI_START="0.0035605830437151634" LOG_EFFECT_SIZE="0.09298433327547707" MODIFIED="2010-06-25 23:38:17 +1000" MODIFIED_BY="[Empty name]" ORDER="286" O_E="0.0" SE="0.10505590708167924" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_" TOTAL_1="199" TOTAL_2="200" VAR="0.011036743612754422" WEIGHT="44.16373344813736"/>
<DICH_DATA CI_END="1.16783699028084" CI_START="0.2958084585862755" EFFECT_SIZE="0.5877551020408164" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.06738222705538882" LOG_CI_START="-0.5289894115939543" LOG_EFFECT_SIZE="-0.23080359226928276" MODIFIED="2010-05-01 07:28:16 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1144" O_E="0.0" SE="0.3503116526298461" STUDY_ID="STD-Schuh-2002" TOTAL_1="35" TOTAL_2="32" VAR="0.12271825396825395" WEIGHT="11.85145749677296"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.86875140578438" CI_END="1.076476544701088" CI_START="0.7848709984662657" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9191818212220358" ESTIMABLE="YES" EVENTS_1="205" EVENTS_2="217" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.03200457143970596" LOG_CI_START="-0.10520171810585138" LOG_EFFECT_SIZE="-0.03659857333307271" METHOD="MH" MODIFIED="2013-01-07 12:32:25 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="15" P_CHI2="0.5508576370903963" P_Q="0.6453196414117945" P_Z="0.29574281921299106" Q="0.21185206963945" RANDOM="YES" SCALE="10.445158627577035" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="907" TOTAL_2="855" WEIGHT="100.0" Z="1.0456063764417016">
<NAME>Admissions at day 1 (outpatients) - subgroup analysis protocolised use of bronchodilator</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.954138719047037" CI_END="1.2908277990469343" CI_START="0.5586564553594937" DF="5" EFFECT_SIZE="0.8491933129123528" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="57" I2="16.024798280140637" ID="CMP-001.15.01" LOG_CI_END="0.11086830972434032" LOG_CI_START="-0.2528551785308121" LOG_EFFECT_SIZE="-0.07099343440323591" MODIFIED="2013-01-07 12:32:20 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="0.310707298032884" P_Z="0.4442049535120729" STUDIES="7" TAU2="0.045513539640723764" TOTAL_1="373" TOTAL_2="344" WEIGHT="19.797810929582614" Z="0.7651118449163179">
<NAME>Protocolised use of bronchodilator</NAME>
<DICH_DATA CI_END="6.20048286508611" CI_START="0.16127776203218527" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7924255116719207" LOG_CI_START="-0.7924255116719207" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-14 18:16:01 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="536" O_E="0.0" SE="0.9309493362512627" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_" TOTAL_1="15" TOTAL_2="15" VAR="0.8666666666666667" WEIGHT="0.7494991602770322">
<FOOTNOTE>Plint 2009 (factorial trial) and Barlas 1998 (parallel multiarm study) contribute two independent comparisons which are shown separately; sensitivity analysis did not show relevant differences when pooling results</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="10.19672740704177" CI_START="0.4964828221752679" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0084608092997827" LOG_CI_START="-0.30409577307705765" LOG_EFFECT_SIZE="0.3521825181113625" MODIFIED="2010-08-14 18:16:00 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1223" O_E="0.0" SE="0.7710022337480251" STUDY_ID="STD-Berger-1998" TOTAL_1="20" TOTAL_2="18" VAR="0.5944444444444443" WEIGHT="1.0927277476936175"/>
<DICH_DATA CI_END="9.909075681283461" CI_START="0.4036703451115336" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9960331453793151" LOG_CI_START="-0.3939731540513527" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2010-08-14 18:15:59 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1224" O_E="0.0" SE="0.816496580927726" STUDY_ID="STD-Goebel-2000" TOTAL_1="24" TOTAL_2="24" VAR="0.6666666666666667" WEIGHT="0.9743489083601418"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-14 18:15:59 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1225" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="46" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.699291526026783" CI_START="0.45499453417999086" EFFECT_SIZE="1.1082251082251082" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.43124979130257723" LOG_CI_START="-0.3419938204631667" LOG_EFFECT_SIZE="0.04462798541970525" MODIFIED="2010-08-14 18:15:59 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1226" O_E="0.0" SE="0.45420712516880724" STUDY_ID="STD-Mesquita-2009" TOTAL_1="33" TOTAL_2="32" VAR="0.20630411255411255" WEIGHT="3.148584537966413"/>
<DICH_DATA CI_END="1.3149856743021993" CI_START="0.47354677401404854" EFFECT_SIZE="0.7891180038121642" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="29" LOG_CI_END="0.1189210215669222" LOG_CI_START="-0.3246371176259998" LOG_EFFECT_SIZE="-0.10285804802953877" MODIFIED="2010-08-15 03:22:39 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="544" O_E="0.0" SE="0.2605482466101223" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" TOTAL_1="199" TOTAL_2="198" VAR="0.06788538881160912" WEIGHT="9.568567703271055">
<FOOTNOTE>G: Glucocorticoid, S:Salbutamol, E: Epinephrine, P: Placebo</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.9471251141566177" CI_START="0.2050968743677248" EFFECT_SIZE="0.44074074074074077" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.0235926473971687" LOG_CI_START="-0.6880409581357444" LOG_EFFECT_SIZE="-0.35581680276645655" MODIFIED="2010-08-14 18:15:58 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1228" O_E="0.0" SE="0.39030022680002296" STUDY_ID="STD-Schuh-2002" TOTAL_1="36" TOTAL_2="34" VAR="0.15233426704014935" WEIGHT="4.2640828720143515"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.44989373982147884" CI_END="1.1270746007103483" CI_START="0.7920358715410343" DF="2" EFFECT_SIZE="0.9448193021236304" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="160" I2="0.0" ID="CMP-001.15.02" LOG_CI_END="0.051952662811499246" LOG_CI_START="-0.10125514863836169" LOG_EFFECT_SIZE="-0.02465124291343119" MODIFIED="2013-01-07 12:32:25 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="0.7985587935744773" P_Z="0.5282241963903253" STUDIES="3" TAU2="0.0" TOTAL_1="534" TOTAL_2="511" WEIGHT="80.20218907041739" Z="0.6307191236170777">
<NAME>No protocolised use of bronchodilator</NAME>
<DICH_DATA CI_END="2.6042495575339197" CI_START="0.17066123450369663" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.4156825990462294" LOG_CI_START="-0.7678651171575919" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2010-08-14 18:15:57 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="537" O_E="0.0" SE="0.695221787153807" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_" TOTAL_1="30" TOTAL_2="15" VAR="0.4833333333333333" WEIGHT="1.3439295287726096"/>
<DICH_DATA CI_END="1.17502236352059" CI_START="0.7961560889355206" EFFECT_SIZE="0.9672131147540983" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="121" LOG_CI_END="0.07004613236193619" LOG_CI_START="-0.09900177909918194" LOG_EFFECT_SIZE="-0.01447782336862286" MODIFIED="2010-08-14 18:15:57 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1230" O_E="0.0" SE="0.09929957999291825" STUDY_ID="STD-Corneli-2007" TOTAL_1="305" TOTAL_2="295" VAR="0.00986040658676997" WEIGHT="65.87618200027423"/>
<DICH_DATA CI_END="1.348355334634231" CI_START="0.5610479636639762" EFFECT_SIZE="0.8697654941373534" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" LOG_CI_END="0.12980435772970553" LOG_CI_START="-0.2510000095741703" LOG_EFFECT_SIZE="-0.06059782592223239" MODIFIED="2010-08-15 03:21:29 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="545" O_E="0.0" SE="0.22368637036631592" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_" TOTAL_1="199" TOTAL_2="201" VAR="0.05003559228765665" WEIGHT="12.982077541370558"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.842797338900413" CI_END="1.0641445016670419" CI_START="0.7002968697439977" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8632595574175335" ESTIMABLE="YES" EVENTS_1="231" EVENTS_2="251" I2="31.53964157940858" I2_Q="51.305261678503214" ID="CMP-001.16" LOG_CI_END="0.02700060541725122" LOG_CI_START="-0.1547178148999694" LOG_EFFECT_SIZE="-0.06385860474135911" METHOD="MH" MODIFIED="2013-01-07 12:32:43 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="16" P_CHI2="0.2111999714073438" P_Q="0.1518462256354538" P_Z="0.16835090248652354" Q="2.0536099678731405" RANDOM="YES" SCALE="2.49" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.017471851515173047" TOTALS="YES" TOTAL_1="787" TOTAL_2="743" WEIGHT="100.0" Z="1.377522049526442">
<NAME>Admissions within 7 days (outpatients) - subgroup analysis protocolised use of bronchodilator</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.6670920408871033" CI_END="1.0501597019807527" CI_START="0.44041266580732563" DF="2" EFFECT_SIZE="0.6800761971079197" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="67" I2="25.011961741868543" ID="CMP-001.16.01" LOG_CI_END="0.021255348988959175" LOG_CI_START="-0.35614019966592486" LOG_EFFECT_SIZE="-0.1674424253384828" MODIFIED="2013-01-07 12:32:39 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="0.26354125633375525" P_Z="0.08200149600440933" STUDIES="4" TAU2="0.04225406912175993" TOTAL_1="304" TOTAL_2="277" WEIGHT="30.219482522628326" Z="1.739189157461814">
<NAME>Protocolised use of bronchodilator</NAME>
<DICH_DATA CI_END="3.4061821332564044" CI_START="0.42276071673927784" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.532267866572387" LOG_CI_START="-0.37390537447713734" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2010-08-15 03:23:17 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1256" O_E="0.0" SE="0.5322906474223771" STUDY_ID="STD-Goebel-2000" TOTAL_1="24" TOTAL_2="24" VAR="0.2833333333333333" WEIGHT="3.7878065608615334"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-15 03:23:17 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1257" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="46" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0683964036649523" CI_START="0.4849019475898856" EFFECT_SIZE="0.7197690580562386" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="47" LOG_CI_END="0.028732417470736377" LOG_CI_START="-0.31434607155401223" LOG_EFFECT_SIZE="-0.1428068270416379" MODIFIED="2010-08-15 03:23:28 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="546" O_E="0.0" SE="0.20152600271904728" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" TOTAL_1="199" TOTAL_2="198" VAR="0.04061272977191745" WEIGHT="19.616081022926696">
<FOOTNOTE>Plint 2009 (factorial trial) and Barlas 1998 (parallel multiarm study) contribute two independent comparisons which are shown separately; sensitivity analysis did not show relevant differences when pooling results</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.9108155575186726" CI_START="0.19986971340321266" EFFECT_SIZE="0.4266666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.04056955986760247" LOG_CI_START="-0.6992530102759856" LOG_EFFECT_SIZE="-0.36991128507179405" MODIFIED="2010-08-15 03:23:18 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1255" O_E="0.0" SE="0.386913919305549" STUDY_ID="STD-Schuh-2002" TOTAL_1="35" TOTAL_2="32" VAR="0.14970238095238092" WEIGHT="6.815594938840098"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.018545344922876347" CI_END="1.1109967759285504" CI_START="0.8168020311825701" DF="1" EFFECT_SIZE="0.9526092710107994" ESTIMABLE="YES" EVENTS_1="184" EVENTS_2="184" I2="0.0" ID="CMP-001.16.02" LOG_CI_END="0.04571279863621282" LOG_CI_START="-0.08788319093793716" LOG_EFFECT_SIZE="-0.02108519615086218" MODIFIED="2013-01-07 12:32:43 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="0.8916779689202782" P_Z="0.5361307263602707" STUDIES="2" TAU2="0.0" TOTAL_1="483" TOTAL_2="466" WEIGHT="69.78051747737167" Z="0.6186746352848437">
<NAME>No protocolised use of bronchodilator</NAME>
<DICH_DATA CI_END="1.1270972176819116" CI_START="0.796259048706326" EFFECT_SIZE="0.9473443715729492" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="131" LOG_CI_END="0.051961377698152976" LOG_CI_START="-0.09894561929596962" LOG_EFFECT_SIZE="-0.023492120798908292" MODIFIED="2010-08-15 03:29:02 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1259" O_E="0.0" SE="0.08864351703603024" STUDY_ID="STD-Corneli-2007" TOTAL_1="284" TOTAL_2="265" VAR="0.007857673112516984" WEIGHT="44.98275705753929"/>
<DICH_DATA CI_END="1.3529287095339466" CI_START="0.6982318611196237" EFFECT_SIZE="0.9719351474352896" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="53" LOG_CI_END="0.13127491273086228" LOG_CI_START="-0.15600033771500318" LOG_EFFECT_SIZE="-0.012362712492070467" MODIFIED="2010-08-15 03:23:31 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="547" O_E="0.0" SE="0.1687469041473254" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_" TOTAL_1="199" TOTAL_2="201" VAR="0.02847551765930663" WEIGHT="24.79776041983239">
<FOOTNOTE>G: Glucocorticoid, S:Salbutamol, E: Epinephrine, P: Placebo</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.86875140578438" CI_END="1.076476544701088" CI_START="0.7848709984662657" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9191818212220358" ESTIMABLE="YES" EVENTS_1="205" EVENTS_2="217" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.03200457143970596" LOG_CI_START="-0.10520171810585138" LOG_EFFECT_SIZE="-0.03659857333307271" METHOD="MH" MODIFIED="2013-01-07 12:32:56 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="17" P_CHI2="0.5508576370903963" P_Q="0.8287298109222225" P_Z="0.29574281921299106" Q="0.04679915771033175" RANDOM="YES" SCALE="10.445158627577035" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="907" TOTAL_2="855" WEIGHT="100.0" Z="1.0456063764417016">
<NAME>Admissions at day 1 (outpatients) - subgroup analysis age</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.660113815402815" CI_END="1.101900017297926" CI_START="0.7874685494262916" DF="2" EFFECT_SIZE="0.9315103908354451" ESTIMABLE="YES" EVENTS_1="175" EVENTS_2="186" I2="0.0" ID="CMP-001.17.01" LOG_CI_END="0.04214218988262911" LOG_CI_START="-0.10376678240613213" LOG_EFFECT_SIZE="-0.03081229626175148" MODIFIED="2013-01-07 12:32:51 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="0.7188828857675269" P_Z="0.4077894711926906" STUDIES="3" TAU2="0.0" TOTAL_1="703" TOTAL_2="694" WEIGHT="88.42682724491584" Z="0.8277899570767215">
<NAME>All &lt; 12 months</NAME>
<DICH_DATA CI_END="1.17502236352059" CI_START="0.7961560889355206" EFFECT_SIZE="0.9672131147540983" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="121" LOG_CI_END="0.07004613236193619" LOG_CI_START="-0.09900177909918194" LOG_EFFECT_SIZE="-0.01447782336862286" MODIFIED="2010-05-08 20:45:51 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="239" O_E="0.0" SE="0.09929957999291825" STUDY_ID="STD-Corneli-2007" TOTAL_1="305" TOTAL_2="295" VAR="0.00986040658676997" WEIGHT="65.87618200027423"/>
<DICH_DATA CI_END="1.3149856743021993" CI_START="0.47354677401404854" EFFECT_SIZE="0.7891180038121642" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="29" LOG_CI_END="0.1189210215669222" LOG_CI_START="-0.3246371176259998" LOG_EFFECT_SIZE="-0.10285804802953877" MODIFIED="2010-08-15 03:23:41 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="289" O_E="0.0" SE="0.2605482466101223" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" TOTAL_1="199" TOTAL_2="198" VAR="0.06788538881160912" WEIGHT="9.568567703271055">
<FOOTNOTE>Plint 2009 (factorial trial) and Barlas 1998 (parallel multiarm study) contribute two independent comparisons which are shown separately; sensitivity analysis did not show relevant differences when pooling results</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.348355334634231" CI_START="0.5610479636639762" EFFECT_SIZE="0.8697654941373534" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" LOG_CI_END="0.12980435772970553" LOG_CI_START="-0.2510000095741703" LOG_EFFECT_SIZE="-0.06059782592223239" MODIFIED="2010-08-15 03:23:43 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="290" O_E="0.0" SE="0.22368637036631592" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_" TOTAL_1="199" TOTAL_2="201" VAR="0.05003559228765665" WEIGHT="12.982077541370558">
<FOOTNOTE>G: Glucocorticoid, S:Salbutamol, E: Epinephrine, P: Placebo</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.030357771967715" CI_END="1.4905710544347186" CI_START="0.514718312797836" DF="5" EFFECT_SIZE="0.8759133622932863" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="31" I2="17.086179807728186" ID="CMP-001.17.02" LOG_CI_END="0.17335268336321455" LOG_CI_START="-0.2884303800195662" LOG_EFFECT_SIZE="-0.05753884832817578" MODIFIED="2013-01-07 12:32:56 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="0.30327623102006795" P_Z="0.6252461583901645" STUDIES="7" TAU2="0.07644010106968581" TOTAL_1="204" TOTAL_2="161" WEIGHT="11.573172755084165" Z="0.48842878562506603">
<NAME>Including &gt; 12 months</NAME>
<DICH_DATA CI_END="2.6042495575339197" CI_START="0.17066123450369663" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.4156825990462294" LOG_CI_START="-0.7678651171575919" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2010-08-12 08:12:07 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="291" O_E="0.0" SE="0.695221787153807" STUDY_ID="STD-Barlas-1998-_x0028_G-vs-P_x0029_" TOTAL_1="30" TOTAL_2="15" VAR="0.4833333333333333" WEIGHT="1.3439295287726096">
<FOOTNOTE>Multi-arm study; contributes two comparisons to this analysis (G: Glucocorticoid, S:Salbutamol, P: Placebo)</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="6.20048286508611" CI_START="0.16127776203218527" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7924255116719207" LOG_CI_START="-0.7924255116719207" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-25 23:40:58 +1000" MODIFIED_BY="[Empty name]" ORDER="292" O_E="0.0" SE="0.9309493362512627" STUDY_ID="STD-Barlas-1998-_x0028_G_x002b_S-vs-S_x0029_" TOTAL_1="15" TOTAL_2="15" VAR="0.8666666666666667" WEIGHT="0.7494991602770322"/>
<DICH_DATA CI_END="10.19672740704177" CI_START="0.4964828221752679" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0084608092997827" LOG_CI_START="-0.30409577307705765" LOG_EFFECT_SIZE="0.3521825181113625" MODIFIED="2010-05-08 20:46:07 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="245" O_E="0.0" SE="0.7710022337480251" STUDY_ID="STD-Berger-1998" TOTAL_1="20" TOTAL_2="18" VAR="0.5944444444444443" WEIGHT="1.0927277476936175"/>
<DICH_DATA CI_END="9.909075681283461" CI_START="0.4036703451115336" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9960331453793151" LOG_CI_START="-0.3939731540513527" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2010-05-08 20:46:07 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="244" O_E="0.0" SE="0.816496580927726" STUDY_ID="STD-Goebel-2000" TOTAL_1="24" TOTAL_2="24" VAR="0.6666666666666667" WEIGHT="0.9743489083601418"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-26 00:33:39 +1000" MODIFIED_BY="[Empty name]" ORDER="243" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="46" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.699291526026783" CI_START="0.45499453417999086" EFFECT_SIZE="1.1082251082251082" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.43124979130257723" LOG_CI_START="-0.3419938204631667" LOG_EFFECT_SIZE="0.04462798541970525" MODIFIED="2010-05-08 20:46:07 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="242" O_E="0.0" SE="0.45420712516880724" STUDY_ID="STD-Mesquita-2009" TOTAL_1="33" TOTAL_2="32" VAR="0.20630411255411255" WEIGHT="3.148584537966413"/>
<DICH_DATA CI_END="0.9471251141566177" CI_START="0.2050968743677248" EFFECT_SIZE="0.44074074074074077" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.0235926473971687" LOG_CI_START="-0.6880409581357444" LOG_EFFECT_SIZE="-0.35581680276645655" MODIFIED="2010-05-08 20:46:07 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="241" O_E="0.0" SE="0.39030022680002296" STUDY_ID="STD-Schuh-2002" TOTAL_1="36" TOTAL_2="34" VAR="0.15233426704014935" WEIGHT="4.2640828720143515"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.842797338900413" CI_END="1.0641445016670419" CI_START="0.7002968697439977" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8632595574175335" ESTIMABLE="YES" EVENTS_1="231" EVENTS_2="251" I2="31.53964157940858" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.02700060541725122" LOG_CI_START="-0.1547178148999694" LOG_EFFECT_SIZE="-0.06385860474135911" METHOD="MH" MODIFIED="2013-01-07 12:33:07 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="18" P_CHI2="0.2111999714073438" P_Q="0.5447320891589258" P_Z="0.16835090248652354" Q="0.3668399506096927" RANDOM="YES" SCALE="2.49" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.017471851515173047" TOTALS="YES" TOTAL_1="787" TOTAL_2="743" WEIGHT="100.0" Z="1.377522049526442">
<NAME>Admissions within 7 days (outpatients) - subgroup analysis age</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.723780707190722" CI_END="1.0595781672460043" CI_START="0.7955043725797464" DF="2" EFFECT_SIZE="0.9180953464288065" ESTIMABLE="YES" EVENTS_1="218" EVENTS_2="231" I2="0.0" ID="CMP-001.18.01" LOG_CI_END="0.02513300101980291" LOG_CI_START="-0.09935742886210548" LOG_EFFECT_SIZE="-0.03711221392115127" MODIFIED="2013-01-07 12:33:03 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="0.42236324598619146" P_Z="0.24257233150657254" STUDIES="3" TAU2="0.0" TOTAL_1="682" TOTAL_2="664" WEIGHT="89.39659850029837" Z="1.168581436195575">
<NAME>All &lt; 12 months</NAME>
<DICH_DATA CI_END="1.1270972176819116" CI_START="0.796259048706326" EFFECT_SIZE="0.9473443715729492" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="131" LOG_CI_END="0.051961377698152976" LOG_CI_START="-0.09894561929596962" LOG_EFFECT_SIZE="-0.023492120798908292" MODIFIED="2010-05-08 20:46:48 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="247" O_E="0.0" SE="0.08864351703603024" STUDY_ID="STD-Corneli-2007" TOTAL_1="284" TOTAL_2="265" VAR="0.007857673112516984" WEIGHT="44.98275705753929"/>
<DICH_DATA CI_END="1.0683964036649523" CI_START="0.4849019475898856" EFFECT_SIZE="0.7197690580562386" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="47" LOG_CI_END="0.028732417470736377" LOG_CI_START="-0.31434607155401223" LOG_EFFECT_SIZE="-0.1428068270416379" MODIFIED="2010-08-15 03:23:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="293" O_E="0.0" SE="0.20152600271904728" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" TOTAL_1="199" TOTAL_2="198" VAR="0.04061272977191745" WEIGHT="19.616081022926696">
<FOOTNOTE>Plint 2009 (factorial trial) and Barlas 1998 (parallel multiarm study) contribute two independent comparisons which are shown separately; sensitivity analysis did not show relevant differences when pooling results</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.3529287095339466" CI_START="0.6982318611196237" EFFECT_SIZE="0.9719351474352896" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="53" LOG_CI_END="0.13127491273086228" LOG_CI_START="-0.15600033771500318" LOG_EFFECT_SIZE="-0.012362712492070467" MODIFIED="2010-08-15 03:23:54 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="294" O_E="0.0" SE="0.1687469041473254" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_" TOTAL_1="199" TOTAL_2="201" VAR="0.02847551765930663" WEIGHT="24.79776041983239">
<FOOTNOTE>G: Glucocorticoid, S:Salbutamol, E: Epinephrine, P: Placebo</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.4697046908031175" CI_END="1.8334299241788814" CI_START="0.24540944178858445" DF="1" EFFECT_SIZE="0.6707764264277822" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" I2="59.50932904148907" ID="CMP-001.18.02" LOG_CI_END="0.26326431537432976" LOG_CI_START="-0.6101087324085269" LOG_EFFECT_SIZE="-0.1734222085170986" MODIFIED="2013-01-07 12:33:07 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.11605997886676811" P_Z="0.4363541742317242" STUDIES="3" TAU2="0.3182173102854964" TOTAL_1="105" TOTAL_2="79" WEIGHT="10.603401499701631" Z="0.7783644885213288">
<NAME>Including &gt; 12 months</NAME>
<DICH_DATA CI_END="3.4061821332564044" CI_START="0.42276071673927784" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.532267866572387" LOG_CI_START="-0.37390537447713734" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2010-05-08 20:46:55 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="251" O_E="0.0" SE="0.5322906474223771" STUDY_ID="STD-Goebel-2000" TOTAL_1="24" TOTAL_2="24" VAR="0.2833333333333333" WEIGHT="3.7878065608615334"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-26 00:34:44 +1000" MODIFIED_BY="[Empty name]" ORDER="250" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="46" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9108155575186726" CI_START="0.19986971340321266" EFFECT_SIZE="0.4266666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.04056955986760247" LOG_CI_START="-0.6992530102759856" LOG_EFFECT_SIZE="-0.36991128507179405" MODIFIED="2010-05-08 20:46:55 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="249" O_E="0.0" SE="0.386913919305549" STUDY_ID="STD-Schuh-2002" TOTAL_1="35" TOTAL_2="32" VAR="0.14970238095238092" WEIGHT="6.815594938840098"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="8.33019574811678" CI_END="0.04289960696091924" CI_START="-0.39488796229270395" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.17599417766589234" ESTIMABLE="YES" I2="15.968361228696216" I2_Q="0.0" ID="CMP-001.19" MODIFIED="2013-01-07 12:33:24 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="19" P_CHI2="0.304380061366882" P_Q="0.4682526694932778" P_Z="0.11506197777912512" Q="0.5260965330119751" RANDOM="YES" SCALE="7.795887209286688" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.017841785359773217" TOTALS="YES" TOTAL_1="322" TOTAL_2="311" UNITS="" WEIGHT="100.0" Z="1.5758430523825926">
<NAME>Length of stay (inpatients) - subgroup analysis protocolised use of bronchodilator</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.876552845559923" CI_END="-0.0039133944379616675" CI_START="-0.2336283966394409" DF="3" EFFECT_SIZE="-0.11877089553870128" ESTIMABLE="YES" I2="0.0" ID="CMP-001.19.01" MODIFIED="2013-01-07 12:33:19 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="0.5984197090720679" P_Z="0.042688665663325666" STUDIES="4" TAU2="0.0" TOTAL_1="102" TOTAL_2="104" WEIGHT="67.05583739556265" Z="2.026743359697946">
<NAME>Protocolised use of bronchodilator</NAME>
<CONT_DATA CI_END="3.3588370411405615" CI_START="-4.996837041140561" EFFECT_SIZE="-0.819" ESTIMABLE="YES" MEAN_1="5.469" MEAN_2="6.288" MODIFIED="2010-05-08 21:06:36 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="253" SD_1="7.87" SD_2="8.778" SE="2.1315886792281935" STUDY_ID="STD-Bentur-2005" TOTAL_1="29" TOTAL_2="32" WEIGHT="0.2734398761927848"/>
<CONT_DATA CI_END="0.892607915895336" CI_START="-2.0926079158953352" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="6.6" MODIFIED="2010-05-08 21:06:36 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="254" SD_1="2.619" SD_2="1.162" SE="0.7615486446020623" STUDY_ID="STD-De-Boeck-1997" TOTAL_1="14" TOTAL_2="15" WEIGHT="2.0864891511479704"/>
<CONT_DATA CI_END="-0.008630944936559248" CI_START="-0.24136905506344075" EFFECT_SIZE="-0.125" ESTIMABLE="YES" MEAN_1="0.654" MEAN_2="0.779" MODIFIED="2010-05-08 21:06:36 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="252" SD_1="0.192" SD_2="0.223" SE="0.059373057862973505" STUDY_ID="STD-Gomez-2007" TOTAL_1="24" TOTAL_2="25" WEIGHT="58.37518083018746"/>
<CONT_DATA CI_END="1.2053703387678127" CI_START="-0.45537033876781263" EFFECT_SIZE="0.375" ESTIMABLE="YES" MEAN_1="2.375" MEAN_2="2.0" MODIFIED="2010-05-13 19:38:59 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="265" SD_1="2.39" SD_2="0.722" SE="0.4236661210704216" STUDY_ID="STD-Klassen-1997" TOTAL_1="35" TOTAL_2="32" WEIGHT="6.320727538034425"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.82486616658769" CI_END="0.20063163467170897" CI_START="-0.8283391335777452" DF="3" EFFECT_SIZE="-0.31385374945301814" ESTIMABLE="YES" I2="37.82210953797912" ID="CMP-001.19.02" MODIFIED="2013-01-07 12:33:24 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="0.1850798726399031" P_Z="0.23183501680392327" STUDIES="4" TAU2="0.0989342495468566" TOTAL_1="220" TOTAL_2="207" WEIGHT="32.944162604437345" Z="1.1956453270043603">
<NAME>No protocolised use of bronchodilator</NAME>
<CONT_DATA CI_END="0.5850320304986812" CI_START="-0.5850320304986812" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.0" MODIFIED="2010-05-08 21:06:36 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="258" SD_1="1.48" SD_2="2.22" SE="0.2984912146923817" STUDY_ID="STD-Cade-2000" TOTAL_1="82" TOTAL_2="79" WEIGHT="11.663675005771099"/>
<CONT_DATA CI_END="0.3476792968530291" CI_START="-2.347679296853029" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.0" MODIFIED="2010-05-08 21:06:36 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="256" SD_1="2.647" SD_2="1.626" SE="0.6876041128731708" STUDY_ID="STD-Richter-1998" TOTAL_1="21" TOTAL_2="19" WEIGHT="2.54218213963027"/>
<CONT_DATA CI_END="-0.1071666458089971" CI_START="-1.0108333541910033" EFFECT_SIZE="-0.5590000000000002" ESTIMABLE="YES" MEAN_1="2.258" MEAN_2="2.817" MODIFIED="2010-05-08 21:06:36 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="257" SD_1="1.246" SD_2="1.742" SE="0.23053145759565324" STUDY_ID="STD-Teeratakulpisarn-2007" TOTAL_1="89" TOTAL_2="85" WEIGHT="17.570927235210867"/>
<CONT_DATA CI_END="3.008958531386528" CI_START="-1.008958531386528" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="5.0" MODIFIED="2010-05-08 21:06:36 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="255" SD_1="4.05" SD_2="3.34" SE="1.0249976771169962" STUDY_ID="STD-Zhang-2003" TOTAL_1="28" TOTAL_2="24" WEIGHT="1.167378223825112"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.33019574811678" CI_END="0.04289960696091927" CI_START="-0.3948879622927039" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.17599417766589232" ESTIMABLE="YES" I2="15.968361228696216" I2_Q="0.0" ID="CMP-001.20" MODIFIED="2013-01-07 12:33:35 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="20" P_CHI2="0.304380061366882" P_Q="0.7502782823710016" P_Z="0.1150619777791252" Q="0.1012973734902309" RANDOM="YES" SCALE="7.795887209286688" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.017841785359773217" TOTALS="YES" TOTAL_1="322" TOTAL_2="311" UNITS="" WEIGHT="99.99999999999997" Z="1.5758430523825924">
<NAME>Length of stay (inpatients) - subgroup analysis age</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.090116516726233" CI_END="0.4491401842243918" CI_START="-0.6521939241968341" DF="3" EFFECT_SIZE="-0.10152686998622114" ESTIMABLE="YES" I2="2.916282160832734" ID="CMP-001.20.01" MODIFIED="2013-01-07 12:33:32 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="0.37793886162783563" P_Z="0.7178303983593581" STUDIES="4" TAU2="0.016519052713120697" TOTAL_1="160" TOTAL_2="154" WEIGHT="15.646675245419267" Z="0.36135993085935914">
<NAME>All &lt; 12 months</NAME>
<CONT_DATA CI_END="3.3588370411405615" CI_START="-4.996837041140561" EFFECT_SIZE="-0.819" ESTIMABLE="YES" MEAN_1="5.469" MEAN_2="6.288" MODIFIED="2010-05-08 21:08:29 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="263" SD_1="7.87" SD_2="8.778" SE="2.1315886792281935" STUDY_ID="STD-Bentur-2005" TOTAL_1="29" TOTAL_2="32" WEIGHT="0.2734398761927848"/>
<CONT_DATA CI_END="0.5850320304986812" CI_START="-0.5850320304986812" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.0" MODIFIED="2010-05-08 21:09:29 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="271" SD_1="1.48" SD_2="2.22" SE="0.2984912146923817" STUDY_ID="STD-Cade-2000" TOTAL_1="82" TOTAL_2="79" WEIGHT="11.663675005771099"/>
<CONT_DATA CI_END="0.3476792968530291" CI_START="-2.347679296853029" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.0" MODIFIED="2010-05-08 21:09:29 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="272" SD_1="2.647" SD_2="1.626" SE="0.6876041128731708" STUDY_ID="STD-Richter-1998" TOTAL_1="21" TOTAL_2="19" WEIGHT="2.54218213963027"/>
<CONT_DATA CI_END="3.008958531386528" CI_START="-1.008958531386528" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="5.0" MODIFIED="2010-05-08 21:09:29 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="273" SD_1="4.05" SD_2="3.34" SE="1.0249976771169962" STUDY_ID="STD-Zhang-2003" TOTAL_1="28" TOTAL_2="24" WEIGHT="1.167378223825112"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.201980582833012" CI_END="0.11801182832681106" CI_START="-0.5284405420506135" DF="3" EFFECT_SIZE="-0.2052143568619012" ESTIMABLE="YES" I2="42.32965786338648" ID="CMP-001.20.02" MODIFIED="2013-01-07 12:33:35 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="0.1575909562031782" P_Z="0.21336369269357536" STUDIES="4" TAU2="0.04514994388054671" TOTAL_1="162" TOTAL_2="157" WEIGHT="84.35332475458071" Z="1.244369320898456">
<NAME>Including &gt; 12 months</NAME>
<CONT_DATA CI_END="0.892607915895336" CI_START="-2.0926079158953352" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="6.6" MODIFIED="2010-05-08 21:09:34 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="274" SD_1="2.619" SD_2="1.162" SE="0.7615486446020623" STUDY_ID="STD-De-Boeck-1997" TOTAL_1="14" TOTAL_2="15" WEIGHT="2.0864891511479704"/>
<CONT_DATA CI_END="-0.008630944936559248" CI_START="-0.24136905506344075" EFFECT_SIZE="-0.125" ESTIMABLE="YES" MEAN_1="0.654" MEAN_2="0.779" MODIFIED="2010-05-08 21:09:34 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="275" SD_1="0.192" SD_2="0.223" SE="0.059373057862973505" STUDY_ID="STD-Gomez-2007" TOTAL_1="24" TOTAL_2="25" WEIGHT="58.37518083018746"/>
<CONT_DATA CI_END="1.2053703387678127" CI_START="-0.45537033876781263" EFFECT_SIZE="0.375" ESTIMABLE="YES" MEAN_1="2.375" MEAN_2="2.0" MODIFIED="2010-05-08 21:08:29 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="266" SD_1="2.39" SD_2="0.722" SE="0.4236661210704216" STUDY_ID="STD-Klassen-1997" TOTAL_1="35" TOTAL_2="32" WEIGHT="6.320727538034425"/>
<CONT_DATA CI_END="-0.1071666458089971" CI_START="-1.0108333541910033" EFFECT_SIZE="-0.5590000000000002" ESTIMABLE="YES" MEAN_1="2.258" MEAN_2="2.817" MODIFIED="2010-05-08 21:08:29 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="270" SD_1="1.246" SD_2="1.742" SE="0.23053145759565324" STUDY_ID="STD-Teeratakulpisarn-2007" TOTAL_1="89" TOTAL_2="85" WEIGHT="17.570927235210867"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.33019574811678" CI_END="0.04289960696091927" CI_START="-0.3948879622927039" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.17599417766589232" ESTIMABLE="YES" I2="15.968361228696216" I2_Q="0.0" ID="CMP-001.21" MODIFIED="2013-03-19 22:20:06 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="21" P_CHI2="0.304380061366882" P_Q="0.7475676530209059" P_Z="0.1150619777791252" Q="0.10358632680846512" RANDOM="YES" SCALE="7.795887209286688" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.017841785359773217" TOTALS="YES" TOTAL_1="322" TOTAL_2="311" UNITS="" WEIGHT="99.99999999999999" Z="1.5758430523825924">
<NAME>Length of stay (inpatients) - subgroup analysis RSV status</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.6562901983878349" CI_END="0.4478615776097427" CI_START="-0.6323701423016757" DF="2" EFFECT_SIZE="-0.09225428234596648" ESTIMABLE="YES" I2="0.0" ID="CMP-001.21.01" MODIFIED="2013-03-19 22:19:58 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="0.7202585642356999" P_Z="0.7377979165452859" STUDIES="3" TAU2="0.0" TOTAL_1="125" TOTAL_2="126" WEIGHT="14.023604033111855" Z="0.33477089680816063">
<NAME>All RSV-positive</NAME>
<CONT_DATA CI_END="3.3588370411405615" CI_START="-4.996837041140561" EFFECT_SIZE="-0.819" ESTIMABLE="YES" MEAN_1="5.469" MEAN_2="6.288" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1276" SD_1="7.87" SD_2="8.778" SE="2.1315886792281935" STUDY_ID="STD-Bentur-2005" TOTAL_1="29" TOTAL_2="32" WEIGHT="0.2734398761927848"/>
<CONT_DATA CI_END="0.5850320304986812" CI_START="-0.5850320304986812" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.0" MODIFIED="2010-05-08 21:07:38 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="261" SD_1="1.48" SD_2="2.22" SE="0.2984912146923817" STUDY_ID="STD-Cade-2000" TOTAL_1="82" TOTAL_2="79" WEIGHT="11.663675005771099"/>
<CONT_DATA CI_END="0.892607915895336" CI_START="-2.0926079158953352" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="6.6" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1277" SD_1="2.619" SD_2="1.162" SE="0.7615486446020623" STUDY_ID="STD-De-Boeck-1997" TOTAL_1="14" TOTAL_2="15" WEIGHT="2.0864891511479704"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.639022970718633" CI_END="0.16947721708573302" CI_START="-0.5688469546946555" DF="4" EFFECT_SIZE="-0.19968486880446126" ESTIMABLE="YES" I2="47.637282734552315" ID="CMP-001.21.02" MODIFIED="2013-03-19 22:20:06 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="0.10573305571567582" P_Z="0.28906656458063407" STUDIES="5" TAU2="0.07103078053507385" TOTAL_1="197" TOTAL_2="185" WEIGHT="85.97639596688813" Z="1.060171577941411">
<NAME>Not all RSV-positive, or NR</NAME>
<CONT_DATA CI_END="-0.008630944936559248" CI_START="-0.24136905506344075" EFFECT_SIZE="-0.125" ESTIMABLE="YES" MEAN_1="0.654" MEAN_2="0.779" MODIFIED="2010-05-08 21:07:42 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="262" SD_1="0.192" SD_2="0.223" SE="0.059373057862973505" STUDY_ID="STD-Gomez-2007" TOTAL_1="24" TOTAL_2="25" WEIGHT="58.37518083018746"/>
<CONT_DATA CI_END="1.2053703387678127" CI_START="-0.45537033876781263" EFFECT_SIZE="0.375" ESTIMABLE="YES" MEAN_1="2.375" MEAN_2="2.0" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1282" SD_1="2.39" SD_2="0.722" SE="0.4236661210704216" STUDY_ID="STD-Klassen-1997" TOTAL_1="35" TOTAL_2="32" WEIGHT="6.320727538034425"/>
<CONT_DATA CI_END="0.3476792968530291" CI_START="-2.347679296853029" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.0" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1283" SD_1="2.647" SD_2="1.626" SE="0.6876041128731708" STUDY_ID="STD-Richter-1998" TOTAL_1="21" TOTAL_2="19" WEIGHT="2.54218213963027"/>
<CONT_DATA CI_END="-0.1071666458089971" CI_START="-1.0108333541910033" EFFECT_SIZE="-0.5590000000000002" ESTIMABLE="YES" MEAN_1="2.258" MEAN_2="2.817" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1279" SD_1="1.246" SD_2="1.742" SE="0.23053145759565324" STUDY_ID="STD-Teeratakulpisarn-2007" TOTAL_1="89" TOTAL_2="85" WEIGHT="17.570927235210867"/>
<CONT_DATA CI_END="3.008958531386528" CI_START="-1.008958531386528" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="5.0" MODIFIED="2010-04-06 09:25:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1280" SD_1="4.05" SD_2="3.34" SE="1.0249976771169962" STUDY_ID="STD-Zhang-2003" TOTAL_1="28" TOTAL_2="24" WEIGHT="1.167378223825112"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.3977242563057755" CI_END="1.0301344540373305" CI_START="0.828303997637214" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9237231654467423" ESTIMABLE="YES" EVENTS_1="393" EVENTS_2="417" I2="0.0" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="0.012893912895062651" LOG_CI_START="-0.08181024260389815" LOG_EFFECT_SIZE="-0.03445816485441777" METHOD="MH" MODIFIED="2013-05-03 00:51:48 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="22" P_CHI2="0.7918129951052374" P_Q="0.8975515353359522" P_Z="0.15379094379309755" Q="0.01657784447428683" RANDOM="YES" SCALE="10.45" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1385" TOTAL_2="1358" WEIGHT="200.0" Z="1.4262681871175933">
<NAME>Admissions (days 1 and 7) (outpatients) - sensitivity analysis with only low overall RoB</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.660113815402815" CI_END="1.101900017297926" CI_START="0.7874685494262916" DF="2" EFFECT_SIZE="0.9315103908354451" ESTIMABLE="YES" EVENTS_1="175" EVENTS_2="186" I2="0.0" ID="CMP-001.22.01" LOG_CI_END="0.04214218988262911" LOG_CI_START="-0.10376678240613213" LOG_EFFECT_SIZE="-0.03081229626175148" MODIFIED="2013-05-03 00:51:37 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="0.7188828857675269" P_Z="0.4077894711926906" STUDIES="3" TAU2="0.0" TOTAL_1="703" TOTAL_2="694" WEIGHT="100.0" Z="0.8277899570767215">
<NAME>Admissions day 1</NAME>
<DICH_DATA CI_END="1.17502236352059" CI_START="0.7961560889355206" EFFECT_SIZE="0.9672131147540983" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="121" LOG_CI_END="0.07004613236193619" LOG_CI_START="-0.09900177909918194" LOG_EFFECT_SIZE="-0.01447782336862286" MODIFIED="2013-05-03 00:51:37 +1000" MODIFIED_BY="[Empty name]" ORDER="1008" O_E="0.0" SE="0.09929957999291825" STUDY_ID="STD-Corneli-2007" TOTAL_1="305" TOTAL_2="295" VAR="0.00986040658676997" WEIGHT="74.49795955905658"/>
<DICH_DATA CI_END="1.3149856743021993" CI_START="0.47354677401404854" EFFECT_SIZE="0.7891180038121642" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="29" LOG_CI_END="0.1189210215669222" LOG_CI_START="-0.3246371176259998" LOG_EFFECT_SIZE="-0.10285804802953877" MODIFIED="2010-08-15 03:24:05 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="295" O_E="0.0" SE="0.2605482466101223" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" TOTAL_1="199" TOTAL_2="198" VAR="0.06788538881160912" WEIGHT="10.820887734407782">
<FOOTNOTE>Plint 2009 (factorial trial) contributes two independent comparisons which are shown separately; sensitivity analysis did not show relevant differences when pooling results</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.348355334634231" CI_START="0.5610479636639762" EFFECT_SIZE="0.8697654941373534" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" LOG_CI_END="0.12980435772970553" LOG_CI_START="-0.2510000095741703" LOG_EFFECT_SIZE="-0.06059782592223239" MODIFIED="2010-08-15 03:24:07 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="296" O_E="0.0" SE="0.22368637036631592" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_" TOTAL_1="199" TOTAL_2="201" VAR="0.05003559228765665" WEIGHT="14.681152706535642">
<FOOTNOTE>G: Glucocorticoid, S:Salbutamol, E: Epinephrine, P: Placebo</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.723780707190723" CI_END="1.0595781672460043" CI_START="0.7955043725797464" DF="2" EFFECT_SIZE="0.9180953464288065" ESTIMABLE="YES" EVENTS_1="218" EVENTS_2="231" I2="0.0" ID="CMP-001.22.02" LOG_CI_END="0.02513300101980291" LOG_CI_START="-0.09935742886210548" LOG_EFFECT_SIZE="-0.03711221392115127" MODIFIED="2013-05-03 00:51:48 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="0.42236324598619124" P_Z="0.24257233150657254" STUDIES="3" TAU2="0.0" TOTAL_1="682" TOTAL_2="664" WEIGHT="100.0" Z="1.168581436195575">
<NAME>Admissions day 7</NAME>
<DICH_DATA CI_END="1.1270972176819116" CI_START="0.796259048706326" EFFECT_SIZE="0.9473443715729492" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="131" LOG_CI_END="0.051961377698152976" LOG_CI_START="-0.09894561929596962" LOG_EFFECT_SIZE="-0.023492120798908292" MODIFIED="2013-05-03 00:51:48 +1000" MODIFIED_BY="[Empty name]" ORDER="1694" O_E="0.0" SE="0.08864351703603024" STUDY_ID="STD-Corneli-2007" TOTAL_1="284" TOTAL_2="265" VAR="0.007857673112516984" WEIGHT="68.05392521832898"/>
<DICH_DATA CI_END="1.0683964036649523" CI_START="0.4849019475898856" EFFECT_SIZE="0.7197690580562386" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="47" LOG_CI_END="0.028732417470736377" LOG_CI_START="-0.31434607155401223" LOG_EFFECT_SIZE="-0.1428068270416379" MODIFIED="2010-08-15 03:24:11 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="297" O_E="0.0" SE="0.20152600271904728" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_E-vs-P_x002b_E_x0029_" TOTAL_1="199" TOTAL_2="198" VAR="0.04061272977191745" WEIGHT="13.166943010047715"/>
<DICH_DATA CI_END="1.3529287095339466" CI_START="0.6982318611196237" EFFECT_SIZE="0.9719351474352896" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="53" LOG_CI_END="0.13127491273086228" LOG_CI_START="-0.15600033771500318" LOG_EFFECT_SIZE="-0.012362712492070467" MODIFIED="2010-08-15 03:24:12 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="298" O_E="0.0" SE="0.1687469041473254" STUDY_ID="STD-Plint-2009-_x0028_G_x002b_P-vs-P_x002b_P_x0029_" TOTAL_1="199" TOTAL_2="201" VAR="0.02847551765930663" WEIGHT="18.77913177162329"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.7167734772867297E-32" CI_END="1.2053703387678127" CI_START="-0.4553703387678126" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.37500000000000006" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-001.23" MODIFIED="2010-08-13 02:44:47 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="23" P_CHI2="0.0" P_Q="1.0" P_Z="0.3760860132834898" Q="0.0" RANDOM="YES" SCALE="7.795887209286688" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="32" UNITS="" WEIGHT="100.00000000000001" Z="0.8851309589082477">
<NAME>Length of stay (inpatients) - sensitivity analysis with only low overall RoB</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.2053703387678127" CI_START="-0.45537033876781263" EFFECT_SIZE="0.375" ESTIMABLE="YES" MEAN_1="2.375" MEAN_2="2.0" MODIFIED="2010-04-30 23:22:19 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1103" SD_1="2.39" SD_2="0.722" SE="0.4236661210704216" STUDY_ID="STD-Klassen-1997" TOTAL_1="35" TOTAL_2="32" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-01-07 12:34:26 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2">
<NAME>Glucocorticoid and epinephrine versus placebo</NAME>
<DICH_OUTCOME CHI2="1.686044058438178E-4" CI_END="0.8739963617032618" CI_START="0.4788671884289958" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6469375398181904" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="89" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.058490375255168765" LOG_CI_START="-0.3197849194251591" LOG_EFFECT_SIZE="-0.18913764734016392" METHOD="MH" MODIFIED="2010-08-15 02:50:17 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="0.9896399389090776" P_Q="0.9896481824703727" P_Z="0.004547778608581927" Q="1.6833617851615986E-4" RANDOM="YES" SCALE="2.79" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="398" TOTAL_2="402" WEIGHT="200.0" Z="2.83743373276245">
<NAME>Admissions (days 1 and 7) (outpatients) - review primary outcome</NAME>
<GROUP_LABEL_1>Glucocorticoid and Epi</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid and epi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0481897411392598" CI_START="0.3972800232889423" DF="0" EFFECT_SIZE="0.6453098827470687" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="36" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.020439904852919886" LOG_CI_START="-0.40090327233074424" LOG_EFFECT_SIZE="-0.19023168373891217" MODIFIED="2010-08-15 02:50:15 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.07675993284345108" STUDIES="1" TAU2="0.0" TOTAL_1="199" TOTAL_2="201" WEIGHT="100.0" Z="1.769803186746072">
<NAME>Admissions day 1</NAME>
<DICH_DATA CI_END="1.0481897411392598" CI_START="0.3972800232889423" EFFECT_SIZE="0.6453098827470687" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="36" LOG_CI_END="0.020439904852919886" LOG_CI_START="-0.40090327233074424" LOG_EFFECT_SIZE="-0.19023168373891217" MODIFIED="2010-08-15 02:50:15 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1710" O_E="0.0" SE="0.24749906796004878" STUDY_ID="STD-Plint-2009" TOTAL_1="199" TOTAL_2="201" VAR="0.061255788641092844" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9507902825648895" CI_START="0.44157789257244057" DF="0" EFFECT_SIZE="0.6479567649568597" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="53" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="-0.02191526557449767" LOG_CI_START="-0.3549926775210058" LOG_EFFECT_SIZE="-0.18845397154775173" MODIFIED="2010-08-15 02:50:17 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="1.0" P_Z="0.026562961556256412" STUDIES="1" TAU2="0.0" TOTAL_1="199" TOTAL_2="201" WEIGHT="100.0" Z="2.2178807912465035">
<NAME>Admissions day 7</NAME>
<DICH_DATA CI_END="0.9507902825648895" CI_START="0.44157789257244057" EFFECT_SIZE="0.6479567649568597" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="53" LOG_CI_END="-0.02191526557449767" LOG_CI_START="-0.3549926775210058" LOG_EFFECT_SIZE="-0.18845397154775173" MODIFIED="2010-08-15 02:50:17 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1717" O_E="0.0" SE="0.19565132053715886" STUDY_ID="STD-Plint-2009" TOTAL_1="199" TOTAL_2="201" VAR="0.03827943922793409" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.14154829900494642" CI_START="-0.5368736517077191" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.33921097535633277" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2013-01-07 12:34:00 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="7.695676972899285E-4" Q="0.0" RANDOM="YES" SCALE="0.63" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="199" TOTAL_2="200" UNITS="" WEIGHT="100.00000000000001" Z="3.3635145852078976">
<NAME>Clinical scores (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid and Epi</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid and epi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.14154829900494642" CI_START="-0.5368736517077191" DF="0" EFFECT_SIZE="-0.33921097535633277" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.01" MODIFIED="2013-01-07 12:34:00 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="7.695676972899285E-4" STUDIES="1" TAU2="0.0" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.00000000000001" Z="3.3635145852078976">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="-0.14154829900494642" CI_START="-0.5368736517077191" EFFECT_SIZE="-0.33921097535633277" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-1.65" MODIFIED="2010-04-23 04:18:07 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1712" SD_1="2.58" SD_2="2.42" SE="0.10085015740621986" STUDY_ID="STD-Plint-2009" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.6117492882711234" CI_START="-0.5317492882711233" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.040000000000000036" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2013-01-07 12:34:06 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.890935533549175" Q="0.0" RANDOM="YES" SCALE="0.71" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="199" TOTAL_2="200" UNITS="" WEIGHT="100.0" Z="0.13712051941274245">
<NAME>O<SUB>2</SUB> saturation (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid and Epi</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glucocorticoid and epi</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6117492882711234" CI_START="-0.5317492882711233" DF="0" EFFECT_SIZE="0.040000000000000036" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.01" MODIFIED="2013-01-07 12:34:06 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.890935533549175" STUDIES="1" TAU2="0.0" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.0" Z="0.13712051941274245">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="0.6117492882711234" CI_START="-0.5317492882711233" EFFECT_SIZE="0.040000000000000036" ESTIMABLE="YES" MEAN_1="-0.73" MEAN_2="-0.77" MODIFIED="2010-04-30 23:32:27 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1121" SD_1="2.56" SD_2="3.23" SE="0.2917141808630203" STUDY_ID="STD-Plint-2009" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.7430405391736883" CI_START="-3.063040539173689" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1600000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2013-01-07 12:34:10 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.23220516924161827" Q="0.0" RANDOM="YES" SCALE="3.47" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="199" TOTAL_2="200" UNITS="" WEIGHT="100.0" Z="1.194697735158945">
<NAME>Respiratory rate (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid and Epi</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid and epi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7430405391736883" CI_START="-3.063040539173689" DF="0" EFFECT_SIZE="-1.1600000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.01" MODIFIED="2013-01-07 12:34:10 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.23220516924161827" STUDIES="1" TAU2="0.0" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.0" Z="1.194697735158945">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="0.7430405391736883" CI_START="-3.063040539173689" EFFECT_SIZE="-1.1600000000000001" ESTIMABLE="YES" MEAN_1="-4.04" MEAN_2="-2.88" MODIFIED="2010-04-30 23:32:27 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1122" SD_1="9.17" SD_2="10.2" SE="0.9709568921595648" STUDY_ID="STD-Plint-2009" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="12.032331581646819" CI_START="4.847668418353184" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="8.440000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2013-01-07 12:34:17 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="4.1279200916184866E-6" Q="0.0" RANDOM="YES" SCALE="12.53" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="199" TOTAL_2="200" UNITS="" WEIGHT="100.0" Z="4.604835509625961">
<NAME>Heart rate (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid and Epi</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid and epi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="12.032331581646819" CI_START="4.847668418353184" DF="0" EFFECT_SIZE="8.440000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.01" MODIFIED="2013-01-07 12:34:17 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="4.1279200916184866E-6" STUDIES="1" TAU2="0.0" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.0" Z="4.604835509625961">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="12.032331581646819" CI_START="4.847668418353184" EFFECT_SIZE="8.440000000000001" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="-3.24" MODIFIED="2010-04-30 23:32:27 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1123" SD_1="17.8" SD_2="18.8" SE="1.8328559146916326" STUDY_ID="STD-Plint-2009" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3776749288889816" CI_START="0.8946587039884178" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1102021736589927" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="86" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.13914675513025276" LOG_CI_START="-0.04834260853114362" LOG_EFFECT_SIZE="0.0454020732995546" METHOD="MH" MODIFIED="2013-01-07 12:34:26 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.3424973437009482" Q="0.0" RANDOM="YES" SCALE="3.61" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.0" Z="0.9492424183729493">
<NAME>Return healthcare visits (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid and Epi</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid and epi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3776749288889816" CI_START="0.8946587039884178" DF="0" EFFECT_SIZE="1.1102021736589927" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="86" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="0.13914675513025276" LOG_CI_START="-0.04834260853114362" LOG_EFFECT_SIZE="0.0454020732995546" MODIFIED="2013-01-07 12:34:26 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.3424973437009482" STUDIES="1" TAU2="0.0" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.0" Z="0.9492424183729493">
<NAME>10 to 30 days</NAME>
<DICH_DATA CI_END="1.3776749288889816" CI_START="0.8946587039884178" EFFECT_SIZE="1.1102021736589927" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="86" LOG_CI_END="0.13914675513025276" LOG_CI_START="-0.04834260853114362" LOG_EFFECT_SIZE="0.0454020732995546" MODIFIED="2010-05-21 08:23:09 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="266" O_E="0.0" SE="0.11013218030202236" STUDY_ID="STD-Plint-2009" TOTAL_1="199" TOTAL_2="200" VAR="0.012129097138077163" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-01-07 12:35:21 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3">
<NAME>Glucocorticoid and salbutamol versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.436173203095408" CI_START="0.1293428526955729" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.5360750466763062" LOG_CI_START="-0.8882575647876688" LOG_EFFECT_SIZE="-0.17609125905568127" METHOD="MH" MODIFIED="2010-06-20 18:00:12 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6279434444203333" Q="0.0" RANDOM="YES" SCALE="10.45" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.48462349729774096">
<NAME>Admissions (day 1) (outpatients) - review primary outcome</NAME>
<GROUP_LABEL_1>Glucocorticoid and Salb</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid and salb</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.436173203095408" CI_START="0.1293428526955729" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5360750466763062" LOG_CI_START="-0.8882575647876688" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2010-04-29 08:00:30 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1249" O_E="0.0" SE="0.8366600265340756" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" VAR="0.7" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.2092395490045358" CI_END="0.09148809003913622" CI_START="-0.7417241149417393" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3251180124513015" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2013-01-07 12:34:47 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="0.9006670097500981" P_Q="0.9006670097500981" P_Z="0.12612831368075947" Q="0.2092395490045358" RANDOM="YES" SCALE="2.76" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="45" TOTAL_2="45" UNITS="" WEIGHT="300.0" Z="1.5295493544634813">
<NAME>Clinical scores (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid and Salb</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid and salb</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4183124744239165" CI_START="-1.022407821256194" DF="0" EFFECT_SIZE="-0.3020476734161388" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.01" MODIFIED="2013-01-07 12:34:38 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.4111823717345626" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.8218147037767466">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="0.4183124744239165" CI_START="-1.022407821256194" EFFECT_SIZE="-0.3020476734161388" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="-0.54" MODIFIED="2010-04-29 08:00:30 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1250" SD_1="2.28" SD_2="1.96" SE="0.36753744126022936" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4976392440072723" CI_START="-0.9387162465062859" DF="0" EFFECT_SIZE="-0.22053850124950686" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.02" MODIFIED="2013-01-07 12:34:42 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="1.0" P_Z="0.5472626432807157" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6018670482457352">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="0.4976392440072723" CI_START="-0.9387162465062859" EFFECT_SIZE="-0.22053850124950686" ESTIMABLE="YES" MEAN_1="-2.07" MEAN_2="-1.47" MODIFIED="2010-04-29 08:00:30 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1251" SD_1="2.75" SD_2="2.54" SE="0.36642395009381473" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2707608768595571" CI_START="-1.1818067809873023" DF="0" EFFECT_SIZE="-0.4555229520638726" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.03" MODIFIED="2013-01-07 12:34:47 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="1.0" P_Z="0.21896563056688656" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.2292832975504435">
<NAME>3 to 6 hours</NAME>
<CONT_DATA CI_END="0.2707608768595571" CI_START="-1.1818067809873023" EFFECT_SIZE="-0.4555229520638726" ESTIMABLE="YES" MEAN_1="-2.39" MEAN_2="-1.07" MODIFIED="2010-04-29 08:00:30 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1252" SD_1="3.25" SD_2="2.31" SE="0.370559783063497" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5576932126306555" CI_END="0.08723510753134456" CI_START="-1.5005760370384955" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7066704647535755" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" MODIFIED="2013-01-07 12:35:03 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7566559809472486" P_Q="0.7566559809472486" P_Z="0.08105430177467969" Q="0.5576932126306555" RANDOM="YES" SCALE="3.33" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="45" TOTAL_2="45" UNITS="" WEIGHT="300.0" Z="1.7446012576393883">
<NAME>O<SUB>2</SUB> saturation (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid and Salb</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glucocorticoid and salb</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0664204087776699" CI_START="-1.74642040877767" DF="0" EFFECT_SIZE="-0.34" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.01" MODIFIED="2013-01-07 12:34:55 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.6356294712402878" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.47381831960386644">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="1.0664204087776699" CI_START="-1.74642040877767" EFFECT_SIZE="-0.34" ESTIMABLE="YES" MEAN_1="-0.14" MEAN_2="0.2" MODIFIED="2010-04-29 08:00:30 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1253" SD_1="1.94" SD_2="1.99" SE="0.7175746186518398" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.700751599708489" CI_START="-2.040751599708489" DF="0" EFFECT_SIZE="-0.6699999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.02" MODIFIED="2013-01-07 12:34:58 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="1.0" P_Z="0.33806430186484104" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.9579969630683655">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="0.7007515997084892" CI_START="-2.0407515997084893" EFFECT_SIZE="-0.6699999999999999" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="0.47" MODIFIED="2010-04-29 08:00:30 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1254" SD_1="1.88" SD_2="1.95" SE="0.6993759122722677" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.26985419862928506" CI_START="-2.429854198629285" DF="0" EFFECT_SIZE="-1.08" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.03" MODIFIED="2013-01-07 12:35:03 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="1.0" P_Z="0.11684833529962307" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.5681405484034738">
<NAME>3 to 6 hours</NAME>
<CONT_DATA CI_END="0.26985419862928506" CI_START="-2.429854198629285" EFFECT_SIZE="-1.08" ESTIMABLE="YES" MEAN_1="-0.59" MEAN_2="0.49" MODIFIED="2010-04-29 08:00:30 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1255" SD_1="1.82" SD_2="1.95" SE="0.688713777026906" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.9111672652080821" CI_END="8.048888433485688" CI_START="-0.6973988095545174" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="3.6757448119655853" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2013-01-07 12:35:21 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6340778221956779" P_Q="0.6340778221956779" P_Z="0.09947535533378117" Q="0.9111672652080821" RANDOM="YES" SCALE="21.75" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="45" TOTAL_2="45" UNITS="" WEIGHT="300.0" Z="1.647402434340421">
<NAME>Heart rate (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid and Salb</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid and salb</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="11.23354843002637" CI_START="-1.89354843002637" DF="0" EFFECT_SIZE="4.67" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.01" MODIFIED="2013-01-07 12:35:11 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.16315915155958943" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.3945249136777191">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="11.23354843002637" CI_START="-1.89354843002637" EFFECT_SIZE="4.67" ESTIMABLE="YES" MEAN_1="3.07" MEAN_2="-1.6" MODIFIED="2010-04-30 23:41:58 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1130" SD_1="11.54" SD_2="5.92" SE="3.3488107341761393" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.363011228759719" CI_START="-14.103011228759717" DF="0" EFFECT_SIZE="-1.8699999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.02" MODIFIED="2013-01-07 12:35:15 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="1.0" P_Z="0.7644746461433973" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.29961001282114424">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="10.363011228759719" CI_START="-14.103011228759717" EFFECT_SIZE="-1.8699999999999997" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="4.47" MODIFIED="2010-04-30 23:41:58 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1131" SD_1="11.43" SD_2="21.3" SE="6.241446947623604" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.982379287366014" CI_START="-2.382379287366014" DF="0" EFFECT_SIZE="4.3" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.03" MODIFIED="2013-01-07 12:35:21 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="1.0" P_Z="0.20723529394497342" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="99.99999999999999" Z="1.2612042464360367">
<NAME>3 to 6 hours</NAME>
<CONT_DATA CI_END="10.982379287366014" CI_START="-2.382379287366014" EFFECT_SIZE="4.3" ESTIMABLE="YES" MEAN_1="2.96" MEAN_2="-1.34" MODIFIED="2010-04-30 23:41:58 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1132" SD_1="12.09" SD_2="5.31" SE="3.409439836688719" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-01-07 12:36:24 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="4">
<NAME>Glucocorticoid versus epinephrine</NAME>
<DICH_OUTCOME CHI2="1.0112931811413584" CI_END="1.454348448476822" CI_START="0.8181761961079956" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0908314633298453" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="76" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.16266847194304446" LOG_CI_START="-0.08715315995048845" LOG_EFFECT_SIZE="0.03775765599627799" METHOD="MH" MODIFIED="2010-06-20 18:00:24 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6031155482466561" P_Q="0.9152632162782791" P_Z="0.5535480474189582" Q="0.011321436890332066" RANDOM="YES" SCALE="94.46" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="430" TOTAL_2="413" WEIGHT="200.0" Z="0.592451865216348">
<NAME>Admissions (days 1 and 7) (outpatients) - review primary outcome</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours epinephrine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0155665679556642" CI_END="1.8849373141688615" CI_START="0.6619551062157756" DF="1" EFFECT_SIZE="1.1170245655359274" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="29" I2="1.5327964159946452" ID="CMP-004.01.01" LOG_CI_END="0.2752969118026939" LOG_CI_START="-0.1791714634060595" LOG_EFFECT_SIZE="0.04806272419831718" MODIFIED="2010-04-23 04:09:18 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="0.31357322771363727" P_Z="0.678467246961543" STUDIES="2" TAU2="0.017000092071796723" TOTAL_1="230" TOTAL_2="214" WEIGHT="100.0" Z="0.41455561515942013">
<NAME>Admissions day 1</NAME>
<DICH_DATA CI_END="81.01190363542146" CI_START="0.2663500355480702" EFFECT_SIZE="4.645161290322581" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9085488374385386" LOG_CI_START="-0.5745472409165846" LOG_EFFECT_SIZE="0.667000798260977" MODIFIED="2010-04-23 04:00:12 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1649" O_E="0.0" SE="1.4585829279496223" STUDY_ID="STD-Barlas-1998" TOTAL_1="30" TOTAL_2="15" VAR="2.1274641577060933" WEIGHT="3.3232554739694566"/>
<DICH_DATA CI_END="1.696293178728441" CI_START="0.6669183049539646" EFFECT_SIZE="1.0636206896551723" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="29" LOG_CI_END="0.22950091566842906" LOG_CI_START="-0.175927362306345" LOG_EFFECT_SIZE="0.026786776681042006" MODIFIED="2010-04-23 04:00:12 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1648" O_E="0.0" SE="0.2381505773847252" STUDY_ID="STD-Plint-2009" TOTAL_1="200" TOTAL_2="199" VAR="0.056715697508677984" WEIGHT="96.67674452603055"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5234367713631334" CI_START="0.7651848518208385" DF="0" EFFECT_SIZE="1.0796808510638298" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="47" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.18282443399818857" LOG_CI_START="-0.11623363618229984" LOG_EFFECT_SIZE="0.03329539890794437" MODIFIED="2010-04-23 04:08:58 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="1.0" P_Z="0.6625304737084656" STUDIES="1" TAU2="0.0" TOTAL_1="200" TOTAL_2="199" WEIGHT="100.0" Z="0.43642214818734465">
<NAME>Admissions day 7</NAME>
<DICH_DATA CI_END="1.5234367713631334" CI_START="0.7651848518208385" EFFECT_SIZE="1.0796808510638298" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="47" LOG_CI_END="0.18282443399818857" LOG_CI_START="-0.11623363618229984" LOG_EFFECT_SIZE="0.03329539890794437" MODIFIED="2010-04-23 04:08:58 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1700" O_E="0.0" SE="0.17566819078534127" STUDY_ID="STD-Plint-2009" TOTAL_1="200" TOTAL_2="199" VAR="0.030859313253795054" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.3747309552440424" CI_END="0.49666095705582336" CI_START="0.14956578562559164" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.3231133713407075" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2013-01-07 12:35:42 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="0.9454115769931983" P_Q="0.9415045832416545" P_Z="2.631720139864968E-4" Q="0.1205521391470924" RANDOM="YES" SCALE="2.12" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="289" TOTAL_2="243" UNITS="" WEIGHT="300.0" Z="3.649088912078966">
<NAME>Clinical scores (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours epinephrine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.25417881609694987" CI_END="0.49996098172156755" CI_START="0.12260264534989943" DF="1" EFFECT_SIZE="0.3112818135357335" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.01" MODIFIED="2013-01-07 12:35:33 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="0.6141479308758111" P_Z="0.0012226733350290226" STUDIES="2" TAU2="0.0" TOTAL_1="229" TOTAL_2="213" WEIGHT="100.0" Z="3.2335373822055917">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="1.093248955184671" CI_START="-0.16257776900150656" EFFECT_SIZE="0.4653355930915821" ESTIMABLE="YES" MEAN_1="-1.135" MEAN_2="-1.93" MODIFIED="2010-04-23 04:00:12 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1656" SD_1="1.72" SD_2="1.589" SE="0.3203698471226967" STUDY_ID="STD-Barlas-1998" TOTAL_1="30" TOTAL_2="15" WEIGHT="9.029183013178685"/>
<CONT_DATA CI_END="0.49381265149524023" CI_START="0.09817018460271823" EFFECT_SIZE="0.2959914180489792" ESTIMABLE="YES" MEAN_1="-1.75" MEAN_2="-2.45" MODIFIED="2010-04-23 04:00:12 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1655" SD_1="2.4" SD_2="2.32" SE="0.10093105536971578" STUDY_ID="STD-Plint-2009" TOTAL_1="199" TOTAL_2="198" WEIGHT="90.97081698682132"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9789462638255264" CI_START="-0.2700888773775946" DF="0" EFFECT_SIZE="0.3544286932239659" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.02" MODIFIED="2013-01-07 12:35:37 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="1.0" P_Z="0.2659977909143091" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0" Z="1.1123265485347946">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="0.9789462638255264" CI_START="-0.2700888773775946" EFFECT_SIZE="0.3544286932239659" ESTIMABLE="YES" MEAN_1="-2.65" MEAN_2="-3.53" MODIFIED="2010-04-23 04:00:12 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1657" SD_1="2.28" SD_2="2.74" SE="0.3186372686068088" STUDY_ID="STD-Barlas-1998" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0485210804579308" CI_START="-0.20444021052604672" DF="0" EFFECT_SIZE="0.42204043496594207" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.03" MODIFIED="2013-01-07 12:35:42 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="1.0" P_Z="0.18671268521602222" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0" Z="1.3203664925725838">
<NAME>3 to 6 hours</NAME>
<CONT_DATA CI_END="1.0485210804579308" CI_START="-0.20444021052604655" EFFECT_SIZE="0.4220404349659421" ESTIMABLE="YES" MEAN_1="-2.915" MEAN_2="-3.95" MODIFIED="2010-04-23 04:00:12 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1658" SD_1="2.67" SD_2="1.75" SE="0.3196388558328561" STUDY_ID="STD-Barlas-1998" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.6196640915259213" CI_END="-0.3957199877894966" CI_START="-1.1959138126807558" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7958169002351262" ESTIMABLE="YES" I2="17.119381131984902" I2_Q="29.613664344505978" ID="CMP-004.03" MODIFIED="2013-01-07 12:36:01 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.30557067913312463" P_Q="0.24153788309900326" P_Z="9.6795745303315E-5" Q="2.841460606486182" RANDOM="YES" SCALE="25.896327934008532" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.04375280938407247" TOTALS="SUB" TOTAL_1="289" TOTAL_2="243" UNITS="" WEIGHT="300.0" Z="3.898486627189644">
<NAME>O<SUB>2</SUB> saturation (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glucocorticoid</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.7782034850397406" CI_END="-0.5213169637098615" CI_START="-1.4641081683489614" DF="1" EFFECT_SIZE="-0.9927125660294114" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.01" MODIFIED="2013-01-07 12:35:52 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="0.37769118424516035" P_Z="3.667435570985721E-5" STUDIES="2" TAU2="0.0" TOTAL_1="229" TOTAL_2="213" WEIGHT="100.0" Z="4.127490512945108">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="0.600970210347549" CI_START="-1.660970210347549" EFFECT_SIZE="-0.5299999999999999" ESTIMABLE="YES" MEAN_1="0.87" MEAN_2="1.4" MODIFIED="2010-04-23 04:00:12 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1667" SD_1="2.018" SD_2="1.72" SE="0.577036220700226" STUDY_ID="STD-Barlas-1998" TOTAL_1="30" TOTAL_2="15" WEIGHT="17.37275606617658"/>
<CONT_DATA CI_END="-0.5714102923221501" CI_START="-1.60858970767785" EFFECT_SIZE="-1.09" ESTIMABLE="YES" MEAN_1="-1.02" MEAN_2="0.07" MODIFIED="2010-04-23 04:00:12 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1668" SD_1="2.57" SD_2="2.7" SE="0.2645914474798616" STUDY_ID="STD-Plint-2009" TOTAL_1="199" TOTAL_2="198" WEIGHT="82.62724393382342"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9371138239380896" CI_START="-1.06711382393809" DF="0" EFFECT_SIZE="-0.06500000000000017" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.02" MODIFIED="2013-01-07 12:35:57 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="1.0" P_Z="0.8988383537746906" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0" Z="0.12712893081791718">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="0.9371138239380896" CI_START="-1.06711382393809" EFFECT_SIZE="-0.06500000000000017" ESTIMABLE="YES" MEAN_1="1.005" MEAN_2="1.07" MODIFIED="2010-04-23 04:00:12 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1669" SD_1="2.172" SD_2="1.25" SE="0.5112919583434368" STUDY_ID="STD-Barlas-1998" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.568918760228395" CI_START="-1.7389187602283949" DF="0" EFFECT_SIZE="-0.5849999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.03" MODIFIED="2013-01-07 12:36:01 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="1.0" P_Z="0.3203985585648438" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0" Z="0.9936392148863143">
<NAME>3 to 6 hours</NAME>
<CONT_DATA CI_END="0.568918760228395" CI_START="-1.7389187602283949" EFFECT_SIZE="-0.5849999999999999" ESTIMABLE="YES" MEAN_1="0.795" MEAN_2="1.38" MODIFIED="2010-04-23 04:00:12 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1670" SD_1="1.804" SD_2="1.89" SE="0.5887448796663401" STUDY_ID="STD-Barlas-1998" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.19999051384539" CI_START="-1.4399905138453895" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.38000000000000034" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.04" MODIFIED="2013-01-07 12:36:09 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6823742697775516" Q="0.0" RANDOM="YES" SCALE="2.34" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="199" TOTAL_2="198" UNITS="" WEIGHT="100.0" Z="0.4092253824727856">
<NAME>Respiratory rate (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours epinephrine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.19999051384539" CI_START="-1.4399905138453895" DF="0" EFFECT_SIZE="0.38000000000000034" ESTIMABLE="YES" I2="0.0" ID="CMP-004.04.01" MODIFIED="2013-01-07 12:36:09 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.6823742697775516" STUDIES="1" TAU2="0.0" TOTAL_1="199" TOTAL_2="198" WEIGHT="100.0" Z="0.4092253824727856">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="2.19999051384539" CI_START="-1.4399905138453895" EFFECT_SIZE="0.38000000000000034" ESTIMABLE="YES" MEAN_1="-3.3" MEAN_2="-3.68" MODIFIED="2010-04-30 23:28:28 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1110" SD_1="9.6" SD_2="8.89" SE="0.9285836516391335" STUDY_ID="STD-Plint-2009" TOTAL_1="199" TOTAL_2="198" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.923389200025861" CI_END="-2.040081781233589" CI_START="-8.31384583161618" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.176963806424884" ESTIMABLE="YES" I2="56.66862120088823" I2_Q="59.55061336440228" ID="CMP-004.05" MODIFIED="2013-01-07 12:36:24 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.07438019361399795" P_Q="0.084396895361457" P_Z="0.0012179911130434649" Q="4.9444507478387525" RANDOM="YES" SCALE="12.534892259530926" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="14.133486681541347" TOTALS="SUB" TOTAL_1="289" TOTAL_2="243" UNITS="" WEIGHT="300.0" Z="3.234633157503395">
<NAME>Heart rate (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours epinephrine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.1631968314273662" CI_END="-3.785676123884411" CI_START="-11.343529784681206" DF="1" EFFECT_SIZE="-7.564602954282808" ESTIMABLE="YES" I2="14.030027164629251" ID="CMP-004.05.01" MODIFIED="2013-01-07 12:36:20 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="0.28080358088174195" P_Z="8.72976700957157E-5" STUDIES="2" TAU2="1.5694619737576676" TOTAL_1="229" TOTAL_2="213" WEIGHT="100.0" Z="3.923428532268384">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="4.033147361293969" CI_START="-11.69314736129397" EFFECT_SIZE="-3.8300000000000005" ESTIMABLE="YES" MEAN_1="2.57" MEAN_2="6.4" MODIFIED="2010-04-30 23:28:28 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1112" SD_1="10.55" SD_2="13.63" SE="4.0118835975137666" STUDY_ID="STD-Barlas-1998" TOTAL_1="30" TOTAL_2="15" WEIGHT="21.044335004591794"/>
<CONT_DATA CI_END="-5.087617455058784" CI_START="-12.032382544941214" EFFECT_SIZE="-8.559999999999999" ESTIMABLE="YES" MEAN_1="-3.76" MEAN_2="4.8" MODIFIED="2010-04-30 23:28:28 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1111" SD_1="17.7" SD_2="17.6" SE="1.7716563020192844" STUDY_ID="STD-Plint-2009" TOTAL_1="199" TOTAL_2="198" WEIGHT="78.95566499540821"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.46791534320146" CI_START="-7.587915343201461" DF="0" EFFECT_SIZE="0.43999999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-004.05.02" MODIFIED="2013-01-07 12:36:15 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="1.0" P_Z="0.9144532700631729" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0" Z="0.10742317480065912">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="8.46791534320146" CI_START="-7.587915343201461" EFFECT_SIZE="0.43999999999999995" ESTIMABLE="YES" MEAN_1="0.57" MEAN_2="0.13" MODIFIED="2010-04-30 23:28:28 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1113" SD_1="11.85" SD_2="13.47" SE="4.095950439153286" STUDY_ID="STD-Barlas-1998" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.685367316381912" CI_START="-8.085367316381912" DF="0" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-004.05.03" MODIFIED="2013-01-07 12:36:24 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="1.0" P_Z="0.9603523568377734" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0" Z="0.04971141878116986">
<NAME>3 to 6 hours</NAME>
<CONT_DATA CI_END="7.685367316381912" CI_START="-8.085367316381912" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.4" MODIFIED="2010-04-30 23:28:28 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1114" SD_1="12.17" SD_2="12.99" SE="4.023220517611897" STUDY_ID="STD-Barlas-1998" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2013-01-07 12:37:18 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="5">
<NAME>Glucocorticoid versus salbutamol</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.855798132104435" CI_START="0.20593936831690612" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.6862606237147656" LOG_CI_START="-0.6862606237147656" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2010-06-20 18:00:43 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="94.46" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="15" WEIGHT="99.99999999999999" Z="0.0">
<NAME>Admissions (day 1) (outpatients) - review primary outcome</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol/albut</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.855798132104435" CI_START="0.20593936831690612" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.6862606237147656" LOG_CI_START="-0.6862606237147656" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-23 04:25:10 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1718" O_E="0.0" SE="0.806225774829855" STUDY_ID="STD-Barlas-1998" TOTAL_1="30" TOTAL_2="15" VAR="0.65" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.6662525162552233" CI_END="0.9297372805371704" CI_START="0.1993164841436974" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.5645268823404339" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" MODIFIED="2013-01-07 12:36:43 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="0.716679769342412" P_Q="0.716679769342412" P_Z="0.0024485354840015185" Q="0.6662525162552233" RANDOM="YES" SCALE="1.7718338423151676" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="90" TOTAL_2="45" UNITS="" WEIGHT="300.0" Z="3.029629942507531">
<NAME>Clinical scores (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sal/alb</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.282479142120661" CI_START="0.011679958015535785" DF="0" EFFECT_SIZE="0.6470795500680984" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.01" MODIFIED="2013-01-07 12:36:33 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.0459347746244624" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0" Z="1.995992174261486">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="1.282479142120661" CI_START="0.011679958015535785" EFFECT_SIZE="0.6470795500680984" ESTIMABLE="YES" MEAN_1="-1.135" MEAN_2="-2.27" MODIFIED="2010-04-23 04:25:10 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1722" SD_1="1.72" SD_2="1.73" SE="0.3241894223896528" STUDY_ID="STD-Barlas-1998" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9801395623758142" CI_START="-0.26895739669208774" DF="0" EFFECT_SIZE="0.35559108284186325" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.02" MODIFIED="2013-01-07 12:36:38 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="1.0" P_Z="0.26445668841617176" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0" Z="1.115919321609307">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="0.9801395623758142" CI_START="-0.26895739669208774" EFFECT_SIZE="0.35559108284186325" ESTIMABLE="YES" MEAN_1="-2.65" MEAN_2="-3.42" MODIFIED="2010-04-23 04:25:10 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1723" SD_1="2.28" SD_2="1.77" SE="0.3186530387600536" STUDY_ID="STD-Barlas-1998" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.3373066478861393" CI_START="0.06133943127635455" DF="0" EFFECT_SIZE="0.699323039581247" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.03" MODIFIED="2013-01-07 12:36:43 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="1.0" P_Z="0.031681496762278175" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0" Z="2.1484062494647826">
<NAME>3 to 6 hours</NAME>
<CONT_DATA CI_END="1.3373066478861393" CI_START="0.06133943127635466" EFFECT_SIZE="0.699323039581247" ESTIMABLE="YES" MEAN_1="-2.915" MEAN_2="-4.63" MODIFIED="2010-04-23 04:25:10 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1724" SD_1="2.67" SD_2="1.75" SE="0.3255078222545034" STUDY_ID="STD-Barlas-1998" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0102149426988813" CI_END="0.8535936809556841" CI_START="-0.44385709196129985" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.20486829449719215" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.03" MODIFIED="2013-01-07 12:36:59 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.603440786514861" P_Q="0.603440786514861" P_Z="0.5359433092238086" Q="1.0102149426988813" RANDOM="YES" SCALE="3.23" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="90" TOTAL_2="45" UNITS="" WEIGHT="300.0" Z="0.618959096052477">
<NAME>O<SUB>2</SUB> saturation (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours salbutamol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glucocorticoid</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.574701532477926" CI_START="-0.7147015324779262" DF="0" EFFECT_SIZE="0.9299999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.01" MODIFIED="2013-01-07 12:36:49 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.2677470465335232" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0" Z="1.1082658279499804">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="2.574701532477926" CI_START="-0.7147015324779262" EFFECT_SIZE="0.9299999999999999" ESTIMABLE="YES" MEAN_1="0.87" MEAN_2="-0.06" MODIFIED="2010-04-30 23:30:29 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1115" SD_1="2.018" SD_2="2.92" SE="0.8391488544948387" STUDY_ID="STD-Barlas-1998" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.3292435465451866" CI_START="-0.8792435465451869" DF="0" EFFECT_SIZE="0.22499999999999987" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.02" MODIFIED="2013-01-07 12:36:53 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="1.0" P_Z="0.6896271673747316" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0" Z="0.3993610810778382">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="1.3292435465451866" CI_START="-0.8792435465451869" EFFECT_SIZE="0.22499999999999987" ESTIMABLE="YES" MEAN_1="1.005" MEAN_2="0.78" MODIFIED="2010-04-30 23:30:29 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1116" SD_1="2.172" SD_2="1.55" SE="0.5633999171695597" STUDY_ID="STD-Barlas-1998" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8830931016050295" CI_START="-0.9530931016050294" DF="0" EFFECT_SIZE="-0.03499999999999992" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.03" MODIFIED="2013-01-07 12:36:59 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="1.0" P_Z="0.9404385145782178" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0" Z="0.07471871789361667">
<NAME>3 to 6 hours</NAME>
<CONT_DATA CI_END="0.8830931016050295" CI_START="-0.9530931016050294" EFFECT_SIZE="-0.03499999999999992" ESTIMABLE="YES" MEAN_1="0.795" MEAN_2="0.83" MODIFIED="2010-04-30 23:30:29 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1117" SD_1="1.804" SD_2="1.29" SE="0.4684234551485796" STUDY_ID="STD-Barlas-1998" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8196939426844869" CI_END="-1.3355121409999162" CI_START="-9.066500894341182" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.201006517670549" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.04" MODIFIED="2013-01-07 12:37:18 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6637520849579592" P_Q="0.6637520849579592" P_Z="0.008361242296468518" Q="0.8196939426844869" RANDOM="YES" SCALE="19.06" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="90" TOTAL_2="45" UNITS="" WEIGHT="300.0" Z="2.637123344303585">
<NAME>Heart rate (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.89260228355449" CI_START="-9.49260228355449" DF="0" EFFECT_SIZE="-3.3000000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.01" MODIFIED="2013-01-07 12:37:09 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.2962759345632028" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0" Z="1.0444528572678953">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="2.89260228355449" CI_START="-9.49260228355449" EFFECT_SIZE="-3.3000000000000003" ESTIMABLE="YES" MEAN_1="2.57" MEAN_2="5.87" MODIFIED="2010-04-30 23:30:29 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1118" SD_1="10.55" SD_2="9.7" SE="3.159549018451842" STUDY_ID="STD-Barlas-1998" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.7791516514102375" CI_START="-14.28084834858976" DF="0" EFFECT_SIZE="-7.529999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.02" MODIFIED="2013-01-07 12:37:13 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="1.0" P_Z="0.02880288131023523" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0" Z="2.1861739505183277">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="-0.7791516514102375" CI_START="-14.28084834858976" EFFECT_SIZE="-7.529999999999999" ESTIMABLE="YES" MEAN_1="0.57" MEAN_2="8.1" MODIFIED="2010-04-30 23:30:29 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1119" SD_1="11.85" SD_2="10.38" SE="3.4443736731080734" STUDY_ID="STD-Barlas-1998" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.152752660332455" CI_START="-12.392752660332455" DF="0" EFFECT_SIZE="-5.12" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.03" MODIFIED="2013-01-07 12:37:18 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="1.0" P_Z="0.16764520567781688" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0" Z="1.3798098284819649">
<NAME>3 to 6 hours</NAME>
<CONT_DATA CI_END="2.152752660332455" CI_START="-12.392752660332455" EFFECT_SIZE="-5.12" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="6.32" MODIFIED="2010-04-30 23:30:29 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1120" SD_1="12.17" SD_2="11.51" SE="3.710656276186195" STUDY_ID="STD-Barlas-1998" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2013-01-07 12:38:30 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="6">
<NAME>Glucocorticoid and epinephrine versus salbutamol</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-06-20 18:01:06 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="125.58" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="23" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Admissions (day 1) (outpatients) - review primary outcome</NAME>
<GROUP_LABEL_1>Glucocorticoid and Epi</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid and salb</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours epinephrine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-21 08:46:05 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="269" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="23" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.120424926456719" CI_END="-0.008849719647397059" CI_START="-0.8376131054770202" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.4232314125622086" ESTIMABLE="YES" I2="67.3225303139556" I2_Q="67.32253031395558" ID="CMP-006.02" MODIFIED="2013-01-07 12:37:52 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="0.04687789560182154" P_Q="0.04687789560182143" P_Z="0.04530389544926996" Q="6.120424926456716" RANDOM="YES" SCALE="2.27" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.27712472128363974" TOTALS="SUB" TOTAL_1="69" TOTAL_2="36" UNITS="" WEIGHT="300.0" Z="2.0018218466964806">
<NAME>Clinical scores (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid and Epi</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid and epi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5247557064246219" CI_START="-0.8738515644586348" DF="0" EFFECT_SIZE="-0.17454792901700644" ESTIMABLE="YES" I2="0.0" ID="CMP-006.02.01" MODIFIED="2013-01-07 12:37:36 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.6246916930707185" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0" Z="0.489211891817689">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="0.5247557064246219" CI_START="-0.8738515644586348" EFFECT_SIZE="-0.17454792901700644" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="-3.3" MODIFIED="2010-04-23 04:27:40 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1740" SD_1="0.959" SD_2="1.386" SE="0.3567941252786511" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6979552400526904" CI_START="-0.6979552400526904" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-006.02.02" MODIFIED="2013-01-07 12:37:42 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0" Z="0.0">
<NAME>12 to 24 hours</NAME>
<CONT_DATA CI_END="0.6979552400526904" CI_START="-0.6979552400526904" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-3.9" MEAN_2="-3.9" MODIFIED="2010-04-23 04:27:40 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1741" SD_1="0.959" SD_2="1.039" SE="0.35610615580595983" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.269064401738789E-31" CI_END="-0.46005136023837623" CI_START="-1.9823735364432442" DF="0" EFFECT_SIZE="-1.2212124483408102" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-006.02.03" MODIFIED="2013-01-07 12:37:52 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="0.0" P_Z="0.0016632506848098573" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0" Z="3.144580632973526">
<NAME>3 to 10 days</NAME>
<CONT_DATA CI_END="-0.46005136023837645" CI_START="-1.9823735364432444" EFFECT_SIZE="-1.2212124483408104" ESTIMABLE="YES" MEAN_1="-5.0" MEAN_2="-4.3" MODIFIED="2010-04-23 04:27:40 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1742" SD_1="0.48" SD_2="0.693" SE="0.3883546300372739" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.341216675553826" CI_END="-2.554957529708587" CI_START="-10.394530245887587" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.474743887798087" ESTIMABLE="YES" I2="68.46031128836448" I2_Q="68.46031128836445" ID="CMP-006.03" MODIFIED="2013-01-07 12:38:12 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="0.04197810056259621" P_Q="0.04197810056259621" P_Z="0.0012058663010129785" Q="6.341216675553823" RANDOM="YES" SCALE="21.94" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="26.155246043394847" TOTALS="SUB" TOTAL_1="69" TOTAL_2="36" UNITS="" WEIGHT="300.0" Z="3.2374889011528487">
<NAME>Respiratory rate (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid and Epi</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid and epi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.3132804050091673" CI_START="-9.51328040500917" DF="0" EFFECT_SIZE="-3.1000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-006.03.01" MODIFIED="2013-01-07 12:37:58 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.3434392522157419" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="99.99999999999999" Z="0.947391657369063">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="3.3132804050091673" CI_START="-9.51328040500917" EFFECT_SIZE="-3.1000000000000014" ESTIMABLE="YES" MEAN_1="-24.0" MEAN_2="-20.9" MODIFIED="2010-04-30 23:35:58 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1124" SD_1="8.21" SD_2="9.66" SE="3.272141965666872" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="23" TOTAL_2="12" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.361464964340744" CI_START="-9.961464964340745" DF="0" EFFECT_SIZE="-2.8000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-006.03.02" MODIFIED="2013-01-07 12:38:06 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="1.0" P_Z="0.44349213014104794" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0" Z="0.7663095726975112">
<NAME>12 to 24 hours</NAME>
<CONT_DATA CI_END="4.361464964340744" CI_START="-9.961464964340745" EFFECT_SIZE="-2.8000000000000007" ESTIMABLE="YES" MEAN_1="-27.3" MEAN_2="-24.5" MODIFIED="2010-04-30 23:35:58 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1125" SD_1="10.58" SD_2="10.09" SE="3.6538757961010844" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.578585311241976E-31" CI_END="-6.843735691109256" CI_START="-20.556264308890746" DF="0" EFFECT_SIZE="-13.700000000000001" ESTIMABLE="YES" I2="100.0" ID="CMP-006.03.03" MODIFIED="2013-01-07 12:38:12 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="0.0" P_Z="8.990101919700825E-5" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0" Z="3.9163464794348006">
<NAME>3 to 10 days</NAME>
<CONT_DATA CI_END="-6.8437356911092575" CI_START="-20.556264308890746" EFFECT_SIZE="-13.700000000000003" ESTIMABLE="YES" MEAN_1="-39.1" MEAN_2="-25.4" MODIFIED="2010-04-30 23:35:58 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1126" SD_1="8.13" SD_2="10.6" SE="3.49815831462827" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7475158014314701" CI_END="1.0839158879905244" CI_START="-8.438508828089809" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.6772964700496424" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.04" MODIFIED="2013-01-07 12:38:30 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="4" P_CHI2="0.6881436366076075" P_Q="0.6881436366076075" P_Z="0.13008481216393986" Q="0.7475158014314701" RANDOM="YES" SCALE="16.54" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="69" TOTAL_2="36" UNITS="" WEIGHT="300.0" Z="1.5137675238540094">
<NAME>Heart rate (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid and Epi</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid and epi</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="9.351789655037778E-33" CI_END="5.800589342687889" CI_START="-12.200589342687888" DF="0" EFFECT_SIZE="-3.1999999999999997" ESTIMABLE="YES" I2="100.0" ID="CMP-006.04.01" MODIFIED="2013-01-07 12:38:20 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="0.0" P_Z="0.4859089103828643" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.00000000000001" Z="0.6968304531773216">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="5.800589342687889" CI_START="-12.200589342687888" EFFECT_SIZE="-3.1999999999999993" ESTIMABLE="YES" MEAN_1="-14.0" MEAN_2="-10.8" MODIFIED="2010-04-30 23:35:58 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1127" SD_1="14.6" SD_2="11.91" SE="4.592221802891986" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.555147700842876" CI_START="-9.355147700842881" DF="0" EFFECT_SIZE="-1.4000000000000021" ESTIMABLE="YES" I2="0.0" ID="CMP-006.04.02" MODIFIED="2013-01-07 12:38:26 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="1.0" P_Z="0.73014884156331" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0" Z="0.34492754648230456">
<NAME>12 to 24 hours</NAME>
<CONT_DATA CI_END="6.555147700842876" CI_START="-9.355147700842881" EFFECT_SIZE="-1.4000000000000021" ESTIMABLE="YES" MEAN_1="-17.6" MEAN_2="-16.2" MODIFIED="2010-04-30 23:35:58 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1128" SD_1="11.93" SD_2="11.11" SE="4.058823408793257" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.6138406062602977" CI_START="-14.213840606260298" DF="0" EFFECT_SIZE="-6.300000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-006.04.03" MODIFIED="2013-01-07 12:38:30 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="1.0" P_Z="0.11869474591892425" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0" Z="1.560275688751496">
<NAME>3 to 10 days</NAME>
<CONT_DATA CI_END="1.6138406062602977" CI_START="-14.213840606260298" EFFECT_SIZE="-6.300000000000001" ESTIMABLE="YES" MEAN_1="-26.8" MEAN_2="-20.5" MODIFIED="2010-04-30 23:35:58 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1129" SD_1="11.22" SD_2="11.4" SE="4.037747973270766" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2013-03-19 22:21:08 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="7">
<NAME>Glucocorticoid and salbutamol versus epinephrine</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="96.12715085961011" CI_START="0.26007220412172094" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.999999999999998" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="1.982846070323241" LOG_CI_START="-0.5849060616512036" LOG_EFFECT_SIZE="0.6989700043360186" METHOD="MH" MODIFIED="2010-06-20 18:01:23 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.28595065344202364" Q="0.0" RANDOM="YES" SCALE="125.58" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="26" WEIGHT="100.0" Z="1.0670469456247629">
<NAME>Admissions (day 1) (outpatients) - review primary outcome</NAME>
<GROUP_LABEL_1>Glucocorticoid and Salb</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid and salb</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours epinephrine</GRAPH_LABEL_2>
<DICH_DATA CI_END="96.12715085961011" CI_START="0.260072204121721" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.982846070323241" LOG_CI_START="-0.5849060616512035" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2010-04-29 08:00:30 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1263" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-29 08:00:30 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1262" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="23" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.227984259510418" CI_END="0.5247417669800488" CI_START="-0.12140220028047075" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.20166978334978905" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.02" MODIFIED="2013-03-19 22:21:08 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="0.6939093667721293" P_Q="0.741874495226391" P_Z="0.2211561862848016" Q="1.2465009501929147" RANDOM="YES" SCALE="2.12" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="99" TOTAL_2="63" UNITS="" WEIGHT="400.0" Z="1.2234595760799372">
<NAME>Clinical scores (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid and Salb</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid and salb</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours epinephrine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0838135906707642" CI_START="-0.3609329609889371" DF="0" EFFECT_SIZE="0.36144031484091355" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.01" MODIFIED="2013-01-07 12:38:42 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.3267553791618443" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.9806702758143963">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="1.0838135906707642" CI_START="-0.3609329609889371" EFFECT_SIZE="0.36144031484091355" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="-1.93" MODIFIED="2010-04-30 07:34:52 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1226" SD_1="2.28" SD_2="1.589" SE="0.36856456625113465" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.9814833093175027" CI_END="0.766722151468805" CI_START="-0.2569680287817781" DF="1" EFFECT_SIZE="0.25487706134351346" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.02" MODIFIED="2013-01-07 12:38:45 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="0.32183309736293453" P_Z="0.3290750757912889" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="26" WEIGHT="99.99999999999999" Z="0.9759786121937999">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="1.2468375873548503" CI_START="-0.21183708900586395" EFFECT_SIZE="0.5175002491744931" ESTIMABLE="YES" MEAN_1="-2.07" MEAN_2="-3.53" MODIFIED="2010-04-30 07:34:52 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1227" SD_1="2.75" SD_2="2.74" SE="0.37211772457722536" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="49.251582342247886"/>
<CONT_DATA CI_END="0.7185008544739825" CI_START="-0.7185008544739825" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-3.2" MEAN_2="-3.2" MODIFIED="2010-04-30 07:34:52 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1228" SD_1="1.439" SD_2="0.995" SE="0.3665888047644883" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="23" TOTAL_2="11" WEIGHT="50.7484176577521"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0190769983573995" CI_START="-0.425730708250103" DF="0" EFFECT_SIZE="0.2966731450536482" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.03" MODIFIED="2013-03-19 22:21:08 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="1.0" P_Z="0.42087274794743657" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="11" WEIGHT="100.0" Z="0.8049080536131721">
<NAME>12 to 24 hours</NAME>
<CONT_DATA CI_END="1.0190769983573995" CI_START="-0.425730708250103" EFFECT_SIZE="0.2966731450536482" ESTIMABLE="YES" MEAN_1="-3.3" MEAN_2="-3.7" MODIFIED="2010-04-30 07:34:52 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1229" SD_1="1.439" SD_2="0.995" SE="0.3685801672897975" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="23" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5632900390724649" CI_START="-0.8758824654368476" DF="0" EFFECT_SIZE="-0.15629621318219133" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.04" MODIFIED="2013-01-07 12:38:56 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="4" P_CHI2="1.0" P_Z="0.6703192917295412" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="11" WEIGHT="100.0" Z="0.42570984061641">
<NAME>3 to 10 days</NAME>
<CONT_DATA CI_END="0.5632900390724649" CI_START="-0.8758824654368476" EFFECT_SIZE="-0.15629621318219133" ESTIMABLE="YES" MEAN_1="-4.7" MEAN_2="-4.5" MODIFIED="2010-04-30 07:34:52 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1230" SD_1="1.439" SD_2="0.663" SE="0.3671425893183042" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="23" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.09252130062865413" CI_END="-0.5248165499238507" CI_START="-2.2480584215201924" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.3864374857220216" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.03" MODIFIED="2013-01-07 12:39:08 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7609960032996761" P_Q="0.7609960032996761" P_Z="0.0016116754575534536" Q="0.09252130062865413" RANDOM="YES" SCALE="4.42" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="200.0" Z="3.1537854129718523">
<NAME>O<SUB>2</SUB> saturation (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid and Salb</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glucocorticoid and salb</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.22794598198839622" CI_START="-2.8520540180116036" DF="0" EFFECT_SIZE="-1.54" ESTIMABLE="YES" I2="0.0" ID="CMP-007.03.01" MODIFIED="2013-01-07 12:39:08 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.021421450470026117" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="2.3004727661791966">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="-0.22794598198839622" CI_START="-2.8520540180116036" EFFECT_SIZE="-1.54" ESTIMABLE="YES" MEAN_1="-0.14" MEAN_2="1.4" MODIFIED="2010-04-29 08:00:30 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1272" SD_1="1.94" SD_2="1.72" SE="0.6694276162015825" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.1275018172677942" CI_START="-2.4124981827322056" DF="0" EFFECT_SIZE="-1.27" ESTIMABLE="YES" I2="0.0" ID="CMP-007.03.02" MODIFIED="2013-01-07 12:39:03 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="1.0" P_Z="0.029354386665116097" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.00000000000001" Z="2.178694284146017">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="-0.1275018172677942" CI_START="-2.4124981827322056" EFFECT_SIZE="-1.27" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="1.07" MODIFIED="2010-04-29 08:00:30 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1273" SD_1="1.88" SD_2="1.25" SE="0.5829179473419337" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6878476544052963" CI_END="4.371598455178271" CI_START="-3.36733469716997" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5021318790041507" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.04" MODIFIED="2013-01-07 12:39:24 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="4" P_CHI2="0.7089830148487686" P_Q="0.7089830148487686" P_Z="0.7992328465066287" Q="0.6878476544052963" RANDOM="YES" SCALE="14.34" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="69" TOTAL_2="33" UNITS="" WEIGHT="300.0" Z="0.2543400696099652">
<NAME>Respiratory rate (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid and Salb</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid and salb</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours epinephrine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.1850737145669985" CI_START="-7.385073714567001" DF="0" EFFECT_SIZE="-0.6000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-007.04.01" MODIFIED="2013-01-07 12:39:14 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.8624011301718679" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="11" WEIGHT="100.0" Z="0.1733184398865565">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="6.185073714566998" CI_START="-7.3850737145670005" EFFECT_SIZE="-0.6000000000000014" ESTIMABLE="YES" MEAN_1="-19.0" MEAN_2="-18.4" MODIFIED="2010-04-30 23:43:12 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1133" SD_1="10.01" SD_2="9.16" SE="3.461835915397831" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="23" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.665331369624761" CI_START="-4.265331369624763" DF="0" EFFECT_SIZE="3.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-007.04.02" MODIFIED="2013-01-07 12:39:19 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="1.0" P_Z="0.4008328128781693" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="11" WEIGHT="100.0" Z="0.8401348098287327">
<NAME>12 to 24 hours</NAME>
<CONT_DATA CI_END="10.665331369624761" CI_START="-4.265331369624763" EFFECT_SIZE="3.1999999999999993" ESTIMABLE="YES" MEAN_1="-20.6" MEAN_2="-23.8" MODIFIED="2010-04-30 23:43:12 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1134" SD_1="11.58" SD_2="9.77" SE="3.808912525184311" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="23" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.671983412749584" CI_START="-6.471983412749581" DF="0" EFFECT_SIZE="-0.3999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-007.04.03" MODIFIED="2013-01-07 12:39:24 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="1.0" P_Z="0.8972664634309839" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="11" WEIGHT="100.0" Z="0.1291152397040238">
<NAME>3 to 10 days</NAME>
<CONT_DATA CI_END="5.671983412749584" CI_START="-6.471983412749581" EFFECT_SIZE="-0.3999999999999986" ESTIMABLE="YES" MEAN_1="-31.9" MEAN_2="-31.5" MODIFIED="2010-04-30 23:43:12 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1135" SD_1="9.01" SD_2="8.17" SE="3.098007647408122" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="23" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.1604263119345615" CI_END="4.720424431165717" CI_START="-2.8694553500572635" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="0.9254845405542267" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.05" MODIFIED="2013-01-07 12:39:47 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.7062805380270469" P_Q="0.6018346795094689" P_Z="0.6326623788106169" Q="1.860613128393418" RANDOM="YES" SCALE="23.94" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="99" TOTAL_2="63" UNITS="" WEIGHT="400.0" Z="0.47798289828580176">
<NAME>Heart rate (outpatients)</NAME>
<GROUP_LABEL_1>Glucocorticoid and Salb</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glucocorticoid and salb</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours epinephrine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.707800354334603" CI_START="-12.367800354334603" DF="0" EFFECT_SIZE="-3.3300000000000005" ESTIMABLE="YES" I2="0.0" ID="CMP-007.05.01" MODIFIED="2013-01-07 12:39:30 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.47020005207359705" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.7221536007252176">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="5.707800354334603" CI_START="-12.367800354334603" EFFECT_SIZE="-3.3300000000000005" ESTIMABLE="YES" MEAN_1="3.07" MEAN_2="6.4" MODIFIED="2010-04-30 23:43:12 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1136" SD_1="11.54" SD_2="13.63" SE="4.61120736177992" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.2998131835411433" CI_END="6.6211384952915475" CI_START="-5.383114251413587" DF="1" EFFECT_SIZE="0.6190121219389804" ESTIMABLE="YES" I2="0.0" ID="CMP-007.05.02" MODIFIED="2013-01-07 12:39:34 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="0.5839996513047674" P_Z="0.8398109716761187" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="26" WEIGHT="100.0" Z="0.20213527498862804">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="11.410040079042835" CI_START="-6.470040079042834" EFFECT_SIZE="2.47" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="0.13" MODIFIED="2010-04-30 23:43:12 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1138" SD_1="11.43" SD_2="13.47" SE="4.561328753773401" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="45.07454367771454"/>
<CONT_DATA CI_END="7.198755693815657" CI_START="-8.998755693815657" EFFECT_SIZE="-0.8999999999999995" ESTIMABLE="YES" MEAN_1="-6.8" MEAN_2="-5.9" MODIFIED="2010-04-30 23:43:12 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1137" SD_1="13.97" SD_2="9.72" SE="4.13209413932991" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="23" TOTAL_2="11" WEIGHT="54.925456322285456"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="13.879923398050138" CI_START="-3.279923398050137" DF="0" EFFECT_SIZE="5.300000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-007.05.03" MODIFIED="2013-01-07 12:39:39 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="1.0" P_Z="0.22600614125983975" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="11" WEIGHT="100.0" Z="1.2107111725989312">
<NAME>12 to 24 hrs</NAME>
<CONT_DATA CI_END="13.879923398050138" CI_START="-3.279923398050137" EFFECT_SIZE="5.300000000000001" ESTIMABLE="YES" MEAN_1="-7.6" MEAN_2="-12.9" MODIFIED="2010-04-30 23:43:12 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1139" SD_1="14.3" SD_2="10.63" SE="4.377592377067884" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="23" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.942517640525807" CI_START="-6.942517640525806" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-007.05.04" MODIFIED="2013-01-07 12:39:47 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="4" P_CHI2="1.0" P_Z="0.8050873103528562" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="11" WEIGHT="100.0" Z="0.2467686032624665">
<NAME>3 to 10 days</NAME>
<CONT_DATA CI_END="8.942517640525807" CI_START="-6.942517640525806" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="-18.1" MEAN_2="-19.1" MODIFIED="2010-04-30 23:43:12 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1140" SD_1="13.3" SD_2="9.8" SE="4.052379382057717" STUDY_ID="STD-Kuyucu-2004" TOTAL_1="23" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2013-01-07 12:40:16 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="8">
<NAME>Glucocorticoid versus glucocorticoid (prednisolone versus budesonide)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="25.6782739076548" CI_START="0.3504908481140964" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="1.4095658271236327" LOG_CI_START="-0.45532331768430767" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" MODIFIED="2010-05-15 02:05:18 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.3159133624715845" Q="0.0" RANDOM="YES" SCALE="59.33" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.0028912207598348">
<NAME>Admissions (day 1) (outpatients) - review primary outcome</NAME>
<GROUP_LABEL_1>Prednisolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Budesonide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prednisone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours budesonide</GRAPH_LABEL_2>
<DICH_DATA CI_END="25.6782739076548" CI_START="0.3504908481140964" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4095658271236327" LOG_CI_START="-0.45532331768430767" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-05-13 19:30:06 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="255" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.6627310560798341" CI_END="0.8454698966095389" CI_START="0.006574940680072083" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.42602241864480545" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.02" MODIFIED="2013-01-07 12:40:01 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="0.7179427580639276" P_Q="0.7179427580639277" P_Z="0.04651532045285534" Q="0.662731056079834" RANDOM="YES" SCALE="1.77" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="45" TOTAL_2="45" UNITS="" WEIGHT="300.0" Z="1.9906868941066056">
<NAME>Clinical scores (outpatients)</NAME>
<GROUP_LABEL_1>Prednisolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Budesonide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prednisolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours budesonide</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.1222119223644893" CI_START="-0.32539773881246103" DF="0" EFFECT_SIZE="0.3984070917760141" ESTIMABLE="YES" I2="0.0" ID="CMP-008.02.01" MODIFIED="2010-05-15 01:56:53 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.2806628046204256" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.0788316381246945">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="1.1222119223644893" CI_START="-0.32539773881246103" EFFECT_SIZE="0.3984070917760141" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-1.47" MODIFIED="2010-05-15 01:56:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1194" SD_1="1.85" SD_2="1.39" SE="0.36929496475330936" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.3957050825947612" CI_START="-0.07957400679154214" DF="0" EFFECT_SIZE="0.6580655379016095" ESTIMABLE="YES" I2="0.0" ID="CMP-008.02.02" MODIFIED="2010-05-15 20:41:41 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="1.0" P_Z="0.08037232348373344" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.7485298382296819">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="1.3957050825947612" CI_START="-0.07957400679154214" EFFECT_SIZE="0.6580655379016095" ESTIMABLE="YES" MEAN_1="-1.93" MEAN_2="-3.27" MODIFIED="2010-05-15 01:56:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1195" SD_1="1.91" SD_2="2.05" SE="0.3763536220622206" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9515628239467899" CI_START="-0.4853770134269093" DF="0" EFFECT_SIZE="0.23309290525994034" ESTIMABLE="YES" I2="0.0" ID="CMP-008.02.03" MODIFIED="2013-01-07 12:40:01 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="1.0" P_Z="0.5248609507889758" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6358703231393228">
<NAME>3 to 6 hours</NAME>
<CONT_DATA CI_END="0.9515628239467899" CI_START="-0.4853770134269093" EFFECT_SIZE="0.23309290525994034" ESTIMABLE="YES" MEAN_1="-2.63" MEAN_2="-3.2" MODIFIED="2010-05-15 01:56:53 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1196" SD_1="2.16" SD_2="2.58" SE="0.36657302090959254" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.37837399375051084" CI_END="-0.7033548393207371" CI_START="-2.1630498115587593" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.4332023254397481" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.03" MODIFIED="2013-01-07 12:40:08 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="0.8276317818405654" P_Q="0.8276317818405654" P_Z="1.187058760193942E-4" Q="0.37837399375051084" RANDOM="YES" SCALE="3.23" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="45" TOTAL_2="45" UNITS="" WEIGHT="300.0" Z="3.8487834703083603">
<NAME>O<SUB>2</SUB> saturation (outpatients)</NAME>
<GROUP_LABEL_1>Prednisolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Budesonide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours budesonide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prednisolone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.18483793212435895" CI_START="-2.735162067875641" DF="0" EFFECT_SIZE="-1.46" ESTIMABLE="YES" I2="0.0" ID="CMP-008.03.01" MODIFIED="2010-05-15 01:57:04 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.024828176526394664" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="2.2440656678218796">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="-0.18483793212435895" CI_START="-2.735162067875641" EFFECT_SIZE="-1.46" ESTIMABLE="YES" MEAN_1="0.14" MEAN_2="1.6" MODIFIED="2010-05-15 01:57:04 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1197" SD_1="1.62" SD_2="1.93" SE="0.650604846790021" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.3982817531898417" CI_START="-3.061718246810158" DF="0" EFFECT_SIZE="-1.73" ESTIMABLE="YES" I2="0.0" ID="CMP-008.03.02" MODIFIED="2010-05-15 20:42:11 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="1.0" P_Z="0.01089222923544268" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="2.546137444144863">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="-0.3982817531898417" CI_START="-3.061718246810158" EFFECT_SIZE="-1.73" ESTIMABLE="YES" MEAN_1="0.14" MEAN_2="1.87" MODIFIED="2010-05-15 01:57:04 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1198" SD_1="1.65" SD_2="2.05" SE="0.6794605703546502" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.026552260537822114" CI_START="-2.366552260537822" DF="0" EFFECT_SIZE="-1.17" ESTIMABLE="YES" I2="0.0" ID="CMP-008.03.03" MODIFIED="2013-01-07 12:40:08 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="1.0" P_Z="0.05530515463533468" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.9164711292101382">
<NAME>3 to 6 hours</NAME>
<CONT_DATA CI_END="0.026552260537822114" CI_START="-2.366552260537822" EFFECT_SIZE="-1.17" ESTIMABLE="YES" MEAN_1="0.21" MEAN_2="1.38" MODIFIED="2010-05-15 01:57:04 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1199" SD_1="1.59" SD_2="1.75" SE="0.6104970652400113" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8060800462415225" CI_END="-3.448389082138969" CI_START="-12.449217990016255" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.948803536077612" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.04" MODIFIED="2013-01-07 12:40:16 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="4" P_CHI2="0.6682855930721721" P_Q="0.6682855930721721" P_Z="5.366493200596174E-4" Q="0.8060800462415225" RANDOM="YES" SCALE="19.06" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="45" TOTAL_2="45" UNITS="" WEIGHT="300.0" Z="3.4617630910108956">
<NAME>Heart rate (outpatients)</NAME>
<GROUP_LABEL_1>Prednisolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Budesonide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prednisolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours budesonide</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.432415417962991" CI_START="-13.292415417962992" DF="0" EFFECT_SIZE="-5.930000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-008.04.01" MODIFIED="2010-05-15 01:55:47 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="1" P_CHI2="1.0" P_Z="0.11441918569122389" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.5786376845790944">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="1.432415417962992" CI_START="-13.292415417962992" EFFECT_SIZE="-5.930000000000001" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="5.53" MODIFIED="2010-05-15 01:55:47 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1191" SD_1="11.07" SD_2="9.44" SE="3.756403421714269" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7925777397260907" CI_START="-15.57257773972609" DF="0" EFFECT_SIZE="-7.39" ESTIMABLE="YES" I2="0.0" ID="CMP-008.04.02" MODIFIED="2010-05-15 20:42:37 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="2" P_CHI2="1.0" P_Z="0.07670736952097244" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.770118696878504">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="0.7925777397260907" CI_START="-15.57257773972609" EFFECT_SIZE="-7.39" ESTIMABLE="YES" MEAN_1="-3.13" MEAN_2="4.26" MODIFIED="2010-05-15 01:55:47 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1192" SD_1="10.68" SD_2="12.14" SE="4.174861275140369" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.8917586464103877" CI_START="-18.708241353589614" DF="0" EFFECT_SIZE="-10.8" ESTIMABLE="YES" I2="0.0" ID="CMP-008.04.03" MODIFIED="2013-01-07 12:40:16 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="3" P_CHI2="1.0" P_Z="0.007436179910800508" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="2.6766521261297167">
<NAME>3 to 6 hours</NAME>
<CONT_DATA CI_END="-2.8917586464103877" CI_START="-18.708241353589614" EFFECT_SIZE="-10.8" ESTIMABLE="YES" MEAN_1="-4.2" MEAN_2="6.6" MODIFIED="2010-05-15 01:55:47 +1000" MODIFIED_BY="Ricardo M Fernandes" ORDER="1193" SD_1="11.04" SD_2="11.06" SE="4.034891159209461" STUDY_ID="STD-Barlas-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-05-06 11:52:04 +1000" MODIFIED_BY="Ricardo M Fernandes">
<FIGURE FILENAME="Figure 1 Flowchart 2012 Update 300dpi 25%.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-03-19 22:25:31 +1000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow of citations through the search and screening procedures of the 2009 review and this 2012 update, studies included in the review and comparisons addressed (GC: glucocorticoids)</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA0UAAAMhCAYAAAAn4hr5AACAAElEQVR42uydCbhVY/v/X8mQMYpK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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-05-06 11:52:04 +1000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.*</P>
<P>*For multi-arm studies (Barlas 1998, Kuyucu 2004 and Plint 2009), we included one overall assessment for all trial comparisons, and two assessments for each separate comparison of glucocorticoids versus placebo (with or without protocolised bronchodilator, or with epinephrine or salbutamol).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA6UAAAHICAMAAACBCrzZAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-05-06 11:52:04 +1000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.*</P>
<P>*For multi-arm studies (Barlas 1998, Kuyucu 2004 and Plint 2009), we included one overall assessment for all trial comparisons, and two assessments for each separate comparison of glucocorticoids versus placebo (with or without protocolised bronchodilator, or with epinephrine or salbutamol).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAm4AAAVOCAIAAABEwSL8AAB4CklEQVR42uzdwW4TydrGcUtIiEUW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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-01-22 15:14:05 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Steroid versus placebo, outcome: 1.1 Admissions (days 1 and 7) (outpatients) - review primary outcome.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2013-01-22 15:14:33 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="5" REF_ID="CMP-001.02" SETTINGS="SHOW_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Steroid versus placebo, outcome: 1.2 Length of stay (inpatients) - review primary outcome.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAALpUlEQVR42u3dT2wjZxnHcadx4nXiOJ1ushJdqRdOK4Q4oFalpRJS
rxzhxJUDB87cuPVAJSo4VipQCQ7cUQ+IgtqKItDeUCWW0FYg1C0rkma6627+1Os1iSebOIndTDzz
LG7m85XWk4yzUfTkm/d93t+8Y88kNaB8HlECEAvEQrWp5/3CdO9fkh0GH9TSJB30Z3uP6cG5VMOG
c4qVJgcPydCJ9IFpB08mzELpU2GSqiYmEys5MYLtuXR8jCIXzjkVJumDGe+EYUCh5v1kjwWUMRWa
4/AQm/fhZaAVIc6cCtNTU97JHut4spAOzZXAHjOjVEhzhJ1pkvckTIXnmgV5hYgeK8l16mKx2aqn
9WXWFBUrfYA6Dbh+Zbnzbmfn0qZSFO+xTG9H49WV1sKHtVq32fpYMYhVHq3e9tWbe8f2pzuKEddj
VY+dzdqN/eNHX1WLycRK9toqA9Up1t+pXds/dl5Ti8mmQhHCSOqd5uDYvdRTDFNheSw+2s0Eu6QW
xCqR27PN9upmt9/4t1qYCkslWbi1sdJYXFeJs/sGJTgHabOX9La2FMJUWPYArwTEKoHBtcH20Ikb
akKs4ly/0uu829m9dP3wzDVF0bwXH6+uDC4KujZIrHJp3c/adNcGTYWlsvNRdnRtkFilsv5Odhy6
Nnh1b2bsz9rsdzazzbP+bJuVrc3ST+cGxxfa/cNTndVe4w+/fLv3t/++SB491mQs73wyMKu/eBiJ
Xv1Xc/H2/nrxa23bak2FE3J4bfD9w1M36nP7XtWean1bfYxYE5NsdzdWGu9/4ajHupVsDD5Yqd8i
jx5r4nXhvX6z333p6ERn89PZwQcffL9JHiNWedTfeG5wtNlPj1Uqi89n935dnlcLYpXH1dtzq+2V
vYZ+661s4Go9cfwqNYg1Cf3a3U92P55pLmw/NfDqG721fnu36Q5WPVbBEevm8Gebq4M0y1VqI1ZR
ju/H+tX8ICWdW3CRmljFOL4f66XfZcePuipDrEIcmwlrf/1Sduz0VUaPVSL1dta1dxv3FcOIVR4L
d7M58GfuYD2FSzrnWxV2hj/bbczc/9OPX3jk9c6s0pgKi/D4h8c///03u/1ac8EdrMQqOGLdVAM9
VgDuKyRWCO4rJFYIZkJigVggVtVXhUpArAhcFCRWCF4fi1gT0e0/m85+xv3zcixiTcJqs7nW+mR7
YexWYzlWXlyEHh6veot3t2bn1n/08rgtoR3G5G0aXCscas2bmVDt3V1mmArL4+uvZ8c1N6MSq0xe
ezo7Ng62wVxv1dMnjt01KMci1gSs/CU7Lq1mLdcz9zv9tU+H7xqUY+mxJmB5++3Bfajt7vb+ePXM
wWvbLh29FJb9WMSahMWdxbXG0uWt7f0XXBv12rZ33E5PrEl47G5yY2X+rcG49eBd5FY3e0YsPVYx
NndvJb3sdRlq69sHa8SNo+d5RazCXDmIht9bUQtilUjz0ex13p9016Aeq1QW2lvz/3jvyfmtOT3W
uXGtcDzdud0vf+fXC//8ydGpJRcLjVgRGLH0WCHYj0WsEOzHIlYIZkJigVggVtVXhUpArAjsxyoo
ljfjG437CouJxasx5Muxuq3Z9NllYp32Sto+hlw51soXe2+2vrtT7TdCGXNJ50gtkp2Xbvbuvgfv
h0KsEWIdFoZc52nwF7Idgss7Vb478TNXhcke2QPyU1/Mjn+/p8dCTvLkWBv/yY6NDWIh7zSXp3c/
uDtxd7XKlRqz0e9oe593phimnWOjX/vn6y/uH1+Z6RLrJM0asUZxs3H21+xeeuP20gc/eHn7j69Y
FY5H3HCsx8q1b+bV793buHbn9lyNWMSC5h3EArGQp8dSAmJFYD8WsWLWOkpArAjcV0isENxXSKwQ
3FdILBALxKo4cixihSDHIlYIcixihSDHIlYIcixihSDHIhaIBWJVHDkWsUKQYxErBDkWsUKQYxEr
BDkWsUKQYxELxAKxKo4ci1ghyLGIFYIci1ghyLGIFYIci1ghyLGIBWKBWBVHjkWsEORYxApBjkWs
EORYxApBjkWsEORYxAKxQKyKI8ciVghyLGKFIMciVghyLGKFIMciVghyLGKBWCBWxZFjESsEORax
QpBjESsEORaxQpBjESsEORaxQCwQq+LIsfJSH3k2rdUStRmBHKuQWGmS/cNJ5FiFpkJOjUOOVWwq
PJoRswemHXBN3pB3bB/jzOFMaEqEVSGmXSzjFCLE4tUY5FiFxEpraZpWuCjd/rPp7PKoZ+RYhcRK
9qluTVabzbXWm9sLmyPWOozJyWzzjC/YaVatJN3eb3+xNfvq+hs/3Dn13M0GZfIxc9bIVL12q3Uv
E6q9u3u6x5JjiRsm5SuvZ8e13unneEWsifnz09mxsa4WpsIy2843n8t6rUs9fhixSuyxnr8+OF6e
P/2cHMuINTmLO4trjaXLW9tzp556/EPKEGtiHvvWb26szL/1VM2qkFgPhzttNdBjBeC+QmKFYCYk
FogFYlUcORaxQrAfi1gh2I9FrBDcV0isEORYxApBjkUsEAvEqjhyLGKFIMciVghyLGKFIMciVghy
LGKFIMciFogFYlUcORaxQpBjESsEORaxQpBjESsEORaxQpBjEQvEArEqjhyLWCHIsYgVghyLWCHI
sYgVghyLWCHIsYgFYoFYFUeORawQ5FjECkGORawQ5FjECkGORawQ5FjEArFArIojxyJWCHIsYoUg
xyJWCHIsYoUgxyJWCHIsYuH/Sn3k2bRW81bQKH3ESpMkSdVmBHKsQmIZrcYhx9JjhSDHyl2pZEyT
lWStliHsGHfaalBIrP0+6/gRgx5L3mAqjIBXxVaF6oKCjMyxEjkWIsRilR5Lj/VQkWMRK2YRrQTE
isB+LGKFYD8WsULQuxMLxAKxKo79WMQKQY5FrBDkWMQKQY5FrBDkWMQKQY5FLBALxKo4cixihSDH
IlYIcixihSDHIlYIcixihSDHIhaIBWJVHDkWsUKQYxErBDkWsUKQYxErBDkWsUKQYxELxAKxKo4c
i1ghyLGIFYIci1ghyLGIFYIci1ghyLGIBWKBWBVHjkWsEORYxApBjkWsEORYxApBjkWsEORYxAKx
QKyKI8ciVghyLGKFIMciVghyLGKFIMciVghyLGKBWCBWxZFjESsEORaxQpBjESsEORaxQpBjESsE
OVZRsVKlQYBYvIKp8CEix8pLffSAlaSH49b+Q6JQGXKsYmIdkAwcU6Qj5FiFpkIyjUOOVazHSlPt
+0jkWIWmwsSgNQY5llUhplIsAxaMWA8PORaxQpBjESsEORaxQpBjESsEORaxQpBjEQvEArEqjhyL
WCHIsYgVghyLWCHIsYgVghyLWCHIsYgFYoFYFUeORawQ5FjECkGORawQ5FjECkGORawQ5FjEArFA
rIojxyJWCHIsYoUgxyJWCHIsYoUgxyJWCHIsYoFYIFbFkWMRKwQ5FrFCkGMRKwQ5FrFCkGMRKwQ5
FrFALBCr4sixiBWCHItYIcixiBWCHItYIcixiBWCHItYIBaIVXHkWMQKQY6Vl7oSnAc51gHZm9Hv
Pab7x4RYBbnRVoMjsw6lShNTYTHkWCNJUmIVQ4415NKIcYpYsCoEsS48cixihSDHGmqykmNLxBOI
G86FHOsU+wvCEV38THLW/0vU7og7cqxCU2G6x9T9WUzDt7k2TT9Mqd+mbMZMhYap0cixCo1Ypj/E
jFipMQsFlznJmBHr8CIjkIckx4iVTF2nVdLkXM63maofZlr7FgEpHmLzri6IaN4TzTsimncgZMSa
SkppUksZissZz0ubFaaze//ciJWW9Tso/Hso5ZuU9F2mtyGu1qow8aMQ6/Mw3iuMEWsKfxEX+o9l
+nusQZNbQk9zMWefqZVz+sVKHnhRrIbJBR2w0imV63OyKixtCXXRvErEDdMxrZYwIyYlhWEX+/KG
5B1WhSAWiAUQC8QCsQBigVggFkAsEAvEAogFYoFYALEwxfwPJiCGkcTfb5EAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2013-01-22 15:14:33 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="6" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Steroid versus placebo, outcome: 1.1 Admissions (days 1 and 7) (outpatients) - review primary outcome.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAxIAAAJACAMAAAAuK6CxAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2013-01-22 23:43:04 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="7" REF_ID="CMP-001.04" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Steroid versus placebo, outcome: 1.4 Clinical scale scores (outpatients) (change from baseline data).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA0sAAAOACAMAAADctRgzAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2013-01-22 23:43:04 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="8" REF_ID="CMP-001.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Steroid versus placebo, outcome: 1.2 Length of stay (inpatients) - review primary outcome.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAyUAAADwCAMAAAApUTusAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2013-01-22 23:43:04 +1000" MODIFIED_BY="Ricardo M Fernandes" NO="9" REF_ID="CMP-001.05" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Glucocorticoid versus placebo, outcome: 1.6 Clinical scores (inpatients) (change from baseline data).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA6IAAAJACAMAAACg3SuIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2010-05-22 01:15:34 +1000" MODIFIED_BY="Ricardo M Fernandes"/>
<APPENDICES MODIFIED="2013-03-20 00:01:43 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-03-20 00:01:43 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-03-19 22:30:34 +1000" MODIFIED_BY="[Empty name]">Search strategy: Cochrane Central Register of Controlled Trials - Ovid version</TITLE>
<APPENDIX_BODY MODIFIED="2013-03-20 00:01:43 +1000" MODIFIED_BY="[Empty name]">
<P>1. exp BRONCHIOLITIS/<BR/>2. (bronchiolitis or wheez*).mp. [mp = title, original title, abstract, MeSH headings, heading words, keyword]<BR/>3. exp Respiratory Syncytial Viruses/ or exp exp Respiratory Syncytial Virus Infections/<BR/>4. Respiratory Syncytial Virus$.mp.<BR/>5. or/1-4<BR/>6. exp Bronchodilator Agents/<BR/>7. exp Adrenergic Agents/<BR/>8. exp Glucocorticoids/ or exp Adrenal Cortex Hormones/<BR/>9. (Glucocorticoid* or Corticoglucocorticoid*).mp.<BR/>10. exp Anti-Inflammatory Agents/<BR/>11. exp Drug Therapy, combination/<BR/>12. exp Epinephrine/<BR/>13. adrenal cortex hormone*.ti,ab.<BR/>14. (epinephrine or adrenalin*).mp.<BR/>15. albuterol.mp.<BR/>16. beclomet?asone.mp.<BR/>17. betamet?asone.mp.<BR/>18. budesonide.mp.<BR/>19. dexamet?asone.mp.<BR/>20. salbutamol.mp.<BR/>21. ipratropium.mp.<BR/>22. prednisolone.mp.<BR/>23. prednisone.mp.<BR/>24. methylprednisone.mp.<BR/>25. terbutaline.mp.<BR/>26. fluticasone.mp.<BR/>27. exp Orciprenaline/ or (orciprenaline or fenoterol).mp.<BR/>28. aminophylline.mp.<BR/>29. androstadienes.mp.<BR/>30. hydrocortisone.mp.<BR/>31. or/6-30<BR/>32. 5 and 31<BR/>33. exp Infant/<BR/>34. (Infant* or infancy or Newborn* or Baby* or Babies or Neonat* or Preterm* or Prematur* or Postmatur*).mp.<BR/>35. or/33-34<BR/>36. 32 and 35</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-03-19 22:30:53 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-03-19 22:30:53 +1000" MODIFIED_BY="[Empty name]">Search strategy: EMBASE - Ovid version</TITLE>
<APPENDIX_BODY MODIFIED="2012-02-17 16:19:22 +1000" MODIFIED_BY="[Empty name]">
<P>1. exp BRONCHIOLITIS/<BR/>2. (bronchiolitis or wheez*).mp.<BR/>3. exp Respiratory Syncytial Pneumovirus/<BR/>4. Respiratory Syncytial Virus$.mp.<BR/>5. or/1-4<BR/>6. exp Bronchodilating Agents/<BR/>7. exp Adrenergic Receptor Stimulating Agents/<BR/>8. exp Glucocorticoid/ or exp corticoglucocorticoid/<BR/>9. (glucocorticoid* or corticoglucocorticoid*).mp.<BR/>10. exp Anti-Inflammatory Agent/<BR/>11. exp Drug combination/<BR/>12. exp Adrenalin/<BR/>13. adrenal cortex hormone*.ti,ab.<BR/>14. (epinephrine or adrenalin*).mp.<BR/>15. albuterol.mp.<BR/>16. betamet?asone.mp.<BR/>17. beclomet?asone.mp.<BR/>18. budesonide.mp.<BR/>19. exp Dexamethasone/ or dexametha?one.mp.<BR/>20. salbutamol.mp.<BR/>21. ipratropium.mp.<BR/>22. exp Prednisolone/ or prednisolone.mp.<BR/>23. exp Prednisone/ or prednisone.mp.<BR/>24. methylprednisone.mp.<BR/>25. terbutaline.mp.<BR/>26. fluticasone.mp.<BR/>27. Orciprenaline/ or Fenoterol/ or (orciprenaline or fenoterol).mp.<BR/>28. aminophylline.mp.<BR/>29. androstadienes.mp.<BR/>30. exp hydrocortisone/<BR/>31. hydrocortisone.mp.<BR/>32. or/6-31<BR/>33. 5 and 32<BR/>34. exp clinical trial/<BR/>35. randomi?ed.ti,ab.<BR/>36. placebo.ti,ab.<BR/>37. dt.fs.<BR/>38. randomly.ti,ab.<BR/>39. trial.ti,ab.<BR/>40. groups.ti,ab.<BR/>41. or/34-40<BR/>42. animal/<BR/>43. human/<BR/>44. 42 not (42 and 43)<BR/>45. 41 not 44<BR/>46. 33 and 45<BR/>47. limit 46 to (child or preschool child &lt;1 to 6 years&gt;)<BR/>48. exp Infant/<BR/>49. (Infant* or infancy or Newborn* or Baby* or Babies or Neonat* or Preterm* or Prematur* or Postmatur*).mp.<BR/>50. 48 or 49<BR/>51. 46 and 50<BR/>52. 47 or 51</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-03-19 22:31:04 +1000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2013-03-19 22:31:04 +1000" MODIFIED_BY="[Empty name]">Search strategy: IRAN MedEx</TITLE>
<APPENDIX_BODY MODIFIED="2012-02-17 16:13:18 +1000" MODIFIED_BY="[Empty name]">
<P>(Bronchiolitis or bronquiolitis or broncho-alveolites virales or bronchiolite*)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2013-03-19 22:31:13 +1000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2013-03-19 22:31:13 +1000" MODIFIED_BY="[Empty name]">Search strategy: LILACS BIREME/OPAS/OMS - Latin American and Caribbean Center on Health Sciences Information</TITLE>
<APPENDIX_BODY MODIFIED="2012-02-17 16:15:42 +1000" MODIFIED_BY="[Empty name]">
<P>wheeze OR Sibilancias OR bronquiolitis OR bronchiolitis OR bronquiolite [Words] and infant OR pediatric OR newborn OR nacidos OR Lactentes OR lactantes OR pediátrica [Words]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2013-03-19 22:31:21 +1000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2013-03-19 22:31:21 +1000" MODIFIED_BY="[Empty name]">Search strategy: MEDLINE - Ovid version</TITLE>
<APPENDIX_BODY MODIFIED="2012-02-17 16:17:16 +1000" MODIFIED_BY="[Empty name]">
<P>1. exp BRONCHIOLITIS/<BR/>2. (bronchiolitis or wheez*).mp.<BR/>3. exp Respiratory Syncytial Viruses/ or exp Respiratory Syncytial Virus Infections/<BR/>4. Respiratory Syncytial Virus$.mp.<BR/>5. or/1-4<BR/>6. exp Bronchodilator Agents/<BR/>7. exp Adrenergic Agents/<BR/>8. exp Glucocorticoids/ or exp Adrenal Cortex Hormones/<BR/>9. (Glucocorticoid* or Corticoglucocorticoid*).mp.<BR/>10. exp Anti-Inflammatory Agents/<BR/>11. exp Drug Therapy, combination/<BR/>12. exp Epinephrine/<BR/>13. (epinephrine or adrenalin*).mp.<BR/>14. albuterol.mp.<BR/>15. betamet?asone.mp.<BR/>16. beclomet?asone.mp.<BR/>17. budesonide.mp.<BR/>18. dexamet?asone.mp.<BR/>19. salbutamol.mp.<BR/>20. ipratropium.mp.<BR/>21. prednisolone.mp.<BR/>22. prednisone.mp.<BR/>23. methylprednisone.mp.<BR/>24. terbutaline.mp.<BR/>25. fluticasone.mp.<BR/>26. exp Orciprenaline/ or (orciprenaline or fenoterol).mp.<BR/>27. aminophylline.mp.<BR/>28. androstadienes.mp.<BR/>29. hydrocortisone.mp.<BR/>30. or/6-29<BR/>31. 5 and 30<BR/>32. randomised controlled trial.pt.<BR/>33. clinical trial.pt.<BR/>34. randomi?ed.ti,ab.<BR/>35. placebo.ti,ab.<BR/>36. dt.fs.<BR/>37. randomly.ti,ab.<BR/>38. trial.ti,ab.<BR/>39. groups.ti,ab.<BR/>40. or/32-39<BR/>41. animals/<BR/>42. humans/<BR/>43. 41 not (41 and 42)<BR/>44. 40 not 43<BR/>45. 44 and 31<BR/>46. exp Infant/<BR/>47. (Infant* or infancy or Newborn* or Baby* or Babies or Neonat* or Preterm* or Prematur* or Postmatur*).mp.<BR/>48. or/46-47<BR/>49. 45 and 48</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2013-03-19 22:31:51 +1000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2013-03-19 22:31:51 +1000" MODIFIED_BY="[Empty name]">Scopus - Elsevier B.V.</TITLE>
<APPENDIX_BODY MODIFIED="2012-02-17 16:18:53 +1000" MODIFIED_BY="[Empty name]">
<P>(((TITLE(bronchiolitis OR wheez*) AND TITLE-ABS-KEY(glucocorticoid* OR glucocorticoid* OR corticoglucocorticoid*))) AND KEY("epinephrine" OR "adrenaline" OR "albuterol" OR "corticoglucocorticoids" OR "hydrocortisone" OR "glucocorticoids" OR ("inhaled glucocorticoids") OR "salbutamol" OR "betamethasone" OR "beclomethasone" OR "dexamethasone" OR "glucocorticoid" OR ("inhaled budesonide") OR "glucocorticoids" OR "bronchodilator" OR ("glucocorticoid use") OR "prednisolone" OR "methylprednisone" OR ("oral prednisolone") OR "prednisone" OR "ipratropium" OR "terbutaline" OR "orciprenaline" OR "fenoterol" OR "aminophylline" OR "androstadienes" OR "hydrocortisone")) AND (TITLE-ABS-KEY("Clinical Trial" OR "Clinical Trials" OR "Randomised Controlled Trial*" OR "Random Allocation" OR "double-blind method" OR "single-blind method" OR placebos OR research design OR comparative study OR evaluation studies OR follow-up studies OR prospective)) AND (infan* OR newborn* OR neonat* OR baby OR babies)</P>
<P>(((TITLE(bronchiolitis) AND TITLE-ABS-KEY(glucocorticoid* OR glucocorticoid*OR corticoglucocorticoid*))) AND KEY("epinephrine" OR "albuterol" OR "corticoglucocorticoids" OR "hydrocortisone" OR "glucocorticoids" OR ("inhaled glucocorticoids") OR "salbutamol" OR "dexamethasone" OR "glucocorticoid" OR ("inhaled budesonide") OR "glucocorticoids"OR "bronchodilator"OR ("glucocorticoid use") OR "prednisolone" OR ("oral prednisolone") OR "prednisone")) AND (TITLE-ABS-KEY("Clinical Trial" OR "Clinical Trials" OR "Randomised Controlled Trial*" OR "Random Allocation" OR "double-blind method" OR "single-blind method" OR placebosOR research design OR comparativestudy OR evaluationstudies OR follow-up studies OR prospective))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2013-03-19 22:32:30 +1000" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2013-01-23 11:20:29 +1000" MODIFIED_BY="[Empty name]">Search details 2013 update</TITLE>
<APPENDIX_BODY MODIFIED="2013-03-19 22:32:30 +1000" MODIFIED_BY="[Empty name]">
<P>Details of the MEDLINE, CENTRAL, EMBASE, SCOPUS and LILACS 2013 update searches.</P>
<P>We used the search strategy below to search CENTRAL and MEDLINE. To identify child studies the search strategy was combined with a filter based on the work of Boluyt (<LINK REF="REF-Boluyt-2008" TYPE="REFERENCE">Boluyt 2008</LINK>). The MEDLINE search was combined with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximising version (2008 revision); Ovid format (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>). The search strategy was adapted to search EMBASE , LILACS and Scopus (all listed below).</P>
<SUBSECTION>
<HEADING LEVEL="5">MEDLINE (Ovid)</HEADING>
<P>1 exp Bronchiolitis/<BR/>2 (bronchiolit* or wheez*).mp.<BR/>3 respiratory syncytial viruses/ or respiratory syncytial virus, human/<BR/>4 Respiratory Syncytial Virus Infections/<BR/>5 respiratory syncytial virus*.mp. or rsv.tw.<BR/>6 or/1-5<BR/>7 exp Bronchodilator Agents/<BR/>8 exp Adrenergic Agents/<BR/>9 exp Glucocorticoids/<BR/>10 exp Adrenal Cortex Hormones/<BR/>11 (glucocorticoid* or corticoglucocorticoid*).mp.<BR/>12 exp Anti-Inflammatory Agents/<BR/>13 Drug Therapy, Combination/<BR/>14 exp Epinephrine/<BR/>15 (epinephrine or adrenalin*).mp.<BR/>16 albuterol.mp.<BR/>17 betamet?asone.mp.<BR/>18 beclomet?asone.mp.<BR/>19 budesonide.mp.<BR/>20 dexamet?asone.mp.<BR/>21 salbutamol.mp.<BR/>22 ipratropium.mp.<BR/>23 prednisolone.mp.<BR/>24 prednisone.mp.<BR/>25 methylprednisone.mp.<BR/>26 terbutaline.mp.<BR/>27 fluticasone.mp.<BR/>28 exp Metaproterenol/<BR/>29 (orciprenaline or fenoterol or metaproterenol).mp.<BR/>30 aminophylline.mp.<BR/>31 (androstadiene or androstadienes).mp.<BR/>32 hydrocortisone.mp.<BR/>33 or/7-32<BR/>34 6 and 33</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Embase.com search strategy</HEADING>
<P>#30 #22 AND #29<BR/>#29 #25 NOT #28<BR/>#28 #27 NOT #26<BR/>#27 'animal'/de OR 'nonhuman'/de OR 'animal experiment'/de<BR/>#26 'animal'/de OR 'nonhuman'/de OR 'animal experiment'/de AND 'human'/exp<BR/>#25 #23 OR #24<BR/>#24 random*:ab,ti OR crossover*:ab,ti OR 'cross over':ab,ti OR placebo*:ab,ti OR allocat*:ab,ti OR (doubl* NEXT/1 blind*):ab,ti OR trial:ti<BR/>#23 'randomized controlled trial'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp<BR/>#22 #18 AND #21<BR/>#21 #19 OR #20<BR/>#20 infant*:ab,ti OR infancy:ab,ti OR newborn*:ab,ti OR baby*:ab,ti OR babies:ab,ti OR neonat*:ab,ti OR preterm*:ab,ti OR prematur*:ab,ti OR postmatur*:ab,ti OR child*:ab,ti OR schoolchild*:ab,ti OR preschool*:ab,ti OR kid:ab,ti OR kids:ab,ti OR toddler*:ab,ti OR adoles*:ab,ti OR teen*:ab,ti OR boy*:ab,ti OR girl*:ab,ti OR minor*:ab,ti OR pubert*:ab,ti<BR/>OR pubescen*:ab,ti OR pediatric*:ab,ti OR paediatric*:ab,ti OR kindergar*:ab,ti OR highschool*:ab,ti OR ((nursery OR primary OR secondary OR elementary OR high) NEXT/1 school*):ab,ti AND [embase]/lim1476119 #19 'infant'/exp OR 'child'/exp OR 'adolescent'/exp OR 'puberty'/exp OR 'pediatrics'/exp OR 'kindergarten'/de OR 'nursery school'/de OR 'primary school'/de OR 'middle school'/de OR 'high school'/de<BR/>#18 #6 AND #17<BR/>#17 #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16<BR/>#16 albuterol:ab,ti OR betamethasone:ab,ti OR betametasone:ab,ti OR beclometasone:ab,ti OR beclomethosone:ab,ti OR budesonide:ab,ti OR dexamethasone:ab,ti OR salbutamol:ab,ti OR ipratropium:ab,ti OR prednisolone:ab,ti OR prednisone:ab,ti OR methylprednisone:ab,ti OR terbutaline:ab,ti OR fluticasone:ab,ti OR orciprenaline:ab,ti OR fenoterol:ab,ti OR metaproterenol:ab,ti OR aminophylline:ab,ti OR androstadiene*:ab,ti OR hydrocortisone:ab,ti<BR/>#15 adrenalin*:ab,ti OR epinephrine:ab,ti<BR/>#14 'adrenalin'/de<BR/>#13 'drug combination'/de<BR/>#12 'antiinflammatory agent'/exp<BR/>#11 'corticosteroid'/exp<BR/>#10 glucocorticoid*:ab,ti OR corticoglucocorticoid*:ab,ti<BR/>#9 'glucocorticoid'/exp<BR/>#8 'adrenergic receptor stimulating agent'/exp<BR/>#7 'bronchodilating agent'/exp<BR/>#6 #1 OR #2 OR #3 OR #4 OR #5<BR/>#5 'respiratory syncytial virus':ab,ti OR 'respiratory syncytial viruses':ab,ti OR rsv:ab,ti<BR/>#4 'respiratory syncytial virus infection'/de<BR/>#3 'respiratory syncytial pneumovirus'/de<BR/>#2 bronchiolit*:ab,ti OR wheez*:ab,ti<BR/>#1 'bronchiolitis'/exp</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Scopus (Elsevier) search strategy</HEADING>
<P>(((TITLE-ABS-KEY(bronchiolitis OR wheez*) AND SUBJAREA(mult OR agri OR bioc OR immu OR neur OR phar OR mult OR medi OR nurs OR vete OR dent OR heal)) AND ((TITLE-ABS-KEY(glucocorticoid* OR corticoglucocorticoid* OR epinephrine OR adrenalin*) OR TITLE-ABS-KEY(albuterol OR betametasone OR betamethasone OR beclomethasone OR beclometasone OR budesonide OR dexamethasone OR dexamethasone) OR TITLE-ABS-KEY(salbutamol OR ipratropium OR prednisolone OR prednisone OR methylprednisone OR terbutaline OR fluticasone) OR TITLE-ABS-KEY (orciprenaline OR fenoterol OR metaproterenol OR aminophylline OR androstadiene* OR hydrocortisone)) AND SUBJAREA(mult OR agri OR bioc OR immu OR neur OR phar OR mult OR medi OR nurs OR vete OR dent OR heal))) AND (TITLE-ABS-KEY(infant* OR infancy OR newborn* OR baby* OR babies OR neonat* OR preterm* OR postmatur* OR child* OR toddler* OR preschool* OR pediatric* OR paediatric*) AND SUBJAREA(mult OR agri OR bioc OR immu OR neur OR phar OR mult OR medi OR nurs OR vete OR dent OR heal))) AND (TITLE-ABS-KEY("clinical trial" OR "clinical trials" OR random* OR placebo* OR "double-blind" OR "single-blind" OR "research design" OR "comparative study" OR "evaluation studies" OR "follow-up studies" OR prospective) AND SUBJAREA(mult OR agri OR bioc OR immu OR neur OR phar OR mult OR medi OR nurs OR vete OR dent OR heal))<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">LILACS (BIREME VHL) search strategy</HEADING>
<P>(MH:Bronchiolitis OR bronchiolit$ OR Bronquiolitis OR Bronquiolite OR MH:C08.127.446.135$ OR MH:C08.381.495.146.135$ OR C08.730.099.135$ OR MH:Bronchopneumonia OR bronchopneumon$ OR Bronconeumonía OR MH:"Respiratory Syncytial Virus Infections" OR "Infecciones por Virus Sincitial Respiratorio" OR "Infecções por Vírus Respiratório Sincicial" OR MH:C02.782.580.600.620.750 OR "respiratory syncytial virus" OR "respiratory syncytial viruses" OR rsv OR MH:"Respiratory Syncytial Viruses" OR "Virus Sincitiales Respiratorios" OR "Vírus Sinciciais Respiratórios" OR "Virus Sincitial Respiratorio" OR MH:B04.820.455.600.670.600.750 OR MH:B04.909.777.455.600.670.600.750 OR MH:"Respiratory Syncytial Virus, Human" OR "Virus Sincitial Respiratorio Humano" OR "Vírus Sincicial Respiratório Humano" OR MH:B04.820.455.600.670.600.750.730 OR MH:B04.909.777.455.600.670.600.750.730 OR Sibilancias OR wheez$ OR Sibiação) AND (MH:"adrenal cortex hormones" OR MH:D06.472.040$ OR Corticoesteroide$ OR Corticosteróide$ OR Corticoid$ OR corticosteroid$ OR MH:glucocorticoids OR MH:D06.472.040.543$ OR MH:D27.505.696.399.472.788$ OR glucocortic$ OR MH:steroids OR steroid$ OR Esteroide$ OR Esteróide$ OR MH:D04.808$ OR MH:epinephrine OR MH:D02.092.211.215.311.461$ OR MH:D02.092.311.461 OR Epinefrina OR adrenalin$ MH:dexamethsone OR dexamethason$ OR dexametason$ OR MH:prednisolone OR prednisol$ OR MH:methylprednisone OR methylprednison$ OR metilprednisol$ OR MH:betamethasone OR betamethason$ OR betametason$ OR MH:hydrocortisone OR hydrocortison$ OR hidrocortison$ OR albuterol OR budesonide OR salbutamol OR ipratropium OR terbutaline OR fluticasone OR MH:metaproterenol OR MH:fenoterol OR metaproterenol OR fenoterol OR orciprenaline OR aminophylline OR androstadiene$) &gt; clinical_trials</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>

<EXTENSION ID="AFF_9B59478682E26AA200C3FEB6F44498DB_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="9B59478682E26AA200C3FEB6F44498DB"><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>Santa Maria Hospital</ORGANISATION><ADDRESS_1>Avenida Professor Egas Moniz</ADDRESS_1><CITY>Lisboa</CITY><ZIP>1649-028</ZIP><REGION>Lisboa</REGION><COUNTRY CODE="PT">Portugal</COUNTRY></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>